"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Cooper Companies Inc. Q1 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to turn the conference over to Kim Duncan, Vice President, Inve",46,"Good day, ladies and gentlemen, and welcome to the Cooper Companies Inc. Q1 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to turn the conference over to Kim Duncan, Vice President, Investor Relations. Please, go ahead."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Good afternoon, and welcome to the Cooper Companies' First Quarter 2016 Earnings Conference Call. I'm Kim Duncan, Vice President of Investor Relations, and giving prepared remarks on today's call are Bob Weiss, Chief Executive Officer; and Greg Matz, Chie",320,"Good afternoon, and welcome to the Cooper Companies' First Quarter 2016 Earnings Conference Call. I'm Kim Duncan, Vice President of Investor Relations, and giving prepared remarks on today's call are Bob Weiss, Chief Executive Officer; and Greg Matz, Chief Financial Officer. 
Before we get started, I'd like to remind you that this conference call contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including all revenue and earnings per share guidance and other statements regarding anticipated results of operations, market or regulatory conditions and integration of any acquisitions or their failure to achieve anticipated benefits. Forward-looking statements depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Events that could cause our actual results and future actions of the company to differ materially from those described in the forward-looking statements are set forth under the caption Forward-Looking Statements in today's earnings release and are described in our SEC filings, including the Business section of Cooper's annual report on Form 10-K. These are publicly available and on request from the company's Investor Relations department. 
Now before I turn the call over to Bob, let me comment on the agenda for the call. Bob will begin by providing highlights on the quarter, followed by Greg, who will then discuss the first quarter financial results. We will keep the formal presentation to roughly 30 minutes and then open the call for questions. We expect the call to last approximately 1 hour. We request that anyone asking questions, please limit yourself to 1 question. Should you have additional questions, please call our Investor line at (925) 460-3663 or e-mail, ir@coopercos.com. As a reminder, this call is being webcast and a copy of the earnings release is available through Investor Relations section of the Cooper Companies website. And with that, I'll turn the call over to Bob for his opening remarks."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thank you, Kim, and good afternoon, everyone. Welcome to our first quarter 2016 conference call. We're off to a good start this year and I'm optimistic about our performance as we move forward. Let me start by touching on 3 key items. First, I'm pleased t",1648,"Thank you, Kim, and good afternoon, everyone. Welcome to our first quarter 2016 conference call. We're off to a good start this year and I'm optimistic about our performance as we move forward. Let me start by touching on 3 key items. First, I'm pleased to report our fiscal first quarter financial results were strong. On a consolidated basis, we reported $450 million in revenue and non-GAAP earnings per share of $1.83. We are raising our fiscal 2016 revenue and earnings guidance to reflect this outperformance and to incorporate updated currency rates. Second, CooperVision posted 4% constant currency revenue growth, which met expectations. As such, we are maintaining our 5% to 7% constant currency revenue guidance at CooperVision for the fiscal year. Third, CooperSurgical had a strong quarter posting revenue growth of 12% or 6% pro forma. This was especially impressive given non-GAAP operating margins expanded 400 basis points over Q1 of last year. As a result of this outperformance, we are raising CooperSurgical's full-year revenue guidance to 15% to 18% or 5% to 8% pro forma. I'll expand on these items as I walk-through this quarter's performance but suffice it to say I'm proud of where we stand and excited about the future. 
CooperVision reported Q1 revenues of $364 million, down 1% year-over-year but up 4% in constant currency. The Americas were down 3% in constant currency due to the tough comp and aggressive promotional activity by Johnson & Johnson associated with their New Delhi Pocahontas shell product, which we discussed last quarter. Going forward, we expect the Americas to return to more normal growth starting in the second quarter. Regarding EMEA, sales grew 8% in constant currency. This was despite the soft on integration disruption we discussed on our last earnings call. These disruptions ended in Q1 that resulted in certain customer concessions that reduced results. EMEA growth was driven by a pro forma of silicone hydrogel products of Affinity, clariti, MyDay and Avaira. We also had a strong quarter in Asia Pacific, growing 12% in constant currency and this growth was also driven by our family silicone hydrogel products. We expect both these regions to continue performing well going forward. 
Within our specialty business, overall sales were up 4% year-over-year and multifocal were flat both within constant currency. This was softer than in the prior quarters due to the Americas where -- which is the largest region with these types of lenses. We remain a global leader in specialty lenses and expect sales to bounce back in Q2 as the Americas return to growth. Looking at silicone hydrogel lenses. This family of products delivered a strong growth of 13% in constant currency. Our Affinity and Avaira combined to grow 7% in constant currency with the only weakness being seen in the Americas. And again, we expect the Americas to rebound in Q2. We remain under index in the two-week and monthly silicon hydrogel space with the market being roughly 77% silicone hydrogel and us at 72% as we anticipate posting nice growth for many years to come. Regarding 1 Day silicone hydrogel lenses, clariti and MyDay, we were solid 50% of constant currency. We remain very optimistic about these products and are committed to our growth strategy which include a two-tiered approach with clariti positioned as the mass market offering and MyDay as the premium offering. Remember, the contact lens market is being driven by 1 Day growth and we strongly believe we have the best product offering in the space as the only company with premium and mass market lenses including the full portfolio of 1 Day, seer, and multifocal lenses. Regarding production on these products, MyDay is ramping up nicely and we are selling everything we can make. Production is also extremely well going extremely well for clariti, we continue to expect clariti post margins to be accretive worldwide gross margins as we exit fiscal year. 
Regarding Proclear, sales of this hydrogel product line were down 4% in constant currency, driven by our continuing shift to silicone. Before moving in the market data, let me finish with a comment on CooperVision's non-GAAP adjustment. As expected, we had around $23 million in charges this quarter but roughly 60%, 40% between manufacturing and operating expenses. With the majority of this soft line integration be how behind us, we expect this number to decline to under $10 million in Q2 with most of the charges in cost of goods associated with accelerated depreciation which relates to decisions we made last year. 
Now let me comment on CooperVision's performance and overall the contact lens market and remember, this information is on the last page of our earnings release. Counted for Q4, we continue taking market share growing 6% with the market up 4%. Regarding the market, the underlying story is changing due to a new product launch and easy comps, while our comp business was soft against difficult comps. Regionally Recently, CVI grew 9% in the EMEA with the market up 5%. In Asia PAC, CooperVision grew 12% with the market up 5% and in the Americas, CooperVision grew 1% with the market up 4%. If we look at the market on a modality basis, assuming each market continue thriving growth with CVI up 14% and the market up 12%. For non-silicon use lenses, CVI grew 2% while the market declined 1% and as you can see, our growth remains diverse and strong. For the full year -- calendar year 2016, CooperVision grew 7% in the market, grew 4%. Going forward, I expect the market to continue growing 4% to 6% over the next 5 years and most likely closer to 6%. The drivers will continue to be the shift to daily geographic expansion and expansion of the where base. We expect to continue to taking market share, led by the strong silicone hydrogel portfolio. 
Moving to CooperSurgical. We reported Q1 revenue of $85 million, up 12% year-on-year or 6% pro forma. We made solid progress in our office and surgical business, growing 7% and in our fertility business growing 6%, both pro forma. These results are much stronger than our initial guidance and there are a number of ongoing opportunities which are driving this. First, we significantly increased our focus on sales during the fiscal fourth quarter of last year. This included existing products, new product launches and acquired products. This new emphasis was seen in our Q1 results and we believe it will continue through the year. Second, we are combining our office and surgical and fertility businesses including transforming to a geographic sales focus. This is enabling us to cross some more effectively, which is especially beneficial with products such as our newly launched disposable scope, which sells to OB/GYN offices but also to fertility centers. This change will also allow us to better manage our infrastructure going forward and we'll reinvest those savings in sales and marketing to continue driving revenue growth. Third, as we continue to progress through the year, we'll be adding more sales personnel in under-penetrated areas and increasing our focus on high-growth areas such as generic testing. We anticipate doing this while leveraging revenue growth to improve operating margins as we did in Q1. All in, CooperSurgical is clearly moving to a more aggressive and efficient business model with a life sciences look and feel. 
With respect to CooperSurgical's products, the office and surgical business, comprised of a diverse portfolio of roughly 600 products sold primarily to obstetricians and gynecologists. As I stated earlier, this product portfolio grew 7% with strength in several key products. Within fertility, we grew 6% pro forma. Sales growth is still being negatively impacted by our strategic decision to exit low margin, non-CSI manufactured capital equipment. This will continue through Q2 but then, become largely immaterial in Q3. Also within fertility, our genetic testing business is performing extremely well. We entered these lab services space with the acquisition of 3 Point Genetics last August and it's proving a every nice strategic sale. Lastly, we're in complimentary, we added complimentary IVF products in mid-December with the acquisition of Research Instruments and we also acquired a small fertility microneedle company at the beginning of February, which we expect to have roughly $1 million of revenue per quarter going forward. These deals are also incorporated in our updated guidance. So overall, I'm very bullish on CooperSurgical. The passion drive of our surgical team is extremely high and I'm really proud of their efforts and excited about our future. 
Now let me touch a little more on guidance. Our fiscal 2016 revenue guidance for CooperVision remains unchanged at 5% to 7% constant currency growth. We are raising our CooperSurgical revenue guidance to 5% to 8% pro forma growth or 15% to 18% on an as-reported basis. We're also raising our non-GAAP earnings per share guidance to $8 to $8.30, up 13% to 17% pro forma. For cash flow, we continue to expect around $300 million of adjusted free cash flow for fiscal 2016. 
In conclusion, we're continuing our successful strategy which we frequently articulated in the past. This includes investing to take market share by expanding geographically, aggressively rolling out new products and investing in emerging markets. We do this while remaining focused on growing earnings per share and cash flow to deliver strong shareholder value. I'm pleased with the results and happy the issues we encountered in the fourth quarter, such as the European Sauflon integration activity are behind us and we remain very optimistic about the underlying fundamentals of our businesses and I believe we are well-positioned to deliver strong results for fiscal 2016 and beyond. With that, let me express my appreciation to our employees, our #1 asset. Their hard work and dedication to creating value is the backbone of our success. And now, I'll turn it over to Greg to cover our financial results."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thanks, Bob, and good afternoon, everyone. Bob provided an overall summary of our performance including a review of the market and our revenue picture. I will focus on primarily are not GAAP results for the quarter. For the reconciliation to GAAP numbers,",1353,"Thanks, Bob, and good afternoon, everyone. Bob provided an overall summary of our performance including a review of the market and our revenue picture. I will focus on primarily are not GAAP results for the quarter. For the reconciliation to GAAP numbers, please refer to our earnings release. Looking at growth margins. In Q1, the non-GAAP gross margin was 61.4% compared with 64.2% in the prior year. Factors which impacted our non-GAAP gross margins were a net unfavorable FX impact with the favorable U.K.-based cost of goods sold impact more than offset by the unfavorable revenue impact. In addition, product mix was a negative as the sales weakness Bob mentioned in the Americas hurt our margins as this region has the greatest amount of torque and multifocal lenses, along with being a strong Biofinity franchise. We expect gross margins to rebound in Q2. CooperVision on a non-GAAP basis reported gross margin of 60.9% versus 64.2% in Q1 of last year. The factors which impacted our non-GAAP gross margin where the unfavorable net FX impact, as well as the product mix I just mentioned. CooperSurgical had non-GAAP gross margin of 63.6% which compares to Q1 '15 at 64%. Strength in the OB/GYN and IVF product families were offset by the inclusion of our 2 recent acquisitions, Repro Genetics and Research Instruments, which have lower gross margins. 
Looking at operating expenses. On a non-GAAP basis, SG&A decreased approximately 3% to $161.8 million or 36% of revenue, down from approximately 38% the prior year. The primary driver behind this was a reduction in G&A where we saw leveraging good management of expenses within the businesses. Now looking at R&D. In Q1, R&D on a non-GAAP basis was $14.8 million or 3.3% of revenue, down from the 3.6% in the prior year. We are seeing investment in CSI offset by synergies from the Sauflon acquisition and CVI. 
Moving to operating margins. For Q1 consolidated GAAP operating income and margins were $57.4 million and 12.8% of revenue versus $73.1 million and 16.4% of revenue in Q1 last year. Non-GAAP operating income and margin were $99.4 million and 22.1% of revenue versus $102.6 million, 23% of revenue for the prior year. The difference in operating margin year-over-year is the reduction in gross margin we discussed partially offset by operating expenses. In Q1, CooperVision non-GAAP operating income and margin were $87.4 million and 24% of revenue versus $98.4 million and 26.6% of revenue in the prior year. CooperSurgical's non-GAAP operating income and margin were $22.8 million and 26.7% of revenue versus Q1 '15 at $17.5 million and 23.1% of revenue. Now looking at depreciation and amortization in Q1. Depreciation was $37.3 million, up $8 million year-over-year which includes $6.1 million of accelerated depreciation related to the Sauflon acquisition, which we excluded in our non-GAAP numbers. Amortization was $16.2 million, up $2.6 million. The year-over-year amortization increase reflects recent acquisition activity. Interest expense was $5.3 million for the quarter, up $1.3 million year-over-year primarily due to acquisitions and higher interest rates. Looking at the effective tax rate. In Q1, the non-GAAP effective tax rate was 3.9% versus a non-GAAP effective tax rate of 10.8% in Q1 '15. The year-over-year effective tax rate was favorably impacted by several items including the release of reserves associated with a prior year tax filing which we've normally have reversed in Q3 of 2017, as well as a reduction in the U.K. tax rate which was enacted in November. Also note, as we've mentioned before the effective tax rate continues to be below the U.S. statutorily rate as a majority of our income is earned in foreign jurisdictions with lower taxes -- lower tax rates. Our earnings per share -- our Q1 earnings per share on a GAAP and non-GAAP basis was $1.05 to $1.83, respectively versus $1.25 and $1.75 for GAAP and non-GAAP in the prior year. Non-GAAP EPS on a pro forma basis, which adjusts for currency and acquisitions, were approximately 15% of the quarter. 
Looking at FX impact. The net currency impact on EPS year-over-year for Q1 was unfavorable by $0.18. This was $0.04 less than we guided as currencies were generally favorable to guidance range. Looking at the balance sheet liquidity. In Q1, we had cash provided by operations of $89.5 million, less capital expenditures of $45.1 million, resulting in $44.4 million of free cash flow. Excluding integration costs of $12.3 million, adjusted free cash flow was $56.7 million. Total debt increased within the quarter by $28.1 million to $1.377 billion primarily due to acquisitions, partially offset by operational cash flow generation. Inventories increased approximately $11.2 million to $430.9 million, up from last quarter, primarily due to an increase in data lenses for CooperVision and an increase due to acquisitions for CooperSurgical. For the quarter, we are seeing months on hand at 6.9 months. DSO was at 57 days, which is consistent with the prior quarter and last year. 
Before I get into guidance, let me comment on our senior credit facilities which we mentioned in our earnings release under Other. We entered the bank market a couple months ago to refinance our $100 billion revolver and raise a small term loans. We price these facilities as investment grade and we're pleasantly surprise with the demand. As such, we closed a five-year replacement of our $1 billion revolver and a new five-year $830 million term loan. We use the term loan proceeds to repay certain existing indebtedness and we'll be reducing our $700 million term loan, which matures in August 2017. Our overall activities were positive as it extends the life of our facilities at very favorable terms and conditions while providing additional flexibility through greater capacity. The financial impact we're expecting is for interest expense to be higher but roughly $1 million per quarter going forward. As Bob mentioned, this is offset by the higher operating income being generated by CooperSurgical. 
Now turning to guidance. Foreign exchange rates have been very volatile. It can have a large impact on our results. Now for guidance on our main currencies, we are using $1.07 for the euro, $1.15 for the yen and $1.38 for the pound. As our rate assumptions, we're expecting a negative impact to full year 2016 revenues or approximately $58 million and an unfavorable $0.41 impact to full-year 2016 EPS. By giving Q1 with a negative $22 million in revenues and $0.18 on EPS, we are looking at a negative $36 million of revenue or $0.23 for Q2 to Q4 with more the negative impact in Q2 and Q3. The negative revenue impact of $58 million is unchanged from our December guidance, which may be surprising. The positive moves from several currencies including the euro and yen are offset by the negative move in the pound, along with a few other currencies like the Russian ruble and the Brazilian real. Having said this, the earnings per share impact was negative as the pound is helping COGS in the back half of the year and positive moves in currencies like the yen are having a positive flow-through impact to our operating income. For 2016 guidance. The revenue range for the company is $1.865 billion to $1.905 billion or approximately 5% to 7% pro forma growth. CooperVision's revenue range is $1.51 billion to $1.54 billion or 5% to 7% constant currency growth. CooperSurgical's revenue range is $355 million to $365 million or 5% to 8% pro forma growth. We expect non-GAAP gross margin to be around 64% for the year. OpEx is expected to be around 40%. Operating margin is expected to be around 24%. Interest expense is expected to be around $24 million. Our effective tax rate is expected to be around 8%. Our expected share count will be around 49.2 million shares. Our non-GAAP EPS is expected to be in the range of $8 to $8.30, which equates to a pro forma EPS of 13% to 17% growth. CapEx is expected to be around $200 million. Adjusted free cash flow is expected to be around $300 million. With that, let me turn it back to Kim for the Q&A session."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Operator, we're ready to take some questions.",7,"Operator, we're ready to take some questions."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Joanne Wuensch of BMO Capital Markets.",16,"[Operator Instructions] Our first question comes from the line of Joanne Wuensch of BMO Capital Markets."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","I have 2 questions. The first one is what did you give for the year-over-year growth of silicone hydrogels? And can you help breakout how your daily silicone hydrogels are doing?",31,"I have 2 questions. The first one is what did you give for the year-over-year growth of silicone hydrogels? And can you help breakout how your daily silicone hydrogels are doing?"
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, Joanne, 2 things. Our year-over-year growth for silicone hydrogel was 13% for the entire family of 4, Affinity, Avaira, clariti and MyDay. For the 1 Day silicone hydrogel, it was 50% constant currency year-over-year.",35,"Yes, Joanne, 2 things. Our year-over-year growth for silicone hydrogel was 13% for the entire family of 4, Affinity, Avaira, clariti and MyDay. For the 1 Day silicone hydrogel, it was 50% constant currency year-over-year."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","And are you planning on launching any next-generation products beyond clariti and MyDay? I mean, I've been hearing about next gen Biofinity for example?",25,"And are you planning on launching any next-generation products beyond clariti and MyDay? I mean, I've been hearing about next gen Biofinity for example?"
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Let's say that our focus is on obviously, the 2 that we're in the middle of which is clariti and MyDay. There will be enhancements along the way of many of our family products. There will be extended ranges of the family and suffice it to say, you can cal",58,"Let's say that our focus is on obviously, the 2 that we're in the middle of which is clariti and MyDay. There will be enhancements along the way of many of our family products. There will be extended ranges of the family and suffice it to say, you can call those future generation upgrades  if you will."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Matt O'Brien of Piper Jaffray.",15,"And our next question comes from the line of Matt O'Brien of Piper Jaffray."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","This is actually, J.P. in for Matt. I'm trying to dig to what you changed in your core EPS for the full year. The $8 to $8.30 when I back out the $0.17 from FX reduction, plus the.$0.36 beat in the quarter. Is there anything changing in the core busines",61,"This is actually, J.P. in for Matt. I'm trying to dig to what you changed in your core EPS for the full year. The $8 to $8.30 when I back out the $0.17 from FX reduction, plus the.
$0.36 beat in the quarter. Is there anything changing in the core business or is that kind of flat from an EPS standpoint?"
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","So we had a $0.26 for the quarter of which $0.04 was foreign exchange compared to guidance or $0.22. And for the back 9 months, we improved it $0.15 in aggregate, $0.14 of which was foreign exchange and $0.01.",39,"So we had a $0.26 for the quarter of which $0.04 was foreign exchange compared to guidance or $0.22. And for the back 9 months, we improved it $0.15 in aggregate, $0.14 of which was foreign exchange and $0.01."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","It's actually, $0.14.",4,"It's actually, $0.14."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","$0.14 in aggregate of which $0.13 is foreign exchange and $0.01 is basically improvement in operations.",16,"$0.14 in aggregate of which $0.13 is foreign exchange and $0.01 is basically improvement in operations."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Chris Pasquale of JPMorgan.",13,"And our next question comes from the line of Chris Pasquale of JPMorgan."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Bob, I wanted to circle back on your comments about the slower growth and towards the multifocal's. I get that the U.S. is the biggest market for those products and you're facing some competitive headwinds there but the new competitive launches are primar",69,"Bob, I wanted to circle back on your comments about the slower growth and towards the multifocal's. I get that the U.S. is the biggest market for those products and you're facing some competitive headwinds there but the new competitive launches are primarily spheres if I'm not mistaken. So can you talk a little bit more about what's causing the slowdown in specialty lenses and how you reverse that?"
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","So the slowdown is really a function not at what's getting on a year-over-year tough comp which is U.S. dominant, if you will. We had 11% growth a year ago against that tough comp. Since the U.S. is so weighted to specialty lenses compared to outside the",138,"So the slowdown is really a function not at what's getting on a year-over-year tough comp which is U.S. dominant, if you will. We had 11% growth a year ago against that tough comp. Since the U.S. is so weighted to specialty lenses compared to outside the U.S. yet it shows up as to what appears to be a deceleration of growth of the lens in our specialty area towards multifocal's. Our expectation is we indicated several times is that the comps are easier post the first quarter, so we expect to return to a more normalized growth rate. It's built into our revenue guidance and certainly, that would impact especially -- heavily because of its U.S. orientation and it will also impact our gross margin going forward since specialty lenses carry a higher gross margin percent."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","And your next question comes from light of Brian Weinstein of William Blair.",13,"And your next question comes from light of Brian Weinstein of William Blair."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","It sounds like you guys are selling everything you can on MyDay but where are you guys sort of building out the capacity for it. It would seem to me that the demand is strong for that. Can you be looking to aggressively build up the capacity to some more",70,"It sounds like you guys are selling everything you can on MyDay but where are you guys sort of building out the capacity for it. It would seem to me that the demand is strong for that. Can you be looking to aggressively build up the capacity to some more product but I don't think I heard anything on the call about where you are on the next capacity build?"
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","As of today  we're still capacity constrained with MyDay. We are rolling out and shortly into Japan. We are ramping up very nicely . We're happy with that, and suffice it to say that within the next year, we will expect to say we are no longer capacity co",53,"As of today  we're still capacity constrained with MyDay. We are rolling out and shortly into Japan. We are ramping up very nicely . We're happy with that, and suffice it to say that within the next year, we will expect to say we are no longer capacity constrain even on MyDay."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Jeff Johnson of Robert Baird.",14,"And our next question comes from the line of Jeff Johnson of Robert Baird."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Maybe 2 questions. Bob, for you. Can you quantify at all the customer payouts in Europe? Is the CVI was 4% constant currency growth, what would have been ex those constant revenue payments. And then also, you mentioned clariti gross margin exiting in the",100,"Maybe 2 questions. Bob, for you. Can you quantify at all the customer payouts in Europe? Is the CVI was 4% constant currency growth, what would have been ex those constant revenue payments. And then also, you mentioned clariti gross margin exiting in the year accretive to company-wide. I think last call, you just talk about maybe going from a low 50s to the low 60s. My definition of accretive to gross margin would be kind of closer to 62, 63. Is that kind of a fair range of where you think those clariti gross margins go during the year?"
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","So on the first item, we're not going to get into the specifics of what concessions we made that impacted revenue but suffice it to say, Europe put up reasonably respectful numbers as -- in the a growth area at 8% constant currency. So that probably will",102,"So on the first item, we're not going to get into the specifics of what concessions we made that impacted revenue but suffice it to say, Europe put up reasonably respectful numbers as -- in the a growth area at 8% constant currency. So that probably will allow you to aged it a little. From the point of view of clariti being accretive, our intent is consistent with what Europe's estimate is that without the drag on our overall gross margin going into the acquisition of clariti and that would be, yes, north of that 62% to 63% range that you assessed."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Larry Keusch of Raymond James.",14,"And our next question comes from the line of Larry Keusch of Raymond James."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Just 2 quick ones. Bob, I think you mentioned roughly $200 million of CapEx spending for the year. Again just coming back to an earlier question around MyDay. Is there a scenario where you might decide to step that up a little bit to again improve your ab",78,"Just 2 quick ones. Bob, I think you mentioned roughly $200 million of CapEx spending for the year. Again just coming back to an earlier question around MyDay. Is there a scenario where you might decide to step that up a little bit to again improve your ability to supply MyDay? And then, the second question is UPP continues to hang around. If that goes away, what would your expectations for the market in the way Cooper's division?"
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, as far as could we do anything to accelerate the MyDay roll out by expanding our CapEx requirement, there are long lead times with MyDay. So we already put in place all of those -- all the orders so to speak and requirements to get that ramped up to",207,"Well, as far as could we do anything to accelerate the MyDay roll out by expanding our CapEx requirement, there are long lead times with MyDay. So we already put in place all of those -- all the orders so to speak and requirements to get that ramped up to where we need to. That's already in the works and built into our forecasted CapEx numbers and things that I indicated are going very well to plan in that arena. Relative to UPP if it went away or in the lateral pricing policy. If it went away tomorrow, I'm not sure there would be much of a significant impact on the industry or the competitive landscape. Suffice it to say, I think many independent eye care practitioners would figure it out that there are workarounds out there to UPP and maybe it's not all that it was cracked up to be when it first came out as a novel new idea. So as long as the eye care practitioners are being taken care of relative to servicing those that write the script, I think nothing major will have changed and license a lot if it went away and I'd be quite applaud that if it happened, actually."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","And the next question comes from the line of David Roman of Goldman Sachs.",14,"And the next question comes from the line of David Roman of Goldman Sachs."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","I want to just start on the competitive dynamic. You talked about in your prepared remarks under the traction J&J has gained but right now it doesn't look like the other large competitors facing significant headwinds. Can you maybe give us some perspectiv",65,"I want to just start on the competitive dynamic. You talked about in your prepared remarks under the traction J&J has gained but right now it doesn't look like the other large competitors facing significant headwinds. Can you maybe give us some perspective on how you expect the landscape to unfold as we pace through 2016 particularly as takes this sort of market recovery plan?"
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","You're correctly. The competitive landscape is pretty jumpy right now, if you will. A lot of changes within all of the competitors,, if you will. Alcon's undergoing a major restructuring within Novartis and they're pulling things out of what we used to ca",356,"You're correctly. The competitive landscape is pretty jumpy right now, if you will. A lot of changes within all of the competitors,, if you will. Alcon's undergoing a major restructuring within Novartis and they're pulling things out of what we used to call out Alcon and probably in the future won't -- I don't know what to call them as they deal with the name. But that's certainly, is not a handicap to us. J&J is not going through another assignment of executives in some of their key areas which is kind of a training ground for J&J in the contact lens space. So there's a change there. They, of course, put a lot of muscle or the executive that was transitioning out -- put a lot of muscle the last 2 months in the last 2 quarters in rolling out OASYS 1 Day. And other thoughts are in the work there. We like change in that sense. We like what J&J did by way of trying to accelerate the death,  if you will, of the 2 weeks space in the U.S. which they happen to own well North 80% of. So anytime they put their own franchise in play, I think other competitors like that. And whether it gross into the so-called when we -- so-called 1 Day or work to go into the 1 month that's putting it all in play. That's fine from our perspective. So we still think we're the 1 to be caught up with relative to complete portfolio of silicone hydrogel 1 Day and mass market and having a silicone hydrogel entry into the 1 Day premium market. So we think, we have the best deck of cards or hand of cards, if you will and like the way the industry continues to perform in good times and in bad times. So growth in the industry is there. Everything we've said about its trading up into 1 Day as a driver of the industry. The fact that it's 4x to 6x or 400% to 600% of revenue for the same patient, all of that is continuing to come about."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Matthew Mishan of KeyBanc.",13,"And our next question comes from the line of Matthew Mishan of KeyBanc."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","I've got 2 real quick. First, I was hoping you could about some of the Cooper specific things that you're doing in the Americas in response to J&J and daily surges that give us more confidence in our return to growth for you guys. And then, just secondly,",59,"I've got 2 real quick. First, I was hoping you could about some of the Cooper specific things that you're doing in the Americas in response to J&J and daily surges that give us more confidence in our return to growth for you guys. And then, just secondly, an update later out with the MyDay launch in Japan?"
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, first on what Cooper is doing. Cooper is continuing to execute its plan which was to roll out MyDay as a premium 1 Day silicone hydrogel and clariti as the mass market 1 Day silicone hydrogel with a complete family of torque, multifocal and fear. No",410,"Well, first on what Cooper is doing. Cooper is continuing to execute its plan which was to roll out MyDay as a premium 1 Day silicone hydrogel and clariti as the mass market 1 Day silicone hydrogel with a complete family of torque, multifocal and fear. Nothing is changing by way of our focus on executing that strategy. We still believe that silicone hydrogel belongs in the 1 Day space. And therefore the fact that 77% of the non-1 Day space is already silicone hydrogel, we still believe we have the right product portfolio in the right space and it will convert into silicone hydrogel as we go forward. And nothing in it -- any of the numbers we're looking at byways of growth of the 1 Day market or the growth of silicone hydrogel causes us to take pause in that view. The fact that J&J put up robust numbers, yes, they came up with a new product and yes, they distributed it widely and deeply. They had very easy comps from the prior year but some of that growth is anomalous. You may recall in the prior years, they were going through that transition where they were the only one that did adopt UPP or unilateral pricing policy for not only new products wherein we were dedicating a lot of time to the eye care professional to learn the new products. They decided to do it for the products they've had in the marketplace for 10 years. So there was nothing new about it. It was no surprise that the eye care professional had to dedicate a whole bunch of new time to learn the new technology but it was easy comps. So nothing changes from the point of view of our expectation as I pointed out, we had a very tough comps in the first quarter. We do not have the same top comps in the second, third, and fourth quarter. So our focus remains on execution. As far as MyDay in Japan, we are rolling it out literally this month, which is March. And we're not doing -- because of capacity limitations, anything like J&J OASYS 1 Day roll out where they hit everyone all over. So we'll be a much more orderly rollout that will be -- I wouldn't go crazy because of our capital limitation, our capacity limitations on having high expectations for significantly moving the needle on the top line this fiscal year."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Anthony Petrone of Jefferies.",13,"And our next question comes from the line of Anthony Petrone of Jefferies."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Two questions as well. Maybe Bob, could you just review for us where were silicone hydrogel daily as a's category just from a market standpoint and what you think it can go over time? And then, on the competitive front, there's been quite a bit of change",80,"Two questions as well. Maybe Bob, could you just review for us where were silicone hydrogel daily as a's category just from a market standpoint and what you think it can go over time? And then, on the competitive front, there's been quite a bit of change going on at Valiant. I'm just wondering if you seeing any changes in the presence of fashion lone in the market place due to these changes over the past 6 months or so?"
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, first of all, silicone hydrogel 1 Day today is around a little north of $600 million. It's sort of 20% of the 1 Day category, which is about $3 billion or north of that. We expect that $3 billion of t$7.4 billion industry,  if you will, to move to a",166,"Well, first of all, silicone hydrogel 1 Day today is around a little north of $600 million. It's sort of 20% of the 1 Day category, which is about $3 billion or north of that. We expect that $3 billion of t$7.4 billion industry,  if you will, to move to about 50% of a $10 billion industry constant currency provisional between now and 2020. So of that $10 billion in 2020 at current exchange rates, we expect half of it to be -- or $5 billion to be in the one-day modality and of that $5 billion, a lot more than 20%, suffice it to say, new parameter is someplace between that 20% which is rapidly going higher and the 77% that is in the non-1 Day modality, that will be someplace in the middle. And what can easily pick the middle of it and say about 50% of the $5 billion, which is 50% of the $10 billion is not a bad gauge for 2020."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from line of John Block of Stifel.",12,"And our next question comes from line of John Block of Stifel."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Let me just get to it upfront. First, can you elaborate a little bit more on the Biofinity and the bare writing, was up 7% year-over-year in the quarter. Since like a decent step down from the recent run rate. Is there something fluctuations there? And th",101,"Let me just get to it upfront. First, can you elaborate a little bit more on the Biofinity and the bare writing, was up 7% year-over-year in the quarter. Since like a decent step down from the recent run rate. Is there something fluctuations there? And then, second, I know you guys want to sort of stay away from a specific 2016 SiHy number but you still have the same expectations that SiHy daily accelerates from that mid-40% pro forma constant currency that you did in '15. In other words, can you maintain this 50-ish percent SiHy daily growth throughout '16?"
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Right. I'll do the latter 1 first. The expectation on the SiHy daily is that it will -- as you indicated, we expect higher growth in 2016 than 2015 and 2015 was mid-40s and this last quarter, in constant currency was 50%. So that we expect to hold or to e",143,"Right. I'll do the latter 1 first. The expectation on the SiHy daily is that it will -- as you indicated, we expect higher growth in 2016 than 2015 and 2015 was mid-40s and this last quarter, in constant currency was 50%. So that we expect to hold or to equal that or exceed it if you're going forward or to exceed 45% of last year for the entire fiscal year. So nothing has changed in our expectation on that and the rolled out there. Relative to Biofinity and Avaira which dropped below double-digit, for the first time in I think ever, at 7%. That 7% is basically anomalous relative to its concentration and -- particularly Avaira, primarily a U.S. product. So that concentration in the American -- Americas  we've sat down and we expect that to normalize going forward to be double-digit."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","[Operator Instructions] Our next question comes from line of Steve Willoughby of Cleveland Research.",14,"[Operator Instructions] Our next question comes from line of Steve Willoughby of Cleveland Research."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Bob, regarding the 1 Day silicone hydrogel market that you were just describing and going looking out to 2 years. I was wondering if you can talk about in particular you guys continue to add capacity there? Kind of where MyDay margins are today? Where are",119,"Bob, regarding the 1 Day silicone hydrogel market that you were just describing and going looking out to 2 years. I was wondering if you can talk about in particular you guys continue to add capacity there? Kind of where MyDay margins are today? Where are you expect MyDay margins to be once you have capacity and it's up and running? And just kind of from a particular perspective, it's my understanding that your other people's 1 Day silicone hydrogels don't have all that great of margins either. And so effectively a quarter of the market moves to one-day silicone hydrogel's over the next 4 years or so. Does that negatively impact the overall margin profile of the industry?"
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","On where is MyDay today? We indicated we expected it to move into the 20s. It is in the 20s as a gross margin. We, longer term expected to move into the 50s, which is more the traditional 1 Day modality, if you will, gross margin. We  relative to -- if al",260,"On where is MyDay today? We indicated we expected it to move into the 20s. It is in the 20s as a gross margin. We, longer term expected to move into the 50s, which is more the traditional 1 Day modality, if you will, gross margin. We  relative to -- if all silicone hydrogel move deeply into the 1 Day modality or as my model was $2.5 billion out of $5 billion out of $10 billion, $10 billion being total  $5 billion being 1 Day, [indiscernible] being silicone hydrogel in 2020, if that were to happen, given where we are with clariti as a mass market, high gross margin 1 Day silicone hydrogel, we think we would be a big enough prayer that it wouldn't undo the train of the entire industry. Having said that, there is no doubt that if we were comparing what the industry would be if it stayed and moved from 2 week and 1 Day into the market modality, where margins would be going up because by definition for monthly compared to the 1 Day, there is no doubt that a 1 Day modality is lower than a monthly modality. A 2 week noncompliant market which is defines our profiles, the U.S. market could only and should only do better no matter what -- where it goes because a noncompliant 2 week isn't an optimal gross margin and the industry is focusing in on how to make compliance better and the best way to do that is to lose the 2 week,, if you will."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our final question comes from the line of Larry Biegelsen of Wells Fargo.",14,"And our final question comes from the line of Larry Biegelsen of Wells Fargo."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Bob, 2 quick clarification and 1 real question. So on the concession, if you expect accelerate in the second quarters, so I know it ask earlier but if you can give us some sense of how much the suppress growth obviously help us understand the underlying t",58,"Bob, 2 quick clarification and 1 real question. So on the concession, if you expect accelerate in the second quarters, so I know it ask earlier but if you can give us some sense of how much the suppress growth obviously help us understand the underlying trends a little bit better. And second just on Joanne's question --"
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Can you come back on -- sorry, could you repeat that question?",12,"Can you come back on -- sorry, could you repeat that question?"
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Sorry, I'll try to speak up. The sales concessions, you're not giving us the number, how much the sales in the quarter but if impacts our ability to understand the underlying trends. And I know you expect to improve in the second quarter. So if you would",148,"Sorry, I'll try to speak up. The sales concessions, you're not giving us the number, how much the sales in the quarter but if impacts our ability to understand the underlying trends. And I know you expect to improve in the second quarter. So if you would give that, it would be helpful -- just a request and Biofinity, Joanne asked about a new version. So just to be clear, you talked about extended ranges, so it certainly, sounds like you're not ready to come out with a sphere version at UPP at 2016. Sorry, guys  just lastly for my real question, does J&J, if they do come out with a monthly lens, Bob, how do you see that for Cooper? Obviously, there's some rumors of that, that we haven't confirmed that but what would be the impact for Cooper if they come out with a monthly lens?"
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","All right, on the concessions, we indicated we were not going to disclose that for the same thing on the fourth quarter call. I think what other than pointing at the EMEA growth of 8% this being fairly robust, meaning, the factors that had gross margin, a",440,"All right, on the concessions, we indicated we were not going to disclose that for the same thing on the fourth quarter call. I think what other than pointing at the EMEA growth of 8% this being fairly robust, meaning, the factors that had gross margin, and I think Greg touched upon them on multiple and concessions is 1 but there clearly foreign exchange and the lag on that is another and quite frankly, the ramping up of MyDay while it's still in the lower gross margin category, all factor. So no one is driving our gross margin 61% and I think we indicated that we're expecting to be in around 64% by the end of the year to give you some indication where direction that will go. Relative to the new version Biofinity, I   so see extended range as an example of things that we we're doing particularly in the area of torque where the extended range, custom lenses matter and 1 of Cooper's claims to fame same and why we're so good at specialty lenses is we're very capable of customizing lenses and giving and addressing 100% of the audience instead of 80%. A lot of our competitors only worry about the Bell curve, the 80%. So when we talk about making by affinity even better, it's things like that. And whether or not we upgrade and add things that some of our competitors have done over the years when they have a product that's been around a long time. Will there be some refreshing of different things perhaps. But we're not going to get any further into that at this juncture. I would just think the extended range just to -- because it is a broadening of the family and the sales quality of the family. As far as J&J. If they move into the monthly, that will only further exacerbate the death of the 2 week. So who's to say they own -- north of 80% of the wear base in the 2 week space, they know better than anyone how noncompliant it is and they know if they can move people from the 2 week space to the monthly space and charge 30%, 40%, 50% or 60% for monthly higher than a 2 week noncompliant, they are much better off even if they don't get -- they have to get the lion's share but even if they don't get it all, as they put people in play. So we view -- net-net net, we view J&J activity putting the 2 week market in play as a plus for Cooper, as a plus for the industry."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","I would now like to turn the conference back to Bob Weiss for closing remarks.",15,"I would now like to turn the conference back to Bob Weiss for closing remarks."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, thank you. I want to thank everyone for joining us today. I hope you are as excited as I am about our start to the new year and our outlook for the new year. We look forward to updating you on our second quarter conference call, which I believe is J",115,"Well, thank you. I want to thank everyone for joining us today. I hope you are as excited as I am about our start to the new year and our outlook for the new year. We look forward to updating you on our second quarter conference call, which I believe is June 2. And in the interim, we'll be able to execute on a number of the things including the launch in Japan. So we will update you more on the progress we're making there as well as the continued expansion of MyDay and our success in the 1 Day silicone hydrogel space. So we look forward to updating you in early June. Thank you."
263609,325035985,947224,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","Ladies and gentlemen, thank you for participating today's conference. This does conclude the program. You may all disconnect. Everyone, have a great day.",23,"Ladies and gentlemen, thank you for participating today's conference. This does conclude the program. You may all disconnect. Everyone, have a great day."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Cooper Companies Inc. Q1 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to turn the conference over to Kim Duncan, Vice President, Inve",46,"Good day, ladies and gentlemen, and welcome to the Cooper Companies Inc. Q1 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to turn the conference over to Kim Duncan, Vice President, Investor Relations. Please, go ahead."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Good afternoon, and welcome to the Cooper Companies' First Quarter 2016 Earnings Conference Call. I'm Kim Duncan, Vice President of Investor Relations, and giving prepared remarks on today's call are: Bob Weiss, Chief Executive Officer; and Greg Matz, Chi",321,"Good afternoon, and welcome to the Cooper Companies' First Quarter 2016 Earnings Conference Call. I'm Kim Duncan, Vice President of Investor Relations, and giving prepared remarks on today's call are: Bob Weiss, Chief Executive Officer; and Greg Matz, Chief Financial Officer. 
Before we get started, I'd like to remind you that this conference call contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including all revenue and earnings per share guidance and other statements regarding anticipated results of operations, market or regulatory conditions and integration of any acquisitions or their future to achieve anticipated benefits. Forward-looking statements depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Events that could cause our actual results and future actions of the company to differ materially from those described in the forward-looking statements are set forth under the caption Forward-Looking Statements in today's earnings release and are described in our SEC filings, including the Business section of Cooper's annual report on Form 10-K. These are publicly available and on request from the company's Investor Relations department. 
Now before I turn the call over to Bob, let me comment on the agenda for the call. Bob will begin by providing highlights on the quarter, followed by Greg, who will then discuss the first quarter financial results. We will keep the formal presentation to roughly 30 minutes, then open the call for questions. We expect the call to last approximately 1 hour. We request that anyone asking questions, please limit yourself to 1 question. Should you have any additional questions, please call our Investor line at (925) 460-3663 or e-mail ir@coopercos.com. As a reminder, this call is being webcast and a copy of the earnings release is available through the Investor Relations section of the Cooper Companies website. And with that, I'll turn the call over to Bob for his opening remarks."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thank you, Kim, and good afternoon, everyone. Welcome to our first quarter 2016 conference call. We're off to a good start this year, and I am optimistic about our performance as we move forward. Let me start by touching on 3 key items: first, I'm pleased",1645,"Thank you, Kim, and good afternoon, everyone. Welcome to our first quarter 2016 conference call. We're off to a good start this year, and I am optimistic about our performance as we move forward. Let me start by touching on 3 key items: first, I'm pleased to report our fiscal first quarter financial results were strong. On a consolidated basis, we reported $450 million in revenue and non-GAAP earnings per share of $1.83. We are raising our fiscal 2016 revenue and earnings guidance to reflect this outperformance and to incorporate updated currency rates; second, CooperVision posted 4% constant currency revenue growth, which met expectations. As such, we are maintaining our 5% to 7% constant currency revenue guidance for CooperVision for the fiscal year; third, CooperSurgical had a strong quarter, posting revenue growth of 12% or 6% pro forma. This was especially impressive given non-GAAP operating margins expanded 400 basis points over Q1 of last year. As a result of this outperformance, we are raising CooperSurgical's full-year revenue guidance to 15% to 18% or 5% to 8% pro forma. I'll expand on these items as I walk through this quarter's performance, but suffice it to say I'm proud of where we stand and excited about the future. 
CooperVision reported Q1 revenues of $364 million, down 1% year-over-year but up 4% in constant currency. The Americas were down 3% in constant currency due to the tough comp and aggressive promotional activity by Johnson & Johnson, associated with their new Dailies silicon hydrogel product, which we discussed last quarter. Going forward, we expect the Americas to return to more normal growth starting in the second quarter. Regarding EMEA, sales grew 8% in constant currency. This was despite the Sauflon integration disruptions we discussed on our last earnings call. These disruptions ended in Q1 but resulted in certain customer concessions that reduced results. EMEA growth was driven by a full family of silicone hydrogel products, Biofinity, clariti, MyDay and Avaira. We also had a strong quarter in Asia Pacific, growing 12% in constant currency and this growth was also driven by our family of silicone hydrogel products. We expect both these regions to continue performing well going forward. 
Within our specialty business, overall Toric sales were up 4% year-over-year and multifocals were flat, both in constant currency. This was softer than in the prior quarters due to the Americas where -- which is the largest regions with these types of lenses. We remain a global leader in specialty lenses and expect sales to bounce back in Q2 as the Americas return to growth. Looking at silicone hydrogel lenses. This family of products delivered a strong growth of 13% in constant currency. Biofinity and Avaira combined to grow 7% in constant currency, with the only weakness being seen in the Americas. And again, we expect the Americas to rebound in Q2. We remain under indexed in the two-week and monthly silicon hydrogel space, with the market being roughly 77% silicone hydrogels and us at 72%, so we anticipate posting nice growth for many years to come. Regarding 1 Day silicone hydrogel lenses, sales of clariti and MyDay, grew a solid 50% in constant currency. We remain very optimistic about these products and are committed to our growth strategy, which includes a two-tiered approach, with clariti positioned as the mass market offering and MyDay as the premium offering. Remember the contact lens market is being driven by 1 Day growth, and we strongly believe we have the best product offering in the space as the only company with premium and mass market lenses, including a full portfolio of 1 Day, Sphere, Toric and multifocal lenses. Regarding production on these products, MyDay is ramping up nicely and we're selling everything we can make. Production is also extremely well, going extremely well for clariti, and we continue to expect clariti gross margins to be accretive to worldwide gross margins as we exit the fiscal year. 
Regarding Proclear, sales of this hydrogel product line were down 4% in constant currency, driven by our continuing shift to silicones. Before moving to market data, let me finish with a comment on CooperVision's non-GAAP adjustment. As expected, we had around $23 million in charges this quarter split roughly 60%, 40% between manufacturing and operating expenses. With the majority of the soft line integration behind us, we expect this number to decline to under $10 million in Q2, with most of the charges in cost of goods associated with accelerated depreciation, which relates to decisions we made last year. 
Now let me comment on CooperVision's performance against overall, the overall contact lens market. And remember, this information is on the last page of our earnings release. Counted for Q4, we continued taking market share, growing 6% with the market up 4%. Regarding the market, the underlying story with J&J's strength, due to a new product launch and easy comps, while Alcon's business was soft against difficult comps. Regionally, CVI grew 9% in EMEA with the market up 5%. In Asia PAC, CooperVision grew 12% with the market up 5% and in the Americas, CooperVision grew 1% with the market up 4%. If we look at the market on a modality basis, the single-use market continued driving growth with CVI up 14% and the market up 12%. For non-silicon use lenses, CVI grew 2% while the market declined 1%, and as you can see, our growth remains diverse and strong. For the full year -- calendar year 2015, CooperVision grew 7% in the market, grew 4%. Going forward, I expect the market to continue growing 4% to 6% over the next 5 years and most likely closer to 6%. The drivers will continue to be the shift to Dailies geographic expansion and expansion of the wearer base. We expect to continue taking market share, led by the strong silicone hydrogel portfolio. 
Moving to CooperSurgical. We reported Q1 revenues of $85 million, up 12% year-over-year or 6% pro forma. We made solid progress in our office and surgical business, growing 7% and in our fertility business, growing 6% both pro forma. These results are much stronger than our initial guidance and there are a number of ongoing activities which are driving this: First, we significantly increased our focus on sales during the fiscal fourth quarter of last year. This included existing products, new product launches and acquired products. This new emphasis was seen in our Q1 results and we believe it will continue through the year. Second, we are combining our office and surgical and fertility businesses, including transforming to a geographic sales focus. This is enabling us to cross-sell more effectively, which is especially beneficial with products such as our newly launched disposable hysteroscope, EndoSee, which sells to OB/GYN offices but also to fertility centers. This change will also allow us to better manage our infrastructure going forward and we'll reinvest those savings in sales and marketing to continue driving revenue growth. Third, as we continue to progress through the year, we'll be adding more sales personnel in under-penetrated areas and increasing our focus on high-growth areas such as genetic testing. We anticipate doing this while leveraging revenue growth to improve operating margins as we did in Q1. All in, CooperSurgical is clearly moving to a more aggressive and efficient business model, with a life sciences look and feel. 
With respect to CooperSurgical's products, the office and surgical business, comprises a diverse portfolio of roughly 600 products sold primarily to obstetricians and gynecologists. As I stated earlier, this product portfolio grew 7%, with strength in several key products. Within fertility, we grew 6% pro forma. Sales growth is still being negatively impacted by our strategic decision to exit low margin, non-CSI manufactured capital equipment. This will continue through Q2 but then, become largely immaterial in Q3. Also within fertility, our genetic testing business is performing extremely well. We entered these lab services faced with the acquisition of Reprogenetics last August and it's proving a very nice strategic sale. Lastly, we are complimentary, we added complimentary IVF products in mid-December, with the acquisition of Research Instruments and we also acquired a small fertility microneedle company at the beginning of February, which we expect to have roughly $1 million of revenue per quarter going forward. These deals are incorporated in our updated guidance. So overall, I'm very bullish on CooperSurgical. The passion drive of our surgical team is extremely high and I am really proud of their efforts and excited about our future. 
Now let me touch a little more on guidance. Our fiscal 2016 revenue guidance for CooperVision remains unchanged at 5% to 7% constant currency growth. We are raising our CooperSurgical revenue guidance to 5% to 8% pro forma growth or 15% to 18% on an as-reported basis. We're also raising our non-GAAP earnings per share guidance to $8 to $8.30, up 13% to 17% pro forma. For cash flow, we continue to expect around $300 million of adjusted free cash flow for fiscal 2016. 
In conclusion, we're continuing our successful strategy which we frequently articulated in the past. This includes investing to take market share by expanding geographically, aggressively rolling out new products and investing in emerging markets. We do this while remaining focused on growing earnings per share and cash flow to deliver strong shareholder value. I'm pleased with the results and happy the issues we encountered in the fourth quarter, such as the European Sauflon integration activity are behind us. I remain very optimistic about the underlying fundamentals of our businesses and I believe we are well-positioned to deliver strong results for fiscal 2016 and beyond. With that, let me express my appreciation to our employees, our #1 asset. Their hard work and dedication to creating value is the backbone of our success. And now, I'll turn it over to Greg to cover our financial results."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thanks, Bob, and good afternoon, everyone. Bob provided an overall summary of our performance, including a review of the market and our revenue picture. A bit of focus on primarily our non-GAAP results for the quarter. For the reconciliation to GAAP numbe",1362,"Thanks, Bob, and good afternoon, everyone. Bob provided an overall summary of our performance, including a review of the market and our revenue picture. A bit of focus on primarily our non-GAAP results for the quarter. For the reconciliation to GAAP numbers, please refer to our earnings release. Looking at gross margins. In Q1, the non-GAAP gross margin was 61.4% compared with 64.2% in the prior year. Factors which impacted our non-GAAP gross margins were a net unfavorable FX impact with the favorable U.K.-based cost of goods sold impact more than offset by the unfavorable revenue impact. In addition, product mix was a negative as the sales weakness Bob mentioned in the Americas hurt our margins as this region has the greatest amount of Toric and multifocal lenses, along with being a strong Biofinity franchise. We expect gross margins to rebound in Q2. CooperVision on a non-GAAP basis reported gross margin of 60.9% versus 64.2% in Q1 of last year. The factors which impacted our non-GAAP gross margin where the unfavorable net FX impact, as well as the product mix I just mentioned. CooperSurgical had non-GAAP gross margin of 63.6% which compares to Q1 '15 at 64%. Strength in the OB/GYN and IVF product families were offset by the inclusion of our 2 recent acquisitions, Reprogenetics and Research Instruments, which have lower gross margins. 
Now looking at operating expenses. On a non-GAAP basis, SG&A decreased approximately 3% to $161.8 million or 36% of revenue, down from approximately 38% the prior year. The primary driver behind this was a reduction in G&A where we saw leverage and good management of expenses within the businesses. Now looking at R&D. In Q1, R&D on a non-GAAP basis was $14.8 million or 3.3% of revenue, down from the 3.6% in the prior year. We are seeing investment in CSI offset by synergies from the Sauflon acquisition and CVI. 
Moving to operating margins. For Q1, consolidated GAAP operating income and margin were $57.4 million and 12.8% of revenue versus $73.1 million and 16.4% of revenue in Q1 last year. Non-GAAP operating income and margin were $99.4 million and 22.1% of revenue versus $102.6 million and 23% of revenue for the prior year. The difference in operating margin year-over-year is the reduction in gross margin we discussed, partially offset by operating expenses. In Q1, CooperVision's non-GAAP operating income and margin were $87.4 million and 24% of revenue versus $98.4 million and 26.6% of revenue in the prior year. CooperSurgical's non-GAAP operating income and margin were $22.8 million and 26.7% of revenue versus Q1 '15 at $17.5 million and 23.1% of revenue. Now looking at depreciation and amortization in Q1. Depreciation was $37.3 million, up $8 million year-over-year, which includes $6.1 million of accelerated depreciation related to the Sauflon acquisition, which we excluded in our non-GAAP numbers. Amortization was $16.2 million, up $2.6 million. The year-over-year amortization increase reflects recent acquisition activity. Interest expense was $5.3 million for the quarter, up $1.3 million year-over-year, primarily due to acquisitions and higher interest rates. Looking at the effective tax rate. In Q1, the non-GAAP effective tax rate was 3.9% versus a non-GAAP effective tax rate of 10.8% in Q1 '15. The year-over-year effective tax rate was favorably impacted by several items, including the release of reserves associated with a prior year tax filing which would normally have reversed in Q3 of 2017, as well as a reduction in the U.K. tax rate, which was enacted in November. Also note, as we've mentioned before, the effective tax rate continues to be below the U.S. statutorily rate as a majority of our income is earned in foreign jurisdictions with lower taxes -- or lower tax rates. Our earnings per share -- our Q1 earnings per share on a GAAP and non-GAAP basis was $1.05 and $1.83, respectively, versus $1.25 and $1.75 for GAAP and non-GAAP in the prior year. Non-GAAP EPS on a pro forma basis, which adjusts for currency and acquisitions, grew approximately 15% in the quarter. 
Looking at FX impact. The net currency impact on EPS year-over-year for Q1 was unfavorable by $0.18. This was $0.04 less than we guided as currencies were generally favorable to guidance rates. Looking at the balance sheet liquidity. In Q1, we had cash provided by operations of $89.5 million, less capital expenditures of $45.1 million, resulting in $44.4 million of free cash flow. Excluding integration cost of $12.3 million, adjusted free cash flow was $56.7 million. Total debt increased within the quarter by $28.1 million to $1.377 billion primarily due to acquisitions, partially offset by operational cash flow generation. Inventories increased approximately $11.2 million to $430.9 million, up from last quarter, primarily due to an increase in daily lenses for CooperVision and an increase due to acquisitions for CooperSurgical. For the quarter, we are seeing months on hand at 6.9 months. DSO was at 57 days, which is consistent with the prior quarter and last year. 
Before I get into guidance, let me comment on our senior credit facilities which we mentioned in our earnings release under Other. We entered the bank market a couple months ago to refinance our $100 billion revolver and raise a small term loan. We priced these facilities as investment grade and we're pleasantly surprised with the demand. As such, we closed a five-year replacement of our $1 billion revolver and a new five-year $830 million term loan. We use the term loan proceeds to repay certain existing indebtedness and we'll be reducing our $700 million term loan, which matures in August of 2017. Overall this activity is very positive as it extends the life of our facilities with very favorable terms and conditions, while providing additional flexibility through greater capacity. The financial impact we're expecting is for interest expense to be higher by roughly $1 million per quarter going forward. As Bob mentioned, this is offset by the higher operating income being generated by CooperSurgical. 
Now turning to guidance. Foreign exchange rates have been very volatile. It can have a large impact on our results. Now for guidance on our main currencies, we are using $1.07 for the euro, $1.15 for the yen and $1.38 for the pound. With our rate assumptions, we are expecting a negative impact to full year 2016 revenues of approximately $58 million and an unfavorable $0.41 impact to full-year 2016 EPS. By giving Q1 with a negative $22 million in revenues and $0.18 on EPS, we are looking at a negative $36 million of revenue or $0.23 for Q2 to Q4, with more of a negative impact in Q2 and Q3. The negative revenue impact of $58 million is unchanged from our December guidance, which may be surprising. The positive moves from several currencies including the euro and the yen are offset by the negative move in the pound, along with a few other currencies like the Russian ruble and the Brazilian real. Having said this, the earnings per share impact is less negative, as the pound is helping COGS in the back half of the year and positive moves in currencies like the yen are having a positive flow-through impact to our operating income. For 2016 guidance. The revenue range for the company is $1.865 billion to $1.905 billion or approximately 5% to 7% pro forma growth. CooperVision's revenue range is $1.51 billion to $1.54 billion or 5% to 7% constant currency growth. CooperSurgical's revenue range is $355 million to $365 million or 5% to 8% pro forma growth. We expect non-GAAP gross margin to be around 64% for the year. OpEx is expected to be around 40%. Operating margin is expected to be around 24%. Interest expense is expected to be around $24 million. Our effective tax rate is expected to be around 8%. Our expected share count will be around 49.2 million shares. Our non-GAAP EPS is expected to be in the range of $8 to $8.30, which equates to a pro forma EPS of 13% to 17% growth. CapEx is expected to be around $200 million. Adjusted free cash flow is expected to be around $300 million. With that, let me turn it back to Kim for the Q&A session."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Operator, we're ready to take some questions.",7,"Operator, we're ready to take some questions."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Joanne Wuensch of BMO Capital Markets.",16,"[Operator Instructions] Our first question comes from the line of Joanne Wuensch of BMO Capital Markets."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","I have 2 questions. The first one is, what did you give for the year-over-year growth of silicone hydrogels? And can you help breakout how did your Dailies silicone hydrogels are doing?",32,"I have 2 questions. The first one is, what did you give for the year-over-year growth of silicone hydrogels? And can you help breakout how did your Dailies silicone hydrogels are doing?"
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, Joanne, 2 things. Our year-over-year growth for silicone hydrogel was 13% for the entire family of 4, Biofinity, Avaira, clariti and MyDay. For the 1 Day silicone hydrogels, it was 50% constant currency year-over-year.",35,"Yes, Joanne, 2 things. Our year-over-year growth for silicone hydrogel was 13% for the entire family of 4, Biofinity, Avaira, clariti and MyDay. For the 1 Day silicone hydrogels, it was 50% constant currency year-over-year."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","And are you planning on launching any next-generation types of products beyond clariti and MyDay? I mean, I've been hearing about next gen Biofinity, for example?",27,"And are you planning on launching any next-generation types of products beyond clariti and MyDay? I mean, I've been hearing about next gen Biofinity, for example?"
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Let's say that our focus is on, obviously the 2 that we're in the middle of, which is clariti and MyDay. There will be enhancements along the way of many of our families' products. There will be extended ranges of the families and so suffice it to say, yo",59,"Let's say that our focus is on, obviously the 2 that we're in the middle of, which is clariti and MyDay. There will be enhancements along the way of many of our families' products. There will be extended ranges of the families and so suffice it to say, you can call those future generation upgrades, if you will."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Matt O'Brien of Piper Jaffray.",15,"And our next question comes from the line of Matt O'Brien of Piper Jaffray."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Hi everyone, this is actually J.P. in for Matt. My one is just on, I'm trying to dig into what you changed in your core EPS for the full year. The $8 to $8.30, when I back out the $0.17 from FX reduction, plus the $0.30 beat in the quarter, is there anyth",68,"Hi everyone, this is actually J.P. in for Matt. My one is just on, I'm trying to dig into what you changed in your core EPS for the full year. The $8 to $8.30, when I back out the $0.17 from FX reduction, plus the $0.30 beat in the quarter, is there anything changing in the core business or is that kind of flat, from an EPS standpoint?"
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","So we had a $0.26 peak for the quarter, of which $0.04 was foreign exchange, compared to guidance or $0.22. And for the back 9 months, we improved it $0.15 in aggregate, $0.14 of which was foreign exchange and $0.01. Did I get it?",44,"So we had a $0.26 peak for the quarter, of which $0.04 was foreign exchange, compared to guidance or $0.22. And for the back 9 months, we improved it $0.15 in aggregate, $0.14 of which was foreign exchange and $0.01. Did I get it?"
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","$0.13.",1,"$0.13."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","It's actually $0.14 in aggregate, of which $0.13 is foreign exchange and $0.01 is basically improvement in operations.",19,"It's actually $0.14 in aggregate, of which $0.13 is foreign exchange and $0.01 is basically improvement in operations."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Chris Pasquale of JPMorgan.",13,"And our next question comes from the line of Chris Pasquale of JPMorgan."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Bob, I wanted to circle back on your comments about the slower growth and towards the multifocals. I get that the U.S. is the biggest market for those products and you're facing some competitive headwinds there, but the new competitive launches are primar",69,"Bob, I wanted to circle back on your comments about the slower growth and towards the multifocals. I get that the U.S. is the biggest market for those products and you're facing some competitive headwinds there, but the new competitive launches are primarily Spheres, if I'm not mistaken. So can you talk a little bit more about what's causing the slowdown in specialty lenses and how you reverse that?"
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","So the slowdown is really a function, not of what's getting on, it's year-over-year tough comps, which is U.S. dominant, if you will. We had 11% growth a year ago, and so it's against that tough comp. Since the U.S. is so weighted to specialty lenses comp",141,"So the slowdown is really a function, not of what's getting on, it's year-over-year tough comps, which is U.S. dominant, if you will. We had 11% growth a year ago, and so it's against that tough comp. Since the U.S. is so weighted to specialty lenses compared to outside the U.S. yet it shows up as what appears to be a deceleration of the growth of the lenses in our specialty area towards in multifocals. Our expectation is, we indicated several times is that the comps are easier post the first quarter, so we expect to return to a more normalized growth rate. It's built into our revenue guidance and certainly, that would impact, especially -- heavily, because of its U.S. orientation, and it will also impact our gross margin going forward, since specialty lenses carry a higher gross margin percent."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","And your next question comes from light of Brian Weinstein of William Blair.",13,"And your next question comes from light of Brian Weinstein of William Blair."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","It sounds like you guys are selling everything you can on MyDay but where are you guys sort of building out the capacity for that? It would seem to me that if demand is strong for that, that you're going to be looking to aggressively build up the capacity",71,"It sounds like you guys are selling everything you can on MyDay but where are you guys sort of building out the capacity for that? It would seem to me that if demand is strong for that, that you're going to be looking to aggressively build up the capacity in some more product, but I don't think I heard anything on the call about where you are on that capacity build?"
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","As of today, we're still capacity constrained with MyDay. We are rolling out shortly into Japan. We are ramping up very nicely. We're happy with that, and suffice it to say that, within the next year, we will expect to say we are no longer capacity constr",50,"As of today, we're still capacity constrained with MyDay. We are rolling out shortly into Japan. We are ramping up very nicely. We're happy with that, and suffice it to say that, within the next year, we will expect to say we are no longer capacity constrained, even on MyDay."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Jeff Johnson of Robert Baird.",14,"And our next question comes from the line of Jeff Johnson of Robert Baird."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Maybe two questions. Bob, for you. Can you quantify at all the customer payouts in Europe? If CVI was 4% constant currency growth, what would it have been x those, I believe were constant revenue payments. And then also, you mentioned clariti gross margin",102,"Maybe two questions. Bob, for you. Can you quantify at all the customer payouts in Europe? If CVI was 4% constant currency growth, what would it have been x those, I believe were constant revenue payments. And then also, you mentioned clariti gross margin exiting the year accretive to company-wide. I think last call, you just talked about maybe going from the low 50%s to the low 60%s. My definition of accretive to gross margin would be kind of closer to 62%, 63%. Is that kind of a fairer range of where you think those clariti gross margins go during the year?"
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","So on the first item, we're not going to get into the specifics of what concessions we made that impacted revenue, but suffice it to say, Europe put up reasonably respectful numbers as -- in the growth area at 8% constant currency. So that probably will a",103,"So on the first item, we're not going to get into the specifics of what concessions we made that impacted revenue, but suffice it to say, Europe put up reasonably respectful numbers as -- in the growth area at 8% constant currency. So that probably will allow you to gauge it a little. From the point of view of clariti being accretive, our intent is consistent with what your assessment is that it would not be a drag on our overall gross margin going into the acquisition of clariti, and that would be, yes, north of that 62%, 63% range that you assessed."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Larry Keusch of Raymond James.",14,"And our next question comes from the line of Larry Keusch of Raymond James."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Just two quick ones. Bob, I think you mentioned roughly $200 million of CapEx spending for the year. Again, just coming back to an earlier question around MyDay. Is there a scenario where you might decide to step that up a little bit to, again improve you",79,"Just two quick ones. Bob, I think you mentioned roughly $200 million of CapEx spending for the year. Again, just coming back to an earlier question around MyDay. Is there a scenario where you might decide to step that up a little bit to, again improve your ability to supply MyDay? And then, the second question is, UPP continues to hang around. If that goes away, what would your expectations be for the market in the way Cooper's positioned?"
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","So as far as could we do anything to accelerate the MyDay roll out by expanding our CapEx requirements, there are long lead times with MyDay. So we've already put in place all of those -- all the orders, so to speak, and requirements to get that ramped up",204,"So as far as could we do anything to accelerate the MyDay roll out by expanding our CapEx requirements, there are long lead times with MyDay. So we've already put in place all of those -- all the orders, so to speak, and requirements to get that ramped up to where we need to. That's already in the works, and built into our forecasted CapEx numbers. And things that I indicated are going very well, to plan in that arena. Relative to UPP, if it went away or unilateral pricing policy, if it went away tomorrow, I'm not sure there would be much of a significant impact on the industry or the competitive landscape. Suffice it to say, I think many independent eye care practitioners figured out that there are workarounds out there to UPP, and maybe it's not all that it was cracked up to be when it first came out as a novel new idea. So as long as the eye care practitioners are being taken care of, relative to servicing those that write the script, I think nothing major will have changed and life would go on if it went away, and I'd be, I'd applaud that if it happened, actually."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of David Roman of Goldman Sachs.",14,"And our next question comes from the line of David Roman of Goldman Sachs."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","I wanted just to start back on the competitive dynamic. You talked about in your prepared remarks under the traction J&J has gained, but right now it doesn't look like the other large competitor is facing some fairly significant headwind. Can you maybe gi",70,"I wanted just to start back on the competitive dynamic. You talked about in your prepared remarks under the traction J&J has gained, but right now it doesn't look like the other large competitor is facing some fairly significant headwind. Can you maybe give us some perspective on how you expect the landscape to unfold as we pace through 2016, particularly as Alcon undertakes this sort of market recovery plan?"
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","You're correct. The competitive landscape is pretty jumpy right now, if you will. A lot of changes within all of the competitors, if you will. Alcon's undergoing a major restructuring within Novartis and they're pulling things out of what we used to call",361,"You're correct. The competitive landscape is pretty jumpy right now, if you will. A lot of changes within all of the competitors, if you will. Alcon's undergoing a major restructuring within Novartis and they're pulling things out of what we used to call Alcon, and will probably in the future, won't -- I don't know what to call, they'll deal with the name. But that's certainly is not a handicap to us. J&J is not going through another assignment of executives in some of their key areas which is kind of a training ground for J&J in the contact lens space. So there's a change there. They, of course, put a lot of muscle or the executive that was transitioning out, put a lot of muscle the last 2 months in, the last 2 quarters in rolling out OASYS 1 Day. And other thoughts are in the work there. We like change in that sense. We like some of what J&J did by way of trying to accelerate the death,  if you will, of the 2 week space in the U.S. which they happen to own well north 80% of. So anytime they put their own franchise in play, I think all the competitors like that. And whether it goes into what the so-called one week, the so-called 1 Day, or were to go into the 1 month that's putting it all in play. That's fine from our perspective. So we still think we're the one to be caught up with, relative to a complete portfolio of silicone hydrogel 1 Day and at both the mass market and having a silicone hydrogel entry into the 1 Day premium market. So we think we have the best deck of cards or hand of cards, if you will and like the way the industry continues to perform in good times and in bad times. So the growth of the industry is there. Everything we've said about, trading up into 1 Day as a driver of the industry. The fact that it's 4x to 6x or 400% to 600% more revenue for the same patient, all of that is continuing to come about."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Matthew Mishan of KeyBanc.",13,"And our next question comes from the line of Matthew Mishan of KeyBanc."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","I got 2 real quick. First, I was hoping you could about some of the Cooper specific things that you're doing in the Americas in response to J&J and their resurgence, that give us more confidence in a return to growth for you guys. And then, just secondly,",60,"I got 2 real quick. First, I was hoping you could about some of the Cooper specific things that you're doing in the Americas in response to J&J and their resurgence, that give us more confidence in a return to growth for you guys. And then, just secondly, an update on where you're at with the MyDay launch in Japan?"
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well first on what Cooper is doing. Cooper is continuing to execute its plan, which was to roll out MyDay as a premium 1 Day silicone hydrogel and clariti as the mass market 1 Day silicone hydrogel with a complete family of Toric, multifocal and Sphere. N",416,"Well first on what Cooper is doing. Cooper is continuing to execute its plan, which was to roll out MyDay as a premium 1 Day silicone hydrogel and clariti as the mass market 1 Day silicone hydrogel with a complete family of Toric, multifocal and Sphere. Nothing is changing by way of our focus on executing that strategy. We still believe that silicone hydrogel belongs in the 1 Day space. And therefore, the fact that 77% of the non-1 Day space is already silicone hydrogel, we still believe we have the right product portfolio in the right space, and it will convert into silicone hydrogel as we go forward. And nothing in it -- any of the numbers we're looking at by way of growth of the 1 Day market or the growth of silicone hydrogels causes us to take pause in that view. The fact that J&J put up robust numbers, yes, they came out with a new product and yes, they distributed it widely and deeply. They had very easy comps from the prior year, though some of that growth is anomalous. And you may recall in the prior years, they were going through that transition where they were the only one that did adopt UPP or unilateral pricing policy for not only new products wherein we were dedicating a lot of time to the eye care professional to learn the new products. They decided to do it for the products they've had in the marketplace for 10 years. So there was nothing new about it. There was no reason to think that the eye care professional had to dedicate a whole bunch of new time to learn the new technology, but it was easy comps. So nothing changes from the point of view of our expectation as I pointed out, we had a very tough comps in the first quarter. We do not have those same tough comps in the second, third, and fourth quarters. So our focus remains on execution. As far as MyDay in Japan, we are rolling it out, literally this month, which is March. And we're not doing -- because of capacity limitations, anything like the J&J OASYS 1 Day roll out where they hit everyone all over, so it will be a much more orderly rollout that will -- I wouldn't go crazy because of our capital limitations, or our capacity limitations on having high expectations for significantly moving the needle on the top line this fiscal year."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Anthony Petrone of Jefferies.",13,"And our next question comes from the line of Anthony Petrone of Jefferies."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Two questions as well. Maybe Bob, could you just review for us where silicone hydrogel Dailies as a category is today, just from a market standpoint, and what you think it can go over time? And then, on the competitive front, there's been quite a bit of c",82,"Two questions as well. Maybe Bob, could you just review for us where silicone hydrogel Dailies as a category is today, just from a market standpoint, and what you think it can go over time? And then, on the competitive front, there's been quite a bit of change going on at Valiant. I'm just wondering if you're seeing any changes in the presence of Bausch & Lomb in the market place, due to these changes over the past 6 months or so."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Okay, well first of all, silicone hydrogel 1 Day today is around a little north of $600 million. It's sort of 20% of the 1 Day category, which is about $3 billion, a little north of that. We expect that $3 billion of $7.4 billion industry,  if you will, t",169,"Okay, well first of all, silicone hydrogel 1 Day today is around a little north of $600 million. It's sort of 20% of the 1 Day category, which is about $3 billion, a little north of that. We expect that $3 billion of $7.4 billion industry,  if you will, to move to about 50% of a $10 billion industry, constant currency provisional between now and 2020. So of that $10 billion in 2020 at current exchange rates, we expect half of it to be -- or $5 billion to be in the one-day modality, and that, of that $5 billion, a lot more than 20%, suffice it to say, your parameter is someplace between that 20%, which is rapidly going higher, and the 77% that is in the non-1 Day modality, it will be someplace in the middle. And one could easily pick the middle of it and say about 50% of the $5 billion, which is 50% of the $10 billion, is not a bad gauge for 2020."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from line of John Block of Stifel.",12,"And our next question comes from line of John Block of Stifel."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Let me just try to get in two upfront. First, can you elaborate a little bit more on the Biofinity, and Avaira, I think it was up 7% year-over-year in the quarter. Seems like a decent step down from the recent run rate. Is there some inventory fluctuation",105,"Let me just try to get in two upfront. First, can you elaborate a little bit more on the Biofinity, and Avaira, I think it was up 7% year-over-year in the quarter. Seems like a decent step down from the recent run rate. Is there some inventory fluctuations there? And then, second, I know you guys want to sort of stay away from a specific 2016 SiHy number, but you still have the same expectations that SiHy Dailies accelerates from that mid-40% pro forma constant currency that you did in '15. In other words, can you maintain this 50-ish percent SiHy daily growth throughout '16?"
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Right. I'll do the latter one first. The expectation on the SiHy daily is that it will -- as you indicated, we expect higher growth in 2016 than 2015, and 2015 was mid-40s and this last quarter, in constant currency was 50%. So that we expect to hold or t",145,"Right. I'll do the latter one first. The expectation on the SiHy daily is that it will -- as you indicated, we expect higher growth in 2016 than 2015, and 2015 was mid-40s and this last quarter, in constant currency was 50%. So that we expect to hold or to equal that or exceed it, if you were going forward or at least exceed the 45% of last year for the entire fiscal year. So nothing has changed in our expectation on that, and the rollout there. Relative to Biofinity and Avaira, which dropped below double-digit, for the first time in I think, ever, at 7%. That 7% is basically anomalous relative to its concentration in, particularly Avaira, primarily a U.S. product. And so that concentration in the American -- Americas, we've sat down and we expect that to normalize going forward and be double-digit."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","[Operator Instructions] Our next question comes from line of Steve Willoughby of Cleveland Research.",14,"[Operator Instructions] Our next question comes from line of Steve Willoughby of Cleveland Research."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Bob, regarding the 1 Day silicone hydrogel market that you were just describing, and going, looking out a few years. I was wondering if you could talk about, and particularly in light of you guys continuing to add capacity there? Kind of where MyDay margi",123,"Bob, regarding the 1 Day silicone hydrogel market that you were just describing, and going, looking out a few years. I was wondering if you could talk about, and particularly in light of you guys continuing to add capacity there? Kind of where MyDay margins are today? Where do you expect MyDay margins to be, once you have capacity and it's up and running? And just kind of from a particular perspective, it's my understanding that other people's 1 Day silicone hydrogels don't have all that great of margins either. And so if effectively a quarter of the market moves to 1 Day silicone hydrogels over the next 4 years or so, does that negatively impact the overall margin profile of the industry?"
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","So on where is MyDay today. We indicated we expected it to move into the 20s. It is in the 20s as a gross margin. We, longer term, expect it to move into the 50s, which is more the traditional 1 Day modality, if you will, gross margin. We, relative to --",265,"So on where is MyDay today. We indicated we expected it to move into the 20s. It is in the 20s as a gross margin. We, longer term, expect it to move into the 50s, which is more the traditional 1 Day modality, if you will, gross margin. We, relative to -- if all the silicone hydrogel moves deeply into the 1 Day modality, or as my model was, $2.5 billion out of $5 billion out of $10 billion, $10 billion being total, $5 billion being 1 Day, $2.5 billion being silicone hydrogel in 2020, if that were to happen, given where we are with clariti as a mass market, high gross margin 1 Day silicone hydrogel, we think we would be a big enough player that it wouldn't put a, undue drain on the entire industry. Having said that, there is no doubt that if we were comparing what the industry would be if it stayed and moved from 2 weekend, 1 Day into the monthly modality, where margins would be going up because, by definition, they're monthlies, compared to the 1 Day, there is no doubt that a 1 Day modality is lower than a monthly modality. A 2 week noncompliant market which is, defines our profiles, the U.S. market could only and should only do better, no matter what you -- where it goes, because a noncompliant 2 week isn't an optimal gross margin and the industry is focusing in on how to make compliance better and the best way to do that is kill off the 2 week, if you will."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our final question comes from the line of Larry Biegelsen of Wells Fargo.",14,"And our final question comes from the line of Larry Biegelsen of Wells Fargo."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Just, Bob, two quick clarifications and one real question. So on the sales concessions, if you expect to accelerate in the second quarters, so I know it was asked earlier, but if you could give us some sense of how much that suppressed growth, it obviousl",63,"Just, Bob, two quick clarifications and one real question. So on the sales concessions, if you expect to accelerate in the second quarters, so I know it was asked earlier, but if you could give us some sense of how much that suppressed growth, it obviously help us understand the underlying trends a little bit better. And second, just on Joanne's question --"
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Larry, can you come back on -- Larry, could you repeat that question?",13,"Larry, can you come back on -- Larry, could you repeat that question?"
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","You're a little hard to hear Larry, a little light.",11,"You're a little hard to hear Larry, a little light."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Sorry, guys, the sales -- I'll try to speak up. The sales concessions, you're not giving us the number, how much it depressed sales in the quarter, but if it impacts our ability to understand the underlying trends, so. And I know you expect to improve in",162,"Sorry, guys, the sales -- I'll try to speak up. The sales concessions, you're not giving us the number, how much it depressed sales in the quarter, but if it impacts our ability to understand the underlying trends, so. And I know you expect to improve in the second quarter. So if you would give that, it would be helpful, but -- anyway, that just a request. And then, on Biofinity, Joanne asked about another, new version. So just to be clear, you talked about extended ranges, so it certainly, it sounds like you're not planning to come out with a Sphere version with UPP in 2016. And sorry, guys, just lastly, for my real question. Does J&J, if they do come out with a monthly lens, Bob, how do you see that for Cooper? Obviously, there's some rumors of that, that we haven't confirmed it but what would be the impact for Cooper if they come out with a monthly lens?"
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","All right, on the concessions, so, yes, we indicated we were not going to disclose that. We said the same thing on the fourth quarter call. I think what, other than me pointing you at the EMEA growth of 8% as being fairly robust, meaning, the factors that",442,"All right, on the concessions, so, yes, we indicated we were not going to disclose that. We said the same thing on the fourth quarter call. I think what, other than me pointing you at the EMEA growth of 8% as being fairly robust, meaning, the factors that hit gross margin, and I think Greg touched upon them, are multiple and concessions is one, but they're clearly foreign exchange and the lag on that is another, and quite frankly, the ramping up of MyDay, while it's still in a lower gross margin category, it all factors. So it's -- no one is driving our gross margin of 61% and I think we indicated we're expecting to be in around 64% by the end of the year to give you some indication where, direction that will go. Relative to, of the new version Biofinity, I, you see extended range as an example of things that we we're doing, particularly in the area of Torics, where extended ranges, custom lenses matter, and 1 of Cooper's claims to fame, and why we're so good in specialty lenses is, we're very capable of customizing lenses, in giving and addressing 100% of the audience, instead of 80%. A lot of our competitors only worry about the Bell curve, the 80%. So when we talk about making Biofinity even better, it's things like that. And whether or not we upgrade and add things that some of our competitors have done over the years when they have a product that's been around a long time, will there be some refreshing of different things? Perhaps. But we're not -- go any further into that at this juncture. I was using the extended range just to -- because it is a broadening of the family and availability of the family. As far as J&J, if they move into the monthly, that will only further exacerbate the death of the 2 week. So who's to say they own  north of 80% of the wearer base in the 2 week space. They know better than anyone how noncompliant it is, and they know if they can move people from the 2 week space to the monthly space and charge 30%, 40%, 50% or 60% for a monthly higher than a 2 week noncompliant, they are much better off, even if they don't get -- they have to get the lion's share, but even if they don't get it all, as they put people in play. So we view -- net-net net, we view J&J activity putting the 2 week market in play as a plus for Cooper, as a plus for the industry."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","I would now like to turn the conference back to Bob Weiss for closing remarks.",15,"I would now like to turn the conference back to Bob Weiss for closing remarks."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, thank you. I want to thank everyone for joining us today. I hope you're as excited as I am about our start to the new year and our outlook for the new year. We look forward to updating you on our second quarter conference call, which I believe is Ju",113,"Well, thank you. I want to thank everyone for joining us today. I hope you're as excited as I am about our start to the new year and our outlook for the new year. We look forward to updating you on our second quarter conference call, which I believe is June 2. And in the interim, we'll be able to execute on a number of the things, including the launch in Japan. So we'll update you more on the progress we're making there, as well as a continued expansion of MyDay, and our success in the 1 Day silicone hydrogel space. So we look forward to updating you in early June. Thank you."
263609,325035985,947338,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may all disconnect. Everyone, have a great day.",24,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may all disconnect. Everyone, have a great day."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Cooper Companies Inc. Q1 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to turn the conference over to Kim Duncan, Vice President, Inve",46,"Good day, ladies and gentlemen, and welcome to the Cooper Companies Inc. Q1 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to turn the conference over to Kim Duncan, Vice President, Investor Relations. Please, go ahead."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Good afternoon, and welcome to the Cooper Companies' First Quarter 2016 Earnings Conference Call. I'm Kim Duncan, Vice President of Investor Relations, and giving prepared remarks on this call are: Bob Weiss, Chief Executive Officer; and Greg Matz, Chief",321,"Good afternoon, and welcome to the Cooper Companies' First Quarter 2016 Earnings Conference Call. I'm Kim Duncan, Vice President of Investor Relations, and giving prepared remarks on this call are: Bob Weiss, Chief Executive Officer; and Greg Matz, Chief Financial Officer. 
Before we get started, I'd like to remind you that this conference call contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including all revenue and earnings per share guidance and other statements regarding anticipated results of operations, market or regulatory conditions and integration of any acquisitions or their future to achieve anticipated benefits. Forward-looking statements depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Events that could cause our actual results and future actions of the company to differ materially from those described in the forward-looking statements are set forth under the caption Forward-Looking Statements in today's earnings release and are described in our SEC filings, including the Business section of Cooper's annual report on Form 10-K. These are publicly available and on request from the company's Investor Relations department. 
Now before I turn the call over to Bob, let me comment on the agenda for the call. Bob will begin by providing highlights on the quarter, followed by Greg, who will then discuss the first quarter financial results. We will keep the formal presentation to roughly 30 minutes, then open the call for questions. We expect the call to last approximately 1 hour. We request that anyone asking questions, please limit yourself to 1 question. Should you have any additional questions, please call our Investor line at (925) 460-3663 or e-mail ir@cooperco.com. As a reminder, this call is being webcast and a copy of the earnings release is available through the Investor Relations section of the Cooper Companies website. And with that, I'll turn the call over to Bob for his opening remarks."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thank you, Kim, and good afternoon, everyone. Welcome to our first quarter 2016 conference call. We're off to a good start this year, and I am optimistic about our performance as we move forward. Let me start by touching on 3 key items: First, I'm pleased",1647,"Thank you, Kim, and good afternoon, everyone. Welcome to our first quarter 2016 conference call. We're off to a good start this year, and I am optimistic about our performance as we move forward. Let me start by touching on 3 key items: First, I'm pleased to report our fiscal first quarter financial results were strong. On a consolidated basis, we reported $450 million in revenue and non-GAAP earnings per share of $1.83. We are raising our fiscal 2016 revenue and earnings guidance to reflect this outperformance and to incorporate updated currency rates. Second, CooperVision posted 4% constant currency revenue growth, which met expectations. As such, we are maintaining our 5% to 7% constant currency revenue guidance for CooperVision for the fiscal year. Third, CooperSurgical had a strong quarter, posting revenue growth of 12% or 6% pro forma. This was especially impressive given non-GAAP operating margins expanded 400 basis points over Q1 of last year. As a result of this outperformance, we are raising CooperSurgical's full-year revenue guidance to 15% to 18% or 5% to 8% pro forma. I'll expand on these items as I walk through this quarter's performance, but suffice it to say, I'm proud of where we stand and excited about the future. 
CooperVision reported Q1 revenues of $364 million, down 1% year-over-year, but up 4% in constant currency. The Americas were down 3% in constant currency due to the tough comp and aggressive promotional activity by Johnson & Johnson, associated with their new daily silicone hydrogel product, which we discussed last quarter. Going forward, we expect the Americas to return to more normal growth starting in the second quarter. Regarding EMEA, sales grew 8% in constant currency. This was despite the Sauflon integration disruptions we discussed on our last earnings call. These disruptions ended in Q1, but resulted in certain customer concessions that reduced results. EMEA growth was driven by a full family of silicone hydrogel products, Biofinity, clariti, MyDay and Avaira. We also had a strong quarter in Asia Pacific, growing 12% in constant currency and this growth was also driven by our family of silicone hydrogel products. We expect both these regions to continue performing well going forward. 
Within our specialty business, overall Toric sales were up 4% year-over-year and multifocals were flat, both in constant currency. This was softer than in the prior quarters due to the Americas where -- which is the largest regions for these types of lenses. We remain a global leader in specialty lenses and expect sales to bounce back in Q2 as the Americas returns to growth. Looking at silicone hydrogel lenses. This family of products delivered a strong growth of 13% in constant currency. Biofinity and Avaira combined to grow 7% in constant currency, with the only weakness being seen in the Americas. And again, we expect the Americas to rebound in Q2. We remain under indexed in the 2-week and monthly silicone hydrogel space, with the market being roughly 77% silicone hydrogels and us at 72%, so we anticipate posting nice growth for many years to come. Regarding 1 Day silicone hydrogel lenses, sales of clariti and MyDay, grew a solid 50% in constant currency. We remain very optimistic about these products and are committed to our growth strategy, which includes a 2-tiered approach, with clariti positioned as the mass market offering and MyDay as the premium offering. Remember the contact lens market is being driven by 1 Day growth, and we strongly believe we have the best product offering in the space as the only company with premium and mass market lenses, including a full portfolio of 1 Day, Sphere, Toric and multifocal lenses. Regarding production on these products, MyDay is ramping up nicely and we're selling everything we can make. Production is also extremely well, going extremely well for clariti, and we continue to expect clariti gross margins to be accretive to worldwide gross margins as we exit the fiscal year. 
Regarding Proclear, sales of this hydrogel product line were down 4% in constant currency, driven by our continuing shift to silicones. Before moving to market data, let me finish with a comment on CooperVision's non-GAAP adjustments. As expected, we had around $23 million in charges this quarter split roughly 60%, 40% between manufacturing and operating expenses. With the majority of the soft line integration behind us, we expect this number to decline to under $10 million in Q2, with most of the charges in cost of goods associated with accelerated depreciation, which relates to decisions we made last year. 
Now let me comment on CooperVision's performance against overall, the overall contact lens market. And remember, this information is on the last page of our earnings release. For calendar Q4, we continued taking market share, growing 6% with the market up 4%. Regarding the market, the underlying story with J&J's strength, due to a new product launch and easy comps, while Alcon's business was soft against difficult comps. Regionally, CVI grew 9% in EMEA with the market up 5%. In Asia PAC, CooperVision grew 12% with the market up 5% and in the Americas, CooperVision grew 1% with the market up 4%. If we look at the market on a modality basis, the single-use market continued driving growth with CVI up 14% and the market up 12%. For non-silicone use lenses, CVI grew 2% while the market declined 1%, and as you can see, our growth remains diverse and strong. For the full year -- calendar year 2015, CooperVision grew 7% and the market grew 4%. Going forward, I expect the market to continue growing 4% to 6% over the next 5 years and most likely closer to 6%. The drivers will continue to be the shift to Dailies geographic expansion and expansion of the wearer base. We expect to continue taking market share, led by the strong silicone hydrogel portfolio. 
Moving to CooperSurgical. We reported Q1 revenues of $85 million, up 12% year-over-year or 6% pro forma. We made solid progress in our office and surgical business, growing 7% and in our fertility business, growing 6% both pro forma. These results are much stronger than our initial guidance and there are a number of ongoing activities which are driving this: First, we significantly increased our focus on sales during the fiscal fourth quarter of last year. This included existing products, new product launches and acquired products. This new emphasis was seen in our Q1 results and we believe it will continue through the year. Second, we are combining our office and surgical and fertility businesses, including transforming to a geographic sales focus. This is enabling us to cross-sell more effectively, which is especially beneficial with products such as our newly launched disposable hysteroscope, EndoSee, which sells to OB/GYN offices but also to fertility centers. This change will also allow us to better manage our infrastructure going forward and we'll reinvest those savings in sales and marketing to continue driving revenue growth. Third, as we continue to progress through the year, we'll be adding more sales personnel in under-penetrated areas and increasing our focus on high-growth areas such as genetic testing. We anticipate doing this while leveraging revenue growth to improve operating margins as we did in Q1. All in, CooperSurgical is clearly moving to a more aggressive and efficient business model, with a life sciences look and feel. 
With respect to CooperSurgical's products, the office and surgical business, comprises a diverse portfolio of roughly 600 products sold primarily to obstetricians and gynecologists. As I stated earlier, this product portfolio grew 7%, with strength in several key products. Within fertility, we grew 6% pro forma. Sales growth is still being negatively impacted by our strategic decision to exit low margin, non-CSI manufactured capital equipment. This will continue through Q2 but then, become largely immaterial in Q3. Also within fertility, our genetic testing business is performing extremely well. We entered these lab services faced with the acquisition of Reprogenetics last August and it's proving a very nice strategic sale. Lastly, we are complementary, we added complementary IVF products in mid-December, with the acquisition of Research Instruments and we also acquired a small fertility microneedle company at the beginning of February, which we expect to have roughly $1 million of revenue per quarter going forward. These deals are incorporated into our updated guidance. So overall, I'm very bullish on CooperSurgical. The passion and drive of our surgical team is extremely high and I am really proud of their efforts and excited about our future. 
Now let me touch a little more on guidance. Our fiscal 2016 revenue guidance for CooperVision remains unchanged at 5% to 7% constant currency growth. We are raising our CooperSurgical revenue guidance to 5% to 8% pro forma growth or 15% to 18% on an as-reported basis. We're also raising our non-GAAP earnings per share guidance to $8 -- to $8.30, up 13% to 17% pro forma. For cash flow, we continue to expect around $300 million of adjusted free cash flow for fiscal 2016. 
In conclusion, we're continuing our successful strategy which we frequently articulated in the past. This includes investing to take market share by expanding geographically, aggressively rolling out new products and investing in emerging markets. We do this while remaining focused on growing earnings per share and cash flow to deliver strong shareholder value. I'm pleased that our results and happy the issues we encountered in the fourth quarter, such as the European Sauflon integration activity are behind us. I remain very optimistic about the underlying fundamentals of our businesses and I believe we are well-positioned to deliver strong results for fiscal 2016 and beyond. With that, let me express my appreciation to our employees, our #1 asset. Their hard work and dedication to creating value is the backbone of our success. And now, I'll turn it over to Greg to cover our financial results."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thanks, Bob, and good afternoon, everyone. Bob provided an overall summary of our performance, including a review of the market and our revenue picture. A bit of focus on primarily our non-GAAP results for the quarter. For the reconciliation to GAAP numbe",1358,"Thanks, Bob, and good afternoon, everyone. Bob provided an overall summary of our performance, including a review of the market and our revenue picture. A bit of focus on primarily our non-GAAP results for the quarter. For the reconciliation to GAAP numbers, please refer to our earnings release. Looking at gross margins. In Q1, the non-GAAP gross margin was 61.4% compared with 64.2% in the prior year. Factors which impacted our non-GAAP gross margins were a net unfavorable FX impact with the favorable U.K.-based cost of goods sold impact more than offset by the unfavorable revenue impact. In addition, product mix was a negative as the sales weakness Bob mentioned in the Americas hurt our margins as this region has the greatest amount of Toric and multifocal lenses, along with being a strong Biofinity franchise. We expect gross margins to rebound in Q2. CooperVision on a non-GAAP basis reported gross margin of 60.9% versus 64.2% in Q1 of last year. The factors which impacted our non-GAAP gross margin where the unfavorable net FX impact, as well as the product mix I just mentioned. CooperSurgical had non-GAAP gross margin of 63.6% which compares to Q1 '15 at 64%. Strength in the OB/GYN and IVF product families were offset by the inclusion of our 2 recent acquisitions, Reprogenetics and Research Instruments, which have lower gross margins. 
Now looking at operating expenses. On a non-GAAP basis, SG&A decreased approximately 3% to $161.8 million or 36% of revenue, down from approximately 38% the prior year. The primary driver behind this was a reduction in G&A where we saw leverage and good management of expenses within the businesses. Now looking at R&D. In Q1, R&D on a non-GAAP basis was $14.8 million or 3.3% of revenue, down from the 3.6% in the prior year. We are seeing investment in CSI offset by synergies from the Sauflon acquisition and CVI. 
Moving to operating margins. For Q1, consolidated GAAP operating income and margins were $57.4 million and 12.8% of revenue versus $73.1 million and 16.4% of revenue in Q1 last year. Non-GAAP operating income and margin were $99.4 million and 22.1% of revenue versus $102.6 million and 23% of revenue for the prior year. The difference in operating margin year-over-year is the reduction in gross margin we discussed, partially offset by operating expenses. In Q1, CooperVision's non-GAAP operating income and margin were $87.4 million and 24% of revenue versus $98.4 million and 26.6% of revenue in the prior year. CooperSurgical's non-GAAP operating income and margin were $22.8 million and 26.7% of revenue versus Q1 '15 at $17.5 million and 23.1% of revenue. Now looking at depreciation and amortization in Q1. Depreciation was $37.3 million, up $8 million year-over-year, which includes $6.1 million of accelerated depreciation related to the Sauflon acquisition, which we exclude in our non-GAAP numbers. Amortization was $16.2 million, up $2.6 million. The year-over-year amortization increase reflects recent acquisition activity. Interest expense was $5.3 million for the quarter, up $1.3 million year-over-year, primarily due to acquisitions and higher interest rates. Looking at the effective tax rate. In Q1, the non-GAAP effective tax rate was 3.9% versus a non-GAAP effective tax rate of 10.8% in Q1 '15. The year-over-year effective tax rate was favorably impacted by several items, including the release of reserves associated with a prior year tax filing which would normally have reversed in Q3 of 2017, as well as a reduction in the U.K. tax rate, which was enacted in November. Also note, as we've mentioned before, the effective tax rate continues to be below the U.S. statutory rate as a majority of our income is earned in foreign jurisdictions with lower taxes -- or lower tax rates. Our earnings per share -- our Q1 earnings per share on a GAAP and non-GAAP basis was $1.05 and $1.83, respectively, versus $1.25 and $1.75 for GAAP and non-GAAP in the prior year. Non-GAAP EPS on a pro forma basis, which adjusts for currency and acquisitions, grew approximately 15% in the quarter. 
Looking at FX impact. The net currency impact on EPS year-over-year for Q1 was unfavorable by $0.18. This was $0.04 less than we guided as currencies were generally favorable to guidance rates. Looking at the balance sheet liquidity. In Q1, we had cash provided by operations of $89.5 million, less capital expenditures of $45.1 million, resulting in $44.4 million of free cash flow. Excluding integration costs of $12.3 million, adjusted free cash flow was $56.7 million. Total debt increased within the quarter by $28.1 million to $1,377,000,000 primarily due to acquisitions, partially offset by operational cash flow generation. Inventories increased approximately $11.2 million to $430.9 million, up from last quarter, primarily due to an increase in daily lenses for CooperVision and an increase due to acquisitions for CooperSurgical. For the quarter, we are seeing months on hand at 6.9 months. DSO was at 57 days, which is consistent with the prior quarter and last year. 
Before I get into guidance, let me comment on our senior credit facilities which we mentioned in our earnings release under Other. We entered the bank market a couple months ago to refinance our $1 billion revolver and raise a small term loan. We priced these facilities as investment-grade and were pleasantly surprised with the demand. As such, we closed a 5-year replacement of our $1 billion revolver and a new 5-year $830 million term loan. We used the term loan proceeds to repay certain existing indebtedness and we'll be reducing our $700 million term loan, which matures in August of 2017. Overall, this activity is very positive as it extends the life of our facilities with very favorable terms and conditions, while providing additional flexibility through greater capacity. The financial impact we're expecting is for interest expense to be higher by roughly $1 million per quarter going forward. As Bob mentioned, this is offset by the higher operating income being generated by CooperSurgical. 
Now turning to guidance. Foreign exchange rates have been very volatile and can have a large impact on our results. For guidance on our main currencies, we are using $1.07 for the euro, $1.15 for the yen and $1.38 for the pound. With our rate assumptions, we are expecting a negative impact to full year 2016 revenues of approximately $58 million and an unfavorable $0.41 impact to full-year 2016 EPS. Given Q1 was a negative $22 million in revenues and $0.18 on EPS, we are looking at a negative $36 million of revenue or $0.23 for Q2 to Q4, with more of a negative impact in Q2 and Q3. The negative revenue impact of $58 million is unchanged from our December guidance, which may be surprising. The positive moves from several currencies including the euro and the yen are offset by the negative move in the pound, along with a few other currencies like the Russian ruble and the Brazilian real. Having said this, the earnings per share impact is less negative, as the pound is helping COGS in the back half of the year and positive moves in currencies like the yen are having a positive flow-through impact to our operating income. For 2016 guidance. The revenue range for the company is $1.865 billion to $1.905 billion or approximately 5% to 7% pro forma growth. CooperVision's revenue range is $1.51 billion to $1.54 billion or 5% to 7% constant currency growth. CooperSurgical's revenue range is $355 million to $365 million or 5% to 8% pro forma growth. We expect non-GAAP gross margin to be around 64% for the year. OpEx is expected to be around 40%. Operating margin is expected to be around 24%. Interest expense is expected to be around $24 million. Our effective tax rate is expected to be around 8%. Our expected share count will be around 49.2 million shares. Our non-GAAP EPS is expected to be in the range of $8 to $8.30, which equates to a pro forma EPS of 13% to 17% growth. CapEx is expected to be around $200 million. Adjusted free cash flow is expected to be around $300 million. With that, let me turn it back to Kim for the Q&A session."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Operator, we're ready to take some questions.",7,"Operator, we're ready to take some questions."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Joanne Wuensch of BMO Capital Markets.",16,"[Operator Instructions] Our first question comes from the line of Joanne Wuensch of BMO Capital Markets."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","I have 2 questions. The first one is, what did you give for the year-over-year growth of silicone hydrogels? And can you help breakout how did your Dailies silicone hydrogels are doing?",32,"I have 2 questions. The first one is, what did you give for the year-over-year growth of silicone hydrogels? And can you help breakout how did your Dailies silicone hydrogels are doing?"
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, Joanne, 2 things. Our year-over-year growth for silicone hydrogel was 13% for the entire family of 4, Biofinity, Avaira, clariti and MyDay. For the 1 Day silicone hydrogels, it was 50% constant currency year-over-year.",35,"Yes, Joanne, 2 things. Our year-over-year growth for silicone hydrogel was 13% for the entire family of 4, Biofinity, Avaira, clariti and MyDay. For the 1 Day silicone hydrogels, it was 50% constant currency year-over-year."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","And are you planning on launching any next-generation types of products beyond clariti and MyDay? I mean, I've been hearing about next gen Biofinity, for example.",27,"And are you planning on launching any next-generation types of products beyond clariti and MyDay? I mean, I've been hearing about next gen Biofinity, for example."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Let's say that our focus is on, obviously the 2 that we're in the middle of, which is clariti and MyDay. There will be enhancements along the way of many of our family of products. There will be extended ranges of the families and so suffice it to say, yo",60,"Let's say that our focus is on, obviously the 2 that we're in the middle of, which is clariti and MyDay. There will be enhancements along the way of many of our family of products. There will be extended ranges of the families and so suffice it to say, you can call those future generation upgrades, if you will."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Matt O'Brien of Piper Jaffray.",15,"And our next question comes from the line of Matt O'Brien of Piper Jaffray."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","This is actually J.P. in for Matt. My one is just on, I'm trying to dig into what you changed in your core EPS for the full year. The $8 to $8.30, when I back out the $0.17 from FX reduction, plus the $0.30 beat in the quarter, is there anything changing",67,"This is actually J.P. in for Matt. My one is just on, I'm trying to dig into what you changed in your core EPS for the full year. The $8 to $8.30, when I back out the $0.17 from FX reduction, plus the $0.30 beat in the quarter, is there anything changing in the core business or is that kind of flat, from an EPS standpoint?"
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","So we had a $0.26 beat [ph] for the quarter, of which $0.04 was foreign exchange, compared to guidance or $0.22. And for the back 9 months, we improved it $0.15 in aggregate, $0.14 of which was foreign exchange and $0.01. Did I get it?",45,"So we had a $0.26 beat [ph] for the quarter, of which $0.04 was foreign exchange, compared to guidance or $0.22. And for the back 9 months, we improved it $0.15 in aggregate, $0.14 of which was foreign exchange and $0.01. Did I get it?"
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","$0.13.",1,"$0.13."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","It's actually $0.14 in aggregate, of which $0.13 is foreign exchange and $0.01 is basically improvement in operations.",19,"It's actually $0.14 in aggregate, of which $0.13 is foreign exchange and $0.01 is basically improvement in operations."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Chris Pasquale of JPMorgan.",13,"And our next question comes from the line of Chris Pasquale of JPMorgan."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Bob, I wanted to circle back on your comments about the slower growth in Toric's and multifocals. I get that the U.S. is the biggest market for those products and you're facing some competitive headwinds there, but the new competitive launches are primari",69,"Bob, I wanted to circle back on your comments about the slower growth in Toric's and multifocals. I get that the U.S. is the biggest market for those products and you're facing some competitive headwinds there, but the new competitive launches are primarily Spheres, if I'm not mistaken. So can you talk a little bit more about what's causing the slowdown in specialty lenses and how you reverse that?"
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","So the slowdown is really a function, not of what's getting on eye [ph], it's year-over-year tough comps, which is U.S. dominant, if you will. We had 11% growth a year ago, and so it's against that tough comp. Since the U.S. is so weighted to specialty le",143,"So the slowdown is really a function, not of what's getting on eye [ph], it's year-over-year tough comps, which is U.S. dominant, if you will. We had 11% growth a year ago, and so it's against that tough comp. Since the U.S. is so weighted to specialty lenses compared to outside the U.S. yet it shows up as what appears to be a deceleration of the growth of the lenses in our specialty area, Toric's, and multifocals. Our expectation is, we indicated several times is that the comps are easier post the first quarter, so we expect to return to a more normalized growth rate. It's built into our revenue guidance and certainly, that would impact, especially -- heavily, because of its U.S. orientation, and it will also impact our gross margin going forward, since specialty lenses carry a higher gross margin percent."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","And your next question comes from line of Brian Weinstein of William Blair.",13,"And your next question comes from line of Brian Weinstein of William Blair."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","It sounds like you guys are selling everything you can on MyDay but where are you guys sort of building out the capacity for that? It would seem to me that if demand is strong for that, that you're going to be looking to aggressively build out the capacit",71,"It sounds like you guys are selling everything you can on MyDay but where are you guys sort of building out the capacity for that? It would seem to me that if demand is strong for that, that you're going to be looking to aggressively build out the capacity in some more product, but I don't think I heard anything on the call about where you are on that capacity build."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","As of today, we're still capacity constrained with MyDay. We are rolling out shortly into Japan. We are ramping up very nicely. We're happy with that, and suffice it to say that, within the next year, we will expect to say we are no longer capacity constr",50,"As of today, we're still capacity constrained with MyDay. We are rolling out shortly into Japan. We are ramping up very nicely. We're happy with that, and suffice it to say that, within the next year, we will expect to say we are no longer capacity constrained, even on MyDay."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Jeff Johnson of Robert Baird.",14,"And our next question comes from the line of Jeff Johnson of Robert Baird."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Maybe 2 questions. Bob, for you. Can you quantify at all the customer payouts in Europe? If CVI was 4% constant currency growth, what would it have been ex those, I believe were contra revenue payments. And then also, you mentioned clariti gross margin ex",102,"Maybe 2 questions. Bob, for you. Can you quantify at all the customer payouts in Europe? If CVI was 4% constant currency growth, what would it have been ex those, I believe were contra revenue payments. And then also, you mentioned clariti gross margin exiting the year accretive to company-wide. I think last call, you just talked about maybe going from the low 50s to the low 60s. My definition of accretive to gross margin would be kind of closer to 62%, 63%. Is that kind of a fairer range of where you think those clariti gross margins go exiting the year?"
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","So on the first item, we're not going to get into the specifics of what concessions we made that impacted revenue, but suffice it to say, Europe put up reasonably respectful numbers as -- in the growth area at 8% constant currency. So that probably will a",103,"So on the first item, we're not going to get into the specifics of what concessions we made that impacted revenue, but suffice it to say, Europe put up reasonably respectful numbers as -- in the growth area at 8% constant currency. So that probably will allow you to gauge it a little. From the point of view of clariti being accretive, our intent is consistent with what your assessment is that it would not be a drag on our overall gross margin going into the acquisition of clariti, and that would be, yes, north of that 62%, 63% range that you assessed."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Larry Keusch of Raymond James.",14,"And our next question comes from the line of Larry Keusch of Raymond James."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Just 2 quick ones. Bob, I think you mentioned roughly $200 million of CapEx spending for the year. Again, just coming back to an earlier question around MyDay. Is there a scenario where you might decide to step that up a little bit to, again improve your",79,"Just 2 quick ones. Bob, I think you mentioned roughly $200 million of CapEx spending for the year. Again, just coming back to an earlier question around MyDay. Is there a scenario where you might decide to step that up a little bit to, again improve your ability to supply MyDay? And then, the second question is, UPP continues to hang around. If that goes away, what would your expectations be for the market in the way Cooper's positioned?"
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","So as far as, could we do anything to accelerate the MyDay roll out by expanding our CapEx requirements? There are long lead times with MyDay. So we've already put in place all of those -- all the orders, so to speak, and requirements to get that ramped u",204,"So as far as, could we do anything to accelerate the MyDay roll out by expanding our CapEx requirements? There are long lead times with MyDay. So we've already put in place all of those -- all the orders, so to speak, and requirements to get that ramped up to where we need to. That's already in the works, and built into our forecasted CapEx numbers. And things that I indicated are going very well, to plan in that arena. Relative to UPP, if it went away or unilateral pricing policy, if it went away tomorrow, I'm not sure there would be much of a significant impact on the industry or the competitive landscape. Suffice it to say, I think many independent eye care practitioners figured out that there are workarounds out there to UPP, and maybe it's not all that it was cracked up to be when it first came out as a novel new idea. So as long as the eye care practitioners are being taken care of, relative to servicing those that write the script, I think nothing major will have changed and life would go on if it went away, and I'd be, I'd applaud that if it happened, actually."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of David Roman of Goldman Sachs.",14,"And our next question comes from the line of David Roman of Goldman Sachs."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","I wanted just to start back on the competitive dynamic. You talked about in your prepared remarks under the traction J&J has gained, but right now it does look like the other large competitor is facing some fairly significant headwind. Can you maybe give",70,"I wanted just to start back on the competitive dynamic. You talked about in your prepared remarks under the traction J&J has gained, but right now it does look like the other large competitor is facing some fairly significant headwind. Can you maybe give us some perspective on how you expect the landscape to unfold as we pace through 2016, particularly as Alcon undertakes this sort of market recovery plan?"
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","You're correct. The competitive landscape is pretty jumpy right now, if you will. A lot of changes within all of the competitors, if you will. Alcon's undergoing a major restructuring within Novartis and they're pulling things out of what we used to call",360,"You're correct. The competitive landscape is pretty jumpy right now, if you will. A lot of changes within all of the competitors, if you will. Alcon's undergoing a major restructuring within Novartis and they're pulling things out of what we used to call Alcon, and will probably in the future, won't -- I don't know what -- how they'll deal with the names. But that's certainly is not a handicap to us. J&J is going through another assignment of executives in some of their key areas which is kind of a training ground for J&J in the contact lens space. So there's a change there. They, of course, put a lot of muscle or the executive that was transitioning out, put a lot of muscle the last 2 months in, the last 2 quarters in rolling out OASYS 1 Day. And other thoughts are in the works there. We'd like change in that sense. We like some of what J&J did by way of trying to accelerate the death, if you will, of the 2-week space in the U.S. which they happen to own well north 80% of. So anytime they put their own franchise in play, I think all the competitors like that. And whether it goes into what the so-called one week, the so-called 1 Day, or were it to go into the 1 month that's putting it all in play. That's fine from our perspective. So we still think we're the one to be caught up with, relative to a complete portfolio of silicone hydrogel 1 Day and at both the mass market and having a silicone hydrogel entry into the 1 Day premium market. So we think we have the best deck of cards or hand of cards, if you will and like the way the industry continues to perform in good times and in bad times. So the growth of the industry is there. Everything we've said about, trading up into 1 Day as a driver of the industry. The fact that it's 4x to 6x or 400% to 600% more revenue for the same patient, all of that is continuing to come about."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Matthew Mishan of KeyBanc.",13,"And our next question comes from the line of Matthew Mishan of KeyBanc."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","I got 2 real quick. First, I was hoping you could talk about some of the Cooper specific things that you're doing in the Americas in response to J&J and their resurgence, that give us more confidence in a return to growth for you guys. And then, just seco",61,"I got 2 real quick. First, I was hoping you could talk about some of the Cooper specific things that you're doing in the Americas in response to J&J and their resurgence, that give us more confidence in a return to growth for you guys. And then, just secondly, an update on where you're at with the MyDay launch in Japan?"
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well first on what Cooper is doing. Cooper is continuing to execute its plan, which was to roll out MyDay as a premium 1 Day silicone hydrogel and clariti as a mass market 1 Day silicone hydrogel with a complete family of Toric, multifocal and Sphere. Not",416,"Well first on what Cooper is doing. Cooper is continuing to execute its plan, which was to roll out MyDay as a premium 1 Day silicone hydrogel and clariti as a mass market 1 Day silicone hydrogel with a complete family of Toric, multifocal and Sphere. Nothing is changing by way of our focus on executing that strategy. We still believe that silicone hydrogel belongs in the 1 Day space. And therefore, the fact that 77% of the non-1 Day space is already silicone hydrogel, we still believe we have the right product portfolio in the right space, and it will convert into silicone hydrogels as we go forward. And nothing in it -- any of the numbers we're looking at by way of growth of the 1 Day market or the growth of silicone hydrogels causes us to take pause in that view. The fact that J&J put up robust numbers, yes, they came out with a new product and yes, they distributed it widely and deeply. They had very easy comps from the prior year, so some of that growth is anomalous. And you may recall in the prior years, they were going through that transition where they were the only one that did adopt UPP or unilateral pricing policy for not only new products wherein we were dedicating a lot of time to the eye care professional to learn the new products. They decided to do it for the products they've had in the marketplace for 10 years. So there was nothing new about it. There was no reason to think that the eye care professional had to dedicate a whole bunch of new time to learn the new technology, but it was easy comps. So nothing changes from the point of view of our expectation as I pointed out, we had a very tough comps in the first quarter. We do not have those same tough comps in the second, third, and fourth quarters. So our focus remains on execution. As far as MyDay in Japan, we are rolling it out, literally this month, which is March. And we're not doing -- because of capacity limitations, anything like the J&J OASYS 1 Day roll out where they hit everyone all over, so it will be a much more orderly rollout that will -- I wouldn't go crazy because of our capital limitations, or our capacity limitations on having high expectations for significantly moving the needle on the top line this fiscal year."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Anthony Petrone of Jefferies.",13,"And our next question comes from the line of Anthony Petrone of Jefferies."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Two questions as well. Maybe Bob, can you just review for us where silicone hydrogel daily as a category is today, just from a market standpoint, and where do you think it can go over time? And then, on the competitive front, there's been quite a bit of c",83,"Two questions as well. Maybe Bob, can you just review for us where silicone hydrogel daily as a category is today, just from a market standpoint, and where do you think it can go over time? And then, on the competitive front, there's been quite a bit of change going on at Valeant. I'm just wondering if you're seeing any changes in the presence of Bausch & Lomb in the market place, due to these changes over the past 6 months or so."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Okay, well first of all, silicone hydrogel 1 Day today is around a little north of $600 million. It's north of 20% of the 1 Day category, which is about $3 billion, a little north of that. We expect that $3 billion of a $7.4 billion industry,  if you will",170,"Okay, well first of all, silicone hydrogel 1 Day today is around a little north of $600 million. It's north of 20% of the 1 Day category, which is about $3 billion, a little north of that. We expect that $3 billion of a $7.4 billion industry,  if you will, to move to about 50% of a $10 billion industry, constant currency provisional between now and 2020. So of that $10 billion in 2020 at current exchange rates, we expect half of it to be -- or $5 billion to be in the one-day modality, and that, of that $5 billion, a lot more than 20%, suffice it to say, your barometer is someplace between that 20%, which is rapidly going higher, and the 77% that is in the non-1 Day modality, it will be someplace in the middle. And one could easily pick the middle of it and say about 50% of the $5 billion, which is 50% of the $10 billion, is not a bad gauge for 2020."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from line of Jon Block of Stifel.",12,"And our next question comes from line of Jon Block of Stifel."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Let me just try to get in 2 upfront. First, can you elaborate a little bit more on the Biofinity, and Avaira, I think it was up 7% year-over-year in the quarter. Seems like a decent step down from the recent run rate. Is there some inventory fluctuations",108,"Let me just try to get in 2 upfront. First, can you elaborate a little bit more on the Biofinity, and Avaira, I think it was up 7% year-over-year in the quarter. Seems like a decent step down from the recent run rate. Is there some inventory fluctuations there? And then, second, I know you guys want to sort of stay away from a specific 2016 SiHy number, but do you still have the same expectations that SiHy Dailies accelerates from sort of that mid-40% pro forma constant currency that you did in '15. In other words, can you maintain this 50-ish percent SiHy daily growth throughout '16?"
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Right. I'll do the latter one first. The expectation on the SiHy daily is that it will -- as you indicated, we expect higher growth in 2016 than 2015, and 2015 was mid-40s and this last quarter, in constant currency was 50%. So that we expect to hold -- t",145,"Right. I'll do the latter one first. The expectation on the SiHy daily is that it will -- as you indicated, we expect higher growth in 2016 than 2015, and 2015 was mid-40s and this last quarter, in constant currency was 50%. So that we expect to hold -- to equal that or exceed it, if you were going forward or at least exceed the 45% of last year for the entire fiscal year. So nothing has changed in our expectation on that, and the rollout there. Relative to Biofinity and Avaira, which dropped below double-digit, for the first time in I think, ever, at 7%. That 7% is basically anomalous relative to its concentration in, particularly Avaira, primarily a U.S. product. And so that concentration in the American -- Americas, we've sat down and we expect that to normalize going forward and be double-digit."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","[Operator Instructions] Our next question comes from line of Steve Willoughby of Cleveland Research.",14,"[Operator Instructions] Our next question comes from line of Steve Willoughby of Cleveland Research."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Bob, regarding the 1 Day silicone hydrogel market that you were just describing, and going, looking out a few years. I was wondering if you could talk about, and particularly in light of you guys continuing to add capacity there, kind of where MyDay margi",123,"Bob, regarding the 1 Day silicone hydrogel market that you were just describing, and going, looking out a few years. I was wondering if you could talk about, and particularly in light of you guys continuing to add capacity there, kind of where MyDay margins are today. Where do you expect MyDay margins to be, once you have capacity and it's up and running? And just kind of from a particular [ph] perspective, it's my understanding that other people's 1 Day silicone hydrogels don't have all that great of margins either. And so if effectively 1/4 of the market moves to 1 Day silicone hydrogels over the next 4 years or so, does that negatively impact the overall margin profile of the industry?"
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","So on, where is MyDay today, we indicated we expected it to move into the 20s. It is in the 20s as a gross margin. We, longer term, expect it to move into the 50s, which is more the traditional 1 Day modality, if you will, gross margin. We, relative to --",262,"So on, where is MyDay today, we indicated we expected it to move into the 20s. It is in the 20s as a gross margin. We, longer term, expect it to move into the 50s, which is more the traditional 1 Day modality, if you will, gross margin. We, relative to -- if all of silicone hydrogel moves deeply into the 1 Day modality, or as my model was, $2.5 billion out of $5 billion out of $10 billion, $10 billion being total, $5 billion being 1 Day, $2.5 billion being silicone hydrogel in 2020, if that were to happen, given where we are with clariti as a mass market, high gross margin 1 Day silicone hydrogel, we think we would be a big enough player that it wouldn't put a, undue drain on the entire industry. Having said that, there is no doubt that if we were comparing what the industry would be if it stayed and moved from 2-week and 1 Day into the monthly modality, where margins would be going up because, by definition, they're monthlies, compared to the 1 Day, there is no doubt that a 1 Day modality is lower than a monthly modality. A 2-week noncompliant market which is, defines or profiles, the U.S. market could only and should only do better, no matter what you -- where it goes, because a noncompliant 2-week isn't an optimal gross margin and the industry is focusing in on how to make compliance better and the best way to do that is kill off the 2-week, if you will."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our final question comes from the line of Larry Biegelsen of Wells Fargo.",14,"And our final question comes from the line of Larry Biegelsen of Wells Fargo."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Just, Bob, a few quick clarifications and then one real question. So on the sales concessions, if you expect to accelerate in the second quarter, so I know it was asked earlier, but if you could give us some sense of how much that suppressed growth, it ob",65,"Just, Bob, a few quick clarifications and then one real question. So on the sales concessions, if you expect to accelerate in the second quarter, so I know it was asked earlier, but if you could give us some sense of how much that suppressed growth, it obviously help us understand the underlying trends a little bit better. And second, just on Joanne's question --"
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Larry, can you come back on -- Larry, could you repeat that question?",13,"Larry, can you come back on -- Larry, could you repeat that question?"
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","You're a little hard to hear Larry, a little light.",11,"You're a little hard to hear Larry, a little light."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Sorry, guys, the sales -- I'll try to speak up. The sales concessions, you're not giving us the number, how much it depressed sales in the quarter, but if it impacts our ability to understand the underlying trends, so. And I know you expect to improve in",161,"Sorry, guys, the sales -- I'll try to speak up. The sales concessions, you're not giving us the number, how much it depressed sales in the quarter, but if it impacts our ability to understand the underlying trends, so. And I know you expect to improve in the second quarter. So if you would give that, it would be helpful, but -- anyway, that just a request. And then, on Biofinity, Joanne asked about another, new version. So just to be clear, you talked about extended ranges, so it sounds like you're not planning to come out with a Sphere [ph] version with UPP in 2016. And sorry, guys, just lastly, for my real question. Does J&J, if they do come out with a monthly lens, Bob, how do you see that for Cooper? Obviously, there's some rumors of that, that we haven't confirmed it, but what would be the impact for Cooper if they come out with a monthly lens?"
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","All right, on the concessions, so, yes, we indicated we were not going to disclose that. We said the same thing on the fourth quarter call. I think what, other than me pointing you at the EMEA growth of 8% as being fairly robust, meaning, the factors that",436,"All right, on the concessions, so, yes, we indicated we were not going to disclose that. We said the same thing on the fourth quarter call. I think what, other than me pointing you at the EMEA growth of 8% as being fairly robust, meaning, the factors that hit gross margin, and I think Greg touched upon them, are multiple and concessions is one, but they're clearly foreign exchange and the lag on that is another, and quite frankly, the ramping up of MyDay, while it's still in a lower gross margin category, it all factors. So it's -- no one is driving our gross margin of 61% and I think we indicated we're expecting to be in around 64% by the end of the year to give you some indication where, direction that will go. Relative to, of the new version Biofinity, I'll use the extended range as an example of things that we we're doing, particularly in the area of Toric's, where extended ranges, custom lenses matter, and one of Cooper's claims to fame, and why we're so good in specialty lenses is, we're very capable of customizing lenses, and giving -- and addressing 100% of the audience, instead of 80%. A lot of our competitors only worry about the Bell curve, the 80%. So when we talk about making Biofinity even better, it's things like that. And whether or not we upgrade and add things that some of our competitors have done over the years when they have a product that's been around a long time, will there be some refreshing of different things? Perhaps. But we're not going any further into that at this juncture. I was using the extended range just to -- because it is a broadening of the family and availability of the family. As far as J&J, if they move into the monthly, that will only further exacerbate the death of the 2-week. So who's to say they own north of 80% of the wearer base in the 2-week space. They know better than anyone how noncompliant it is, and they know if they can move people from the 2-week space to the monthly space and charge 30%, 40%, 50% or 60% for a monthly higher than a 2-week noncompliant, they are much better off, even if they don't get -- they have to get the lion's share, but even if they don't get it all, as they put people in play. So we view -- net-net-net, we view J&J activity putting the 2-week market in play as a plus for Cooper, as a plus for the industry."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","I would now like to turn the conference back to Bob Weiss for closing remarks.",15,"I would now like to turn the conference back to Bob Weiss for closing remarks."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, thank you. I want to thank everyone for joining us today. I hope you're as excited as I am about our start to the new year and our outlook for the new year. We look forward to updating you on our second quarter conference call, which I believe is Ju",113,"Well, thank you. I want to thank everyone for joining us today. I hope you're as excited as I am about our start to the new year and our outlook for the new year. We look forward to updating you on our second quarter conference call, which I believe is June 2. And in the interim, we'll be able to execute on a number of other things, including the launch in Japan. So we'll update you more on the progress we're making there, as well as a continued expansion of MyDay, and our success in the 1 Day silicone hydrogel space. So we look forward to updating you in early June. Thank you."
263609,325035985,947426,"The Cooper Companies Inc., Q1 2016 Earnings Call, Mar 03, 2016",2016-03-03,"Earnings Calls","The Cooper Companies, Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may all disconnect. Everyone, have a great day.",24,"Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. You may all disconnect. Everyone, have a great day."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Cooper Companies Second Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference may be recorded. I'd now like to introduce your host for today's conference, Miss Kim",48,"Good day, ladies and gentlemen, and welcome to the Cooper Companies Second Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference may be recorded. I'd now like to introduce your host for today's conference, Miss Kim Duncan, Vice President, Investor Relations. Ma'am, please go ahead."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Good afternoon, and welcome to the Cooper Companies Second Quarter 2016 Earnings Conference Call.  I'm Kim Duncan, Vice President of Investor Relations. And giving prepared remarks on today's call are Bob Weiss, Chief Executive Officer; and Greg Matz, Chi",320,"Good afternoon, and welcome to the Cooper Companies Second Quarter 2016 Earnings Conference Call.  I'm Kim Duncan, Vice President of Investor Relations. And giving prepared remarks on today's call are Bob Weiss, Chief Executive Officer; and Greg Matz, Chief Financial Officer. 
Before we get started, I'd like to remind you that this conference call contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including all revenue and earnings per share guidance and other statements regarding anticipated results of operations, market or regulatory conditions and integration of any acquisitions or their failure to achieve anticipated benefits. Forward-looking statements depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Events that could cause our actual results and future actions of the company to differ materially from those described in the forward-looking statements are set forth under the caption Forward-Looking Statements in today's earnings release and are described in our SEC filings, including the Business section of Cooper's annual report on Form 10-K. These are publicly available and on request from the company's Investor Relations department. 
Now before I turn the call over to Bob, let me comment on the agenda for the call. Bob will begin by providing highlights on the quarter, followed by Greg, who will then discuss second quarter financial results. We will keep the formal presentation to roughly 30 minutes, then open the call for questions. We expect the call to last approximately 1 hour. We request that anyone asking questions, please limit yourself to 1 question. Should you have any additional questions, please call our Investor line at (925) 460-3663 or email ir@cooperco.com. As a reminder, this call is being webcast, and a copy of the earnings release is available through the Investor Relations section of The Cooper Companies website. And with that, I'll turn the call over to Bob for his opening remarks."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thank you, Kim, and good afternoon, everyone. Welcome to the Second Quarter 2016 Conference Call. Let me start by highlighting 3 key areas; first, I'm pleased to report strong financial results for our fiscal second quarter. On a consolidated basis, we re",1256,"Thank you, Kim, and good afternoon, everyone. Welcome to the Second Quarter 2016 Conference Call. Let me start by highlighting 3 key areas; first, I'm pleased to report strong financial results for our fiscal second quarter. On a consolidated basis, we reported $484 million in revenue and non-GAAP earnings per share of $2.05; second, CooperVision posted 9% revenue growth on both a constant currency and as-reported basis and strong results in all key areas of the business. Since we use silicone hydrogel, grew 52%, while 2 week and monthly silicone hydrogel lenses grew a combined 14% both in constant currency; third, CooperSurgical had another strong quarter posting revenue growth of 23% and pro forma growth of 6%. We also closed several strategic acquisitions since our last earnings call. 
Moving into the details, CooperVision reported second quarter revenues of $391 million, up 9%. This was our strongest quarter growth quarter since 2014 and really shows the strength of our product portfolio. Regarding revenue by geography, the Americas grew 9% in constant currency, showing a nice rebound from last quarter. Strength was seen in multiple categories led by silicone hydrogel products. Our enhanced clarity lens has been extremely well received and MyDay had another strong quarter. Our toric and multifocal also posted strong growth driven by Biofinity family. EMEA had another strong quarter and sales grew 5% in constant currency. Growth was driven by our family of silicone hydrogel products, Biofinity, clariti, MyDay and Avaira. We also launched of Avaira Vitality in EMEA during the quarter and it is being well received. Avaira Vitality is our new 2 week silicone hydrogel lens which is an enhanced replacement for the original Avaira lens. It was developed using improved manufacturing processes, resulting in a higher quality product at a lower cost per unit. We expect to launch this lens in the U.S. later this year subject to FDA approval. Asia Pacific had a very strong quarter, up 18% in constant currency. Growth was strong throughout the region and Biofinity and Proclear 1 Day stood out in Japan. Also in Japan, we began our MyDay launch during the quarter and we're seeing full signs that MyDay could be a very successful premium offering in that market. 
Turning to our product categories. Toric and multifocals grew a healthy 15% year-over-year in constant currency. We saw a very nice rebound in the U.S. which bolstered our strength throughout the rest of the world. We remained the global leader in specialty lenses. 
Looking at silicone hydrogel lenses. These products grew 20% in constant currency and now represent 60% of our total sales. Within the two-week and monthly space, Biofinity and Avaira combined to grow 14% in constant currency. We remain under index in the two-week and monthly silicone hydrogel space at 74% of sales versus the market at 79%, so we anticipate a very nice growth for many years to come. Regarding our silicone hydrogel 1 Day lenses, clariti and MyDay, they combined to grow 52% in constant currency. We remain very optimistic about these products and are committed to our growth strategy which includes a two-tier approach with clariti positioned as the mass market offering and MyDay as the premium offering. Remember the biggest driver in the contact lens market is the 1 Day growth and we strongly believe we have the best product offering in the space as the only company with premium and mass market lenses including a full portfolio of 1 Day silicone hydrogel, sphere, toric and multifocal lenses. 
Before finishing with market data, let me make a quick comment on matters. We continue to finalize our Sauflon inspiration activities and we're very close to being done. Provision had a very small non-GAAP adjustment this quarter or smaller non-GAAP adjustment this quarter of roughly $9 million excluding amortization. We forecast similar charges in Q3 and Q4, mostly within costs of goods but it should end this fiscal year. 
Now let me comment on the overall contact lens market and remember, this information is on the last page of the earnings release. For calendar Q1, we continue taking share growing 9% with the market up 3%. Geographically, CooperVision grew 9% in the Americas. The market was flat. In Asia Pacific, CooperVision grew 14% with the market up 5%, and in EMEA, we grew 6%, in line with the market. On modality basis, single-use lenses continue driving growth and CVI -- with CVI up 14% and the market up 9%. For non-single-use lenses, we grew 6% while the market declined 1%. We also see -- as you can see, our growth remains diverse and strong. On a trailing 12 month basis, CooperVision grew 8% and the market grew 5%. Going forward, I expect the market to continue growing forward to 6% over the next 5 years and most likely closer to 6%. The drivers will continue to be a shift to daily geographic expansion and an expansion of the wear base. We expect to continue taking market share, led by our strong silicone hydrogel portfolio. 
Moving to CooperSurgical. We reported second quarter revenues of $93 million, up 23% year-over-year or up 6% pro forma. Our fertility products led the way up 60% or 8% pro forma and our office and surgical products grew 5%. We continued executing on several initiatives which are driving success including transitioning to a geographic sales model, adding sales representative in under-penetrated areas and increasing our focus on high-growth areas such as IBF kinetic testing. These moves are clearly gaining traction as we saw growth throughout core business in Q2. Going forward, I believe we'll continue to see solid growth as the business keeps moving into more aggressive and efficient business model. 
Regarding acquisitions. We've completed several over the past few months, so let me touch on those in the strategic rationale. At the beginning of April, we added Genesis Genetics, a genetic testing lab company focused on free implantation, genetic screening and diagnosis used during the IBF process. This is a nice addition to our genetic testing platform. At the beginning of May, we added complementary IBF capital equipment products through the acquisition of Case Systems, a small acquisition of roughly $7 million in revenue per year. And finally, we added the assets of Recombine last week. Recombine is a genetic testing company specializing in carrier screening, which is a great fit within our IBF and genetic testing franchise as it adds the #1 carrier screening test sold to the IBF clinics. As you can see, we're very focused on combining a full-service provider within the IBF global market and we truly believe this strategy will yield success for many years to come. These deals are all Incorporated into our updated guidance. With that, let me touch on our guidance details. We are raising our fiscal 2016 revenue guidance for CooperVision to 5.5% to 7% constant currency growth. Our CooperSurgical revenue guidance is also raised to 6% to 8% pro forma growth or up 24% to 27% on an as-reported basis. We're also raising our non-GAAP EPS guidance to $8.20 to $8.50. 
In conclusion, I'm very pleased with our results and remain optimistic about the underlying fundamentals of our business. I believe we're well-positioned to deliver solid results for the remainder of the fiscal year and beyond. With that, let me express my appreciation to our employees, our #1 asset. Their hard work and dedication to creating value is the backbone of our success. And now, I'll turn it over to Greg to cover the financial results."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thanks, Bob, and good afternoon, everyone. I'll provide overall summary of our performance, including a review of the market and our revenue picture. We're going to focus primarily on our non-GAAP results for the quarter. For the reconciliation to GAAP nu",1143,"Thanks, Bob, and good afternoon, everyone. I'll provide overall summary of our performance, including a review of the market and our revenue picture. We're going to focus primarily on our non-GAAP results for the quarter. For the reconciliation to GAAP numbers, please refer to our earnings release. Looking at gross margins. In Q2, the non-GAAP gross margin was 63.2% compared to 63.4% in the prior year. Although CooperVision had positives from currency and strong Biofinity sales, it's margin was lower than expected. The primary items driving this were a negative margin impact from stronger Asia Pac sales where we have higher 1 Day sales and charges associated with idle equipment and legacy hydrogel inventory. Regarding these last 2 items, let me cover them separately. We have made a lot of progress improving our manufacturing operations, including some very recent successes. For competitive reasons, I won't get into specifics but our production per line has increased materially resulting in lower cost per unit and a lesser need for future CapEx. This has resulted in idling from equipment, which hurts us in Q2 and will also negatively impact Q3 and Q4. We anticipate this being a short-term negative as we will grow into this production over time. The other item is our legacy hydrogel inventory, where we wrote off more than we planned. As our silicone hydrogel sales were very strong and we're forecasting that to continue. Our disbursements in Q2 we expect will negatively impact Q3 and Q4. Now, to be clear, we're not excluding these items from earnings, so they are negatively impacting our non-GAAP earnings per share. 
CooperVision, on a non-GAAP basis, reported gross margin of 62.8% versus 63.3% in Q2 of last year. The factors which impacted margin were the items I just mentioned. CooperSurgical had non-GAAP gross margin of 64.8%, which compares to Q2 '15 of 63.5%. Strength in the OB/GYN and IBF product families drove this gross margin. 
SG&A. On a non-GAAP basis, SG&A increased approximately 6% to $171.6 million or 35% of revenue, down from approximately 37% of revenue the prior year. Primary driver behind this leverage was strong SG&A controls. Now, looking at R&D. In Q2, R&D on a non-GAAP basis was $16.6 million or 3.4% of revenue, flat in dollars and down from 3.8% of revenue in the prior year. We're seeing investments in CSI offset by synergies from the Sauflon acquisition and CVI. 
Now moving to operating margins. For Q2, consolidated GAAP operating income and margin were $89.8 million and 18.6% of revenue versus $71 million and 16.3% of revenue in Q2 last year. Non-GAAP operating income and margin were $117.6 million and 24.3% of revenue versus $96.7 million and 22.2% of revenue for the prior year. Primarily difference in operating margin year-over-year is the operating expense leverage. In Q2, CooperVision, on a non-GAAP operating income and margin were $102.4 million and 26.2% of revenue versus $88.8 million and 24.7% of revenue in the prior year. CooperSurgical's non-GAAP operating income and margin were $26.6 million and 28.8% of revenue versus Q2 '15 of $18.8 million of operating income and 25% of revenue. 
Moving on to depreciation and amortization. In Q2, depreciation was $33.7 million, up $1.5 million year-over-year. Amortization was $14.3 million, up $2 million, reflecting our recent acquisition activity. Interest expense of $7.6 million for the quarter, up $2.9 million year-over-year, primarily due to higher debt and interest rate associated with acquisitions. Looking at the effective tax rate. In Q2, the non-GAAP effective tax rate was 9.4% versus a non-GAAP effective tax rate of 8.4% in Q2 '15. 
Earnings per share. And our Q2 earnings per share on GAAP and non-GAAP basis was $1.52 and $2.05, respectively versus $1.23 and $1.72 for GAAP and non-GAAP in the prior year. Non-GAAP earnings per share on a pro forma basis, which adjust for currency and acquisitions, were approximately 13% in the quarter. Now looking at FX. Net currency impact on earnings per share year-over-year for Q2 was a favorable $0.10. 
Moving on to the balance sheet. In Q2, we had cash provided by operations of $97.8 million less capital expenditures of $41.1 million, resulting in $56.7 million of free cash flow. Excluding integration costs of $9 million, adjusted free cash flow was $65.7 million. Total debt increase within the quarter by $64.1 million to $1, 441, 400,000, primarily due to higher average cash balances and acquisitions, partially offset by operational cash flow. Inventories increased from last quarter, approximately $2.7 million, to $433.6 million. This is entirely driven by CSI acquisitions. In CooperVision, we saw inventories declined as growth in silicone daily inventory to support our product launches was offset by a reduction in our hydrogel inventory. For the quarter, we're seeing months on hand at 7 months. Day sales outstanding is at 54 days, which is down 3 days from the prior quarter and 2 days from last year. 
Now turning to guidance. For our main currencies, we are using 1.10 for the euro, 112 for the yen and 1.46 for the pound. The consolidated revenue range is being raised to $1.929 billion to $1.960 billion or approximately 5.5% to 7% pro forma growth. CooperVision's revenue range is being raised to $1.545 billion to $1.567 billion or roughly 5.5% to 7% constant currency growth. CooperSurgical's revenue range is being raised to $384 million to $393 million or roughly 68% pro forma growth. Note that roughly half of the increase in guidance is from currency, while the other half is primarily from acquisitions. We expect non-GAAP gross margin to be around 63% for the year. This is a reduction from the previous guidance of around 64% as it incorporates the CooperVision items I mentioned earlier, along with lower gross margins from CooperSurgical, associated with recent acquisitions. Having said that, we still expect improving Q3 and Q4 gross margins around 64% each quarter. OpEx expected to be around 39%. Operating margins still expected to be around 24%. Interest expense is expected to be around $28 million. Our effective tax rate is expected to be around 8%. Our expected share count will be around 49.1 million shares and our non-GAAP earnings per share is expected to be $0.20 higher on the top and bottom of our range to $8.20 to $8.50, which equates to a pro forma earnings per share of 10% to 14% growth. From our last guidance, currency is roughly a $0.40 positive and we have actually improved our operational performance by roughly $0.10, but we are expecting the idle legacy inventory write-offs to negatively impact us by roughly $0.30. CapEx is expected to be around $200 million. We finished paying for equipment we have ordered over the prior year and those adjusted free cash flow is still expected to be around $300 million. With that, let me turn it back to Kim for the Q&A session."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Operator, we're ready to take some questions.",7,"Operator, we're ready to take some questions."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Matthew O'Brien with Piper Jaffray.",15,"[Operator Instructions] Our first question comes from the line of Matthew O'Brien with Piper Jaffray."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Just 1 for Bob and then 1 for Greg. On the increase in CVI, I guess, this question is for Bob. The increased CVI outlook for the year. Can you just give us a sense for how much of that is coming from improved manufacturing of MyDay, especially launching i",128,"Just 1 for Bob and then 1 for Greg. On the increase in CVI, I guess, this question is for Bob. The increased CVI outlook for the year. Can you just give us a sense for how much of that is coming from improved manufacturing of MyDay, especially launching into Japan? Largest disruptions in the markets that you're seeing? And then, how much are you incorporating, the J&J launch as far of somewhat of a headwind into your fiscal Q4. And then, for Greg, this is typically a really strong free cash flow quarter for you guys, just sticking $300[ph] million outlook for the year. So can you just help us rectify a little bit of a softness that we in Q2 versus that outlook for the year?"
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes. The foreign exchange as Greg indicated is a big driver of the top line overall improvement. In terms of the constant currency growth, you're correct, there is a modest -- in the guidance, there's a modest deceleration compared to what we had previous",124,"Yes. The foreign exchange as Greg indicated is a big driver of the top line overall improvement. In terms of the constant currency growth, you're correct, there is a modest -- in the guidance, there's a modest deceleration compared to what we had previously forecasted to anticipate,  if you will, some impact of the J&J rollout. Beyond that, it's pretty much at the same range at 5.5% to 7%, so modest at both. MyDay impact in Japan is -- once again, we just rolled that product out in March of this year, so minimal impact in terms of the overall any update on the guidance, if you will. And of course, we are already knew about MyDay in Japan in our previous March guidance."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Matt, on the free cash flow, nothing really jumps out because the numbers in that far of the prior year and we did have a much stronger Q1. So if you look at kind of halfway through the year, we're actually, probably ahead of last year.",46,"Matt, on the free cash flow, nothing really jumps out because the numbers in that far of the prior year and we did have a much stronger Q1. So if you look at kind of halfway through the year, we're actually, probably ahead of last year."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Jeff Johnson with Robert Baird.",13,"Our next question comes from the line of Jeff Johnson with Robert Baird."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Sorry, about that. Guys, can hear me, okay?",8,"Sorry, about that. Guys, can hear me, okay?"
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","We can.",2,"We can."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","All right, great. So Bob, let me ask you one question and I have a modeling question for Greg as well. But the question for you, just on the Biofinity and Avaira business, obviously that little bounce back very nicely this quarter. I think you said 14% co",117,"All right, great. So Bob, let me ask you one question and I have a modeling question for Greg as well. But the question for you, just on the Biofinity and Avaira business, obviously that little bounce back very nicely this quarter. I think you said 14% constant currency in the quarter year-over-year. 7% last quarter so kind of average right around double digits. Is that how we should think about that business going forward you got the launch coming from J&J it was referenced in the prior question. You also have Ultra kind of gaining some traffic down right. Just how do you think about that by Biofinity Avaira bucket over the next couple of years?"
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, I think taking the 2 quarters, the 7 and 13 being in around low double-digit is the right way to think about it.",24,"Yes, I think taking the 2 quarters, the 7 and 13 being in around low double-digit is the right way to think about it."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Right, that's helpful. And Greg, question for you. I think at the very end, did you say $0.30 is the EPS impact of the inventory write-off and that is included in your non-GAAP EPS guidance? Is that correct?",38,"Right, that's helpful. And Greg, question for you. I think at the very end, did you say $0.30 is the EPS impact of the inventory write-off and that is included in your non-GAAP EPS guidance? Is that correct?"
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes.",1,"Yes."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Okay. So for next year, we should been thinking about adding just kind of building off a base of $0.30 higher assuming you're not going to have that kind of write-offs next year? Would that be the fair way to take kind of this year's EPS, add $0.30 back a",61,"Okay. So for next year, we should been thinking about adding just kind of building off a base of $0.30 higher assuming you're not going to have that kind of write-offs next year? Would that be the fair way to take kind of this year's EPS, add $0.30 back and build that off as our base assumption going into next year?"
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","It's probably a little early to get into next year's guidance, which we will come out later in the year and discuss.",23,"It's probably a little early to get into next year's guidance, which we will come out later in the year and discuss."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","And keep in mind, Jeff, there's a balance between -- some of that is write off as Greg indicated. Some of it is idle equipment as we grow into it. So we're growing, given the substantial growth of our 1 Day modality and our unit growth, we're anticipating",74,"And keep in mind, Jeff, there's a balance between -- some of that is write off as Greg indicated. Some of it is idle equipment as we grow into it. So we're growing, given the substantial growth of our 1 Day modality and our unit growth, we're anticipating that we'll start consuming more and more of that as each quarter goes by. But that $30 million overall supposed to write-off as well as idle."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, and Jeff, just to build on that a little bit, I think without giving guidance, I think we feel comfortable that we would see gross margins improve year-over-year.",29,"Yes, and Jeff, just to build on that a little bit, I think without giving guidance, I think we feel comfortable that we would see gross margins improve year-over-year."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Joanne Wuensch with demo capital markets.",14,"Our next question comes from the line of Joanne Wuensch with demo capital markets."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Could you hear me, okay?",5,"Could you hear me, okay?"
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","We can.",2,"We can."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Wonderful. I think what a couple of people are trying to get at and I know speaking with investors, the big concern right now is the J&J month relaunch starting at the end of June, beginning of July. How can you -- how do you think about that product laun",70,"Wonderful. I think what a couple of people are trying to get at and I know speaking with investors, the big concern right now is the J&J month relaunch starting at the end of June, beginning of July. How can you -- how do you think about that product launch and how do we get comfortable that we're not going to see a similar hiccup to what happened last fall?"
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, without knowing exactly what J&J is up to, in hindsight, we know what they did is they sold the pipeline a lot and then, we sought in their negative U.S. results in the most recent quarter. So no one can say they can't do that again. Having said tha",403,"Well, without knowing exactly what J&J is up to, in hindsight, we know what they did is they sold the pipeline a lot and then, we sought in their negative U.S. results in the most recent quarter. So no one can say they can't do that again. Having said that, this is a product coming into the monthly modality. It is -- it's basically coming in with only a sphere not at toric and multifocal, so it's not a family of products going against a family of products. That is a big distinction as contrasted to the pipeline dragging everything in under 1 umbrella as they did their whole family of products and going after  a sphere going after a sphere. In that case, it was always the 1 Day going against Total1 primarily in that space but it consumed, it took all the air out of the practitioner's office, if you will or filled up all the space. And there clearly is no guarantee they would try flooding the market again. As far as the way we think about it longer-term, Biofinity's very established product wherein we continue to expand the offerings under that umbrella. It's a very global product and it's 1 where -- it's been in the monthly and we also have a Avaira Splash vitality coming out in the 2 week, which is the sweet spot of the market in terms of the number of wearers. There are more wearers in the 2 week part of the market than there are in the monthly. Quite frankly, as some of you know, I would always tell you to do that it's a good strategy for J&J, if they are intent on trading up and basically migrating the noncompliant wearer base they have in the 2 week space into a compliant monthly modality. That would be a good trade up in modalities because a noncompliant wearer is 1 who is basically only using 24 lenses a year compared to a monthly using 24 and conversely they're getting the price point of a 2 week wear and that's a pretty big part of that 2 week modality. So we think -- we'll continue to see that market grow the monthly and we'll get our fair share with Biofinity. in the meantime, we'll be more active down the road in the 2 week space and we'll basically neutralize it for the most part."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Steve Willoughby from Cleveland Research.",13,"Our next question comes from the line of Steve Willoughby from Cleveland Research."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Hey, guys, can you hear me, okay?",7,"Hey, guys, can you hear me, okay?"
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","We can, Steve.",3,"We can, Steve."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Okay, Bob. Just, regarding the charge or the idle equipment and inventory write-off that you guys took in the quarter, a couple of questions regarding that. I guess, for the idle equipment, is that -- the idle equipment charges relate to newly purchased e",61,"Okay, Bob. Just, regarding the charge or the idle equipment and inventory write-off that you guys took in the quarter, a couple of questions regarding that. I guess, for the idle equipment, is that -- the idle equipment charges relate to newly purchased equipment that you don't need quite yet or is that existing equipment that you idling from some reason?"
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","So to qualify as idle it's basically been put in production and then is taken out of production. So I'll answer the question with a little color. It could be very new equipment that was put in production, example, our facility at Hungary where they got re",123,"So to qualify as idle it's basically been put in production and then is taken out of production. So I'll answer the question with a little color. It could be very new equipment that was put in production, example, our facility at Hungary where they got real good at making it then all of a sudden, we park the equipment because so many --  so much product was coming off of the other line. So as yields go up, and cost are coming down, that's the good news. The bad news is you put it -- if you put equipment that you were using and you idle it, it becomes a direct period charge as supposed of moving through with the inventory."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Is this sort of what happened with Avaira and Gen 2 line a number of years ago?",17,"Is this sort of what happened with Avaira and Gen 2 line a number of years ago?"
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Absolutely.",1,"Absolutely."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Okay and [indiscernible].",3,"Okay and [indiscernible]."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","So what happened is our manufacturing people got very good at what they were doing. We always knew that if we -- that they would deliver. We just didn't know how well they would deliver. Delivering a lot more units per dollar spent of capital. That's the",128,"So what happened is our manufacturing people got very good at what they were doing. We always knew that if we -- that they would deliver. We just didn't know how well they would deliver. Delivering a lot more units per dollar spent of capital. That's the good news but it also turned short-term into the bad news. As I think Greg indicated, we'll grow out of that fairly quickly when you look at the rapid unit growth in many of these areas where we have become very efficient. And that includes MyDay, that includes Biofinity, that includes Avaira, that includes Vitality, and that includes clariti in the bucket. Take all of those products became the cost and going down through efficiencies and yields by our manufacturing people."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","The next question comes from the line of Lawrence Keusch with Raymond James.",13,"The next question comes from the line of Lawrence Keusch with Raymond James."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","This is actually, John in for Larry. I just had a good question. I guess, what's the right way to calibrate expectation for MyDay in Japan. You obviously just launch in the quarter but maybe shorter term and then maybe a little bit longer-term in '16 and",48,"This is actually, John in for Larry. I just had a good question. I guess, what's the right way to calibrate expectation for MyDay in Japan. You obviously just launch in the quarter but maybe shorter term and then maybe a little bit longer-term in '16 and '17?"
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, you can see some of the numbers we're putting up in the region and Japan is certainly, been stellar within that region also. Right now, we have a good portfolio of 3 products with MyDay being the third one in but Biofinity is very well. Proclear 1 D",267,"Well, you can see some of the numbers we're putting up in the region and Japan is certainly, been stellar within that region also. Right now, we have a good portfolio of 3 products with MyDay being the third one in but Biofinity is very well. Proclear 1 Day is doing very well, as well  now, MyDay. We will be -- we're early a month and a half into the launch, if you will through the end of April and very pleased with the progress we're making. It's biggest market by far in terms of the 1 Day modality anyplace in the world and therefore, MyDay is a very good fit in a very good market and we think the combination of MyDay as a silicone hydrogel and Proclear 1 Day as a hydrogel is a good entree into that market. As Japan has been historically pretty lethargic the last -- I want to say, 7, 8 years, it's showing a little bit worldwide than it has and the only reason it's been lethargic is because it grew so rapidly in the prior decade compared to this decade. It got ahead of itself on the 1 Day modality became the first to adapt that because they were anti- lens care regimen and wanted the lenses to be boiled and therefore, everyone migrated into the 1 Day modality rather than boiling lenses everyday. So I'll just say that we're pretty excited about MyDay there. It's going to take some work. It's only a sphere thus far, so there will be other plans relative to leverage the MyDay experience."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Matt Mishan with KeyBanc.",12,"Our next question comes from the line of Matt Mishan with KeyBanc."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Bob, first, on CooperVision, just want to better understand the sequential improvement in growth this quarter versus the previous several quarters. Is it your sense that the impact of the Johnson & Johnson launch has now fully waned or is there something",76,"Bob, first, on CooperVision, just want to better understand the sequential improvement in growth this quarter versus the previous several quarters. Is it your sense that the impact of the Johnson & Johnson launch has now fully waned or is there something that you've been doing to improve your results and to improve share? Just trying to get a sense of whether or not this is Johnson & Johnson or this is you guys doing something."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","So I think it's a combination. I think, the pair that left the room is now back in the room with the eye care professional, he has room for products and so it's more normalized in that sense and that's obvious from the weak numbers that changed they put u",135,"So I think it's a combination. I think, the pair that left the room is now back in the room with the eye care professional, he has room for products and so it's more normalized in that sense and that's obvious from the weak numbers that changed they put up domestically [indiscernible] numbers worldwide. We, relative to our products -- I think I'll make a point in saying that our numbers that we put up is not a function of any price -- pricing or anything to do with channel sales. So it's a good quarter. The inventory on hand and distributors in the pipeline is very normalized. In fact, it's a little less than it was at the beginning of the period. So it's a reflection of pretty solid numbers around the world."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Brian Weinstein with William Blair.",13,"Our next question comes from the line of Brian Weinstein with William Blair."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","A little bit of a longer-term question but can you talk about what you expect longer term in terms of the split between clariti and MyDay and kind of what you think your share longer term is there? And then, how do you think about manufacturing -- manufac",58,"A little bit of a longer-term question but can you talk about what you expect longer term in terms of the split between clariti and MyDay and kind of what you think your share longer term is there? And then, how do you think about manufacturing -- manufacture pricing levels in the daily silicone hydrogel market longer-term?"
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","So I think the split between clariti and MyDay is easier to relate to the U.S. The U.S. can be primarily where clariti is after the mass market and MyDay is after the premium market. I would have normally said, think of that as like a 75% mass market, 25%",453,"So I think the split between clariti and MyDay is easier to relate to the U.S. The U.S. can be primarily where clariti is after the mass market and MyDay is after the premium market. I would have normally said, think of that as like a 75% mass market, 25% premium market. And I think that's the U.S. portion of the model. I think when you get into certain regions of the world, for example, Japan were only MyDay is playing, then -- so if you're factoring that into the overall global result, you'll end up with MyDay outgrowing because it's coming off of a lower base and it's just getting into Japan at least for the foreseeable future are growing as a percent, getting more of its share of the bucket, so it's instead of saying 75%, 25%, MyDay may move up that spectrum and get a higher portion in the interim. When clariti is available throughout Asia Pac and around the world, that may come back more into the mass market premium split. But for now, 1 point is we're not capacity constraint on either of these products. We will continue in the case of MyDay expanding the portfolio offering, so that will help. Right now, it's a sphere completing with clariti which has a sphere, multifocal and a toric and that will weigh wait more towards the clariti piece. Relative to margins, we will continue to focus from a pricing point of view being keenly aware of that two-tier market, the premium market which we'll call the players there in the U.S. clearly Total1, oasis and MyDay and TruEye is the 1 that's there on that space but oasis will consume more and more of TruEye. And in the mass market, then clariti remains the only game in town relative to silicone hydrogel in the 1 Day mass market. So that is a function of watching the migration of hydrogels into this silicone hydrogel space in that mass market arena. Cost of goods gross margins, we expect as we've indicated in the past to have our 1 Day silicone hydrogel franchise and most notably clariti not a drag on our overall gross margin for the next several years anyway, MyDay is ramping up the learning curve, moving very nicely and I would say, the indicator of some of the idling and the indicator of us having enough MyDay capacity is just how well that's ramping up. As it ramps up cost of goods come down to the yields and deficiencies, so we're very pleased with that, and we expect more than -- probably more than 50% out of MyDay as we get down the road a couple of years."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of David Roman with Goldman Sachs.",13,"Our next question comes from the line of David Roman with Goldman Sachs."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","I was hoping you could just touch in a little bit more detail firstly the strength in Asia Pacific. I think last quarter, you have kind of said that you're ramping capacity in Japan that wouldn't be a significant contributor until the much later part of t",109,"I was hoping you could just touch in a little bit more detail firstly the strength in Asia Pacific. I think last quarter, you have kind of said that you're ramping capacity in Japan that wouldn't be a significant contributor until the much later part of the year and into the next fiscal year but any other regions driving, A, within Asia Pac that you can call out? And then, secondly on the 6 to 8% pro forma guidance for CSI  that is quite a bit above where those end markets are growing, so maybe you could just speak to the sustainability of that on a go forward basis?"
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","So relative to Asia Pac, I would emphasize that the numbers are very little to do with MyDay. It's very early in the game, so it didn't -- so the strengths you're seeing there is just how well some of the geographic expansions are going, how well Japan is",302,"So relative to Asia Pac, I would emphasize that the numbers are very little to do with MyDay. It's very early in the game, so it didn't -- so the strengths you're seeing there is just how well some of the geographic expansions are going, how well Japan is going x MyDay and then, the MyDay launch but it is not the driver of that 18% which -- and MyDay was only launched mid-March so really pulling up a month and a half in Japan in that period -- in the quarter. Relative to what to expect in that region, we certainly expect continued robust numbers out of Asia Pac for the foreseeable future, #1, we're under Index. Number 2, we're delivering a lot of these new products, clariti coming into the more and more of Asia Pac and of course, MyDay, which we talked about. So we're pretty optimistic that we'll see a continued strength in that market. Relative to surgical and the 6% to 8%, a lot of that growth is a reflection of, #1, the emphasis on early selling the product and the global realignment with the selling effort. We have some -- obviously, even some good products in the surgical side that are driving organic growth there. The acquisitions we made are the expectation there keenly is double-digit in many of those acquisitions so we expect to drive a lot of the genetic testing and surround the IBF process so that we are the key player that the IBF centers are engaging with and we're pretty optimistic about that and obviously, the last 2 quarters have indicated it's a pretty successful strategy. Going forward, the 6% to 8% reflect some of the more recent acquisitions having more organic topline growth potential than our historic legacy products within CooperSurgical."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","The next question comes from the line of Larry Biegelsen with Wells Fargo.",13,"The next question comes from the line of Larry Biegelsen with Wells Fargo."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Greg, based on the guidance, is the second half implied to provision guidance, the midpoint about 5%. And should we think about Q3 and Q4 a similar growth or would you expect Q4 to potentially be lower because the J&J launch comes in July? And Greg, can y",89,"Greg, based on the guidance, is the second half implied to provision guidance, the midpoint about 5%. And should we think about Q3 and Q4 a similar growth or would you expect Q4 to potentially be lower because the J&J launch comes in July? And Greg, can you just tell us what the FX assumption is? It looks like you're assuming about, for the year  0 impact on EPS. Is that math, right? What is it on sales and is there some conservatism in your FX assumptions right now?"
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, Larry, I think for CVI, the midpoint kind of growth for Q3/Q4 would be about 6.1%. I think if you do the math. If you look at from a seasonality, we're not giving quarterly seasonality but I think you can look at past seasonality for CooperVision gen",182,"Yes, Larry, I think for CVI, the midpoint kind of growth for Q3/Q4 would be about 6.1%. I think if you do the math. If you look at from a seasonality, we're not giving quarterly seasonality but I think you can look at past seasonality for CooperVision generally is fairly consistent. On the FX fronts, I think you got that right. When you look at FX, we basically  for the year, see about no impact on the earnings per share. On the revenue front, again, you're looking at about right around $30 million of revenue production. Now on the rates, are we being conservative? Well, if you look at today's rates, I think you can say we're being conservative. We did use the rates for the euro at 1.10, the pound at 1.46 and the yen at 112 and we start setting those rates a couple of days ago, the yen was at 1 point was at 111.3, so the yen has kind of basically strengthened the last couple of days but those were the rates that the model is based on."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Next question comes from the line of Mike Weinstein with JPMorgan.",11,"Next question comes from the line of Mike Weinstein with JPMorgan."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","This is Andrew in for Mike. I have 2 questions. The first being product specific and the second regarding the market. So can you talk about, Bob, the slide design changes due to clariti lens and what you're seeing in the way of market adoption with this d",52,"This is Andrew in for Mike. I have 2 questions. The first being product specific and the second regarding the market. So can you talk about, Bob, the slide design changes due to clariti lens and what you're seeing in the way of market adoption with this design versus before the change?"
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Sure, you want to ask the second?",7,"Sure, you want to ask the second?"
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Yes, I could ask the second. The second is around UPP. So the U.S. market growth in the quarter was probably the lowest in a while, I believe, and I was just wondering whether or not this is a result of some pricing war that's going on within the market a",68,"Yes, I could ask the second. The second is around UPP. So the U.S. market growth in the quarter was probably the lowest in a while, I believe, and I was just wondering whether or not this is a result of some pricing war that's going on within the market and just your general thoughts around the UPP and how you think that might benefit you moving forward."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Sure. Product relative to the enhancement that we made to clariti. I think you've seen the overall silicone hydrogel 1 Day numbers were 52% growth. So suffice it to say that the enhancement, as well as -- of course, we had some activity in the fourth quar",415,"Sure. Product relative to the enhancement that we made to clariti. I think you've seen the overall silicone hydrogel 1 Day numbers were 52% growth. So suffice it to say that the enhancement, as well as -- of course, we had some activity in the fourth quarter regarding our integration process in Europe that caused some bumps then but suffice it to say we're running on all cylinders now with clariti in the marketplace and the enhancement is certainly been very beneficial in that process. As far as UPP and the markets, 3% growth in the market, is much as anything is probably much more influence by the J&J cycle that they put the market through with strong market 2 quarters ago and that's followed by basically a void in the U.S. in this quarter. So were not for that  it would be more normalized. The trailing four quarters is a much better gauge, that is approaching 5% worldwide relative to the U.S. and UPP and whether or not there's any pricing post-UPP or a decline in pricing, I would say that certainly, I know that some vendors may -- and retailers and they have also J&J prices but by and large of the market is continue to drive itself as in the past, pricing is not really a factor. It's all about trading up and shelf space and fit and it remains that way. The focus on getting a new fit in the marketplace where you have a new product trying to  get a conversion onto your product. There is a fair amount of stickiness to most of these products, so I would say the real driver of your product doing well is the new fit arena is the big contributor. Pricing, to me, this market is traded up for 30 years and it continues to do a phenomenal job and over that 30 years, there may be 1 or 2 price scrimmages. UPP was  a fairly shallow attempt at a marketing strategy that was obviously, beneficial to the independent compared to the retailers whether or not it's worth anything. Can it continue to be debated? There's obviously a lot of emotions on both sides of the table on that in the marketplace but if UPP went away tomorrow, it would not be the end of the world. If it stays where it is, it's okay also. So I don't see that as a material catalyst one way or the other in the marketplace."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Anthony Petrone with Jefferies.",12,"Our next question comes from the line of Anthony Petrone with Jefferies."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Maybe 1 for Bob on Bob on Japan and 1 for Greg on margins. On Japan, can you maybe give us a recap of the size of the daily market in Japan and maybe were Cooper shares today and how MyDay can benefit that going forward? And then, for Greg, just a quick o",92,"Maybe 1 for Bob on Bob on Japan and 1 for Greg on margins. On Japan, can you maybe give us a recap of the size of the daily market in Japan and maybe were Cooper shares today and how MyDay can benefit that going forward? And then, for Greg, just a quick one on margins. I believe that royalty does roll off internationally toward the end of this year. I just want to confirm if that is the case and what do you expect the margin benefit from that will be?"
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, the overall market in Japan is around $1.2 billion at current exchange rates. It would have been a lot bigger than that but obviously, sliding against the dollar for a number of years. Of that, $1.2 billion basically 2/3 over 60% is the 1 Day modalit",86,"Yes, the overall market in Japan is around $1.2 billion at current exchange rates. It would have been a lot bigger than that but obviously, sliding against the dollar for a number of years. Of that, $1.2 billion basically 2/3 over 60% is the 1 Day modality and our share in that market is still very under indexed in that market, so far overall market share worldwide this most recent quarter 23% worldwide. We are well in the mid-teens at best in Japan in that space."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","And Anthony, this is Greg. On the royalty, it did roll off within the quarter. We're not really providing any kind of color on the rate itself. Again, we talked about that over the last couple of years that we have obligations to not disclosing that rate",57,"And Anthony, this is Greg. On the royalty, it did roll off within the quarter. We're not really providing any kind of color on the rate itself. Again, we talked about that over the last couple of years that we have obligations to not disclosing that rate and so from that perspective  we really can't share that."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","[Operator Instructions]  Our next question comes from the line of Jon Block with Stifel.",14,"[Operator Instructions]  Our next question comes from the line of Jon Block with Stifel."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Maybe first one  Bob, just CVI was strong and one of the better results since 2014 but to be fair if you go back then, we were sort of hit after that with a series of quarters where there was inventory drawdowns that went the company. So I just want to ma",79,"Maybe first one  Bob, just CVI was strong and one of the better results since 2014 but to be fair if you go back then, we were sort of hit after that with a series of quarters where there was inventory drawdowns that went the company. So I just want to make sure and ask if you would to your level of confidence that the sell in if you would in this particular quarter total the sellout and demand?"
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, I think I mentioned -- comment a while ago that relative to the quality of what's pricing or any pricing influencing or what pipeline influencing the answer is no. In fact, our pipeline -- the inventory on hand was slightly better than at the beginni",73,"Yes, I think I mentioned -- comment a while ago that relative to the quality of what's pricing or any pricing influencing or what pipeline influencing the answer is no. In fact, our pipeline -- the inventory on hand was slightly better than at the beginning of the period. In both cases  kind of where we want it, So the drawdown -- the inventory drawdown where the pipeline is where we want it."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Steven Lichtman with Oppenheimer & Co.",13,"Our next question comes from the line of Steven Lichtman with Oppenheimer & Co."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Most of my questions have been answered. 1 follow up on CSI. Bob, do you anticipate continuing to add to the portfolio through tuck in M&A or are you feeling that the portfolio is where you want it to be at this point?",43,"Most of my questions have been answered. 1 follow up on CSI. Bob, do you anticipate continuing to add to the portfolio through tuck in M&A or are you feeling that the portfolio is where you want it to be at this point?"
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, we won't obviously, get into a lot of color on what's in the pipeline but suffice it to say, we're focused in on rounding out the portfolio in front of the IBF centers. It is a boutique area where there are little things out there to continue to buy",69,"Well, we won't obviously, get into a lot of color on what's in the pipeline but suffice it to say, we're focused in on rounding out the portfolio in front of the IBF centers. It is a boutique area where there are little things out there to continue to buy up and so don't be surprised if we don't continue to have some acquisitions on a go forward basis."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","And that concludes today's question-and-answer session. I'd like to turn the call back to Bob Weiss for any closing remarks.",21,"And that concludes today's question-and-answer session. I'd like to turn the call back to Bob Weiss for any closing remarks."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, I want to thank everyone for joining us. Hopefully, everyone is excited about our quarterly results as we are pleased about them. Not only are  we pleased where we've been but very optimistic about where we're going as I think you would see from the",118,"Well, I want to thank everyone for joining us. Hopefully, everyone is excited about our quarterly results as we are pleased about them. Not only are  we pleased where we've been but very optimistic about where we're going as I think you would see from the guidance that Greg talked to. Yes  we have some short-term challenges with idle capacity. It's a silver lining problem because it means that to some degree, our capital requirements on go forward basis would be somewhat less certainly, than they have been in the past. So we look forward to updating you on our continued progress. On our next quarterly call, which is September 1, I believe. Thank you. That concludes, operator."
263609,334265350,994934,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Ladies and gentlemen, thank you for your participation in today's conference. This concludes the program and you may now disconnect. Everyone, have a great day.",25,"Ladies and gentlemen, thank you for your participation in today's conference. This concludes the program and you may now disconnect. Everyone, have a great day."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Good day, ladies and gentlemen, and welcome to The Cooper Companies Second Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference may be recorded. I'd now like to introduce your host for today's conference, Miss Kim",48,"Good day, ladies and gentlemen, and welcome to The Cooper Companies Second Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference may be recorded. I'd now like to introduce your host for today's conference, Miss Kim Duncan, Vice President, Investor Relations. Ma'am, please go ahead."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Good afternoon, and welcome to The Cooper Companies Second Quarter 2016 Earnings Conference Call.  I'm Kim Duncan, Vice President of Investor Relations. And giving prepared remarks on today's call are Bob Weiss, Chief Executive Officer; and Greg Matz, Chi",320,"Good afternoon, and welcome to The Cooper Companies Second Quarter 2016 Earnings Conference Call.  I'm Kim Duncan, Vice President of Investor Relations. And giving prepared remarks on today's call are Bob Weiss, Chief Executive Officer; and Greg Matz, Chief Financial Officer. 
Before we get started, I'd like to remind you that this conference call contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including all revenue and earnings per share guidance and other statements regarding anticipated results of operations, market or regulatory conditions and integration of any acquisitions or their failure to achieve anticipated benefits. Forward-looking statements depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Events that could cause our actual results and future actions of the company to differ materially from those described in the forward-looking statements are set forth under the caption Forward-Looking Statements in today's earnings release and are described in our SEC filings, including the Business section of Cooper's annual report on Form 10-K. These are publicly available and on request from the company's Investor Relations department. 
Now before I turn the call over to Bob, let me comment on the agenda for the call. Bob will begin by providing highlights on the quarter, followed by Greg, who will then discuss second quarter financial results. We will keep the formal presentation to roughly 30 minutes, then open the call for questions. We expect the call to last approximately 1 hour. We request that anyone asking questions, please limit yourself to 1 question. Should you have any additional questions, please call our Investor line at (925) 460-3663 or email ir@cooperco.com. 
As a reminder, this call is being webcast, and a copy of the earnings release is available through the Investor Relations section of The Cooper Companies website. 
And with that, I'll turn the call over to Bob for his opening remarks."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thank you, Kim, and good afternoon, everyone. Welcome to the Second Quarter 2016 Conference Call. Let me start by highlighting 3 key areas. First, I'm pleased to report strong financial results for our fiscal second quarter. On a consolidated basis, we re",1266,"Thank you, Kim, and good afternoon, everyone. Welcome to the Second Quarter 2016 Conference Call. Let me start by highlighting 3 key areas. First, I'm pleased to report strong financial results for our fiscal second quarter. On a consolidated basis, we reported $484 million in revenue and non-GAAP earnings per share of $2.05. 
Second, CooperVision posted 9% revenue growth on both a constant currency and as-reported basis and strong results in all key areas of the business. Since we used silicone hydrogel, lenses grew 52%, while 2-week and monthly silicone hydrogel lenses grew a combined 14% both in constant currency. 
Third, CooperSurgical had another strong quarter, posting revenue growth of 23% and pro forma growth of 6%. We also closed several strategic acquisitions since our last earnings call. 
Moving into the details, CooperVision reported second quarter revenues of $391 million, up 9%. This was our strongest quarter -- growth quarter since 2014 and really shows the strength of our product portfolio. Regarding revenue by geography, the Americas grew 9% in constant currency, showing a nice rebound from last quarter. Strength was seen in multiple categories led by silicone hydrogel products. Our enhanced clariti lens has been extremely well received and MyDay had another strong quarter. Our toric and multifocals also posted strong growth driven by the Biofinity family. 
EMEA had another strong quarter and sales grew 5% in constant currency. Growth was driven by our family of silicone hydrogel products, Biofinity, clariti, MyDay and Avaira. We also launched Avaira Vitality in EMEA during the quarter and it is being well received. Avaira Vitality is our new 2-week silicone hydrogel lens, which is an enhanced replacement for the original Avaira lens. It was developed using improved manufacturing processes, resulting in a higher quality product at a lower cost per unit. We expect to launch this lens in the U.S. later this year subject to FDA approval. 
Asia Pacific had a very strong quarter, up 18% in constant currency. Growth was strong throughout the region and Biofinity and Proclear 1 Day stood out in Japan. Also within Japan, we began our MyDay launch during the quarter and we're seeing early signs that MyDay could be a very successful premium offering in that market. 
Turning to our product categories. Toric and multifocals grew a healthy 13% year-over-year in constant currency. We saw a very nice rebound in the U.S., which bolstered our strength throughout the rest of the world. We remained the global leader in specialty lenses. 
Looking at silicone hydrogel lenses. These products grew 20% in constant currency and now represent 60% of our total sales. Within the 2-week and monthly space, Biofinity and Avaira combined to grow 14% in constant currency. We remain under index in the 2-week and monthly silicone hydrogel space at 74% of sales versus the market at 79%, so we anticipate a very nice growth for many years to come. 
Regarding our silicone hydrogel 1 Day lenses, clariti and MyDay, they combined to grow 52% in constant currency. We remain very optimistic about these products and are committed to our growth strategy, which includes a 2-tier approach with clariti positioned as the mass market offering and MyDay as the premium offering. Remember the biggest driver in the contact lens market is the 1 Day growth, and we strongly believe we have the best product offering in the space as the only company with premium and mass market lenses, including a full portfolio of 1 Day silicone hydrogel, sphere, toric and multifocal lenses. 
Before finishing with market data, let me make a quick comment on integration matters. We continue to finalize our Sauflon integration activities and we're very close to being done. You'll note that provision had a very small non-GAAP adjustment this quarter -- or a smaller non-GAAP adjustment this quarter of roughly $9 million excluding amortization. We forecast similar charges in Q3 and Q4, mostly within costs of goods, but these should end this fiscal year. 
Now let me comment on the overall contact lens market and remember, this information is on the last page of the earnings release. For calendar Q1, we continue taking share, growing 9%, with the market up 3%. Geographically, CooperVision grew 9% in the Americas while market was flat. In Asia Pacific, CooperVision grew 14%, with the market up 5%. And in EMEA, we grew 6%, in line with the market. 
On modality basis, single-use lenses continue driving growth and CVI -- with CVI up 14% and the market up 9%. For non-single-use lenses, we grew 6% while the market declined 1%. We also see -- as you can see, our growth remains diverse and strong. On a trailing 12 month basis, CooperVision grew 8% and the market grew 5%. Going forward, I expect the market to continue growing forward to 6% over the next 5 years and most likely closer to 6%. The drivers will continue to be a shift to dailies' geographic expansion and an expansion of the wear base. We expect to continue taking market share, led by our strong silicone hydrogel portfolio. 
Moving to CooperSurgical. We reported second quarter revenues of $93 million, up 23% year-over-year or up 6% pro forma. Our fertility products led the way up 60% or 8% pro forma and our office and surgical products grew 5%. We continued executing on several initiatives, which are driving success, including transitioning to a geographic sales model, adding sales representatives in under-penetrated areas and increasing our focus on high-growth areas such as IVF and genetic testing. These moves are clearly gaining traction as we saw growth throughout core business in Q2. Going forward, I believe we'll continue to see solid growth as the business keeps moving into a more aggressive and efficient business model. 
Regarding acquisitions. We've completed several over the past few months, so let me touch on those and the strategic rationale. At the beginning of April, we added Genesis Genetics, a genetic testing lab company focused on preimplantation genetic screening and diagnosis using -- used during the IVF process. This is a nice addition to our existing genetic testing platform. 
At the beginning of May, we added complementary IVF capital equipment products through the acquisition of K-Systems, a small acquisition with roughly $7 million in revenue per year. 
And finally, we added the assets of Recombine last week. Recombine is a genetic testing company specializing in carrier screening, which is a great fit within our IVF and genetic testing franchise as it adds the #1 carrier screening test sold to the IVF clinics. 
As you can see, we're very focused on combining a full-service provider within the IVF global market, and we truly believe this strategy will yield success for many years to come. These deals are all incorporated into our updated guidance. With that, let me touch on our guidance details. 
We are raising our fiscal 2016 revenue guidance for CooperVision to 5.5% to 7% constant currency growth. Our CooperSurgical revenue guidance is also raised to 6% to 8% pro forma growth or up 24% to 27% on an as-reported basis. We're also raising our non-GAAP EPS guidance to $8.20 to $8.50. 
In conclusion, I'm very pleased with our results and remain optimistic about the underlying fundamentals of our business. I believe we're well positioned to deliver solid results through the remainder of the fiscal year and beyond. With that, let me express my appreciation to our employees, our #1 asset. Their hard work and dedication to creating value is the backbone of our success. 
And now I'll turn it over to Greg to cover the financial results."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thanks, Bob, and good afternoon, everyone. I'll provide the overall summary of our performance, including a review of the market and our revenue picture. We're going to focus primarily on our non-GAAP results for the quarter. For the reconciliation to GAA",1144,"Thanks, Bob, and good afternoon, everyone. I'll provide the overall summary of our performance, including a review of the market and our revenue picture. We're going to focus primarily on our non-GAAP results for the quarter. For the reconciliation to GAAP numbers, please refer to our earnings release. 
Looking at gross margins. In Q2, the non-GAAP gross margin was 63.2% compared to 63.4% in the prior year. Although CooperVision had positives from currency and strong Biofinity sales, its margin was lower than expected. The primary items driving this were a negative margin impact from stronger Asia Pac sales, where we have higher 1 Day sales, and charges associated with idle equipment and legacy hydrogel inventory. 
Regarding these last 2 items, let me cover them separately. We have made a lot of progress improving our manufacturing operations, including some very recent successes. For competitive reasons, I won't get into specifics but our production per line has increased materially, resulting in lower cost per unit and a lesser need for future CapEx. This has resulted in idling from equipment, which hurts us in Q2 and will also negatively impact Q3 and Q4. We anticipate this being a short-term negative as we will grow into this production over time. 
The other item is our legacy hydrogel inventory, where we wrote off more than we planned, as our silicone hydrogel sales were very strong and we're forecasting that to continue. Disbursements in Q2 and we expect it will negatively impact Q3 and Q4. To be clear, we're not excluding these items from earnings, so they are negatively impacting our non-GAAP earnings per share. 
CooperVision on a non-GAAP basis reported gross margin of 62.8% versus 63.3% in Q2 of last year. The factors which impacted margin were the items I just mentioned. CooperSurgical had non-GAAP gross margin of 64.8%, which compares to Q2 '15 of 63.5%. Strength in the OB/GYN and IVF product families drove this quarter's margin. 
SG&A. On a non-GAAP basis, SG&A increased approximately 6% to $171.6 million or 35% of revenue, down from approximately 37% of revenue in the prior year. Primary driver behind this leverage was strong SG&A controls. 
Now looking at R&D. In Q2, R&D on a non-GAAP basis was $16.6 million or 3.4% of revenue, flat in dollars and down from 3.8% of revenue in the prior year. We're seeing investments in CSI, offset by synergies from the Sauflon acquisition in CVI. 
Now moving to operating margins. For Q2, consolidated GAAP operating income and margin were $89.8 million and 18.6% of revenue versus $71 million and 16.3% of revenue in Q2 last year. Non-GAAP operating income and margin were $117.6 million and 24.3% of revenue versus $96.7 million and 22.2% of revenue for the prior year. Primary difference in operating margin year-over-year is the operating expense leverage. 
In Q2, CooperVision, on a non-GAAP operating income and margin, were $102.4 million and 26.2% of revenue versus $88.8 million and 24.7% of revenue in the prior year. 
CooperSurgical's non-GAAP operating income and margin were $26.6 million and 28.8% of revenue versus Q2 '15 of $18.8 million of operating income and 25% of revenue. 
Moving on to depreciation and amortization. In Q2, depreciation was $33.7 million, up $1.5 million year-over-year. Amortization was $14.3 million, up $2 million, reflecting our recent acquisition activity. 
Interest expense was $7.6 million for the quarter, up $2.9 million year-over-year, primarily due to higher debt and interest rate associated with acquisitions. Looking at the effective tax rate. In Q2, the non-GAAP effective tax rate was 9.4% versus a non-GAAP effective tax rate of 8.4% in Q2 '15. 
Earnings per share. Our Q2 earnings per share on a GAAP and non-GAAP basis was $1.52 and $2.05, respectively versus $1.23 and $1.72 for GAAP and non-GAAP in the prior year. Non-GAAP earnings per share on a pro forma basis, which adjust for currency and acquisitions, were approximately 13% in the quarter. 
Now looking at FX. The net currency impact on earnings per share year-over-year for Q2 was a favorable $0.10. 
Moving on to the balance sheet. In Q2, we had cash provided by operations of $97.8 million less capital expenditures of $41.1 million, resulting in $56.7 million of free cash flow. Excluding integration costs of $9 million, adjusted free cash flow was $65.7 million. 
Total debt increase within the quarter by $64.1 million to $1,441,400,000, primarily due to higher average cash balances and acquisitions, partially offset by operational cash flow. 
Inventories increased from last quarter, approximately $2.7 million, to $433.6 million. This is entirely driven by CSI acquisitions. In CooperVision, we saw inventories decline as growth in silicone daily inventory to support our product launches was offset by a reduction in our hydrogel inventory. For the quarter, we're seeing months on hand at 7 months. Day sales outstanding is at 54 days, which is down 3 days from the prior quarter and 2 days from last year. 
Now turning to guidance. For our main currencies, we are using 1.10 for the euro, 112 for the yen and 1.46 for the pound. 
The consolidated revenue range is being raised to $1.929 billion to $1.960 billion or approximately 5.5% to 7% pro forma growth. CooperVision's revenue range is being raised to $1.545 billion to $1.567 billion or roughly 5.5% to 7% constant currency growth. CooperSurgical's revenue range is being raised to $384 million to $393 million or roughly 68% pro forma growth. Note that roughly half of the increase in guidance is from currency, while the other half is primarily from acquisitions. 
We expect non-GAAP gross margin to be around 63% for the year. This is a reduction from the previous guidance of around 64% as it incorporates the CooperVision items I mentioned earlier, along with lower gross margins from CooperSurgical, associated with recent acquisitions. Having said that, we still expect improving Q3 and Q4 gross margins around 64% each quarter. 
OpEx expected to be around 39%. Operating margins still expected to be around 24%. 
Interest expense is expected to be around $28 million. 
Our effective tax rate is expected to be around 8%. 
Our expected share count will be around 49.1 million shares. 
And our non-GAAP earnings per share is expected to be $0.20 higher on the top and bottom of our range to $8.20 to $8.50, which equates to a pro forma earnings per share of 10% to 14% growth. 
From our last guidance, currency is roughly a $0.40 positive, and we have actually improved our operational performance by roughly $0.10, but we are expecting the idle legacy inventory write-off to negatively impact us by roughly $0.30. 
CapEx is expected to be around $200 million. 
We finished paying for equipment we have ordered over the prior year, and thus, adjusted free cash flow is still expected to be around $300 million. 
With that, let me turn it back to Kim for the Q&A session."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Operator, we're ready to take some questions.",7,"Operator, we're ready to take some questions."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Matthew O'Brien with Piper Jaffray.",15,"[Operator Instructions] 
Our first question comes from the line of Matthew O'Brien with Piper Jaffray."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Just one for Bob and then one for Greg. On the increase in CVI -- I guess, this question is for Bob -- increase to CVI's outlook for the year, can you just give us a sense for how much of that is coming from improved manufacturing of MyDay, especially lau",137,"Just one for Bob and then one for Greg. On the increase in CVI -- I guess, this question is for Bob -- increase to CVI's outlook for the year, can you just give us a sense for how much of that is coming from improved manufacturing of MyDay, especially launching into Japan? Or are there disruptions in the markets that you're seeing? And then, how much are you incorporating the J&J launch as far of somewhat of a headwind into your fiscal Q4? And then, for Greg, this is typically a really strong free cash flow quarter for you guys that you're sticking with the $300 million outlook for the year. So can you just help us rectify a little bit of a softness that we saw here in Q2 versus that outlook for the year?"
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes. The foreign exchange, as Greg indicated, is a big driver of the top line overall improvement. In terms of the constant currency growth, you're correct, there is a modest -- in the guidance, there's a modest deceleration compared to what we had previo",125,"Yes. The foreign exchange, as Greg indicated, is a big driver of the top line overall improvement. In terms of the constant currency growth, you're correct, there is a modest -- in the guidance, there's a modest deceleration compared to what we had previously forecasted to anticipate,  if you will, some impact of the J&J rollout. Beyond that, it's pretty much at the same range at 5.5% to 7%, so modest at both. MyDay impact in Japan is -- once again, we just rolled that product out in March of this year, so a fairly minimal impact in terms of the overall any update on the guidance, if you will. And of course, we already knew about MyDay in Japan in our previous March guidance."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, Matt, on the free cash flow, nothing really jumps out. The number isn't that far off of the prior year. And we did have a much stronger Q1, so if you look at kind of halfway through the year, we're actually or probably ahead of where we were last yea",51,"Yes, Matt, on the free cash flow, nothing really jumps out. The number isn't that far off of the prior year. And we did have a much stronger Q1, so if you look at kind of halfway through the year, we're actually or probably ahead of where we were last year."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Jeff Johnson with Robert Baird.",13,"Our next question comes from the line of Jeff Johnson with Robert Baird."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Sorry, about that. Guys, can hear me, okay?",8,"Sorry, about that. Guys, can hear me, okay?"
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","We can.",2,"We can."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","All right, great. So Bob, let me ask you one question and I have a modeling question for Greg as well. But the question for you, just on the Biofinity and Avaira business, obviously that bounced back very nicely this quarter. I think you said 14% constant",119,"All right, great. So Bob, let me ask you one question and I have a modeling question for Greg as well. But the question for you, just on the Biofinity and Avaira business, obviously that bounced back very nicely this quarter. I think you said 14% constant currency in the quarter year-over-year. 7% last quarter, so kind of averaging right around double digits. Is that how we should think about that business going forward? Obviously, you've got the launch coming from J&J, as it was referenced in the prior question. You also have Ultra [ph] kind of gaining some traction, it sounds like. So just how do you think about that Biofinity/Avaira bucket over the next couple of years?"
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, I think taking the 2 quarters, the 7% and 13%, being in around low double digit is the right way to think about it.",25,"Yes, I think taking the 2 quarters, the 7% and 13%, being in around low double digit is the right way to think about it."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Right, that's helpful. And Greg, question for you. I think at the very end, did you say $0.30 is the EPS impact of the inventory write-off and that is included in your non-GAAP EPS guidance? Is that correct?",38,"Right, that's helpful. And Greg, question for you. I think at the very end, did you say $0.30 is the EPS impact of the inventory write-off and that is included in your non-GAAP EPS guidance? Is that correct?"
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes.",1,"Yes."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Okay. So for next year, we should been thinking about adding just kind of building off a base that's $0.30 higher, assuming you're not going to have that kind of write-offs next year? Would that be the fair way to take kind of this year's EPS, add $0.30 b",61,"Okay. So for next year, we should been thinking about adding just kind of building off a base that's $0.30 higher, assuming you're not going to have that kind of write-offs next year? Would that be the fair way to take kind of this year's EPS, add $0.30 back and build that off as our base assumption going into next year?"
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Jeff, It's just probably a little early to get into next year's guidance, which we will come out later in the year and discuss.",24,"Jeff, It's just probably a little early to get into next year's guidance, which we will come out later in the year and discuss."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","And keep in mind, Jeff, there's a balance between -- some of that is write-off, as Greg indicated. Some of it is idle equipment as we grow into it. So we're growing. Given the substantial growth of our 1 Day modality and our unit growth, we're anticipatin",73,"And keep in mind, Jeff, there's a balance between -- some of that is write-off, as Greg indicated. Some of it is idle equipment as we grow into it. So we're growing. Given the substantial growth of our 1 Day modality and our unit growth, we're anticipating that we'll start consuming more and more of that as each quarter goes by. But that $30 million overall is both write-offs as well as idle."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, and Jeff, just to build on that a little bit, I think without giving guidance, I think we feel comfortable that we would see gross margins improve year-over-year.",29,"Yes, and Jeff, just to build on that a little bit, I think without giving guidance, I think we feel comfortable that we would see gross margins improve year-over-year."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Joanne Wuensch with BMO Capital Markets.",14,"Our next question comes from the line of Joanne Wuensch with BMO Capital Markets."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Can you hear me, okay?",5,"Can you hear me, okay?"
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","We can.",2,"We can."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Wonderful. I think what a couple of people were trying to get at, and I know -- and speaking with those investors, the big concern right now is the J&J monthly launch starting at the end of June, beginning of July. How can you -- how do you think about th",73,"Wonderful. I think what a couple of people were trying to get at, and I know -- and speaking with those investors, the big concern right now is the J&J monthly launch starting at the end of June, beginning of July. How can you -- how do you think about that product launch and how do we get comfortable that we're not going to see a similar hiccup to what happened last fall?"
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, without knowing exactly what J&J is up to, in hindsight, we know what they did is they sold the pipeline a lot. And then, we sought in their negative U.S. results in the most recent quarter. So no one can say they can't do that again. Having said th",396,"Well, without knowing exactly what J&J is up to, in hindsight, we know what they did is they sold the pipeline a lot. And then, we sought in their negative U.S. results in the most recent quarter. So no one can say they can't do that again. Having said that, this is a product coming into the monthly modality. It's basically coming in with only a sphere, not at toric and a multifocal, so it's not a family of products going against a family of products. And that is a big distinction as contrasted to the pipeline dragging everything in under one umbrella, as they did their whole family of products, and going after a sphere going after a sphere. In that case, it was always the 1 Day going against Total1 primarily in that space. But it consumed -- it took all the air out of the practitioner's office, if you will, or filled up all the space. And there clearly is no guarantee they wouldn't try flooding the market again. As far as the way we think about it longer-term, Biofinity is a very established product, wherein we continue to expand the offerings under that umbrella. It's a very global product, and it's one where -- it's [indiscernible] in the monthly and we also have Avaira Splash Vitality [ph] coming out in the 2-week, which is the sweet spot of the market in terms of the number of wearers. There are more wearers in the 2-week part of the market than there are in the monthly. Quite frankly, as some of you know, I've always held the view that it's a good strategy for J&J if they're intent on trading up and basically migrating the noncompliant wearer base they have in the 2-week space into a compliant monthly modality. That would be a good trade-up in modalities because a noncompliant wearer is one who is basically only using 24 lenses a year compared to a monthly using 24 and conversely they're getting the price point of a 2-week wear. And that's a pretty big part of that 2-week modality. So we think -- yes, we'll continue to see that market grow, the monthly, and we'll get our fair share with Biofinity. In the meantime, we'll be more active down the road in the 2-week space, and we'll basically neutralize it for the most part."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Steve Willoughby with Cleveland Research.",13,"Our next question comes from the line of Steve Willoughby with Cleveland Research."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Hey, guys. Can you hear me, okay?",7,"Hey, guys. Can you hear me, okay?"
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","We can, Steve.",3,"We can, Steve."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Okay, Bob. Just regarding the charge or the idle equipment and inventory write-off that you guys took in the quarter, a couple of questions regarding that. I guess, first, the idle equipment, is that -- the idle equipment charge, it relates to newly purch",62,"Okay, Bob. Just regarding the charge or the idle equipment and inventory write-off that you guys took in the quarter, a couple of questions regarding that. I guess, first, the idle equipment, is that -- the idle equipment charge, it relates to newly purchased equipment that you don't need quite yet? Or is that existing equipment that you're idling for some reason?"
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","So to qualify as idle, it's basically been put in production and then is taken out of production. So I'll answer the question with a little color. It could be very new equipment that was put in production. Example, our facility at Hungary, where they got",123,"So to qualify as idle, it's basically been put in production and then is taken out of production. So I'll answer the question with a little color. It could be very new equipment that was put in production. Example, our facility at Hungary, where they got real good at making it, and all of a sudden, we parked the equipment because so many --  so much product was coming off of the other line. So as yields go up and costs are coming down, that's the good news. The bad news is if you put it -- if you put equipment that you were using and you idle it, it becomes a direct period charge as opposed to moving through with the inventory."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Okay. is this sort of what happened with Avaira and the Gen 2 line a number of years ago then?",20,"Okay. is this sort of what happened with Avaira and the Gen 2 line a number of years ago then?"
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Absolutely.",1,"Absolutely."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Okay. And [indiscernible]",3,"Okay. And [indiscernible]"
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","So what happened is our manufacturing people got very good at what they were doing. We always knew that if we -- that they would deliver. We just didn't know how well they would deliver. So they're delivering a lot more units per dollar spent of capital.",132,"So what happened is our manufacturing people got very good at what they were doing. We always knew that if we -- that they would deliver. We just didn't know how well they would deliver. So they're delivering a lot more units per dollar spent of capital. That's the good news. But it also turned short-term into the bad news. As I think Greg indicated, we'll grow out of that fairly quickly when you look at the rapid unit growth in many of these areas, where we have become very efficient. And that includes MyDay, that includes Biofinity, that includes Avaira, that includes Vitality, and that includes clariti in the bucket. They -- all of those products became -- the costs are going down through efficiencies and yields by our manufacturing people."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Lawrence Keusch with Raymond James.",13,"Our next question comes from the line of Lawrence Keusch with Raymond James."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","This is actually John in for Larry. I just had a quick question. I guess, what's the right way to calibrate expectation for MyDay in Japan? You obviously just launch in the quarter, but maybe shorter term and then maybe a little bit longer term in '16 and",49,"This is actually John in for Larry. I just had a quick question. I guess, what's the right way to calibrate expectation for MyDay in Japan? You obviously just launch in the quarter, but maybe shorter term and then maybe a little bit longer term in '16 and '17?"
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, you can see some of the numbers we're putting up in the region and Japan has certainly been stellar within that region also. Right now, we have a good portfolio of 3 products, with MyDay being the third one in, but Biofinity is doing very well. Proc",276,"Well, you can see some of the numbers we're putting up in the region and Japan has certainly been stellar within that region also. Right now, we have a good portfolio of 3 products, with MyDay being the third one in, but Biofinity is doing very well. Proclear 1 Day is doing very well as well now MyDay. We will be -- we're early 1.5 months into the launch, if you will, through the end of April and are very pleased with the progress we're making. It's the biggest market by far in terms of the 1 Day modality anyplace in the world, and therefore, MyDay is a very good fit in a very good market. And we think the combination of MyDay as a silicone hydrogel and Proclear 1 Day as a hydrogel will be -- is a good entree into that market. As Japan has been historically pretty lethargic in the last -- I want to say, 7, 8 years. It's showing a little bit more life than it has. And the only reason it's been lethargic is because it grew so rapidly in the prior decade compared to this decade. It got ahead of itself on the 1 Day modality and became the first to adapt that because there were very anti-lens care regimens and wanted the lenses to be boiled, and therefore, everyone migrated into the 1 Day modality rather than boiling lenses every day. And I'll just say that we're pretty excited about MyDay there. It's going to take some work. It's only a sphere thus far, so there will be other plans relative to how to leverage the MyDay experience."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Matt Mishan with KeyBanc.",12,"Our next question comes from the line of Matt Mishan with KeyBanc."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Bob, first, on CooperVision, I just want to better understand the sequential improvement in growth this quarter versus the previous several quarters. Is it your sense that the impact of the Johnson & Johnson launch has now fully waned? Or is there somethi",78,"Bob, first, on CooperVision, I just want to better understand the sequential improvement in growth this quarter versus the previous several quarters. Is it your sense that the impact of the Johnson & Johnson launch has now fully waned? Or is there something that you've been doing to improve your results and to improve share? I'm just trying to get a sense of whether or not this is Johnson & Johnson or this is you guys doing something."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","So I think it's a combination. I think the air that left the room is now back in the room. The eye care professional, he has room for products, and so it's more normalized in that sense and that's obvious from the weak numbers that J&J put up domestically",137,"So I think it's a combination. I think the air that left the room is now back in the room. The eye care professional, he has room for products, and so it's more normalized in that sense and that's obvious from the weak numbers that J&J put up domestically, and [indiscernible] Alcon put up numbers worldwide. We -- relative to our products, I think I'll make a point in saying that our numbers that we put up is not a function of any price -- pricing or anything to do with channel sales. So it's a good quarter. The inventory on hand at distributors and the pipeline is very normalized. In fact, it's a little less than it was at the beginning of the period. So it's a reflection of pretty solid numbers around the world."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Brian Weinstein with William Blair.",13,"Our next question comes from the line of Brian Weinstein with William Blair."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","It's a little bit of a longer-term question, but can you talk about what you expect longer term in terms of the split between clariti and MyDay and kind of what you think your share longer term is there? And then, how do you think about manufacturing -- m",60,"It's a little bit of a longer-term question, but can you talk about what you expect longer term in terms of the split between clariti and MyDay and kind of what you think your share longer term is there? And then, how do you think about manufacturing -- manufacturer pricing levels in the daily silicone hydrogel market longer term?"
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","So I think the split between clariti and MyDay, it's easier to relate in the U.S. The U.S. [indiscernible] primarily where clariti is after the mass market and MyDay is after the premium market. I would have normally said, think of that as like a 75% mass",455,"So I think the split between clariti and MyDay, it's easier to relate in the U.S. The U.S. [indiscernible] primarily where clariti is after the mass market and MyDay is after the premium market. I would have normally said, think of that as like a 75% mass market, 25% premium market. And I think that's the U.S. portion of the model. I think when you get into certain regions of the world, for example, Japan, where only MyDay is playing, then -- so if you're factoring that into the overall global results, you'll end up with MyDay outgrowing because it's coming off of a lower base and it's just getting into Japan, at least for the foreseeable future, outgrowing as a percent, getting more of its share of the bucket. So it's instead of saying 75%-25%, MyDay may move up that spectrum and get a higher portion in the interim. When clariti is available throughout Asia Pac and around the world, that may come back more into the mass market premium split. But for now, one point is we're not capacity constrained on either of these products. We will continue, in the case of MyDay, expanding the portfolio offering, so that will help. Right now, it's a sphere competing with clariti, which has a sphere, a multifocal and a toric, and that will weigh more towards the clariti piece. Relative to margins, we will continue to focus -- from a pricing point of view, being keenly aware of that 2-tier market, the premium market, which we'll call the players there in the U.S., clearly Total1, OASYS and MyDay. And TruEye is the other one that's kind of there on that space, but OASYS will consume more and more of TruEye. And in the mass market, then clariti remains the only game in town relative to a silicone hydrogel in the 1 Day mass market. So that is a function of watching the migration of hydrogels into this silicone hydrogel space in that mass market arena. Cost of goods gross margins, we expect, as we've indicated in the past, to have our 1 Day silicone hydrogel franchise, and most notably clariti, not a drag on our overall gross margin for the next several years. Anyway, MyDay is ramping up the learning curve, moving very nicely. And I would say, the indicator of some of the idling and the indicator of us having enough MyDay capacity is just how well that's ramping up. As it ramps up, the cost of goods come down to the yields and deficiencies, so we're very pleased with that, and we expect more than -- currently more than 50% out of MyDay as we get down the road a couple of years."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of David Roman with Goldman Sachs.",13,"Our next question comes from the line of David Roman with Goldman Sachs."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","I was hoping you could just touch on in a little bit more detail firstly the strength in Asia Pacific. I think last quarter, you have kind of said that you're ramping capacity in Japan. That wouldn't be a significant contributor till the much later part o",111,"I was hoping you could just touch on in a little bit more detail firstly the strength in Asia Pacific. I think last quarter, you have kind of said that you're ramping capacity in Japan. That wouldn't be a significant contributor till the much later part of the year and into the next fiscal year. But any other regions driving, a, within Asia Pac that you can call out? And then, secondly on the 6% to 8% pro forma guidance for CSI, that is quite a bit above where those end markets, I think, are growing, so maybe you could just speak to the sustainability of that on a go-forward basis?"
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","So relative to Asia Pac, I would emphasize that the numbers you see have very little to do with MyDay. It's very early in the game, so it didn't -- so the strength you're seeing there is just how well some of the geographic expansions are going, how well",310,"So relative to Asia Pac, I would emphasize that the numbers you see have very little to do with MyDay. It's very early in the game, so it didn't -- so the strength you're seeing there is just how well some of the geographic expansions are going, how well Japan is going ex MyDay, and then the MyDay launch. But it is not the driver of that 18%, which -- and MyDay was only launched mid-March, so really, it's only got 1.5 months in Japan in that period -- in the quarter. Relative to what to expect in that region, we certainly expect continued robust numbers out of Asia Pac for the foreseeable future. Number one, we're under-indexed. Number two, we're delivering a lot of these new products, clariti coming into the more and more of Asia Pac, and of course, MyDay, which we talked about. So we're pretty optimistic that we'll see a continued strength in that market. Relative to surgical and the 6% to 8%, a lot of that growth is a reflection of, number one, the emphasis on really selling the product and the global realignment with the selling effort. We have some -- obviously, even some good products in the surgical side that are driving organic growth there. The acquisitions we've made are -- the expectation there keenly is -- clearly is double-digit in many of those acquisitions, so we expect to drive a lot of the genetic testing and surround the IVF process so that we are the key player that the IVF centers are engaging with. And we're pretty optimistic about that, and obviously, the last 2 quarters have indicated it's a pretty successful strategy. I think going forward, the 6% to 8% reflects some of the more recent acquisitions having more organic top line growth potential than our historic legacy products within CooperSurgical."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Larry Biegelsen with Wells Fargo.",13,"Our next question comes from the line of Larry Biegelsen with Wells Fargo."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Hey, Greg, based on the guidance, is the second half implied CooperVision guidance, the midpoint about 5%? And should we think about Q3 and Q4 a similar growth or would you expect Q4 to potentially be lower because the J&J launch comes in July? And Greg,",89,"Hey, Greg, based on the guidance, is the second half implied CooperVision guidance, the midpoint about 5%? And should we think about Q3 and Q4 a similar growth or would you expect Q4 to potentially be lower because the J&J launch comes in July? And Greg, can you just tell us what the FX assumption is? It looks like you're assuming about, for the year 0 impact on EPS. Is that math, right? What is it on sales? And is there some conservatism in your FX assumptions right now?"
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, Larry, I think for CVI, the midpoint kind of growth for Q3/Q4 would be about 6.1%, I think if you do the math. If you look at from a seasonality, we're not giving quarterly seasonality. But I think you can look at past seasonality for CooperVision. I",189,"Yes, Larry, I think for CVI, the midpoint kind of growth for Q3/Q4 would be about 6.1%, I think if you do the math. If you look at from a seasonality, we're not giving quarterly seasonality. But I think you can look at past seasonality for CooperVision. It generally is fairly consistent. On the FX fronts, yes, I think you've got that right. When you look at FX, we basically for the year see about no impact on the earnings per share. On the revenue front, again, you're looking at about right around $30 million of revenue reduction. Now on the rates, are we being conservative? Well, if you look at today's rates, I think you can say we're being conservative. We did use the rates for the euro at 1.10, the pound at 1.46 and the yen at 112, and we start setting those rates a couple of days ago. The yen was at 1 point -- or was that 111.3, so the yen has kind of -- has basically strengthened in the last couple of days. But those were the rates that the model is based on."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Mike Weinstein with JPMorgan.",12,"Our next question comes from the line of Mike Weinstein with JPMorgan."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","This is Andrew [ph] in for Mike. I have 2 questions, the first being product-specific and the second regarding the market. So can you talk about, Bob, the slight design changes in the clariti lens and what you are seeing in the way of market adoption with",53,"This is Andrew [ph] in for Mike. I have 2 questions, the first being product-specific and the second regarding the market. So can you talk about, Bob, the slight design changes in the clariti lens and what you are seeing in the way of market adoption with this design versus before the change?"
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Sure, do you want to ask the second?",8,"Sure, do you want to ask the second?"
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Yes, I could ask the second. The second is around UPP. So the U.S. market growth in the quarter was probably the lowest in a while, I believe, and I was just wondering whether or not this is a result of some pricing war that's going on within the market a",68,"Yes, I could ask the second. The second is around UPP. So the U.S. market growth in the quarter was probably the lowest in a while, I believe, and I was just wondering whether or not this is a result of some pricing war that's going on within the market and just your general thoughts around the UPP and how you think that might benefit you moving forward."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Sure. The product relative to the enhancement that we made to clariti, I think you've seen the overall silicone hydrogel 1 Day numbers were 52% growth. So suffice it to say that the enhancement as well as -- of course, we had some activity in the fourth q",421,"Sure. The product relative to the enhancement that we made to clariti, I think you've seen the overall silicone hydrogel 1 Day numbers were 52% growth. So suffice it to say that the enhancement as well as -- of course, we had some activity in the fourth quarter regarding our integration process in Europe that caused some bumps then. But suffice it to say we're running on all cylinders now with clariti in the marketplace and the enhancement is certainly been very beneficial in that process. As far as UPP and the market, 3% growth in the market. It's much -- if anything, it's probably much more influenced by the J&J cycle that they put the market through with a strong market 2 quarters ago, and that's followed by basically a void in the U.S. in this quarter. So were it not for that, it would be more normalized. The trailing four quarters is a much better gauge that is approaching 5% worldwide relative to the U.S. and UPP. And whether or not there's any pricing post-UPP or a decline in pricing, I would say that certainly, I know that some vendors may have -- or retailers may have altered J&J prices, but by and large, the market continues to drive itself with. As in the past, pricing is not really a factor. It's all about trading up and shelf space and first fits, and it remains that way. The focus on getting a new fit in the marketplace or where you have a new product, trying to get a conversion onto your product. There is a fair amount of stickiness to most of these products, so I would say the real driver of your product doing well, the new fit arena is the big contributor. Pricing, to me, this market has traded up for 30 years and it continues to do a phenomenal job. And over that 30 years, there has been but maybe 1 or 2 price scrimmages. UPP was a fairly shallow attempt at a marketing strategy that was obviously, beneficial to the independents compared to the retailers. Whether or not it was worth anything, it continued to be debated. There's obviously a lot of emotions on both sides of the table on that in the marketplace. But if UPP went away tomorrow, it would not be the end of the world. If it stays where it is, it's okay also. So I don't see that as a material catalyst one way or the other in the marketplace."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Anthony Petrone with Jefferies.",12,"Our next question comes from the line of Anthony Petrone with Jefferies."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Maybe one for Bob on Japan and then one for Greg on margins. On Japan, can you maybe give us a recap of the size of the daily market in Japan and maybe where Cooper share is today and how MyDay can benefit that going forward? And then, for Greg, just a qu",93,"Maybe one for Bob on Japan and then one for Greg on margins. On Japan, can you maybe give us a recap of the size of the daily market in Japan and maybe where Cooper share is today and how MyDay can benefit that going forward? And then, for Greg, just a quick one on margins. I believe the CIBA royalty does roll off internationally toward the end of this year. I just want to confirm if that is the case and what do you expect the margin benefit from that will be?"
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, the overall market in Japan is around $1.2 billion at current exchange rates. It would have been a lot bigger than that, but obviously, the yen kept sliding against the dollar for a number of years. Of that $1.2 billion, basically 2/, 3 over 60%, is",91,"Yes, the overall market in Japan is around $1.2 billion at current exchange rates. It would have been a lot bigger than that, but obviously, the yen kept sliding against the dollar for a number of years. Of that $1.2 billion, basically 2/, 3 over 60%, is the 1 Day modality. And our share in that market is still very underindexed in that market. So far, our overall market share worldwide is, this most recent quarter, 23% worldwide. We are well in the mid-teens at best in Japan in that space."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","And Anthony, this is Greg. On the CIBA royalty, it did roll off within the quarter. We're not really providing any kind of color on the rate itself. Again, we've talked about that over the last couple of years that we have obligations of not disclosing th",58,"And Anthony, this is Greg. On the CIBA royalty, it did roll off within the quarter. We're not really providing any kind of color on the rate itself. Again, we've talked about that over the last couple of years that we have obligations of not disclosing that rate. And so from that perspective, we really can't share that."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","[Operator Instructions]  Our next question comes from the line of Jon Block with Stifel.",14,"[Operator Instructions]  Our next question comes from the line of Jon Block with Stifel."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Maybe first one, Bob. Just CVI was strong and one of the better results since 2014. But to be fair, if you go back then, we were sort of hit after that with a series of quarters where there was inventory drawdowns that went against the company. So I just",80,"Maybe first one, Bob. Just CVI was strong and one of the better results since 2014. But to be fair, if you go back then, we were sort of hit after that with a series of quarters where there was inventory drawdowns that went against the company. So I just want to make sure and ask, if you would, sort of your level of confidence that the sell-in, if you would, in this particular quarter totaled the sellout and demand?"
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, I think I mentioned -- I commented a while ago that relative to the quality of what pricing or any pricing influencing or what pipeline influencing, the answer is no. In fact, our pipeline -- the inventory on hand was slightly better than at the begi",74,"Yes, I think I mentioned -- I commented a while ago that relative to the quality of what pricing or any pricing influencing or what pipeline influencing, the answer is no. In fact, our pipeline -- the inventory on hand was slightly better than at the beginning of the period in both cases, kind of where we want it. So the drawdown -- the inventory drawdown or the pipeline is where we want it."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Steven Lichtman with Oppenheimer & Co.",13,"Our next question comes from the line of Steven Lichtman with Oppenheimer & Co."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Most of my questions have been answered. I had one follow-up on CSI. Bob, do you anticipate continuing to add to the portfolio through tuck-in M&A? Or are you feeling that the portfolio is where you want it to be at this point?",43,"Most of my questions have been answered. I had one follow-up on CSI. Bob, do you anticipate continuing to add to the portfolio through tuck-in M&A? Or are you feeling that the portfolio is where you want it to be at this point?"
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, we won't obviously get into a lot of color on what's in the pipeline, but suffice it to say we're focused in on rounding out the portfolio in front of the IVF centers. It is a boutique area, where there are little things out there to continue to buy",68,"Well, we won't obviously get into a lot of color on what's in the pipeline, but suffice it to say we're focused in on rounding out the portfolio in front of the IVF centers. It is a boutique area, where there are little things out there to continue to buy up, and so don't be surprised if we don't continue to have some acquisitions on a go-forward basis."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","So that concludes today's question-and-answer session. I'd like to turn the call back to Bob Weiss for closing remarks.",20,"So that concludes today's question-and-answer session. I'd like to turn the call back to Bob Weiss for closing remarks."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, I want to thank everyone for joining us. Hopefully, everyone is excited about our quarterly results as we are pleased about them. Not only are we pleased where we've been but very optimistic about where we're going, as I think you would see from the",120,"Well, I want to thank everyone for joining us. Hopefully, everyone is excited about our quarterly results as we are pleased about them. Not only are we pleased where we've been but very optimistic about where we're going, as I think you would see from the guidance that Greg talked to you. Yes, we have some short-term challenges with idle capacity. It's a silver lining problem because it means that to some degree, our capital requirements on go forward basis will be somewhat less certainly than they have been in the past. So we look forward to updating you on our continued progress, on our next quarterly call, which is September 1, I believe. Thank you. That concludes it. Operator."
263609,334265350,995004,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Ladies and gentlemen, thank you for your participation in today's conference. This concludes the program, and you may now disconnect. Everyone, have a great day.",25,"Ladies and gentlemen, thank you for your participation in today's conference. This concludes the program, and you may now disconnect. Everyone, have a great day."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Good day, ladies and gentlemen, and welcome to The Cooper Companies Second Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference may be recorded. I'd now like to introduce your host for today's conference, Miss Kim",48,"Good day, ladies and gentlemen, and welcome to The Cooper Companies Second Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference may be recorded. I'd now like to introduce your host for today's conference, Miss Kim Duncan, Vice President, Investor Relations. Ma'am, please go ahead."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Good afternoon, and welcome to The Cooper Companies Second Quarter 2016 Earnings Conference Call. I'm Kim Duncan, Vice President of Investor Relations. And giving prepared remarks on today's call are Bob Weiss, Chief Executive Officer; and Greg Matz, Chie",320,"Good afternoon, and welcome to The Cooper Companies Second Quarter 2016 Earnings Conference Call. I'm Kim Duncan, Vice President of Investor Relations. And giving prepared remarks on today's call are Bob Weiss, Chief Executive Officer; and Greg Matz, Chief Financial Officer. 
Before we get started, I'd like to remind you that this conference call contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including all revenue and earnings per share guidance and other statements regarding anticipated results of operations, market or regulatory conditions and integration of any acquisitions or their failure to achieve anticipated benefits. Forward-looking statements depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Events that could cause our actual results and future actions of the company to differ materially from those described in the forward-looking statements are set forth under the caption Forward-Looking Statements in today's earnings release and are described in our SEC filings, including the Business section of Cooper's annual report on Form 10-K. These are publicly available and on request from the company's Investor Relations department. 
Now before I turn the call over to Bob, let me comment on the agenda for the call. Bob will begin by providing highlights on the quarter, followed by Greg, who will then discuss second quarter financial results. We will keep the formal presentation to roughly 30 minutes, then open the call for questions. We expect the call to last approximately 1 hour. We request that anyone asking questions, please limit yourself to 1 question. Should you have any additional questions, please call our Investor line at (925) 460-3663 or email ir@cooperco.com. 
As a reminder, this call is being webcast, and a copy of the earnings release is available through the Investor Relations section of The Cooper Companies website. 
And with that, I'll turn the call over to Bob for his opening remarks."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thank you, Kim, and good afternoon, everyone. Welcome to the Second Quarter 2016 Conference Call. Let me start by highlighting 3 key areas. First, I'm pleased to report strong financial results for our fiscal second quarter. On a consolidated basis, we re",1262,"Thank you, Kim, and good afternoon, everyone. Welcome to the Second Quarter 2016 Conference Call. Let me start by highlighting 3 key areas. First, I'm pleased to report strong financial results for our fiscal second quarter. On a consolidated basis, we reported $484 million in revenue and non-GAAP earnings per share of $2.05. 
Second, CooperVision posted 9% revenue growth on both a constant currency and as-reported basis and strong results in all key areas of the business. Single-use silicone hydrogel lenses grew 52%, while 2-week and monthly silicone hydrogel lenses grew a combined 14%, both in constant currency. 
Third, CooperSurgical had another strong quarter, posting revenue growth of 23% and pro forma growth of 6%. We also closed several strategic acquisitions since our last earnings call. 
Moving into the details, CooperVision reported second quarter revenues of $391 million, up 9%. This was our strongest quarter -- growth quarter since 2014 and really shows the strength of our product portfolio. Regarding revenue by geography, the Americas grew 9% in constant currency, showing a nice rebound from last quarter. Strength was seen in multiple categories led by silicone hydrogel products. Our enhanced clariti lens has been extremely well received and MyDay had another strong quarter. Our toric and multifocals also posted strong growth driven by the Biofinity family. 
EMEA had another strong quarter and sales grew 5% in constant currency. Growth was driven by our family of silicone hydrogel products, Biofinity, clariti, MyDay and Avaira. We also launched Avaira Vitality in EMEA during the quarter and it is being well received. Avaira Vitality is our new 2-week silicone hydrogel lens, which is an enhanced replacement for the original Avaira lens. It was developed using improved manufacturing processes, resulting in a higher quality product at a lower cost per unit. We expect to launch this lens in the U.S. later this year subject to FDA approval. 
Asia Pacific had a very strong quarter, up 18% in constant currency. Growth was strong throughout the region and Biofinity and Proclear 1 Day stood out in Japan. Also within Japan, we began our MyDay launch during the quarter and we're seeing early signs that MyDay could be a very successful premium offering in that market. 
Turning to our product categories. Toric and multifocals grew a healthy 13% year-over-year in constant currency. We saw a very nice rebound in the U.S., which bolstered our strength throughout the rest of the world. We remained the global leader in specialty lenses. 
Looking at silicone hydrogel lenses. These products grew 20% in constant currency and now represent 60% of our total sales. Within the 2-week and monthly space, Biofinity and Avaira combined to grow 14% in constant currency. We remain under indexed in the 2-week and monthly silicone hydrogel space at 74% of sales versus the market at 79%, so we anticipate a very nice growth for many years to come. 
Regarding our silicone hydrogel 1 Day lenses, clariti and MyDay, they combined to grow 52% in constant currency. We remain very optimistic about these products and are committed to our growth strategy, which includes a 2-tier approach with clariti positioned as the mass market offering and MyDay as the premium offering. Remember the biggest driver in the contact lens market is the 1 Day growth, and we strongly believe we have the best product offering in the space as the only company with premium and mass market lenses, including a full portfolio of 1 Day silicone hydrogel, sphere, toric and multifocal lenses. 
Before finishing with market data, let me make a quick comment on integration matters. We continue to finalize our Sauflon integration activities and we're very close to being done. You'll note CooperVision had a very small non-GAAP adjustment this quarter -- or a smaller non-GAAP adjustment this quarter of roughly $9 million excluding amortization. We forecast similar charges in Q3 and Q4, mostly within cost of goods, but these should end this fiscal year. 
Now let me comment on the overall contact lens market and remember, this information is on the last page of the earnings release. For calendar Q1, we continue taking share, growing 9%, with the market up 3%. Geographically, CooperVision grew 9% in the Americas while market was flat. In Asia Pacific, CooperVision grew 14%, with the market up 5%. And in EMEA, we grew 6%, in line with the market. 
On a modality basis, single-use lenses continue driving growth and CVI -- with CVI up 14% and the market up 9%. For non-single-use lenses, we grew 6% while the market declined 1%. We also see -- as you can see, our growth remains diverse and strong. On a trailing 12-month basis, CooperVision grew 8% and the market grew 5%. Going forward, I expect the market to continue growing 4% to 6% over the next 5 years and most likely closer to 6%. The drivers will continue to be a shift to dailies' geographic expansion and an expansion of the wear base. We expect to continue taking market share, led by our strong silicone hydrogel portfolio. 
Moving to CooperSurgical. We reported second quarter revenues of $93 million, up 23% year-over-year or up 6% pro forma. Our fertility products led the way up 60% or 8% pro forma and our office and surgical products grew 5%. We continued executing on several initiatives, which are driving success, including transitioning to a geographic sales model, adding sales representatives in under-penetrated areas and increasing our focus on high-growth areas such as IVF and genetic testing. These moves are clearly gaining traction as we saw growth throughout our business in Q2. Going forward, I believe we'll continue to see solid growth as the business keeps moving into a more aggressive and efficient business model. 
Regarding acquisitions. We've completed several over the past few months, so let me touch on those and the strategic rationale. At the beginning of April, we added Genesis Genetics, a genetic testing lab company focused on preimplantation genetic screening and diagnosis using -- used during the IVF process. This is a nice addition to our existing genetic testing platform. 
At the beginning of May, we added complementary IVF capital equipment products through the acquisition of K-Systems, a small acquisition with roughly $7 million in revenue per year. 
And finally, we added the assets of Recombine last week. Recombine is a genetic testing company specializing in carrier screening, which is a great fit within our IVF and genetic testing franchise as it adds the #1 carrier screening test sold to the IVF clinics. 
As you can see, we're very focused on combining a full-service provider within the IVF global market, and we truly believe this strategy will yield success for many years to come. These deals are all incorporated into our updated guidance. With that, let me touch on our guidance details. 
We are raising our fiscal 2016 revenue guidance for CooperVision to 5.5% to 7% constant currency growth. Our CooperSurgical revenue guidance is also raised to 6% to 8% pro forma growth or up 24% to 27% on an as-reported basis. We're also raising our non-GAAP EPS guidance to $8.20 to $8.50. 
In conclusion, I'm very pleased with our results and remain optimistic about the underlying fundamentals of our business. I believe we're well-positioned to deliver solid results through the remainder of the fiscal year and beyond. With that, let me express my appreciation to our employees, our #1 asset. Their hard work and dedication to creating value is the backbone of our success. 
And now I'll turn it over to Greg to cover the financial results."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thanks, Bob, and good afternoon, everyone. I'll provide the overall summary of our performance, including a review of the market and our revenue picture. We're going to focus primarily on our non-GAAP results for the quarter. For the reconciliation to GAA",1149,"Thanks, Bob, and good afternoon, everyone. I'll provide the overall summary of our performance, including a review of the market and our revenue picture. We're going to focus primarily on our non-GAAP results for the quarter. For the reconciliation to GAAP numbers, please refer to our earnings release. 
Looking at gross margins. In Q2, the non-GAAP gross margin was 63.2% compared to 63.4% in the prior year. Although CooperVision had positives from currency and strong Biofinity sales, its margin was lower than expected. The primary items driving this were a negative margin impact from stronger Asia Pac sales, where we have higher 1 Day sales, and charges associated with idle equipment and legacy hydrogel inventory. 
Regarding these last 2 items, let me cover them separately. We have made a lot of progress improving our manufacturing operations, including some very recent successes. For competitive reasons, I won't get into specifics, but our production per line has increased materially, resulting in lower cost per unit and a lesser need for future CapEx. This has resulted in idling from equipment, which hurts us in Q2 and will also negatively impact Q3 and Q4. We anticipate this being a short-term negative as we will grow into this production over time. 
The other item is our legacy hydrogel inventory, where we wrote off more than we planned, as our silicone hydrogel sales were very strong and we're forecasting that to continue. This hurts us in Q2 and we expect it will negatively impact Q3 and Q4. To be clear, we're not excluding these items from earnings, so they are negatively impacting our non-GAAP earnings per share. 
CooperVision on a non-GAAP basis reported gross margin of 62.8% versus 63.3% in Q2 of last year. The factors which impacted margin were the items I just mentioned. CooperSurgical had non-GAAP gross margin of 64.8%, which compares to Q2 '15 of 63.5%. Strength in the OB/GYN and IVF product families drove this quarter's margin. 
SG&A. On a non-GAAP basis, SG&A increased approximately 6% to $171.6 million or 35% of revenue, down from approximately 37% of revenue the prior year. Primary driver behind this leverage was strong SG&A controls. 
Now looking at R&D. In Q2, R&D on a non-GAAP basis was $16.6 million or 3.4% of revenue, flat in dollars and down from 3.8% of revenue in the prior year. We're seeing investment in CSI, offset by synergies from the Sauflon acquisition in CVI. 
Now moving to operating margins. For Q2, consolidated GAAP operating income and margin were $89.8 million and 18.6% of revenue versus $71 million and 16.3% of revenue in Q2 last year. Non-GAAP operating income and margin were $117.6 million and 24.3% of revenue versus $96.7 million and 22.2% of revenue for the prior year. Primary difference in operating margin year-over-year is the operating expense leverage. 
In Q2, CooperVision, on a non-GAAP operating income and margin, were $102.4 million and 26.2% of revenue versus $88.8 million and 24.7% of revenue in the prior year. 
CooperSurgical's non-GAAP operating income and margin were $26.6 million and 28.8% of revenue versus Q2 '15 of $18.8 million of operating income and 25% of revenue. 
Moving on to depreciation and amortization. In Q2, depreciation was $33.7 million, up $1.5 million year-over-year. Amortization was $14.3 million, up $2 million, reflecting our recent acquisition activity. 
Interest expense was $7.6 million for the quarter, up $2.9 million year-over-year, primarily due to higher debt and interest rates associated with acquisitions. Looking at the effective tax rate. In Q2, the non-GAAP effective tax rate was 9.4% versus a non-GAAP effective tax rate of 8.4% in Q2 '15. 
Earnings per share. Our Q2 earnings per share on a GAAP and non-GAAP basis was $1.52 and $2.05, respectively, versus $1.23 and $1.72 for GAAP and non-GAAP in the prior year. Non-GAAP earnings per share on a pro forma basis, which adjusts for currency and acquisitions, grew approximately 13% in the quarter. 
By looking at FX, the net currency impact on earnings per share year-over-year for Q2 was a favorable $0.10. 
Moving on to the balance sheet. In Q2, we had cash provided by operations of $97.8 million less capital expenditures of $41.1 million, resulting in $56.7 million of free cash flow. Excluding integration costs of $9 million, adjusted free cash flow was $65.7 million. 
Total debt increased within the quarter by $64.1 million to $1,441,400,000, primarily due to higher average cash balances and acquisitions, partially offset by operational cash flow. 
Inventories increased from last quarter, approximately $2.7 million, to $433.6 million. This is entirely driven by CSI acquisitions. In CooperVision, we saw inventories decline as growth in silicone daily inventory to support our product launches was offset by a reduction in our hydrogel inventory. For the quarter, we're seeing months on hand at 7 months. Days sales outstanding is at 54 days, which is down 3 days from the prior quarter and 2 days from last year. 
Now turning to guidance. For our main currencies, we are using 1.10 for the euro, 112 for the yen and 1.46 for the pound. 
The consolidated revenue range is being raised to $1.929 billion to $1.960 billion or approximately 5.5% to 7% pro forma growth. CooperVision's revenue range is being raised to $1.545 billion to $1.567 billion or roughly 5.5% to 7% constant currency growth. CooperSurgical's revenue range is being raised to $384 million to $393 million or roughly 6% to 8% pro forma growth. Note that roughly half of the increase in guidance is from currency, while the other half is primarily from acquisitions. 
We expect non-GAAP gross margin to be around 63% for the year. This is a reduction from the previous guidance of around 64% as it incorporates the CooperVision items I mentioned earlier, along with lower gross margins from CooperSurgical, associated with recent acquisitions. Having said that, we still expect improving Q3 and Q4 gross margins of around 64% each quarter. 
OpEx is expected to be around 39%. Operating margins still expected to be around 24%. 
Interest expense is expected to be around $28 million. 
Our effective tax rate is expected to be around 8%. 
Our expected share count will be around 49.1 million shares. 
And our non-GAAP earnings per share is expected to be $0.20 higher on the top and bottom of our range to $8.20 to $8.50, which equates to a pro forma earnings per share of 10% to 14% growth. 
From our last guidance, currency is roughly a $0.40 positive, and we have actually improved our operational performance by roughly $0.10, but we are expecting the idle legacy inventory write-off to negatively impact us by roughly $0.30. 
CapEx is expected to be around $200 million. 
We finished paying for equipment we have ordered over the prior year, and thus, adjusted free cash flow is still expected to be around $300 million. 
With that, let me turn it back to Kim for the Q&A session."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Operator, we're ready to take some questions.",7,"Operator, we're ready to take some questions."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Matthew O'Brien with Piper Jaffray.",15,"[Operator Instructions] 
Our first question comes from the line of Matthew O'Brien with Piper Jaffray."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Just one for Bob and then one for Greg. On the increase in CVI -- I guess, this question is for Bob -- increase to CVI's outlook for the year, can you just give us a sense for how much of that is coming from improved manufacturing of MyDay, especially lau",136,"Just one for Bob and then one for Greg. On the increase in CVI -- I guess, this question is for Bob -- increase to CVI's outlook for the year, can you just give us a sense for how much of that is coming from improved manufacturing of MyDay, especially launching into Japan? Or just disruptions in the markets that you're seeing? And then, how much are you incorporating the J&J launch as far of somewhat of a headwind into your fiscal Q4? And then, for Greg, this is typically a really strong free cash flow quarter for you guys, but you're sticking with the $300 million outlook for the year. So can you just help us rectify a little bit of a softness that we saw here in Q2 versus that outlook for the year?"
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes. The foreign exchange, as Greg indicated, is a big driver of the top line overall improvement. In terms of the constant currency growth, you're correct, there is a modest -- in the guidance, there's a modest deceleration compared to what we had previo",125,"Yes. The foreign exchange, as Greg indicated, is a big driver of the top line overall improvement. In terms of the constant currency growth, you're correct, there is a modest -- in the guidance, there's a modest deceleration compared to what we had previously forecasted to anticipate, if you will, some impact of the J&J rollout. Beyond that, it's pretty much in the same range at 5.5% to 7%, so modest at both. MyDay impact in Japan is -- once again, we just rolled that product out in March of this year, so a fairly minimal impact in terms of the overall any update on the guidance, if you will. And of course, we already knew about MyDay in Japan in our previous March guidance."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, Matt, on the free cash flow, nothing really jumps out. The number isn't that far off of the prior year. And we did have a much stronger Q1, so if you look at kind of halfway through the year, we're actually probably ahead of where we were last year.",50,"Yes, Matt, on the free cash flow, nothing really jumps out. The number isn't that far off of the prior year. And we did have a much stronger Q1, so if you look at kind of halfway through the year, we're actually probably ahead of where we were last year."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Jeff Johnson with Robert Baird.",13,"Our next question comes from the line of Jeff Johnson with Robert Baird."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Sorry, about that. Guys, can hear me, okay?",8,"Sorry, about that. Guys, can hear me, okay?"
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","We can.",2,"We can."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","All right, great. So Bob, let me ask you one question and then I have a modeling question for Greg, as well. But the question for you, just on the Biofinity and Avaira business, obviously that bounced back very nicely this quarter. I think you said 14% co",118,"All right, great. So Bob, let me ask you one question and then I have a modeling question for Greg, as well. But the question for you, just on the Biofinity and Avaira business, obviously that bounced back very nicely this quarter. I think you said 14% constant currency in the quarter year-over-year. 7% last quarter, so kind of averaging right around double digits. Is that how we should think about that business going forward? Obviously, you've got the launch coming from J&J, as was referenced in the prior question. You also have ULTRA kind of gaining some traction, it sounds like. So just how do you think about that Biofinity/Avaira bucket over the next couple of years?"
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, I think taking the 2 quarters, the 7% and 13%, being in around low double digit is the right way to think about it.",25,"Yes, I think taking the 2 quarters, the 7% and 13%, being in around low double digit is the right way to think about it."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Right, that's helpful. And Greg, question for you. I think at the very end, did you say $0.30 is the EPS impact of the inventory write-off and that is included in your non-GAAP EPS guidance? Is that correct?",38,"Right, that's helpful. And Greg, question for you. I think at the very end, did you say $0.30 is the EPS impact of the inventory write-off and that is included in your non-GAAP EPS guidance? Is that correct?"
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes.",1,"Yes."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Okay. So for next year, we should been thinking about adding just kind of building off a base that's $0.30 higher, assuming you're not going to have that kind of write-offs next year? Would that be the fair way to take kind of this year's EPS, add $0.30 b",61,"Okay. So for next year, we should been thinking about adding just kind of building off a base that's $0.30 higher, assuming you're not going to have that kind of write-offs next year? Would that be the fair way to take kind of this year's EPS, add $0.30 back and build that off as our base assumption going into next year?"
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Jeff, it's probably a little early to get into next year's guidance, which we would come out later in the year and discuss.",23,"Jeff, it's probably a little early to get into next year's guidance, which we would come out later in the year and discuss."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","And keep in mind, Jeff, there's a balance between -- some of that is write-off, as Greg indicated. Some of it is idle equipment as we grow into it. So we're growing. Given the substantial growth of our 1 Day modality and our unit growth, we're anticipatin",73,"And keep in mind, Jeff, there's a balance between -- some of that is write-off, as Greg indicated. Some of it is idle equipment as we grow into it. So we're growing. Given the substantial growth of our 1 Day modality and our unit growth, we're anticipating that we'll start consuming more and more of that as each quarter goes by. But that $30 million overall is both write-offs as well as idle."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, and Jeff, just to build on that a little bit, I think without giving guidance, I think we feel comfortable that we would see gross margins improve year-over-year.",29,"Yes, and Jeff, just to build on that a little bit, I think without giving guidance, I think we feel comfortable that we would see gross margins improve year-over-year."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Joanne Wuensch with BMO Capital Markets.",14,"Our next question comes from the line of Joanne Wuensch with BMO Capital Markets."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Can you hear me, okay?",5,"Can you hear me, okay?"
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","We can.",2,"We can."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Wonderful. I think what a couple of people were trying to get at, and I know in speaking with investors, the big concern right now is the J&J monthly launch starting at the end of June, beginning of July. How can you -- how do you think about that product",71,"Wonderful. I think what a couple of people were trying to get at, and I know in speaking with investors, the big concern right now is the J&J monthly launch starting at the end of June, beginning of July. How can you -- how do you think about that product launch and how do we get comfortable that we're not going to see a similar hiccup to what happened last fall?"
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, without knowing exactly what J&J is up to, in hindsight, we know what they did is they sold the pipeline a lot. And then, we saw it in their negative U.S. results in the most recent quarter. So no one is going to say they can't do that again. Having",399,"Well, without knowing exactly what J&J is up to, in hindsight, we know what they did is they sold the pipeline a lot. And then, we saw it in their negative U.S. results in the most recent quarter. So no one is going to say they can't do that again. Having said that, this is a product coming into the monthly modality. It's basically coming in with only a sphere, not a toric and a multifocal, so it's not a family of products going against a family of products. And that is a big distinction as contrasted to the pipeline dragging everything in under one umbrella, as they did their whole family of products, and going after a sphere going after a sphere. In that case, it was always the 1 Day going against Total1 primarily in that space. But it consumed -- it took all the air out of the practitioner's office, if you will, or filled up all the space. And there clearly is no guarantee they wouldn't try flooding the market again. As far as the way we think about it longer-term, Biofinity is a very established product, wherein we continue to expand the offerings under that umbrella. It's a very global product, and it's one where -- it's good in the monthly and we also have Avaira Splash Vitality [ph] coming out in the 2-week, which is the sweet spot of the market in terms of the number of wearers. There are more wearers in the 2-week part of the market than there are in the monthly. Quite frankly, as some of you know, I've always held the view that it's a good strategy for J&J if they're intent on trading up and basically migrating the noncompliant wearer base they have in the 2-week space into a compliant monthly modality. That would be a good trade-up in modalities because a noncompliant wearer is one who is basically only using 24 lenses a year compared to a monthly using 24 and conversely they're getting the price point of a 2-week wearer. And that's a pretty big part of that 2-week modality. So we think -- yes, we'll continue to see that market grow, the monthly, and we'll get our fair share with Biofinity. In the meantime, we'll be more active down the road in the 2-week space, and we'll basically neutralize it for the most part."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Steve Willoughby with Cleveland Research.",13,"Our next question comes from the line of Steve Willoughby with Cleveland Research."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Hey, guys. Can you hear me, okay?",7,"Hey, guys. Can you hear me, okay?"
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","We can, Steve.",3,"We can, Steve."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Okay, Bob. Just regarding the charges or the idle equipment and inventory write-off that you guys took in the quarter, a couple of questions regarding that. I guess, first, the idle equipment, is that -- the idle equipment charge, it relates to newly purc",62,"Okay, Bob. Just regarding the charges or the idle equipment and inventory write-off that you guys took in the quarter, a couple of questions regarding that. I guess, first, the idle equipment, is that -- the idle equipment charge, it relates to newly purchased equipment that you don't need quite yet? Or is that existing equipment that you're idling for some reason?"
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, so to qualify as idle, it's basically been put in production and then is taken out of production. So I'll answer the question with a little color. It could be very new equipment that was put in production. Example, our facility in Hungary, where they",124,"Yes, so to qualify as idle, it's basically been put in production and then is taken out of production. So I'll answer the question with a little color. It could be very new equipment that was put in production. Example, our facility in Hungary, where they got real good at making it, and all of a sudden, we parked the equipment because so many -- so much product was coming off of the other line. So as yields go up and costs are coming down, that's the good news. The bad news is if you put it -- if you put equipment that you were using and you idle it, it becomes a direct period charge as opposed to moving through with the inventory."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Okay. So this sort of what happened with Avaira and then Gen 2 line a number of years ago then?",20,"Okay. So this sort of what happened with Avaira and then Gen 2 line a number of years ago then?"
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Absolutely.",1,"Absolutely."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Okay. And [indiscernible]",3,"Okay. And [indiscernible]"
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","So what happened is our manufacturing people got very good at what they were doing. We always knew that if we -- that they would deliver. We just didn't know how well they would deliver. So they're delivering a lot more units per dollar spent of capital.",132,"So what happened is our manufacturing people got very good at what they were doing. We always knew that if we -- that they would deliver. We just didn't know how well they would deliver. So they're delivering a lot more units per dollar spent of capital. That's the good news. But it also turned short-term into the bad news. As I think Greg indicated, we'll grow out of that fairly quickly when you look at the rapid unit growth in many of these areas, where we have become very efficient. And that includes MyDay, that includes Biofinity, that includes Avaira, that includes Vitality, and that includes clariti in the bucket. They -- all of those products became -- the costs are going down through efficiencies and yields by our manufacturing people."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Lawrence Keusch with Raymond James.",13,"Our next question comes from the line of Lawrence Keusch with Raymond James."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","This is actually John in for Larry. I just had a quick question. I guess, what's the right way to calibrate expectations for MyDay in Japan? You obviously just launched in the quarter, but maybe shorter term and then maybe a little bit longer term in '16",49,"This is actually John in for Larry. I just had a quick question. I guess, what's the right way to calibrate expectations for MyDay in Japan? You obviously just launched in the quarter, but maybe shorter term and then maybe a little bit longer term in '16 and '17?"
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, you can see some of the numbers we're putting up in the region and Japan has certainly been stellar within that region also. Right now, we have a good portfolio of 3 products, with MyDay being the third one in, but Biofinity is doing very well. Proc",276,"Well, you can see some of the numbers we're putting up in the region and Japan has certainly been stellar within that region also. Right now, we have a good portfolio of 3 products, with MyDay being the third one in, but Biofinity is doing very well. Proclear 1 Day is doing very well as well now, MyDay. We will be -- we're early -- 1.5 months into the launch, if you will, through the end of April and are very pleased with the progress we're making. It's the biggest market by far in terms of the 1 Day modality anyplace in the world, and therefore, MyDay is a very good fit in a very good market. And we think the combination of MyDay as a silicone hydrogel and Proclear 1 Day as a hydrogel will be -- is a good entree into that market. As Japan has been historically pretty lethargic the last -- I want to say, 7, 8 years. It's showing a little bit more life than it has. And the only reason it's been lethargic is because it grew so rapidly in the prior decade compared to this decade. It got ahead of itself on the 1 Day modality and became the first to adopt that because they were very anti-lens care regimens and wanted the lenses to be boiled, and therefore, everyone migrated into the 1 Day modality rather than boiling lenses every day. And I'll just say that we're pretty excited about MyDay there. It's going to take some work. It's only a sphere thus far, so there will be other plans relative to how to leverage the MyDay experience."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Matt Mishan with KeyBanc.",12,"Our next question comes from the line of Matt Mishan with KeyBanc."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Bob, first, on CooperVision, I just want to better understand the sequential improvement in growth this quarter versus the previous several quarters. Is it your sense that the impact of the Johnson & Johnson launch has now fully waned? Or is there somethi",78,"Bob, first, on CooperVision, I just want to better understand the sequential improvement in growth this quarter versus the previous several quarters. Is it your sense that the impact of the Johnson & Johnson launch has now fully waned? Or is there something that you've been doing to improve your results and to improve share? I'm just trying to get a sense of whether or not this is Johnson & Johnson or this is you guys doing something."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","So I think it's a combination. I think the air that left the room is now back in the room. The eye care professional, he has room for products, and so it's more normalized in that sense and that's obvious from the weak numbers that J&J put up domestically",138,"So I think it's a combination. I think the air that left the room is now back in the room. The eye care professional, he has room for products, and so it's more normalized in that sense and that's obvious from the weak numbers that J&J put up domestically, and [indiscernible] Alcon put up numbers worldwide. We -- relative to our products, I think I'll make a point of saying that our numbers that we put up -- it's not a function of any price -- pricing or anything to do with channel sales. So it's a good quarter. The inventory on hand at distributors and the pipeline is very normalized. In fact, it's a little less than it was at the beginning of the period. So it's a reflection of pretty solid numbers around the world."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Brian Weinstein with William Blair.",13,"Our next question comes from the line of Brian Weinstein with William Blair."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","It's a little bit of a longer-term question, but can you talk about what you expect longer term in terms of the split between clariti and MyDay and kind of what you think your share longer term is there? And then, how do you think about manufacturing -- m",60,"It's a little bit of a longer-term question, but can you talk about what you expect longer term in terms of the split between clariti and MyDay and kind of what you think your share longer term is there? And then, how do you think about manufacturing -- manufacturer pricing levels in the daily silicone hydrogel market longer term?"
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","So I think the split between clariti and MyDay, it's easier to relate in the U.S. The U.S. is going to be primarily where clariti is after the mass market and MyDay is after the premium market. I would have normally said, think of that as like a 75% mass",458,"So I think the split between clariti and MyDay, it's easier to relate in the U.S. The U.S. is going to be primarily where clariti is after the mass market and MyDay is after the premium market. I would have normally said, think of that as like a 75% mass market, 25% premium market. And I think that's the U.S. portion of the model. I think when you get into certain regions of the world, for example, Japan, where only MyDay is playing, then -- so if you're factoring that into the overall global results, you'll end up with MyDay outgrowing because it's coming off of a lower base and it's just getting into Japan, at least for the foreseeable future, outgrowing as a percent, getting more of its share of the bucket. So instead of saying 75%-25%, MyDay may move up that spectrum and get a higher portion in the interim. When clariti is available throughout Asia Pac and around the world, that may come back more into the mass market premium split. But for now, one point is we're not capacity constrained on either of these products. We will continue, in the case of MyDay, expanding the portfolio offering, so that will help. Right now, it's a sphere competing with clariti, which has a sphere, a multifocal and a toric, and that will weight more towards the clariti piece. Relative to margins, we will continue to focus in -- from a pricing point of view, being keenly aware of that 2-tier market, the premium market, which we'll call the players there in the U.S., clearly Total1, OASYS and MyDay. And TruEye is the other one that's kind of there in that space, but OASYS will consume more and more of TruEye. And in the mass market, then clariti remains the only game in town relative to a silicone hydrogel in the 1 Day mass market. So that is a function of watching the migration of hydrogels into this silicone hydrogel space in that mass market arena. Cost of goods gross margins, we expect, as we've indicated in the past, to have our 1 Day silicone hydrogel franchise, and most notably clariti, not a drag on our overall gross margin for the next several years. Anyway, MyDay is ramping up the learning curve, moving very nicely. And I would say, the indicator of some of the idling and the indicator of us having enough MyDay capacity is just how well that's ramping up. As it ramps up, the cost of goods come down to the yields and deficiencies, so we're very pleased with that, and we expect more than -- clearly more than 50% out of MyDay as we get down the road a couple of years."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of David Roman with Goldman Sachs.",13,"Our next question comes from the line of David Roman with Goldman Sachs."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","I was hoping you could just touch on in a little bit more detail, firstly, the strength in Asia Pacific. I think last quarter, you had kind of said that you were ramping capacity in Japan. That wouldn't be a significant contributor till the much later par",112,"I was hoping you could just touch on in a little bit more detail, firstly, the strength in Asia Pacific. I think last quarter, you had kind of said that you were ramping capacity in Japan. That wouldn't be a significant contributor till the much later part of the year and into the next fiscal year. But any other regions driving, a, within Asia Pac that you could call out? And then, secondly on the 6% to 8% pro forma guidance for CSI, that is quite a bit above where those end markets, I think, are growing, so maybe you could just speak to the sustainability of that on a go-forward basis?"
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","So relative to Asia Pac, I would emphasize that the numbers you see are -- very little to do with MyDay. It's very early in the game, so it didn't -- so the strength you're seeing there is just how well some of the geographic expansions are going, how wel",310,"So relative to Asia Pac, I would emphasize that the numbers you see are -- very little to do with MyDay. It's very early in the game, so it didn't -- so the strength you're seeing there is just how well some of the geographic expansions are going, how well Japan is going ex MyDay, and then the MyDay launch. But it is not the driver of that 18%, which -- and MyDay was only launched mid-March, so really, it's only got 1.5 months in Japan in that period -- in the quarter. Relative to what to expect in that region, we certainly expect continued robust numbers out of Asia Pac for the foreseeable future. Number one, we're under-indexed. Number two, we're delivering a lot of these new products, clariti coming into more and more of Asia Pac, and of course, MyDay, which we talked about. So we're pretty optimistic that we'll see a continued strength in that market. Relative to surgical and the 6% to 8%, a lot of that growth is a reflection of, number one, the emphasis on really selling the product and the global realignment with the selling effort. We have some -- obviously, even some good products in the surgical side that are driving organic growth there. The acquisitions we've made are -- the expectation there keenly is -- clearly is double-digit in many of those acquisitions, so we expect to drive a lot of the genetic testing and surround the IVF process, so that we are the key player that the IVF centers are engaging with. And we're pretty optimistic about that, and obviously, the last 2 quarters have indicated it's a pretty successful strategy. I think going forward, the 6% to 8% reflects some of the more recent acquisitions having more organic top line growth potential than our historic legacy products within CooperSurgical."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Larry Biegelsen with Wells Fargo.",13,"Our next question comes from the line of Larry Biegelsen with Wells Fargo."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Greg, based on the guidance, is the second half implied CooperVision guidance, the midpoint about 5%? And should we think about Q3 and Q4 as similar growth or would you expect Q4 to potentially be lower because the J&J launch comes in July? And Greg, can",88,"Greg, based on the guidance, is the second half implied CooperVision guidance, the midpoint about 5%? And should we think about Q3 and Q4 as similar growth or would you expect Q4 to potentially be lower because the J&J launch comes in July? And Greg, can you just tell us what the FX assumption is? It looks like you're assuming about, for the year 0 impact on EPS. Is that math, right? What is it on sales? And is there some conservatism in your FX assumptions right now?"
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, Larry, I think for CVI, the midpoint kind of growth for Q3/Q4 would be about 6.1%, I think if you do the math. If you look at from a seasonality, we're not giving quarterly seasonality. But I think you can look at past seasonality for CooperVision. I",189,"Yes, Larry, I think for CVI, the midpoint kind of growth for Q3/Q4 would be about 6.1%, I think if you do the math. If you look at from a seasonality, we're not giving quarterly seasonality. But I think you can look at past seasonality for CooperVision. It generally is fairly consistent. On the FX fronts, yes, I think you've got that right. When you look at FX, we basically for the year see about no impact on the earnings per share. On the revenue front, again, you're looking at about right around $30 million of revenue reduction. Now on the rates, are we being conservative? Well, if you look at today's rates, I think you can say we're being conservative. We did use the rates for the euro at 1.10, the pound at 1.46 and the yen at 112, and we start setting those rates a couple of days ago. The yen was at 1 point -- or was that 111.3, so the yen has kind of -- has basically strengthened in the last couple of days. But those were the rates that the model is based on."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Mike Weinstein with JPMorgan.",12,"Our next question comes from the line of Mike Weinstein with JPMorgan."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","This is Andrew [ph] in for Mike. I have 2 questions, the first being product-specific and the second regarding the market. So can you talk about, Bob, the slight design changes in the clariti lens and what you are seeing in the way of market adoption with",53,"This is Andrew [ph] in for Mike. I have 2 questions, the first being product-specific and the second regarding the market. So can you talk about, Bob, the slight design changes in the clariti lens and what you are seeing in the way of market adoption with this design versus before the change?"
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Sure, do you want to ask the second?",8,"Sure, do you want to ask the second?"
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Yes, I could ask the second. The second is around UPP. So the U.S. market growth in the quarter was probably the lowest in a while, I believe, and I was just wondering whether or not this was a result of some pricing war that's going on within the market",68,"Yes, I could ask the second. The second is around UPP. So the U.S. market growth in the quarter was probably the lowest in a while, I believe, and I was just wondering whether or not this was a result of some pricing war that's going on within the market and just your general thoughts around the UPP and how you think that might benefit you moving forward."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Sure. The product relative to the enhancement that we made to clariti, I think you've seen the overall silicone hydrogel 1 Day numbers were 52% growth. So suffice it to say that the enhancement as well as -- of course, we had some activity in the fourth q",425,"Sure. The product relative to the enhancement that we made to clariti, I think you've seen the overall silicone hydrogel 1 Day numbers were 52% growth. So suffice it to say that the enhancement as well as -- of course, we had some activity in the fourth quarter regarding our integration process in Europe that caused some bumps then. But suffice it to say we're running on all cylinders now with clariti in the marketplace and the enhancement has certainly been very beneficial in that process. As far as UPP and the market, the 3% growth in the market, as much as anything, it's probably much more influenced by the J&J cycle stuff [ph] that they put the market through with a strong market 2 quarters ago, and that followed by basically a void in the U.S. in this quarter. So were it not for that, it would be more normalized. The trailing 4 quarters is a much better gauge that is approaching 5% worldwide relative to the U.S. and UPP. And whether or not there's any pricing post-UPP or a decline in pricing, I would say that certainly, I know that some vendors may have -- or retailers may have altered J&J prices, but by and large, the market continues to drive itself the way it has the past. Pricing is not really a factor. It's all about trading up and shelf space and first fits, and it remains that way. The focus on getting a new fit in the marketplace or where you have a new product, trying to get a conversion onto your product. There is a fair amount of stickiness to most of these products, so I would say the real driver of your product doing well is the new fit arena is the big contributor. Pricing, to me, this market has traded up for 30 years and it continues to do a phenomenal job. And over that 30 years, there has been but maybe 1 or 2 price skirmishes. UPP was a fairly shallow attempt at a marketing strategy that was, obviously, beneficial to the independents compared to the retailers. Whether or not it was worth anything, it continued to be debated. There's obviously a lot of emotions on both sides of the table on that in the marketplace. But if UPP went away tomorrow, it would not be the end of the world. If it stays where it is, it's okay also. So I don't see that as a material catalyst one way or the other in the marketplace."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Anthony Petrone with Jefferies.",12,"Our next question comes from the line of Anthony Petrone with Jefferies."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Maybe one for Bob on Japan and then one for Greg on margins. On Japan, can you maybe give us a recap of the size of the daily market in Japan and maybe where Cooper's share is today and how MyDay can benefit that going forward? And then, for Greg, just a",93,"Maybe one for Bob on Japan and then one for Greg on margins. On Japan, can you maybe give us a recap of the size of the daily market in Japan and maybe where Cooper's share is today and how MyDay can benefit that going forward? And then, for Greg, just a quick one on margins. I believe the CIBA royalty does roll off internationally toward the end of this year. I just want to confirm if that is the case and what do you expect the margin benefit from that will be?"
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, the overall market in Japan is around $1.2 billion at current exchange rates. It would have been a lot bigger than that, but obviously, the yen kept sliding against the dollar for a number of years. Of that $1.2 billion, basically 2/3, over 60%, is t",94,"Yes, the overall market in Japan is around $1.2 billion at current exchange rates. It would have been a lot bigger than that, but obviously, the yen kept sliding against the dollar for a number of years. Of that $1.2 billion, basically 2/3, over 60%, is the 1 Day modality. And our share in that market is -- we are still very under indexed in that market. So far, our overall market share worldwide is, this most recent quarter, 23% worldwide. We are well in the mid-teens at best in Japan in that space."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","And Anthony, this is Greg. On the CIBA royalty, it did roll off within the quarter. We're not really providing any kind of color on the rate itself. Again, we've talked about that over the last couple of years that we have obligations of not disclosing th",58,"And Anthony, this is Greg. On the CIBA royalty, it did roll off within the quarter. We're not really providing any kind of color on the rate itself. Again, we've talked about that over the last couple of years that we have obligations of not disclosing that rate. And so from that perspective, we really can't share that."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","[Operator Instructions] Our next question comes from the line of Jon Block with Stifel.",14,"[Operator Instructions] Our next question comes from the line of Jon Block with Stifel."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Maybe first one, Bob. Just CVI was strong and one of the better results since 2014. But to be fair, if you go back then, we were sort of hit after that with a series of quarters where there was inventory drawdowns that went against the company. So I just",80,"Maybe first one, Bob. Just CVI was strong and one of the better results since 2014. But to be fair, if you go back then, we were sort of hit after that with a series of quarters where there was inventory drawdowns that went against the company. So I just want to make sure and ask, if you would, sort of your level of confidence that the sell-in, if you would, in this particular quarter totaled the sellout and demand?"
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, I think I mentioned -- I commented [ph] a while ago that relative to the quality of what's pricing or any pricing influencing or was pipeline influencing, the answer is no. In fact, our pipeline -- the inventory on hand was slightly better than at th",75,"Yes, I think I mentioned -- I commented [ph] a while ago that relative to the quality of what's pricing or any pricing influencing or was pipeline influencing, the answer is no. In fact, our pipeline -- the inventory on hand was slightly better than at the beginning of the period in both cases, kind of where we want it. So the drawdown -- the inventory drawdown or the pipeline is where we want it."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Steven Lichtman with Oppenheimer & Co.",13,"Our next question comes from the line of Steven Lichtman with Oppenheimer & Co."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Most of my questions have been answered. I had one follow-up on CSI. Bob, do you anticipate continuing to add to the portfolio through tuck-in M&A? Or are you feeling that the portfolio is where you want it to be at this point?",43,"Most of my questions have been answered. I had one follow-up on CSI. Bob, do you anticipate continuing to add to the portfolio through tuck-in M&A? Or are you feeling that the portfolio is where you want it to be at this point?"
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, we won't obviously get into a lot of color on what's in the pipeline, but suffice it to say we're focused in on rounding out the portfolio in front of the IVF centers. It is a boutique area, where there are little things out there to continue to buy",68,"Well, we won't obviously get into a lot of color on what's in the pipeline, but suffice it to say we're focused in on rounding out the portfolio in front of the IVF centers. It is a boutique area, where there are little things out there to continue to buy up, and so don't be surprised if we don't continue to have some acquisitions on a go-forward basis."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","So that concludes today's question-and-answer session. I'd like to turn the call back to Bob Weiss for closing remarks.",20,"So that concludes today's question-and-answer session. I'd like to turn the call back to Bob Weiss for closing remarks."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, I want to thank everyone for joining us. Hopefully, everyone is as excited about our quarterly results as we are pleased about them. Not only are we pleased where we've been, but very optimistic about where we're going, as I think you would see from",120,"Well, I want to thank everyone for joining us. Hopefully, everyone is as excited about our quarterly results as we are pleased about them. Not only are we pleased where we've been, but very optimistic about where we're going, as I think you would see from the guidance that Greg talked to. Yes, we have some short-term challenges with idle capacity. It's a silver lining problem because it means that to some degree, our capital requirements on go forward basis will be somewhat less certainly than they have been in the past. So we look forward to updating you on our continued progress, on our next quarterly call, which is September 1, I believe. Thank you. That concludes it. Operator."
263609,334265350,995038,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Ladies and gentlemen, thank you for your participation in today's conference. This concludes the program, and you may now disconnect. Everyone, have a great day.",25,"Ladies and gentlemen, thank you for your participation in today's conference. This concludes the program, and you may now disconnect. Everyone, have a great day."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Good day, ladies and gentlemen, and welcome to The Cooper Companies Second Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference may be recorded. I'd now like to introduce your host for today's conference, Miss Kim",48,"Good day, ladies and gentlemen, and welcome to The Cooper Companies Second Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference may be recorded. I'd now like to introduce your host for today's conference, Miss Kim Duncan, Vice President, Investor Relations. Ma'am, please go ahead."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Good afternoon, and welcome to The Cooper Companies Second Quarter 2016 Earnings Conference Call. I'm Kim Duncan, Vice President of Investor Relations. And giving prepared remarks on today's call are Bob Weiss, Chief Executive Officer; and Greg Matz, Chie",320,"Good afternoon, and welcome to The Cooper Companies Second Quarter 2016 Earnings Conference Call. I'm Kim Duncan, Vice President of Investor Relations. And giving prepared remarks on today's call are Bob Weiss, Chief Executive Officer; and Greg Matz, Chief Financial Officer. 
Before we get started, I'd like to remind you that this conference call contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including all revenue and earnings per share guidance and other statements regarding anticipated results of operations, market or regulatory conditions and integration of any acquisitions or their failure to achieve anticipated benefits. Forward-looking statements depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Events that could cause our actual results and future actions of the company to differ materially from those described in the forward-looking statements are set forth under the caption Forward-Looking Statements in today's earnings release and are described in our SEC filings, including the Business section of Cooper's annual report on Form 10-K. These are publicly available and on request from the company's Investor Relations department. 
Now before I turn the call over to Bob, let me comment on the agenda for the call. Bob will begin by providing highlights on the quarter, followed by Greg, who will then discuss second quarter financial results. We will keep the formal presentation to roughly 30 minutes, then open the call for questions. We expect the call to last approximately 1 hour. We request that anyone asking questions, please limit yourself to 1 question. Should you have any additional questions, please call our Investor line at (925) 460-3663 or email ir@cooperco.com. 
As a reminder, this call is being webcast, and a copy of the earnings release is available through the Investor Relations section of The Cooper Companies website. 
And with that, I'll turn the call over to Bob for his opening remarks."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thank you, Kim, and good afternoon, everyone. Welcome to the Second Quarter 2016 Conference Call. Let me start by highlighting 3 key areas. First, I'm pleased to report strong financial results for our fiscal second quarter. On a consolidated basis, we re",1262,"Thank you, Kim, and good afternoon, everyone. Welcome to the Second Quarter 2016 Conference Call. Let me start by highlighting 3 key areas. First, I'm pleased to report strong financial results for our fiscal second quarter. On a consolidated basis, we reported $484 million in revenue and non-GAAP earnings per share of $2.05. 
Second, CooperVision posted 9% revenue growth on both a constant currency and as-reported basis and strong results in all key areas of the business. Single-use silicone hydrogel lenses grew 52%, while 2-week and monthly silicone hydrogel lenses grew a combined 14%, both in constant currency. 
Third, CooperSurgical had another strong quarter, posting revenue growth of 23% and pro forma growth of 6%. We also closed several strategic acquisitions since our last earnings call. 
Moving into the details, CooperVision reported second quarter revenues of $391 million, up 9%. This was our strongest quarter -- growth quarter since 2014 and really shows the strength of our product portfolio. Regarding revenue by geography, the Americas grew 9% in constant currency, showing a nice rebound from last quarter. Strength was seen in multiple categories led by silicone hydrogel products. Our enhanced clariti lens has been extremely well received and MyDay had another strong quarter. Our toric and multifocals also posted strong growth driven by the Biofinity family. 
EMEA had another strong quarter and sales grew 5% in constant currency. Growth was driven by our family of silicone hydrogel products, Biofinity, clariti, MyDay and Avaira. We also launched Avaira Vitality in EMEA during the quarter and it is being well received. Avaira Vitality is our new 2-week silicone hydrogel lens, which is an enhanced replacement for the original Avaira lens. It was developed using improved manufacturing processes, resulting in a higher quality product at a lower cost per unit. We expect to launch this lens in the U.S. later this year subject to FDA approval. 
Asia Pacific had a very strong quarter, up 18% in constant currency. Growth was strong throughout the region and Biofinity and Proclear 1 Day stood out in Japan. Also within Japan, we began our MyDay launch during the quarter and we're seeing early signs that MyDay could be a very successful premium offering in that market. 
Turning to our product categories. Toric and multifocals grew a healthy 13% year-over-year in constant currency. We saw a very nice rebound in the U.S., which bolstered our strength throughout the rest of the world. We remained the global leader in specialty lenses. 
Looking at silicone hydrogel lenses. These products grew 20% in constant currency and now represent 60% of our total sales. Within the 2-week and monthly space, Biofinity and Avaira combined to grow 14% in constant currency. We remain under indexed in the 2-week and monthly silicone hydrogel space at 74% of sales versus the market at 79%, so we anticipate a very nice growth for many years to come. 
Regarding our silicone hydrogel 1 Day lenses, clariti and MyDay, they combined to grow 52% in constant currency. We remain very optimistic about these products and are committed to our growth strategy, which includes a 2-tier approach with clariti positioned as the mass market offering and MyDay as the premium offering. Remember the biggest driver in the contact lens market is the 1 Day growth, and we strongly believe we have the best product offering in the space as the only company with premium and mass market lenses, including a full portfolio of 1 Day silicone hydrogel, sphere, toric and multifocal lenses. 
Before finishing with market data, let me make a quick comment on integration matters. We continue to finalize our Sauflon integration activities and we're very close to being done. You'll note CooperVision had a very small non-GAAP adjustment this quarter -- or a smaller non-GAAP adjustment this quarter of roughly $9 million excluding amortization. We forecast similar charges in Q3 and Q4, mostly within cost of goods, but these should end this fiscal year. 
Now let me comment on the overall contact lens market and remember, this information is on the last page of the earnings release. For calendar Q1, we continue taking share, growing 9%, with the market up 3%. Geographically, CooperVision grew 9% in the Americas while market was flat. In Asia Pacific, CooperVision grew 14%, with the market up 5%. And in EMEA, we grew 6%, in line with the market. 
On a modality basis, single-use lenses continue driving growth and CVI -- with CVI up 14% and the market up 9%. For non-single-use lenses, we grew 6% while the market declined 1%. We also see -- as you can see, our growth remains diverse and strong. On a trailing 12-month basis, CooperVision grew 8% and the market grew 5%. Going forward, I expect the market to continue growing 4% to 6% over the next 5 years and most likely closer to 6%. The drivers will continue to be a shift to dailies' geographic expansion and an expansion of the wear base. We expect to continue taking market share, led by our strong silicone hydrogel portfolio. 
Moving to CooperSurgical. We reported second quarter revenues of $93 million, up 23% year-over-year or up 6% pro forma. Our fertility products led the way up 60% or 8% pro forma and our office and surgical products grew 5%. We continued executing on several initiatives, which are driving success, including transitioning to a geographic sales model, adding sales representatives in under-penetrated areas and increasing our focus on high-growth areas such as IVF and genetic testing. These moves are clearly gaining traction as we saw growth throughout our business in Q2. Going forward, I believe we'll continue to see solid growth as the business keeps moving into a more aggressive and efficient business model. 
Regarding acquisitions. We've completed several over the past few months, so let me touch on those and the strategic rationale. At the beginning of April, we added Genesis Genetics, a genetic testing lab company focused on preimplantation genetic screening and diagnosis using -- used during the IVF process. This is a nice addition to our existing genetic testing platform. 
At the beginning of May, we added complementary IVF capital equipment products through the acquisition of K-Systems, a small acquisition with roughly $7 million in revenue per year. 
And finally, we added the assets of Recombine last week. Recombine is a genetic testing company specializing in carrier screening, which is a great fit within our IVF and genetic testing franchise as it adds the #1 carrier screening test sold to the IVF clinics. 
As you can see, we're very focused on combining a full-service provider within the IVF global market, and we truly believe this strategy will yield success for many years to come. These deals are all incorporated into our updated guidance. With that, let me touch on our guidance details. 
We are raising our fiscal 2016 revenue guidance for CooperVision to 5.5% to 7% constant currency growth. Our CooperSurgical revenue guidance is also raised to 6% to 8% pro forma growth or up 24% to 27% on an as-reported basis. We're also raising our non-GAAP EPS guidance to $8.20 to $8.50. 
In conclusion, I'm very pleased with our results and remain optimistic about the underlying fundamentals of our business. I believe we're well-positioned to deliver solid results through the remainder of the fiscal year and beyond. With that, let me express my appreciation to our employees, our #1 asset. Their hard work and dedication to creating value is the backbone of our success. 
And now I'll turn it over to Greg to cover the financial results."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thanks, Bob, and good afternoon, everyone. I'll provide the overall summary of our performance, including a review of the market and our revenue picture. We're going to focus primarily on our non-GAAP results for the quarter. For the reconciliation to GAA",1149,"Thanks, Bob, and good afternoon, everyone. I'll provide the overall summary of our performance, including a review of the market and our revenue picture. We're going to focus primarily on our non-GAAP results for the quarter. For the reconciliation to GAAP numbers, please refer to our earnings release. 
Looking at gross margins. In Q2, the non-GAAP gross margin was 63.2% compared to 63.4% in the prior year. Although CooperVision had positives from currency and strong Biofinity sales, its margin was lower than expected. The primary items driving this were a negative margin impact from stronger Asia Pac sales, where we have higher 1 Day sales, and charges associated with idle equipment and legacy hydrogel inventory. 
Regarding these last 2 items, let me cover them separately. We have made a lot of progress improving our manufacturing operations, including some very recent successes. For competitive reasons, I won't get into specifics, but our production per line has increased materially, resulting in lower cost per unit and a lesser need for future CapEx. This has resulted in idling from equipment, which hurts us in Q2 and will also negatively impact Q3 and Q4. We anticipate this being a short-term negative as we will grow into this production over time. 
The other item is our legacy hydrogel inventory, where we wrote off more than we planned, as our silicone hydrogel sales were very strong and we're forecasting that to continue. This hurts us in Q2 and we expect it will negatively impact Q3 and Q4. To be clear, we're not excluding these items from earnings, so they are negatively impacting our non-GAAP earnings per share. 
CooperVision on a non-GAAP basis reported gross margin of 62.8% versus 63.3% in Q2 of last year. The factors which impacted margin were the items I just mentioned. CooperSurgical had non-GAAP gross margin of 64.8%, which compares to Q2 '15 of 63.5%. Strength in the OB/GYN and IVF product families drove this quarter's margin. 
SG&A. On a non-GAAP basis, SG&A increased approximately 6% to $171.6 million or 35% of revenue, down from approximately 37% of revenue the prior year. Primary driver behind this leverage was strong SG&A controls. 
Now looking at R&D. In Q2, R&D on a non-GAAP basis was $16.6 million or 3.4% of revenue, flat in dollars and down from 3.8% of revenue in the prior year. We're seeing investment in CSI, offset by synergies from the Sauflon acquisition in CVI. 
Now moving to operating margins. For Q2, consolidated GAAP operating income and margin were $89.8 million and 18.6% of revenue versus $71 million and 16.3% of revenue in Q2 last year. Non-GAAP operating income and margin were $117.6 million and 24.3% of revenue versus $96.7 million and 22.2% of revenue for the prior year. Primary difference in operating margin year-over-year is the operating expense leverage. 
In Q2, CooperVision, on a non-GAAP operating income and margin, were $102.4 million and 26.2% of revenue versus $88.8 million and 24.7% of revenue in the prior year. 
CooperSurgical's non-GAAP operating income and margin were $26.6 million and 28.8% of revenue versus Q2 '15 of $18.8 million of operating income and 25% of revenue. 
Moving on to depreciation and amortization. In Q2, depreciation was $33.7 million, up $1.5 million year-over-year. Amortization was $14.3 million, up $2 million, reflecting our recent acquisition activity. 
Interest expense was $7.6 million for the quarter, up $2.9 million year-over-year, primarily due to higher debt and interest rates associated with acquisitions. Looking at the effective tax rate. In Q2, the non-GAAP effective tax rate was 9.4% versus a non-GAAP effective tax rate of 8.4% in Q2 '15. 
Earnings per share. Our Q2 earnings per share on a GAAP and non-GAAP basis was $1.52 and $2.05, respectively, versus $1.23 and $1.72 for GAAP and non-GAAP in the prior year. Non-GAAP earnings per share on a pro forma basis, which adjusts for currency and acquisitions, grew approximately 13% in the quarter. 
By looking at FX, the net currency impact on earnings per share year-over-year for Q2 was a favorable $0.10. 
Moving on to the balance sheet. In Q2, we had cash provided by operations of $97.8 million less capital expenditures of $41.1 million, resulting in $56.7 million of free cash flow. Excluding integration costs of $9 million, adjusted free cash flow was $65.7 million. 
Total debt increased within the quarter by $64.1 million to $1,441,400,000, primarily due to higher average cash balances and acquisitions, partially offset by operational cash flow. 
Inventories increased from last quarter, approximately $2.7 million, to $433.6 million. This is entirely driven by CSI acquisitions. In CooperVision, we saw inventories decline as growth in silicone daily inventory to support our product launches was offset by a reduction in our hydrogel inventory. For the quarter, we're seeing months on hand at 7 months. Days sales outstanding is at 54 days, which is down 3 days from the prior quarter and 2 days from last year. 
Now turning to guidance. For our main currencies, we are using 1.10 for the euro, 112 for the yen and 1.46 for the pound. 
The consolidated revenue range is being raised to $1.929 billion to $1.960 billion or approximately 5.5% to 7% pro forma growth. CooperVision's revenue range is being raised to $1.545 billion to $1.567 billion or roughly 5.5% to 7% constant currency growth. CooperSurgical's revenue range is being raised to $384 million to $393 million or roughly 6% to 8% pro forma growth. Note that roughly half of the increase in guidance is from currency, while the other half is primarily from acquisitions. 
We expect non-GAAP gross margin to be around 63% for the year. This is a reduction from the previous guidance of around 64% as it incorporates the CooperVision items I mentioned earlier, along with lower gross margins from CooperSurgical, associated with recent acquisitions. Having said that, we still expect improving Q3 and Q4 gross margins of around 64% each quarter. 
OpEx is expected to be around 39%. Operating margins still expected to be around 24%. 
Interest expense is expected to be around $28 million. 
Our effective tax rate is expected to be around 8%. 
Our expected share count will be around 49.1 million shares. 
And our non-GAAP earnings per share is expected to be $0.20 higher on the top and bottom of our range to $8.20 to $8.50, which equates to a pro forma earnings per share of 10% to 14% growth. 
From our last guidance, currency is roughly a $0.40 positive, and we have actually improved our operational performance by roughly $0.10, but we are expecting the idle legacy inventory write-off to negatively impact us by roughly $0.30. 
CapEx is expected to be around $200 million. 
We finished paying for equipment we have ordered over the prior year, and thus, adjusted free cash flow is still expected to be around $300 million. 
With that, let me turn it back to Kim for the Q&A session."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Operator, we're ready to take some questions.",7,"Operator, we're ready to take some questions."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Matthew O'Brien with Piper Jaffray.",15,"[Operator Instructions] 
Our first question comes from the line of Matthew O'Brien with Piper Jaffray."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Just one for Bob and then one for Greg. On the increase in CVI -- I guess, this question is for Bob -- increase to CVI's outlook for the year, can you just give us a sense for how much of that is coming from improved manufacturing of MyDay, especially lau",136,"Just one for Bob and then one for Greg. On the increase in CVI -- I guess, this question is for Bob -- increase to CVI's outlook for the year, can you just give us a sense for how much of that is coming from improved manufacturing of MyDay, especially launching into Japan? Or just disruptions in the markets that you're seeing? And then, how much are you incorporating the J&J launch as far of somewhat of a headwind into your fiscal Q4? And then, for Greg, this is typically a really strong free cash flow quarter for you guys, but you're sticking with the $300 million outlook for the year. So can you just help us rectify a little bit of a softness that we saw here in Q2 versus that outlook for the year?"
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes. The foreign exchange, as Greg indicated, is a big driver of the top line overall improvement. In terms of the constant currency growth, you're correct, there is a modest -- in the guidance, there's a modest deceleration compared to what we had previo",125,"Yes. The foreign exchange, as Greg indicated, is a big driver of the top line overall improvement. In terms of the constant currency growth, you're correct, there is a modest -- in the guidance, there's a modest deceleration compared to what we had previously forecasted to anticipate, if you will, some impact of the J&J rollout. Beyond that, it's pretty much in the same range at 5.5% to 7%, so modest at both. MyDay impact in Japan is -- once again, we just rolled that product out in March of this year, so a fairly minimal impact in terms of the overall any update on the guidance, if you will. And of course, we already knew about MyDay in Japan in our previous March guidance."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, Matt, on the free cash flow, nothing really jumps out. The number isn't that far off of the prior year. And we did have a much stronger Q1, so if you look at kind of halfway through the year, we're actually probably ahead of where we were last year.",50,"Yes, Matt, on the free cash flow, nothing really jumps out. The number isn't that far off of the prior year. And we did have a much stronger Q1, so if you look at kind of halfway through the year, we're actually probably ahead of where we were last year."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Jeff Johnson with Robert Baird.",13,"Our next question comes from the line of Jeff Johnson with Robert Baird."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Sorry, about that. Guys, can hear me, okay?",8,"Sorry, about that. Guys, can hear me, okay?"
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","We can.",2,"We can."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","All right, great. So Bob, let me ask you one question and then I have a modeling question for Greg, as well. But the question for you, just on the Biofinity and Avaira business, obviously that bounced back very nicely this quarter. I think you said 14% co",118,"All right, great. So Bob, let me ask you one question and then I have a modeling question for Greg, as well. But the question for you, just on the Biofinity and Avaira business, obviously that bounced back very nicely this quarter. I think you said 14% constant currency in the quarter year-over-year. 7% last quarter, so kind of averaging right around double digits. Is that how we should think about that business going forward? Obviously, you've got the launch coming from J&J, as was referenced in the prior question. You also have ULTRA kind of gaining some traction, it sounds like. So just how do you think about that Biofinity/Avaira bucket over the next couple of years?"
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, I think taking the 2 quarters, the 7% and 13%, being in around low double digit is the right way to think about it.",25,"Yes, I think taking the 2 quarters, the 7% and 13%, being in around low double digit is the right way to think about it."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Right, that's helpful. And Greg, question for you. I think at the very end, did you say $0.30 is the EPS impact of the inventory write-off and that is included in your non-GAAP EPS guidance? Is that correct?",38,"Right, that's helpful. And Greg, question for you. I think at the very end, did you say $0.30 is the EPS impact of the inventory write-off and that is included in your non-GAAP EPS guidance? Is that correct?"
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes.",1,"Yes."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Okay. So for next year, we should been thinking about adding just kind of building off a base that's $0.30 higher, assuming you're not going to have that kind of write-offs next year? Would that be the fair way to take kind of this year's EPS, add $0.30 b",61,"Okay. So for next year, we should been thinking about adding just kind of building off a base that's $0.30 higher, assuming you're not going to have that kind of write-offs next year? Would that be the fair way to take kind of this year's EPS, add $0.30 back and build that off as our base assumption going into next year?"
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Jeff, it's probably a little early to get into next year's guidance, which we would come out later in the year and discuss.",23,"Jeff, it's probably a little early to get into next year's guidance, which we would come out later in the year and discuss."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","And keep in mind, Jeff, there's a balance between -- some of that is write-off, as Greg indicated. Some of it is idle equipment as we grow into it. So we're growing. Given the substantial growth of our 1 Day modality and our unit growth, we're anticipatin",73,"And keep in mind, Jeff, there's a balance between -- some of that is write-off, as Greg indicated. Some of it is idle equipment as we grow into it. So we're growing. Given the substantial growth of our 1 Day modality and our unit growth, we're anticipating that we'll start consuming more and more of that as each quarter goes by. But that $30 million overall is both write-offs as well as idle."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, and Jeff, just to build on that a little bit, I think without giving guidance, I think we feel comfortable that we would see gross margins improve year-over-year.",29,"Yes, and Jeff, just to build on that a little bit, I think without giving guidance, I think we feel comfortable that we would see gross margins improve year-over-year."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Joanne Wuensch with BMO Capital Markets.",14,"Our next question comes from the line of Joanne Wuensch with BMO Capital Markets."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Can you hear me, okay?",5,"Can you hear me, okay?"
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","We can.",2,"We can."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Wonderful. I think what a couple of people were trying to get at, and I know in speaking with investors, the big concern right now is the J&J monthly launch starting at the end of June, beginning of July. How can you -- how do you think about that product",71,"Wonderful. I think what a couple of people were trying to get at, and I know in speaking with investors, the big concern right now is the J&J monthly launch starting at the end of June, beginning of July. How can you -- how do you think about that product launch and how do we get comfortable that we're not going to see a similar hiccup to what happened last fall?"
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, without knowing exactly what J&J is up to, in hindsight, we know what they did is they sold the pipeline a lot. And then, we saw it in their negative U.S. results in the most recent quarter. So no one is going to say they can't do that again. Having",399,"Well, without knowing exactly what J&J is up to, in hindsight, we know what they did is they sold the pipeline a lot. And then, we saw it in their negative U.S. results in the most recent quarter. So no one is going to say they can't do that again. Having said that, this is a product coming into the monthly modality. It's basically coming in with only a sphere, not a toric and a multifocal, so it's not a family of products going against a family of products. And that is a big distinction as contrasted to the pipeline dragging everything in under one umbrella, as they did their whole family of products, and going after a sphere going after a sphere. In that case, it was always the 1 Day going against Total1 primarily in that space. But it consumed -- it took all the air out of the practitioner's office, if you will, or filled up all the space. And there clearly is no guarantee they wouldn't try flooding the market again. As far as the way we think about it longer-term, Biofinity is a very established product, wherein we continue to expand the offerings under that umbrella. It's a very global product, and it's one where -- it's good in the monthly and we also have Avaira Splash Vitality [ph] coming out in the 2-week, which is the sweet spot of the market in terms of the number of wearers. There are more wearers in the 2-week part of the market than there are in the monthly. Quite frankly, as some of you know, I've always held the view that it's a good strategy for J&J if they're intent on trading up and basically migrating the noncompliant wearer base they have in the 2-week space into a compliant monthly modality. That would be a good trade-up in modalities because a noncompliant wearer is one who is basically only using 24 lenses a year compared to a monthly using 24 and conversely they're getting the price point of a 2-week wearer. And that's a pretty big part of that 2-week modality. So we think -- yes, we'll continue to see that market grow, the monthly, and we'll get our fair share with Biofinity. In the meantime, we'll be more active down the road in the 2-week space, and we'll basically neutralize it for the most part."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Steve Willoughby with Cleveland Research.",13,"Our next question comes from the line of Steve Willoughby with Cleveland Research."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Hey, guys. Can you hear me, okay?",7,"Hey, guys. Can you hear me, okay?"
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","We can, Steve.",3,"We can, Steve."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Okay, Bob. Just regarding the charges or the idle equipment and inventory write-off that you guys took in the quarter, a couple of questions regarding that. I guess, first, the idle equipment, is that -- the idle equipment charge, it relates to newly purc",62,"Okay, Bob. Just regarding the charges or the idle equipment and inventory write-off that you guys took in the quarter, a couple of questions regarding that. I guess, first, the idle equipment, is that -- the idle equipment charge, it relates to newly purchased equipment that you don't need quite yet? Or is that existing equipment that you're idling for some reason?"
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, so to qualify as idle, it's basically been put in production and then is taken out of production. So I'll answer the question with a little color. It could be very new equipment that was put in production. Example, our facility in Hungary, where they",124,"Yes, so to qualify as idle, it's basically been put in production and then is taken out of production. So I'll answer the question with a little color. It could be very new equipment that was put in production. Example, our facility in Hungary, where they got real good at making it, and all of a sudden, we parked the equipment because so many -- so much product was coming off of the other line. So as yields go up and costs are coming down, that's the good news. The bad news is if you put it -- if you put equipment that you were using and you idle it, it becomes a direct period charge as opposed to moving through with the inventory."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Okay. So this sort of what happened with Avaira and then Gen 2 line a number of years ago then?",20,"Okay. So this sort of what happened with Avaira and then Gen 2 line a number of years ago then?"
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Absolutely.",1,"Absolutely."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Okay. And [indiscernible]",3,"Okay. And [indiscernible]"
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","So what happened is our manufacturing people got very good at what they were doing. We always knew that if we -- that they would deliver. We just didn't know how well they would deliver. So they're delivering a lot more units per dollar spent of capital.",132,"So what happened is our manufacturing people got very good at what they were doing. We always knew that if we -- that they would deliver. We just didn't know how well they would deliver. So they're delivering a lot more units per dollar spent of capital. That's the good news. But it also turned short-term into the bad news. As I think Greg indicated, we'll grow out of that fairly quickly when you look at the rapid unit growth in many of these areas, where we have become very efficient. And that includes MyDay, that includes Biofinity, that includes Avaira, that includes Vitality, and that includes clariti in the bucket. They -- all of those products became -- the costs are going down through efficiencies and yields by our manufacturing people."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Lawrence Keusch with Raymond James.",13,"Our next question comes from the line of Lawrence Keusch with Raymond James."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","This is actually John in for Larry. I just had a quick question. I guess, what's the right way to calibrate expectations for MyDay in Japan? You obviously just launched in the quarter, but maybe shorter term and then maybe a little bit longer term in '16",49,"This is actually John in for Larry. I just had a quick question. I guess, what's the right way to calibrate expectations for MyDay in Japan? You obviously just launched in the quarter, but maybe shorter term and then maybe a little bit longer term in '16 and '17?"
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, you can see some of the numbers we're putting up in the region and Japan has certainly been stellar within that region also. Right now, we have a good portfolio of 3 products, with MyDay being the third one in, but Biofinity is doing very well. Proc",276,"Well, you can see some of the numbers we're putting up in the region and Japan has certainly been stellar within that region also. Right now, we have a good portfolio of 3 products, with MyDay being the third one in, but Biofinity is doing very well. Proclear 1 Day is doing very well as well now, MyDay. We will be -- we're early -- 1.5 months into the launch, if you will, through the end of April and are very pleased with the progress we're making. It's the biggest market by far in terms of the 1 Day modality anyplace in the world, and therefore, MyDay is a very good fit in a very good market. And we think the combination of MyDay as a silicone hydrogel and Proclear 1 Day as a hydrogel will be -- is a good entree into that market. As Japan has been historically pretty lethargic the last -- I want to say, 7, 8 years. It's showing a little bit more life than it has. And the only reason it's been lethargic is because it grew so rapidly in the prior decade compared to this decade. It got ahead of itself on the 1 Day modality and became the first to adopt that because they were very anti-lens care regimens and wanted the lenses to be boiled, and therefore, everyone migrated into the 1 Day modality rather than boiling lenses every day. And I'll just say that we're pretty excited about MyDay there. It's going to take some work. It's only a sphere thus far, so there will be other plans relative to how to leverage the MyDay experience."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Matt Mishan with KeyBanc.",12,"Our next question comes from the line of Matt Mishan with KeyBanc."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Bob, first, on CooperVision, I just want to better understand the sequential improvement in growth this quarter versus the previous several quarters. Is it your sense that the impact of the Johnson & Johnson launch has now fully waned? Or is there somethi",78,"Bob, first, on CooperVision, I just want to better understand the sequential improvement in growth this quarter versus the previous several quarters. Is it your sense that the impact of the Johnson & Johnson launch has now fully waned? Or is there something that you've been doing to improve your results and to improve share? I'm just trying to get a sense of whether or not this is Johnson & Johnson or this is you guys doing something."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","So I think it's a combination. I think the air that left the room is now back in the room. The eye care professional, he has room for products, and so it's more normalized in that sense and that's obvious from the weak numbers that J&J put up domestically",138,"So I think it's a combination. I think the air that left the room is now back in the room. The eye care professional, he has room for products, and so it's more normalized in that sense and that's obvious from the weak numbers that J&J put up domestically, and [indiscernible] Alcon put up numbers worldwide. We -- relative to our products, I think I'll make a point of saying that our numbers that we put up -- it's not a function of any price -- pricing or anything to do with channel sales. So it's a good quarter. The inventory on hand at distributors and the pipeline is very normalized. In fact, it's a little less than it was at the beginning of the period. So it's a reflection of pretty solid numbers around the world."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Brian Weinstein with William Blair.",13,"Our next question comes from the line of Brian Weinstein with William Blair."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","It's a little bit of a longer-term question, but can you talk about what you expect longer term in terms of the split between clariti and MyDay and kind of what you think your share longer term is there? And then, how do you think about manufacturing -- m",60,"It's a little bit of a longer-term question, but can you talk about what you expect longer term in terms of the split between clariti and MyDay and kind of what you think your share longer term is there? And then, how do you think about manufacturing -- manufacturer pricing levels in the daily silicone hydrogel market longer term?"
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","So I think the split between clariti and MyDay, it's easier to relate in the U.S. The U.S. is going to be primarily where clariti is after the mass market and MyDay is after the premium market. I would have normally said, think of that as like a 75% mass",458,"So I think the split between clariti and MyDay, it's easier to relate in the U.S. The U.S. is going to be primarily where clariti is after the mass market and MyDay is after the premium market. I would have normally said, think of that as like a 75% mass market, 25% premium market. And I think that's the U.S. portion of the model. I think when you get into certain regions of the world, for example, Japan, where only MyDay is playing, then -- so if you're factoring that into the overall global results, you'll end up with MyDay outgrowing because it's coming off of a lower base and it's just getting into Japan, at least for the foreseeable future, outgrowing as a percent, getting more of its share of the bucket. So instead of saying 75%-25%, MyDay may move up that spectrum and get a higher portion in the interim. When clariti is available throughout Asia Pac and around the world, that may come back more into the mass market premium split. But for now, one point is we're not capacity constrained on either of these products. We will continue, in the case of MyDay, expanding the portfolio offering, so that will help. Right now, it's a sphere competing with clariti, which has a sphere, a multifocal and a toric, and that will weight more towards the clariti piece. Relative to margins, we will continue to focus in -- from a pricing point of view, being keenly aware of that 2-tier market, the premium market, which we'll call the players there in the U.S., clearly Total1, OASYS and MyDay. And TruEye is the other one that's kind of there in that space, but OASYS will consume more and more of TruEye. And in the mass market, then clariti remains the only game in town relative to a silicone hydrogel in the 1 Day mass market. So that is a function of watching the migration of hydrogels into this silicone hydrogel space in that mass market arena. Cost of goods gross margins, we expect, as we've indicated in the past, to have our 1 Day silicone hydrogel franchise, and most notably clariti, not a drag on our overall gross margin for the next several years. Anyway, MyDay is ramping up the learning curve, moving very nicely. And I would say, the indicator of some of the idling and the indicator of us having enough MyDay capacity is just how well that's ramping up. As it ramps up, the cost of goods come down to the yields and deficiencies, so we're very pleased with that, and we expect more than -- clearly more than 50% out of MyDay as we get down the road a couple of years."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of David Roman with Goldman Sachs.",13,"Our next question comes from the line of David Roman with Goldman Sachs."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","I was hoping you could just touch on in a little bit more detail, firstly, the strength in Asia Pacific. I think last quarter, you had kind of said that you were ramping capacity in Japan. That wouldn't be a significant contributor till the much later par",112,"I was hoping you could just touch on in a little bit more detail, firstly, the strength in Asia Pacific. I think last quarter, you had kind of said that you were ramping capacity in Japan. That wouldn't be a significant contributor till the much later part of the year and into the next fiscal year. But any other regions driving, a, within Asia Pac that you could call out? And then, secondly on the 6% to 8% pro forma guidance for CSI, that is quite a bit above where those end markets, I think, are growing, so maybe you could just speak to the sustainability of that on a go-forward basis?"
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","So relative to Asia Pac, I would emphasize that the numbers you see are -- very little to do with MyDay. It's very early in the game, so it didn't -- so the strength you're seeing there is just how well some of the geographic expansions are going, how wel",310,"So relative to Asia Pac, I would emphasize that the numbers you see are -- very little to do with MyDay. It's very early in the game, so it didn't -- so the strength you're seeing there is just how well some of the geographic expansions are going, how well Japan is going ex MyDay, and then the MyDay launch. But it is not the driver of that 18%, which -- and MyDay was only launched mid-March, so really, it's only got 1.5 months in Japan in that period -- in the quarter. Relative to what to expect in that region, we certainly expect continued robust numbers out of Asia Pac for the foreseeable future. Number one, we're under-indexed. Number two, we're delivering a lot of these new products, clariti coming into more and more of Asia Pac, and of course, MyDay, which we talked about. So we're pretty optimistic that we'll see a continued strength in that market. Relative to surgical and the 6% to 8%, a lot of that growth is a reflection of, number one, the emphasis on really selling the product and the global realignment with the selling effort. We have some -- obviously, even some good products in the surgical side that are driving organic growth there. The acquisitions we've made are -- the expectation there keenly is -- clearly is double-digit in many of those acquisitions, so we expect to drive a lot of the genetic testing and surround the IVF process, so that we are the key player that the IVF centers are engaging with. And we're pretty optimistic about that, and obviously, the last 2 quarters have indicated it's a pretty successful strategy. I think going forward, the 6% to 8% reflects some of the more recent acquisitions having more organic top line growth potential than our historic legacy products within CooperSurgical."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Larry Biegelsen with Wells Fargo.",13,"Our next question comes from the line of Larry Biegelsen with Wells Fargo."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Greg, based on the guidance, is the second half implied CooperVision guidance, the midpoint about 5%? And should we think about Q3 and Q4 as similar growth or would you expect Q4 to potentially be lower because the J&J launch comes in July? And Greg, can",88,"Greg, based on the guidance, is the second half implied CooperVision guidance, the midpoint about 5%? And should we think about Q3 and Q4 as similar growth or would you expect Q4 to potentially be lower because the J&J launch comes in July? And Greg, can you just tell us what the FX assumption is? It looks like you're assuming about, for the year 0 impact on EPS. Is that math, right? What is it on sales? And is there some conservatism in your FX assumptions right now?"
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, Larry, I think for CVI, the midpoint kind of growth for Q3/Q4 would be about 6.1%, I think if you do the math. If you look at from a seasonality, we're not giving quarterly seasonality. But I think you can look at past seasonality for CooperVision. I",189,"Yes, Larry, I think for CVI, the midpoint kind of growth for Q3/Q4 would be about 6.1%, I think if you do the math. If you look at from a seasonality, we're not giving quarterly seasonality. But I think you can look at past seasonality for CooperVision. It generally is fairly consistent. On the FX fronts, yes, I think you've got that right. When you look at FX, we basically for the year see about no impact on the earnings per share. On the revenue front, again, you're looking at about right around $30 million of revenue reduction. Now on the rates, are we being conservative? Well, if you look at today's rates, I think you can say we're being conservative. We did use the rates for the euro at 1.10, the pound at 1.46 and the yen at 112, and we start setting those rates a couple of days ago. The yen was at 1 point -- or was that 111.3, so the yen has kind of -- has basically strengthened in the last couple of days. But those were the rates that the model is based on."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Mike Weinstein with JPMorgan.",12,"Our next question comes from the line of Mike Weinstein with JPMorgan."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","This is Andrew [ph] in for Mike. I have 2 questions, the first being product-specific and the second regarding the market. So can you talk about, Bob, the slight design changes in the clariti lens and what you are seeing in the way of market adoption with",53,"This is Andrew [ph] in for Mike. I have 2 questions, the first being product-specific and the second regarding the market. So can you talk about, Bob, the slight design changes in the clariti lens and what you are seeing in the way of market adoption with this design versus before the change?"
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Sure, do you want to ask the second?",8,"Sure, do you want to ask the second?"
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Yes, I could ask the second. The second is around UPP. So the U.S. market growth in the quarter was probably the lowest in a while, I believe, and I was just wondering whether or not this was a result of some pricing war that's going on within the market",68,"Yes, I could ask the second. The second is around UPP. So the U.S. market growth in the quarter was probably the lowest in a while, I believe, and I was just wondering whether or not this was a result of some pricing war that's going on within the market and just your general thoughts around the UPP and how you think that might benefit you moving forward."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Sure. The product relative to the enhancement that we made to clariti, I think you've seen the overall silicone hydrogel 1 Day numbers were 52% growth. So suffice it to say that the enhancement as well as -- of course, we had some activity in the fourth q",425,"Sure. The product relative to the enhancement that we made to clariti, I think you've seen the overall silicone hydrogel 1 Day numbers were 52% growth. So suffice it to say that the enhancement as well as -- of course, we had some activity in the fourth quarter regarding our integration process in Europe that caused some bumps then. But suffice it to say we're running on all cylinders now with clariti in the marketplace and the enhancement has certainly been very beneficial in that process. As far as UPP and the market, the 3% growth in the market, as much as anything, it's probably much more influenced by the J&J cycle stuff [ph] that they put the market through with a strong market 2 quarters ago, and that followed by basically a void in the U.S. in this quarter. So were it not for that, it would be more normalized. The trailing 4 quarters is a much better gauge that is approaching 5% worldwide relative to the U.S. and UPP. And whether or not there's any pricing post-UPP or a decline in pricing, I would say that certainly, I know that some vendors may have -- or retailers may have altered J&J prices, but by and large, the market continues to drive itself the way it has the past. Pricing is not really a factor. It's all about trading up and shelf space and first fits, and it remains that way. The focus on getting a new fit in the marketplace or where you have a new product, trying to get a conversion onto your product. There is a fair amount of stickiness to most of these products, so I would say the real driver of your product doing well is the new fit arena is the big contributor. Pricing, to me, this market has traded up for 30 years and it continues to do a phenomenal job. And over that 30 years, there has been but maybe 1 or 2 price skirmishes. UPP was a fairly shallow attempt at a marketing strategy that was, obviously, beneficial to the independents compared to the retailers. Whether or not it was worth anything, it continued to be debated. There's obviously a lot of emotions on both sides of the table on that in the marketplace. But if UPP went away tomorrow, it would not be the end of the world. If it stays where it is, it's okay also. So I don't see that as a material catalyst one way or the other in the marketplace."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Anthony Petrone with Jefferies.",12,"Our next question comes from the line of Anthony Petrone with Jefferies."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Maybe one for Bob on Japan and then one for Greg on margins. On Japan, can you maybe give us a recap of the size of the daily market in Japan and maybe where Cooper's share is today and how MyDay can benefit that going forward? And then, for Greg, just a",93,"Maybe one for Bob on Japan and then one for Greg on margins. On Japan, can you maybe give us a recap of the size of the daily market in Japan and maybe where Cooper's share is today and how MyDay can benefit that going forward? And then, for Greg, just a quick one on margins. I believe the CIBA royalty does roll off internationally toward the end of this year. I just want to confirm if that is the case and what do you expect the margin benefit from that will be?"
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, the overall market in Japan is around $1.2 billion at current exchange rates. It would have been a lot bigger than that, but obviously, the yen kept sliding against the dollar for a number of years. Of that $1.2 billion, basically 2/3, over 60%, is t",94,"Yes, the overall market in Japan is around $1.2 billion at current exchange rates. It would have been a lot bigger than that, but obviously, the yen kept sliding against the dollar for a number of years. Of that $1.2 billion, basically 2/3, over 60%, is the 1 Day modality. And our share in that market is -- we are still very under indexed in that market. So far, our overall market share worldwide is, this most recent quarter, 23% worldwide. We are well in the mid-teens at best in Japan in that space."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","And Anthony, this is Greg. On the CIBA royalty, it did roll off within the quarter. We're not really providing any kind of color on the rate itself. Again, we've talked about that over the last couple of years that we have obligations of not disclosing th",58,"And Anthony, this is Greg. On the CIBA royalty, it did roll off within the quarter. We're not really providing any kind of color on the rate itself. Again, we've talked about that over the last couple of years that we have obligations of not disclosing that rate. And so from that perspective, we really can't share that."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","[Operator Instructions] Our next question comes from the line of Jon Block with Stifel.",14,"[Operator Instructions] Our next question comes from the line of Jon Block with Stifel."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Maybe first one, Bob. Just CVI was strong and one of the better results since 2014. But to be fair, if you go back then, we were sort of hit after that with a series of quarters where there was inventory drawdowns that went against the company. So I just",80,"Maybe first one, Bob. Just CVI was strong and one of the better results since 2014. But to be fair, if you go back then, we were sort of hit after that with a series of quarters where there was inventory drawdowns that went against the company. So I just want to make sure and ask, if you would, sort of your level of confidence that the sell-in, if you would, in this particular quarter totaled the sellout and demand?"
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, I think I mentioned -- I commented [ph] a while ago that relative to the quality of what's pricing or any pricing influencing or was pipeline influencing, the answer is no. In fact, our pipeline -- the inventory on hand was slightly better than at th",75,"Yes, I think I mentioned -- I commented [ph] a while ago that relative to the quality of what's pricing or any pricing influencing or was pipeline influencing, the answer is no. In fact, our pipeline -- the inventory on hand was slightly better than at the beginning of the period in both cases, kind of where we want it. So the drawdown -- the inventory drawdown or the pipeline is where we want it."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Steven Lichtman with Oppenheimer & Co.",13,"Our next question comes from the line of Steven Lichtman with Oppenheimer & Co."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Most of my questions have been answered. I had one follow-up on CSI. Bob, do you anticipate continuing to add to the portfolio through tuck-in M&A? Or are you feeling that the portfolio is where you want it to be at this point?",43,"Most of my questions have been answered. I had one follow-up on CSI. Bob, do you anticipate continuing to add to the portfolio through tuck-in M&A? Or are you feeling that the portfolio is where you want it to be at this point?"
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, we won't obviously get into a lot of color on what's in the pipeline, but suffice it to say we're focused in on rounding out the portfolio in front of the IVF centers. It is a boutique area, where there are little things out there to continue to buy",68,"Well, we won't obviously get into a lot of color on what's in the pipeline, but suffice it to say we're focused in on rounding out the portfolio in front of the IVF centers. It is a boutique area, where there are little things out there to continue to buy up, and so don't be surprised if we don't continue to have some acquisitions on a go-forward basis."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","So that concludes today's question-and-answer session. I'd like to turn the call back to Bob Weiss for closing remarks.",20,"So that concludes today's question-and-answer session. I'd like to turn the call back to Bob Weiss for closing remarks."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, I want to thank everyone for joining us. Hopefully, everyone is as excited about our quarterly results as we are pleased about them. Not only are we pleased where we've been, but very optimistic about where we're going, as I think you would see from",120,"Well, I want to thank everyone for joining us. Hopefully, everyone is as excited about our quarterly results as we are pleased about them. Not only are we pleased where we've been, but very optimistic about where we're going, as I think you would see from the guidance that Greg talked to. Yes, we have some short-term challenges with idle capacity. It's a silver lining problem because it means that to some degree, our capital requirements on go forward basis will be somewhat less certainly than they have been in the past. So we look forward to updating you on our continued progress, on our next quarterly call, which is September 1, I believe. Thank you. That concludes it. Operator."
263609,334265350,995247,"The Cooper Companies Inc., Q2 2016 Earnings Call, Jun 02, 2016",2016-06-02,"Earnings Calls","The Cooper Companies, Inc.","Operator","Ladies and gentlemen, thank you for your participation in today's conference. This concludes the program, and you may now disconnect. Everyone, have a great day.",25,"Ladies and gentlemen, thank you for your participation in today's conference. This concludes the program, and you may now disconnect. Everyone, have a great day."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Cooper Companies Third Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the meeting over",52,"Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Cooper Companies Third Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the meeting over to Kim Duncan, Vice President of Investor Relations. Please, go ahead."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Good afternoon, and welcome to The Cooper Companies Third Quarter 2016 Earnings Conference Call.  I'm Kim Duncan, Vice President of Investor Relations, and giving prepared remarks on today's call are: Bob Weiss, Chief Executive Officer; and Greg Matz, Chi",322,"Good afternoon, and welcome to The Cooper Companies Third Quarter 2016 Earnings Conference Call.  I'm Kim Duncan, Vice President of Investor Relations, and giving prepared remarks on today's call are: Bob Weiss, Chief Executive Officer; and Greg Matz, Chief Financial Officer. 
Before we get started, I'd like to remind you that this conference call contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including all revenue and earnings per share guidance and other statements regarding anticipated results of operations, market or regulatory conditions and integration of any acquisitions or their failure to achieve anticipated benefits. Forward-looking statements depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Events that could cause our actual results and future actions of the company to differ materially from those described in the forward-looking statements are set forth under the caption Forward-Looking Statements in today's earnings release and are described in our SEC filings, including the business section of Cooper's annual report on Form 10-K. These are publicly available and on request from the company's Investor Relations department. 
Now before I turn the call over to Bob, let me comment on the agenda for the call. Bob will begin by providing highlights on the quarter, followed by Greg, who will then discuss the third quarter financial results. We will keep the formal presentation to roughly 30 minutes, and then open up the call for questions. We expect the call to last approximately 1 hour. We request that anyone asking questions, please limit yourself to 1 question. Should you have any additional questions, please call our Investor line at (925) 460-3663 or email ir@cooperco.com. As a reminder, this call is being webcast, and a copy of the earnings release is available through the Investor Relations section of The Cooper Companies website. With that, I'll turn the call over to Bob for his opening remarks."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thank you, Kim, and good afternoon, everyone. Welcome to our third quarter 2016 conference call. Let me start by highlighting 3 key points. First, I'm pleased to report another strong quarter including the first-ever quarter with revenues over $500 millio",1295,"Thank you, Kim, and good afternoon, everyone. Welcome to our third quarter 2016 conference call. Let me start by highlighting 3 key points. First, I'm pleased to report another strong quarter including the first-ever quarter with revenues over $500 million. This includes the CooperVision recording revenues over $400 million for the first time and CooperSurgical recording revenues over $100 million for the first time. This resulted in non-GAAP earnings per share of $2.30 and free cash flow of $98 million. 
Second, CooperVision posted strong results in all key areas of its business, resulting in 6% as recorded in cost of currency growth, single-use silicone hydrogel grew 40% while 2 week and monthly silicone hydrogel lenses grew a combined 11% both in constant currency. 
Third, CooperSurgical had another strong quarter posting revenue growth of 38% or 6% pro forma. Fertility was the highlight posting the strongest quarter in many years with growth of 108% or 10% pro forma. 
Moving into details, CooperVision reported second quarter revenues of $410 million, up 6%. This was another strong quarter and continue to show the strength of our product portfolio. The Americas grew 6% in constant currency with strength in multiple category led by Biofinity and our 1 Day silicone hydrogel franchise. Our enhanced clariti lens continues to perform well and MyDay had another strong quarter. During the quarter, we received FDA approval for Vera Vitality and launch in the U.S. in late July. You'll recall, Vera Vitality is the replacement product for Avaira in the two-week silicone hydrogel market. The market reaction has been positive. We remain optimistic about this upgraded product. We also introduced Biofinity at the American Optimistic Conference in July and again, the launch is August. This premium Biofinity product has received excellent reviews and we're confident we will have great success in its offering. 
EMEA posted a solid quarter from 3% year-over-year in constant currency against the tough comp. Growth was driven by Biofinity and the 1 Day silicone hydrogel franchise. Asia Pacific had a very strong quarter with 16% constant currency growth. Growth was strong throughout the region driven by Biofinity and the 1 Day silicone hydrogel franchise. Within Japan, our MyDay launch is progressing well and we introduced MyDay toric during the quarter. We believe both MyDay Sear and toric have a potential to be a very successful premium offering in this market. 
Turning to our product categories. toric screw a healthy  10% year-over-year and multifocal grew 5%, both in constant currency. We remained the global leader in specialty lenses and our success with Biofinity and clariti in both of these categories should continue to drive growth for many years. 
Looking at silicone hydrogel lenses, this product grew 16% in constant currency and now represents 61% of our total sales. The ended 2 week and monthly space, Biofinity and Avaira combined to grow 11% in constant currency. We remain under index for the two-week and monthly silicone hydrogel space at 75% of revenue versus the market at 79%, so we expect to continue growing faster than the market given our strong product portfolio. 
Regarding our silicone hydrogel 1 Day lenses, clariti and MyDay, they combined to grow 40% in constant currency. The biggest driver in our contact lens market is 1 Day growth and we strongly believe we have the best product portfolio offering in this space as the only company with premium and mass market lenses including a full portfolio of 1 Day, silicone hydrogel, sear, toric and multifocal lenses. Now let me comment on the overall contact lens market and remember, this information is on the last page of the earnings release. For the calendar quarter Q2, we continue taking share growth 10% with a market of 5%. Geographically, CooperVision grew 8% in the Americas while the market was up 4%. In Asian-Pacific, we grew 20% with the market up 4% and in EMEA, we grew 9% with the market up 7%. On a modality basis, single used lenses continue driving growth with CooperVision up 18% and the market up 10%. For non-silicone hydrogel, for non single-use lenses, we grew 7% while the market grew 1%. As you can see our growth remains diverse and strong. On a trailing 12 month basis, CooperVision grew 8% and the market grew 5%. Going forward, I expect market to continue growing 4% to 6% over the next 5 years and most likely closer to 6%. The drivers will continue to be the shift to daily geographic expansion and expansion of the wearer base. We expect to continue taking market share led by our strong silicone hydrogel portfolio. 
Moving to CooperSurgical, we recorded Q2 revenues of $105 million, up 38% year-over-year, driven by strong organic growth and acquisitions. On a pro forma basis, growth was up 6%. Our fertility products led up 108% or 10% pro forma. Within fertility, we had growth throughout the business and continue to believe our market leading product portfolio, which includes medical devices, genetic testing and capital equipment is the broadest portfolio in the space and should continue to drive growth for many years to come. Within our office and surgical category are moderated a slightly from the last quarters, up 3%. We're continuing to execute on several product launches including our disposable EndoSee and we believe we will -- we're well-positioned in this segment going forward. Regarding acquisitions, we've been actively working on integrating the deals we've done over the past year and the rationale behind these deals remains intact. We are very focused on becoming a full-service provider within the global IDF space. 
Finally, on CooperSurgical, we're continuing to execute on several initiatives which should significantly strengthen the business and pay dividends for many years to come. These include: transitioning to a geographic sales model, adding sales reps in under-penetrated areas, launching products in new markets and increasing our focus on high growth areas such as IDF genetic testing. To some degree, these investments are masking our strong underlying operating performance but it's critical that we lay the groundwork to support the business on a long term growth perspective. 
Now turning to guidance. I'll let Greg go through the details but let me touch on a few items. For Q4, we're guiding CooperVision to roughly 5% to 7.5% constant currency growth and CooperSurgical, roughly 5% to 8% pro forma growth. So similar growth to Q3. Regarding non-GAAP earnings per share for Q4, we're guiding to $2.15 to $2.30. Regarding fiscal 2017, it's too early to provide financial guidance but I will say it should be a strong year given the momentum in our 2 businesses as well as recent currency moves. From a longer-term perspective, we're still targeting operating margins of 27% or higher in 2020. 
In conclusion, I want to express my appreciation to our employees for all their hard work and dedication. I also want to say a special thank you to Greg Matz, who has announced his planned retirement after more than 6 years of service to our company including roughly the last 5 years as our CFO. Greg will be greatly missed and we wish him the best in his future endeavors. With Greg's departure, we have announced that Al White, who many of you know really well will succeed Greg as CFO. Al will assume this role in addition to his current leadership responsibilities with CooperSurgical. I'm very confident that his leadership and abilities will allow us to continue driving long-term shareholder value. From a timing perspective, Greg will remain CFO until the end of fiscal year, and then Al will take over the position. Greg will remain with us through March of next year to ensure a smooth transition. And now, I'll turn it over to Greg to cover our financial results."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thanks, Bob, and good afternoon, everyone. Bob provided overall summary of our performance including a review of the market and our revenue picture. I'm going to focus primarily on our non-GAAP results for the quarter. For the reconciliation to GAAP numbe",1171,"Thanks, Bob, and good afternoon, everyone. Bob provided overall summary of our performance including a review of the market and our revenue picture. I'm going to focus primarily on our non-GAAP results for the quarter. For the reconciliation to GAAP numbers, please refer to our earnings release. Looking at gross margins. In Q3, the non-GAAP gross margin was 63.6% compared with 62.4% in the prior year. This increase is largely due to a favorable mix led by Biofinity and favorable FX offset by recent CSI acquisitions which have lowered gross margin. CooperVision on a non-GAAP basis reported gross margin of 64.2% versus 61.8% in Q3 of last year. The factors which impacted margin were the items I just mentioned. CooperSurgical had a non-GAAP gross margin of 61.2% which compares to Q3 '15 of 65.4%. Acquisitions in the genetic testing space where the primary drivers for this reduction. 
Now looking at operating expenses. On a non-GAAP basis, SG&A increased approximately 8% to $179.7 million or 35% of revenue, down to approximately 36% of revenue in the prior year. The primary driver behind this drop was strong spending controls as we had leverage in both CooperVision and CooperSurgical. Now looking at R&D Q3. R&D on a non-GAAP basis decreased 2% to $16 million or 3.1% of revenue, down from 3.5% of revenue in the prior year. The primary driver is the leverage we're seeing from the Sauflon acquisition. 
Now moving to operating margins. For Q3, consolidated GAAP operating income and margin were $102.7 million and 19.9% of revenue versus $50.3 million and 10.9% of revenue Q3 last year. Non-GAAP operating income and margin were $131.6 million and 25.6% of revenue versus $106.1 million and 23% of revenue for the prior year. The primary difference in the operating margin year-over-year is improved gross margins and operating expense leverage. In Q3, CooperVision's non-GAAP operating income and margin were $119.4 million and 29.1% of revenue versus $97.7 million and 25.3% of revenue in the prior year. CooperSurgical's non-GAAP operating income and margin were $23.5 million and 22.4% of revenue versus Q3 '15 of $19.5 million of operating income and 25.6% of revenue. Depreciation and amortization, Q3. Depreciation was $33.9 million, down $7.5 million year-over-year. Amortization was $15.6 million, up $3.1 million, reflecting our recent acquisition activity. Interest expense was $8 million for the quarter, up $3.3 million year-over-year, primarily due to higher debt and interest rate associated with acquisitions. 
Looking at the effective tax rate. In Q3, the non-GAAP effective tax rate was 7.7% versus a non-GAAP effective tax rate of 3.1% in Q3 '15. As a reminder, in the prior year, we had a higher dollar amount of Q3 discreet items related to prior years which reversed in that quarter. On earnings per share. Our Q3 earnings per share on a GAAP and a non-GAAP basis was $1.79 and $2.30, respectively versus $0.91 and $1.97 for GAAP and non-GAAP in the prior year. Now looking at some balance sheet and liquidity items. In Q3, we had cash provided by operations of $128.9 million with capital expenditures of $31.1 million, resulting in $97.8 million of free cash flow. Excluding integration cost of $6.9 million, adjusted free cash flow was $104.3 million. Total debt increased slightly within the quarter by $2.7 million to $1,444,100,000 primarily due to average higher cash balances and acquisitions, largely offset by operational cash flow generation. Inventory decreased by approximately $3.3 million to $430.3 million from last quarter and CooperVision, we saw overall inventory decline as growth in silicon daily inventory to support our product launches were offset by a reduction in our hydrogel inventory. In CooperSurgical, we saw a small increase largely due to new acquisitions. For the quarter we're seeing month long hand at 6.5 months, down from 7 months last quarter. Days sales outstanding is at 54 days, same as last quarter and down 1 day from the prior year. 
Now turning to guidance. For our main currencies, we're using 1.10 for the euro, 104 for the yen and 1.30 for the pound. In looking at the full year, the consolidated revenue range is being raised at the low end to reflect our Q3 performance and is now $1.944 to $1.957 billion or approximately 6% to 7% pro forma growth, up from the previous 5.5% to 7% range. For the fourth quarter, CooperVision's revenue range is $390 million to $400 million or roughly 5% to 7.5% constant currency growth. And CooperSurgical's revenue range is $106 million to $109 million or roughly 5% to 8% pro forma revenue growth. We expect non-GAAP gross margin for the fourth quarter to be slightly over 64%, driven by a strong quarter for CooperVision. This would result in a full year gross margin around 63%. OpEx is expected to be slightly under 39% for the fourth quarter as well as for the full year. Operating margin is expected to be around 26% in Q4 which would result in the full year margins being in the mid-24% range. Interest expense is expected to be a little over $7 million in Q4 or slightly over $28 million for the year. Our effective tax rate guidance is the same as last quarter, thus a full year rate of around 8% translates to 10.5% to 11% in Q4. Our expected share count is around 49.1 million shares. Our non-GAAP earnings per share is expected to be $2.15 to $2.30 in the fourth quarter, which equates to $8.32 to $8.47 for the full year. From our last earnings call, currency was a positive in Q3 helping roughly $0.04 but we are expecting a negative impact in Q4 of roughly $0.02 from our previous guidance. Unfortunately, some of the positives we experienced in Q3 from currency such as the yen and the euro are now being more than offset by the move in the pound since Brexit occurred in late June. As Bob mentioned, as currency hold, we should see a lot of benefit next year led by cost of goods which roughly 40% of CooperVision's product is manufactured in pound was roughly a 6 months lag to the P&L. To be clear, this is roughly 40% of CooperVision's manufacturing, so on a consolidated basis, this is roughly 30% of our total cost of goods. Also note, the pound move associated with Brexit occurred in late June, so this positive impact starts in January, so more muted positive impact in fiscal Q1 versus the remainder of the year. The other point to note, as I mentioned earlier, is our effective tax rate guidance remains changed which means Q4 tax rate range about 10.5% to 11%. Regarding cash flow, our CapEx was low this quarter but we do expect around $50 million in Q4, so around $170 million of CapEx for the year now. This should result in free cash flow over $300 million and adjusted free cash flow and excluding integration related activity of well north $300 million. With that, let me turn it back to Kim for the Q&A session."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thank you, Greg. Operator, we're ready to take some questions.",10,"Thank you, Greg. Operator, we're ready to take some questions."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Jeff Johnson from Robert W. Baird.",16,"[Operator Instructions] Our first question comes from the line of Jeff Johnson from Robert W. Baird."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","And so, Bob, I just want to start with you just on kind on the monthly trend here. It's always tough to read CLI data and try to translate that given the off 1 month, how your fiscal quarter closes but if I look, it looks as it maybe the forward month slo",103,"And so, Bob, I just want to start with you just on kind on the monthly trend here. It's always tough to read CLI data and try to translate that given the off 1 month, how your fiscal quarter closes but if I look, it looks as it maybe the forward month slowed a little bit looking at CLI data versus you reported number for the quarter, there has been some question of utilization issues out there, so just any color you can give us an kind of the monthly gating of what you have been seeing here over the last few months?"
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Good question, Jeff, and that's kind of off the page July must have been soft relatively speaking. There's really primarily about 1 answer to that and it's industry-wide answer but not for the reason most people would say. Rarely in the past we talked abo",185,"Good question, Jeff, and that's kind of off the page July must have been soft relatively speaking. There's really primarily about 1 answer to that and it's industry-wide answer but not for the reason most people would say. Rarely in the past we talked about workdays in a month but in this case, I'll highlight back at July this year, were 19 workdays compared to 22 last year because of the way we test sell and that translate to about a 17% -- 16%, 17% reduction in revenue we had the same revenue per day or the orders per day. So pretty profound impact that weighted did heavily because of the anomaly of the way we can sell. Conversely, you get some of that back in August, relative to the fourth quarter however, probably the best way to look at it is workdays were down 3% this year in the third quarter and they will be up 1.5% in the fourth quarter. So there's one more workday in the fourth quarter, so it smooths out within the quarter anomaly between July and August by workday."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And the next question comes from the line of Brian Weinstein from William Blair.",14,"And the next question comes from the line of Brian Weinstein from William Blair."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Can you guys just talk a little bit about what you're seeing obviously, from the competitive launch from J&J and then, also you have a couple lunches in the FRP space. How are you seeing that kind of two-week and month space playing out at this point and",63,"Can you guys just talk a little bit about what you're seeing obviously, from the competitive launch from J&J and then, also you have a couple lunches in the FRP space. How are you seeing that kind of two-week and month space playing out at this point and any color you can talk about with respect to your competitive launch in general?"
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, the competitive launch at J&J has been active and taking OASYS two week which was their sweet spot and expanding into a 1 Day -- 1 week and then a 1 Day and now they're moving with a different package into the monthly modality with Vita. The amount o",501,"Yes, the competitive launch at J&J has been active and taking OASYS two week which was their sweet spot and expanding into a 1 Day -- 1 week and then a 1 Day and now they're moving with a different package into the monthly modality with Vita. The amount of push they put behind Vita was nothing compared to a year ago when they launch the OASYS 1 Day modality. So a lot more muted. Having said that, there were a lot more active once in the space albeit leveraging their franchise,, if you will. Interestingly, they still do not call OASYS 1 Day a silicone hydrogel lens but as well know, it is a silicone hydrogel lens. As I think I indicated in the past, it was my belief that there would be some swamping of the 2 week noncompliance into the monthly compliance, which in essence is a clever way of saying is a trade up strategy and I think we're seeing more and more of that as they're trying to continue the deceleration or the negative growth of the 2 week space, which they own 90% of, and migrate it into more profitable profit. And there's no doubt profitable pocket means the 1 Day modality but quite frankly, their strategy is not shortsighted, so to speak, when it comes to monthly price point yields more revenue than a two-week compliance. And most -- the vast majority of the 2 week wears are noncompliant. As far as our product, the non-1 Day space, we are rolled out initially Biofinity and it's just getting very early in the game but so far so good. There's a lot of excitement about a novel wins that really address people with iPhones and being in front of screens -- TV screens and computer screens professionally. So there's a lot of interest by the eye care professionals that we have engaged in discussions thus far. We also are -- approval to launch vitality in the 2 weeks space and vitality is targeted to replace our low gross margin, Avaira in the 2 weeks space. The low gross margin came about a number of years ago when we had to recall and had to change the manufacturing technique which became very cumbersome. So it is a significant step up in gross margin and it's very early in that launch, I think it was late July. And the attempt there, it will probably take us to our 3 years to roll up the entire family of the toric and the sear worldwide in this migration. This year we'll go faster and the majority of the Avaira product line is 70% of it or more is the sear side so that 1 will show up quicker. But it's an inventory turn and when you have toric, it takes longer to transition trends, if you will that. So we're excited about that and then of course we have all the actions going on in the 1 Day space."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of John Buck from Stifel.",12,"Our next question comes from the line of John Buck from Stifel."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Maybe 2 I'll ask them both upfront. The CSI margin decent sequential pull back from fiscal Q2 results. Not asking for guidance for next year but sort of a 61% gross margin the right place to be looking forward when we look at the recent acquisitions weigh",100,"Maybe 2 I'll ask them both upfront. The CSI margin decent sequential pull back from fiscal Q2 results. Not asking for guidance for next year but sort of a 61% gross margin the right place to be looking forward when we look at the recent acquisitions weighing on the margin a bit. And then separately on CVI, Bob, didn't you just talk with the EMEA market. You're gaining a lot of share in APAC and you seem to be well-positioned in the U.S. to be accelerating. Can you talk about what you're seeing in the EMEA market regarding share?"
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","John, on the gross margin, I think what you should expect to see 61 is the low point. You should see it a little bit higher than that and again the base business will kick in a little bit. The new acquisitions come with a lower gross margin so you did see",57,"John, on the gross margin, I think what you should expect to see 61 is the low point. You should see it a little bit higher than that and again the base business will kick in a little bit. The new acquisitions come with a lower gross margin so you did see that pressure especially in Q3."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","As far as the EMEA market, we continue to gain share there and happy to say, we're right on the heels of the #1 player there, which is in the market. And so that happens to be the part of the world where we have the highest market share in EMEA. Overall m",162,"As far as the EMEA market, we continue to gain share there and happy to say, we're right on the heels of the #1 player there, which is in the market. And so that happens to be the part of the world where we have the highest market share in EMEA. Overall market share is 23% but in Europe, it's 33% contrast to where we're weakest, yes, but growing fast in Asia PAC. So the market there remains focused in on the 1 Day modality, Eastern Europe continues to be robust area. And then, Biofinity continues to charge very nicely there. And then, of course, the other thing is the U.S. market was the first one to arrive with specialty lenses, toric and multifocal and now the rest of the world including EMEA is catching up. So we have a more robust market there which plays to Cooper's strengths recognizing that we're #1 in the world in the specialty lens area overall."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Matt Mishan from KeyBanc.",13,"And our next question comes from the line of Matt Mishan from KeyBanc."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Bob, could you give us a sense of what is driving the double-digit growth in Asia PAC? And with MyDay being a bigger piece of it there going into next year, is double-digit growth sustainable for a little bit? And then, can you talk a little bit about wha",65,"Bob, could you give us a sense of what is driving the double-digit growth in Asia PAC? And with MyDay being a bigger piece of it there going into next year, is double-digit growth sustainable for a little bit? And then, can you talk a little bit about what you see is the opportunity for MyDay toric in Japan and why you launch there first?"
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Sure. First of all, double-digit in Asia PAC is somewhat a reflection of maturity in that market with a fabulous product portfolio. We have a great product portfolio, a lot of it emanated out of EMEA. So it started in Europe and it came to the U.S. and re",291,"Sure. First of all, double-digit in Asia PAC is somewhat a reflection of maturity in that market with a fabulous product portfolio. We have a great product portfolio, a lot of it emanated out of EMEA. So it started in Europe and it came to the U.S. and really, Asia PAC is the last to get it all. In addition, we we're clearly under indexed overall in that market. We have invested over the last 3 or 4 years heavily in some areas like China and the surrounding geographic area. So we're starting to get momentum there. As far as MyDay in Japan, MyDay is a 1 Day product. There are silicone hydrogel players in the Japanese market. TruEye, started there, so in essence, this silicone hydrogel market part for all practical purposes in Japan. The beauty of having a MyDay toric in Japan. First of all, we have clariti available in the rest of the world. Clariti has a sear, a toric and a multifocal. In Japan, we only have MyDay at this juncture and have been a toric to go along with it have a halo effect. We will be the only one in the Japanese market with a silicone hydrogel sear and a toric. While the toric market is not as mature as even the European market, it's early in the cycle there. It is a nice halo effect for lot of practitioners wanted particularly more so some of your independents in Japan. So it's a good story with not only the large retailers that exist there but also the independents. So, yes, I do expect that we will put up robust numbers going forward, double-digit numbers, certainly, in many quarters going forward in the Asia PAC marketplace."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And the next question comes from the line of Matt O'Brien from Piper Jaffray.",15,"And the next question comes from the line of Matt O'Brien from Piper Jaffray."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","This is actually, JP in for Matt. I just wanted to dig deeper on gross margins and I know you're not giving guidance for 2017 but you've got a lot going on. You've  got a weaker British pound which, as you said after 6 months, once you work around and see",164,"This is actually, JP in for Matt. I just wanted to dig deeper on gross margins and I know you're not giving guidance for 2017 but you've got a lot going on. You've  got a weaker British pound which, as you said after 6 months, once you work around and see a benefit there and clariti as it continues to ramp should be accretive to the gross margin, you launch the 2 week product that the gross margin as well. So I'm trying to think of is the reason why we can't get above 65% next year and then, just a longer-term question on gross margin, when you did the Sauflon acquisition, you've gotten visibility of doing silicone hydrogel without having the need for alcohol and the manufacturing process and just trying to think of where you can think that manufacturing ability and start launching your own organic products with that, kind of unique process and when we should expect some products like that?"
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","On the gross margin, you've covered a lot of the points that they are our business and tailwinds where clariti is coming in at not only we bought the company. The pound as we mentioned, well  especially the pound at these rates as I mentioned in the earli",148,"On the gross margin, you've covered a lot of the points that they are our business and tailwinds where clariti is coming in at not only we bought the company. The pound as we mentioned, well  especially the pound at these rates as I mentioned in the earlier comments will have a nice impact not going forward. At the same time, again, we are -- we saw the acquisitions that CooperSurgical doing and that will have some overall impact on the gross margins because as we get into more lab based businesses, they're going to come with lower gross margin. And so as you said, we're not giving guidance for next year. You see the gross margin start to edge up throughout the entire year, so you can see that where we're looking at in the fourth quarter is again higher than we were in the third quarter."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","And I think the comment on the Sauflon platform, yes, we're ecstatic about alcohol free nature of it and the fact that it's so flexible that we have the sear, the toric and the multifocal to leverage. We're ecstatic by the fact that we were able to ramp u",129,"And I think the comment on the Sauflon platform, yes, we're ecstatic about alcohol free nature of it and the fact that it's so flexible that we have the sear, the toric and the multifocal to leverage. We're ecstatic by the fact that we were able to ramp up very quickly and therefore, we're not capacity constraint. So that is clearly a tailwind in high gross margin area. However, I would agree with Greg's point that with the surgical acquisition we have made and with surgical now in around 61, going up a little from there, there is a mix headwind that comes into play. So directionally you're right there's tremendous amount of tailwinds to help us out and we'll see where that all lands down on the road."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Next question?",2,"Next question?"
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","Your next question comes from the line of Joanne Wuensch from BMO Capital Markets.",14,"Your next question comes from the line of Joanne Wuensch from BMO Capital Markets."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Congratulations to Greg and Al. Multipart question. First, 2 multipart questions. FX. We all the saw the surge in the stock price after the Brexit moment and so I'm sort of clears what you're thinking of the FX impact, maybe for 2017. Without giving guida",147,"Congratulations to Greg and Al. Multipart question. First, 2 multipart questions. FX. We all the saw the surge in the stock price after the Brexit moment and so I'm sort of clears what you're thinking of the FX impact, maybe for 2017. Without giving guidance but maybe as a contributor, so that we can all put our heads around it with no surprises when you do give guidance. The second part of that question has to do with what was the FX impact on EPS in the third quarter and the current thinking for the full year? And then, my second question has to be more big picture. We've all been very worried and very focused and now J&J's product launches and while and Bausch has struggled, is there anything you see coming down for the pike that we should be aware of as we look forward?"
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Joanne I'll jump in on the FX parts questions real quick. So from the third quarter perspective, if you look at the actual, we had a $0.06 benefit year-over-year and that was about $0.04 above what we have guided too, what was in our guidance in Q3 -- or",247,"Joanne I'll jump in on the FX parts questions real quick. So from the third quarter perspective, if you look at the actual, we had a $0.06 benefit year-over-year and that was about $0.04 above what we have guided too, what was in our guidance in Q3 -- or I'm sorry, Q2. If you look to the full year, we're looking at FX is about flat, it's about up $0.02 for the full year, year-over-year. Talking about Brexit, one of the things to keep in mind and I mentioned that so it hit in late June, we would start to see the benefit of that really coming in January. So Q1 will be a little bit of a benefit and then provided the rates stay where they at, you'll get that benefit throughout the rest of the year. So it is a benefit from a CooperVision perspective, about 40% of our COGS are in pound based manufacturing. And that's 30% roughly for the total company. So you will see that flow through again a good part of next year provided the pound stays at about these rates. It's definitely down quite a bit from prior years and that's -- we win more on -- when that happens from a pound perspective on the manufacturing than we lose on the revenue but in the short term like Q4, we actually get impacted by the revenue first and the benefit will come out outside of the fiscal year."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","As far some of the product launches go, J&J, when we look at J&J, B&L and Alcon, J&J is that 1 that probably has their act together, the best of the 3 and Alcon obviously is still in a remaking mode. B&L is in a remaking mode, changing their structure yet",545,"As far some of the product launches go, J&J, when we look at J&J, B&L and Alcon, J&J is that 1 that probably has their act together, the best of the 3 and Alcon obviously is still in a remaking mode. B&L is in a remaking mode, changing their structure yet again, I think, and J&J, with a fairly weak product portfolio is a good marketing company. And so, I would compliment them on making the best of the product portfolio they have. Some of their programs, the whole disruption they've caused in the marketplace over the last few years with directions going on all the way with UPP and then going the other way, they've taken some bumps in terms of the messaging. So 1 Day, they're saying to you we're the friend with the independents, with these products and then, the next day, they are saying, well, we have a different story to tell you but it's not going to be UPP. So there's no doubt there some reaction that. As far as Vita for example, the new product launch in the monthly space, very much it's moving into a space where it's going against some franchise products and Biofinity is a franchise product. Biofinity is a product that has a toric, a sphere and a multifocal plus now it has things like, which is an enhanced product for people -- that like 99% of the people on the planet, using more and more technology. So I don't expect them to get to robust but I do think that's a lot different than what they did a year ago with OASYS 1 Day, where they basically said, we want to participate in the shift of silicone hydrogel where leaving the 2 weeks space and catch them in the 1 Day market with a huge trade up. So they're playing out that strategy to a large degree, they cannibalize TruEye in the U.S. Not worldwide, but in the U.S. and OASYS 1 Day and TruEye and MyDay are giving a competition in this case, Alcon's subtle 1 -- run for their money. Alcon get out here first when it was only one competitive in that space which was TruEye. J&J knew that was a deficient product in the U.S. and I'm not sure why in the U.S. is actually done pretty well historically in Japan but for whatever reason, the U.S. is weak in product. So product rollouts, we hear a lot of noise about B&L on, which is their answer to trying of refresh the product line for monthly products, monthly silicone hydrogel products. They've gone and expended now, I think, from beyond a fear but a lot of what B&L is doing is it's capturing some of their legacy products Pure Vision and Softline 66. So when you put it all together B&L has some new products, Ultra  but it's about holding breakeven with our entire product portfolio including the fall off of their legacy product. The worldwide thinks the last quarter, they're probably 1% to 2% growth. So they would have lost some margins here last quarter. Alcon, likewise, 2% numbers in a market growing 5% so last year, so the gainers were Cooper and with a robust 10% in J&J."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Larry Biegelsen from Wells Fargo.",14,"And our next question comes from the line of Larry Biegelsen from Wells Fargo."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Just for my multipart question here. Bob, is it safe to assume that August bounce back from what sounds like a weak July because of the day count? Second, on 2017, you guys had historically given some color even last year you did on EPS. Is it safe to ass",121,"Just for my multipart question here. Bob, is it safe to assume that August bounce back from what sounds like a weak July because of the day count? Second, on 2017, you guys had historically given some color even last year you did on EPS. Is it safe to assume that you're pretty comfortable with consensus top and bottom line at this point roughly speaking otherwise you went out there with something out of whack  you would call it out? And lastly, the inventory write-offs and the idle equipment charges we saw in fiscal Q2 which resulted in that $0.30 hit. Should we -- are those over or do you expect more of those either in the fourth quarter or 2017?"
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Okay, first question on August and then July, yes, it's safe to assume that the anomalies between the weak July and August have to do with workdays not anything ingrained in the marketplace. Relative to 2017 where we educated we're not prepared at this ju",340,"Okay, first question on August and then July, yes, it's safe to assume that the anomalies between the weak July and August have to do with workdays not anything ingrained in the marketplace. Relative to 2017 where we educated we're not prepared at this juncture to put specifics on the line. No, we wouldn't comment one way or the other on what consensus is out there. I would highlight, however, that some of the analysts has more aggressive foreign exchange rate and some analysts maybe I think Greg kind of hit a nail in the head, some of the models on the impact of that pound, et cetera emphasizing that is 30% of our worldwide instead of our 40% of our worldwide cost of goods is an important attribute. So hopefully we gave some color for people to sharpen the pencil with their models, in some case. So beyond saying there's a lot of tailwinds that we're standing by and happy with and the foreign exchange rates will be whatever they are and they change literally by the hour, we're not going to add any color at this juncture. As far as the 10-10-10 hit. $0.10 in the second quarter, $0.10 in the third quarter, $0.10 in the fourth quarter due to idle equipment and inventory write-off that were over and above normal, they are in the numbers. There are other write-offs that are routine and they continue throughout 2016 and will continue throughout 2017. Directionally, we indicated that a lot of those call-out charges are associated with some of our improving efficiencies a lot more than we thought that led us to idling some equipment, so directionally, you can see the growth numbers in our 1 Day silicone hydrogel franchise of 40%. That certainly, will go towards improving absorption and importantly, when something goes from idle to use in production, it goes from a direct period charge which is what the 10-10-10 to the balance sheet and is making inventory. So that will continue throughout 2017, if you will."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Larry Keusch with Raymond James.",14,"And our next question comes from the line of Larry Keusch with Raymond James."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","I guess, a two-part additional question here. On the CapEx, I mean, if you go back and look at it tends to be cyclical and you do get into periods where there's an investment, as you guys bring out the lines and expand capacity, there's also periods of ti",177,"I guess, a two-part additional question here. On the CapEx, I mean, if you go back and look at it tends to be cyclical and you do get into periods where there's an investment, as you guys bring out the lines and expand capacity, there's also periods of time you grow into that capacity and in this case, you've got some of these idle equipments sitting around that will add to that. So I just want to get your take on where you think CapEx can go here over the next several years, I think you said $170-ish million for this year but where does it go and how does that translate to free cash flow generation? And I guess, along with that, should we expect no additional software and integration charges next year? And then the other part of the question is, I think certainly, the odds of an interest rate increase have gone up and you can see something coming in this month and how you're thinking about that and what's built into your guidance?"
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, a few things on that. The cyclicality of the CapEx and you're absolutely right, we ramped up for Biofinity and Avaira the last decade, we're very capital intent. We got real efficient. We ramped down and then all of a sudden, particularly with the S",402,"Well, a few things on that. The cyclicality of the CapEx and you're absolutely right, we ramped up for Biofinity and Avaira the last decade, we're very capital intent. We got real efficient. We ramped down and then all of a sudden, particularly with the Sauflon acquisition and the MyDay without silicone hydrogel 1 Day, it became very capital intensive again over the last several years. And lo and behold, we've got real efficient and here we are again a little ahead of ourselves in a perfect world. Translation there is we think we have a pretty long run way on improving efficiencies that will continue over the next several -- multiple years and that will be cap on CapEx requirements. We've taken the CapEx this year from $200 million down to $30 million, to $170 million. The outlook for post 2016 will be for less than that. We're thinking in that $150 million range. So year-over-year, a reduction of in that $50 million range. When you look at cash flow, we've now taken our to $300 million to a lot stronger statement about $300 million. So we're $300 million headed towards $400 million, no real change in that signal on that going forward. There is, in my opinion, multiple tiers of runway of some of those efficiencies that were talking about. As far as Sauflon or interest charges, the -- what's built into our thinking is given that we have followed cash flow generation, we see that as part of a minimizer. So when you have $1.4 million in debt worldwide, you're generating $300 million to $400 million in cash flow, that will sort of offset. We do expect that probably between now and year-end, there will be some movement in rates and of course, we've guided through year-end so at this juncture, we haven't really guided the treasure goes crazy then that will obviously, influence the guidance we come out within in December but I think foreign-exchange volatility and interest rates depending on who got their mouth open at a given moment out there since like the government is very more proactive in trying to direct economic thinking, which is a detriment, I think  overall because it does create uncertainty about volatility but we're still in the low inflationary modality. We can all speculate and pretend we're autonomous. So stay tuned and we'll refresh what our thinking is in December."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Steve Willoughby from Cleveland Research.",14,"And our next question comes from the line of Steve Willoughby from Cleveland Research."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Just first on this year's guidance. Greg, if I heard you correctly, it sounds like FX was an incremental $0.04 positive here in the third quarter but an incremental $0.02 had been versus what you're expecting for the fourth quarter. So I'm just trying to",85,"Just first on this year's guidance. Greg, if I heard you correctly, it sounds like FX was an incremental $0.04 positive here in the third quarter but an incremental $0.02 had been versus what you're expecting for the fourth quarter. So I'm just trying to correlate that to the guidance -- the full year guidance you've given were you brought down the high-end, just a little bit and it looks like net debt FX is about an incremental $0.02 positive to your previous guidance."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, the last time we gave guidance we talked it being about a loss and lesson it's net-net you're right it's a $0.02 positive for '16 at this point year-over-year.",30,"Yes, the last time we gave guidance we talked it being about a loss and lesson it's net-net you're right it's a $0.02 positive for '16 at this point year-over-year."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","So what's the driver to the production, I guess, of the full year guidance then?",16,"So what's the driver to the production, I guess, of the full year guidance then?"
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","The reduction to the full year guidance?",7,"The reduction to the full year guidance?"
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Correct, yes. I mean, ... sorry, go ahead, Bob.",9,"Correct, yes. I mean, ... sorry, go ahead, Bob."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","The overall for your guidance, we raised the midpoint of our guidance.",12,"The overall for your guidance, we raised the midpoint of our guidance."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, we actually, raised the midpoint by $0.04. Here's the FX that we experienced and it was related to probably an operational increase.",23,"Yes, we actually, raised the midpoint by $0.04. Here's the FX that we experienced and it was related to probably an operational increase."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","So we took it up ourselves.",6,"So we took it up ourselves."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes on the line of Andrew Hanover from JPMorgan.",13,"And our next question comes on the line of Andrew Hanover from JPMorgan."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","I wanted to go back to the fewer and extra selling days in the third quarter and expect in the fourth quarter and what was the impact on growth in the third quarter and what are [indiscernible] the fourth quarter?",40,"I wanted to go back to the fewer and extra selling days in the third quarter and expect in the fourth quarter and what was the impact on growth in the third quarter and what are [indiscernible] the fourth quarter?"
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, few work days in the quarter, it would be a 3% headwind in Q3 and 1.5% tailwind in Q4, all of the things being equal.",26,"Yes, few work days in the quarter, it would be a 3% headwind in Q3 and 1.5% tailwind in Q4, all of the things being equal."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question will come from the line of Steven Lichtman with Oppenheimer.",14,"And our next question will come from the line of Steven Lichtman with Oppenheimer."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","2 questions. Bob, within your 1 Day silicone hydrogel franchise, in the recent period here last few months, the incremental contribution from MyDay and clariti pretty balance or is 1 been contributing more incrementally over the last few months and where",85,"2 questions. Bob, within your 1 Day silicone hydrogel franchise, in the recent period here last few months, the incremental contribution from MyDay and clariti pretty balance or is 1 been contributing more incrementally over the last few months and where do you see the mix going between those 2 products over time? And then, Greg, it's actually, popping up here in the fourth quarter, why are we going to see that move higher and any change in your thoughts on tax rate beyond '16?"
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","So in the midst of MyDay and clariti, obviously MyDay is off a smaller base, so it's percentage is higher and clariti, which has a big European franchise has a bigger hurdle. clariti is still the 1 that is targeting the mass market and therefore, will alw",121,"So in the midst of MyDay and clariti, obviously MyDay is off a smaller base, so it's percentage is higher and clariti, which has a big European franchise has a bigger hurdle. clariti is still the 1 that is targeting the mass market and therefore, will always be most likely the bigger product. It's the 1 with the toric and the multifocal will also make it a bigger product. So it's still about, I don't know, 70/30-ish. However, with MyDay off of a lower base going in to Japan  you may see it as that rollout occurs take over somewhat bigger portion of the pie given Japan is such a huge 1 Day market. I guess, Greg on the tax rate?"
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","On the tax rate since the March guidance we've been guiding to the 8% for the year around 8% and so we're still holding to that. And when you look at it, things have been choppy and it also depends a lot of times when discrete released this year. We have",114,"On the tax rate since the March guidance we've been guiding to the 8% for the year around 8% and so we're still holding to that. And when you look at it, things have been choppy and it also depends a lot of times when discrete released this year. We have discrete released in Q1 were normally in Q3. Typically, Q4 is a higher quarter. Last year was an exception to that and that was based on a lot of work around the integration and restructuring cost which will a lot deductions. So the Q4 rate being in that 10.5% to 11% is probably more typical outside just the last year or so."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","Thank you and that concludes our question-and-answer session for today. I would like to turn the conference back over to Bob Weiss for any closing comments.",27,"Thank you and that concludes our question-and-answer session for today. I would like to turn the conference back over to Bob Weiss for any closing comments."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, I want to once again thank Greg for 6 great years and wish him the best going forward. He will be around as we indicated throughout the transition period throughout the rest of this calendar year and we look forward to updating you on our year-end r",104,"Well, I want to once again thank Greg for 6 great years and wish him the best going forward. He will be around as we indicated throughout the transition period throughout the rest of this calendar year and we look forward to updating you on our year-end results in December and I think the date there is December 8, if I'm not mistaken. And a lot of good stuff going on, so we look forward to giving you an update on that. Everyone have a great Labor Day weekend and summer is coming. Summer's gone already and life goes on. With that, we'll conclude."
263609,378695672,1040800,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","Thank you. Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program and you may now disconnect. Everyone, have a great day.",28,"Thank you. Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program and you may now disconnect. Everyone, have a great day."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","Good day, ladies and gentlemen, and thank you for standing by. Welcome to The Cooper Companies Third Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to hand the meeting over",52,"Good day, ladies and gentlemen, and thank you for standing by. Welcome to The Cooper Companies Third Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to hand the meeting over to Kim Duncan, Vice President of Investor Relations. Please go ahead."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Good afternoon, and welcome to The Cooper Companies Third Quarter 2016 Earnings Conference Call.  I'm Kim Duncan, Vice President of Investor Relations. And giving prepared remarks on today's call are Bob Weiss, Chief Executive Officer; and Greg Matz, Chie",321,"Good afternoon, and welcome to The Cooper Companies Third Quarter 2016 Earnings Conference Call.  I'm Kim Duncan, Vice President of Investor Relations. And giving prepared remarks on today's call are Bob Weiss, Chief Executive Officer; and Greg Matz, Chief Financial Officer.
Before we get started, I'd like to remind you that this conference call contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including all revenue and earnings per share guidance and other statements regarding anticipated results of operations, market or regulatory conditions and integration of any acquisitions or their failure to achieve anticipated benefits. Forward-looking statements depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Events that could cause our actual results and future actions of the company to differ materially from those described in forward-looking statements are set forth under the caption Forward-Looking Statements in today's earnings release and are described in our SEC filings, including the Business section of Cooper's annual report on Form 10-K. These are publicly available and on request from the company's Investor Relations department.
Before I turn the call over to Bob, let me comment on the agenda for the call. Bob will begin by providing highlights on the quarter, followed by Greg, who will then discuss the third quarter financial results. We will keep the formal presentation to roughly 30 minutes and then open up the call for questions. We expect the call to last approximately 1 hour. We request that anyone asking questions, please limit yourself to one question. Should you have any additional questions, please call our Investor line at (925) 460-3663 or email ir@cooperco.com. As a reminder, this call is being webcast, and a copy of the earnings release is available through the Investor Relations section of The Cooper Companies website.
And with that, I'll turn the call over to Bob for his opening remarks."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thank you, Kim, and good afternoon, everyone. Welcome to our third quarter 2006 (sic) [ 2016 ] conference call.Let me start by highlighting 3 key points. First, I'm pleased to report another strong quarter, including the first-ever quarter with revenues",1311,"Thank you, Kim, and good afternoon, everyone. Welcome to our third quarter 2006 (sic) [ 2016 ] conference call.
Let me start by highlighting 3 key points. First, I'm pleased to report another strong quarter, including the first-ever quarter with revenues over $500 million. This includes CooperVision reporting revenues over $400 million for the first time and CooperSurgical reporting revenues over $100 million for the first time. This resulted in non-GAAP earnings per share of $2.30 and free cash flow of $98 million.
Second, CooperVision posted strong results in all key areas of its business, resulting in 6% as reported in constant currency growth. Single-use silicone hydrogel lenses grew 40%, while 2-week and monthly silicone hydrogel lenses grew a combined 11%, both in constant currency.
Third, CooperSurgical had another strong quarter, posting revenue growth of 38% or 6% pro forma. Fertility was the highlight, posting the strongest quarter in many years with growth of 108% or 10% pro forma.
Moving into details. CooperVision reported second quarter revenues of $410 million, up 6%. This was another strong quarter and continues to show the strength of our product portfolio. The Americas grew 6% in constant currency with strength in multiple categories led by Biofinity and our 1 Day silicone hydrogel franchise. Our enhanced clariti lens continues to perform well, and MyDay had another strong quarter.
During the quarter, we received FDA approval for Avaira Vitality, and again, the launch in the U.S. in late July. You'll recall, Avaira Vitality is the replacement product for Avaira in the 2-week silicone hydrogel market. The market reaction has been positive. We remain optimistic about this upgraded product.
We also introduced Biofinity Energys at the American Optometric Association conference in July, and again, the launch in August. This premium Biofinity product has received excellent reviews, and we're confident we will have great success in this offering.
EMEA posted a solid quarter from 3% year-over-year in constant currency against the tough comp. Growth was driven by Biofinity and the 1 Day silicone hydrogel franchise. Asia Pacific had a very strong quarter with 16% constant currency growth. Growth was strong throughout the region, driven by Biofinity and the 1 Day silicone hydrogel franchise. Within Japan, our MyDay sphere launch is progressing well, and we introduced MyDay toric during the quarter. We believe both MyDay sphere and toric have the potential to be a very successful premium offering in this market.
Turning to our product categories. Torics grew a healthy  10% year-over-year and multifocals grew 5%, both in constant currency. We remain the global leader in specialty lenses, and our success with Biofinity and clariti in both of these categories should continue to drive growth for many years.
Looking at silicone hydrogel lenses. These products grew 16% in constant currency and now represents 61% of our total sales. Within the 2-week and monthly space, Biofinity and Avaira combined to grow 11% in constant currency. We remain under-indexed for the 2-week and monthly silicone hydrogel space at 75% of revenue versus the market at 79%, so we expect to continue growing faster than the market given our strong product portfolio.
Regarding our silicone hydrogel 1 Day lenses, clariti and MyDay, they combined to grow 40% in constant currency. The biggest driver in the contact lens market is 1 Day growth, and we strongly believe we have the best product portfolio offering in this space as the only company with premium and mass market lenses, including a full portfolio of 1 Day silicone hydrogel, sphere, toric and multifocal lenses.
Now let me comment on the overall contact lens market. And remember, this information is on the last page of the earnings release. For the calendar quarter Q2, we continued taking share, growing 10% with the market up 5%. Geographically, CooperVision grew 8% in the Americas while the market was up 4%. In Asian Pacific, we grew 20% with the market up 4%. And in EMEA, we grew 9% with the market up 7%. On a modality basis, single-use lenses continue driving growth with CooperVision up 18% and the market up 10%. For non-silicone hydrogel -- for non-single-use lenses, we grew 7% while the market grew 1%.
As you can see, our growth remains diverse and strong. On a trailing 12-month basis, CooperVision grew 8% and the market grew 5%. Going forward, I expect market to continue growing 4% to 6% over the next 5 years and most likely closer to 6%. The drivers will continue to be the shift to daily geographic expansion and the expansion of the wearer base. We expect to continue taking market share led by our strong silicone hydrogel portfolio.
Moving to CooperSurgical. We reported Q2 revenues of $105 million, up 38% year-over-year, driven by strong organic growth and acquisitions. On a pro forma basis, growth was up 6%.
Our fertility products led the way, up 108% or 10% pro forma. Within fertility, we had growth throughout the business and continue to believe our market-leading product portfolio, which includes medical devices, genetic testing and capital equipment, is the broadest portfolio in the space and should continue to drive growth for many years to come.
Within our office and surgical category, our growth moderated slightly from the last few quarters, up 3%. We're continuing to execute on several product launches, including our disposable hysteroscope EndoSee, and we believe we will -- we're well positioned in this segment going forward. Regarding acquisitions, we've been actively working on integrating the deals we've done over the past year, and the strategic rationale behind these deals remains intact. We are very focused on becoming a full-service provider within the global IVF space.
Finally, on CooperSurgical, we're continuing to execute on several initiatives, which should significantly strengthen the business and pay dividends for many years to come. These include transitioning to a geographic sales model, adding sales reps in under-penetrated areas, launching products in new markets and increasing our focus on high-growth areas such as IVF genetic testing. To some degree, these investments are masking our strong underlying operating performance, but it's critical that we lay the groundwork to support the business on a long-term growth -- from a long-term growth perspective.
Now turning to guidance. I'll let Greg go through the details, but let me touch on a few items. For Q4, we're guiding CooperVision to roughly 5% to 7.5% constant currency growth and CooperSurgical roughly to 5% to 8% pro forma growth. So similar growth to Q3. Regarding non-GAAP earnings per share for Q4, we're guiding to $2.15 to $2.30. Regarding fiscal 2017, it's too early to provide financial guidance, but I will say it should be a strong year given the momentum in our 2 businesses as well as recent currency moves. From a longer-term perspective, we're still targeting operating margins of 27% or higher in 2020.
In conclusion, I want to express my appreciation to our employees for all their hard work and dedication. I also want to say a special thank you to Greg Matz, who has announced his planned retirement after more than 6 years of service of our company, including roughly the last 5 years as our CFO. Greg will be greatly missed and we wish him the best in his future endeavors. With Greg's departure, we have announced that Al White, who many of you know really well, will succeed Greg as CFO. Al will assume this role in addition to his current leadership responsibilities with CooperSurgical. I am very confident that his leadership and abilities will allow us to continue driving long-term shareholder value. From a timing perspective, Greg will remain CFO until the end of the fiscal year, and then Al will take over the position. Greg will remain with us through March of next year to ensure a smooth transition.
And now I'll turn it over to Greg to cover our financial results."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thanks, Bob, and good afternoon, everyone. Bob provided overall summary of our performance, including a review of the market and our revenue picture. I'm going to focus primarily on our non-GAAP results for the quarter. For the reconciliation to GAAP numb",1175,"Thanks, Bob, and good afternoon, everyone. Bob provided overall summary of our performance, including a review of the market and our revenue picture. I'm going to focus primarily on our non-GAAP results for the quarter. For the reconciliation to GAAP numbers, please refer to our earnings release.
Looking at gross margins. In Q3, the non-GAAP gross margin was 63.6% compared with 62.4% in the prior year. This increase is largely due to a favorable mix led by Biofinity and favorable FX offset by recent CSI acquisitions, which have lower gross margins. CooperVision on a non-GAAP basis reported gross margin of 64.2% versus 61.8% in Q3 of last year. The factors which impacted margin were the items I just mentioned. CooperSurgical had a non-GAAP gross margin of 61.2%, which compares to Q3 '15 of 65.4%. Acquisitions in the genetic testing space where the primary drivers for this reduction.
Now looking at operating expenses. On a non-GAAP basis, SG&A increased approximately 8% to $179.7 million or 35% of revenue, down to approximately 36% of revenue in the prior year. The primary driver behind this drop was strong spending controls as we had leverage in both CooperVision and CooperSurgical.
Now looking at R&D. In Q3, R&D on a non-GAAP basis decreased 2% to $16 million or 3.1% of revenue, down from 3.5% of revenue in the prior year. The primary driver is the leverage we're seeing from the Sauflon acquisition.
Moving to operating margins. For Q3, consolidated GAAP operating income and margin were $102.7 million and 19.9% of revenue versus $50.3 million and 10.9% of revenue in Q3 last year. Non-GAAP operating income and margin were $131.6 million and 25.6% of revenue versus $106.1 million and 23% of revenue for the prior year. The primary difference in the operating margin year-over-year is improved gross margins and operating expense leverage. In Q3, CooperVision's non-GAAP operating income and margin were $119.4 million and 29.1% of revenue versus $97.7 million and 25.3% of revenue in the prior year. CooperSurgical's non-GAAP operating income and margin were $23.5 million and 22.4% of revenue versus Q3 '15 of $19.5 million of operating income and 25.6% of revenue.
Looking at depreciation and amortization. In Q3, depreciation was $33.9 million, down $7.5 million year-over-year. Amortization was $15.6 million, up $3.1 million, reflecting our recent acquisition activity. Interest expense was $8 million for the quarter, up $3.3 million year-over-year, primarily due to higher debt and interest rate associated with acquisitions.
Looking at the effective tax rate. In Q3, the non-GAAP effective tax rate was 7.7% versus a non-GAAP effective tax rate of 3.1% in Q3 '15. As a reminder, in the prior year, we had a higher dollar amount of Q3 discreet items related to prior years, which reversed in that quarter.
On earnings per share, our Q3 earnings per share on a GAAP and a non-GAAP basis was $1.79 and $2.30, respectively, versus $0.91 and $1.97 for GAAP and non-GAAP in the prior year.
Looking at some balance sheet and liquidity items. In Q3, we had cash provided by operations of $128.9 million with capital expenditures of $31.1 million, resulting in $97.8 million of free cash flow. Excluding integration cost of $6.5 million, adjusted free cash flow was $104.3 million. Total debt increased slightly within the quarter by $2.7 million to $1,444,100,000, primarily due to higher average cash balances and acquisitions, largely offset by operational cash flow generation.
Inventory decreased by approximately $3.3 million to $430.3 million from last quarter. In CooperVision, we saw overall inventory decline as growth in silicone daily inventory to support our product launches were offset by a reduction in our hydrogel inventory. In CooperSurgical, we saw a small increase largely due to new acquisitions. For the quarter, we're seeing month on hand at 6.5 months, down from 7 months last quarter. Days sales outstanding is at 54 days, same as last quarter and down 1 day from the prior year.
Now turning to guidance. For our main currencies, we're using 1.10 for the euro, 104 for the yen and 1.30 for the pound.
And looking at the full year. The consolidated revenue range is being raised on the low end to reflect our Q3 performance and is now $1.944 to $1.957 billion or approximately 6% to 7% pro forma growth, up from the previous 5.5% to 7% range.
For the fourth quarter, CooperVision's revenue range is $390 million to $400 million or roughly 5% to 7.5% constant currency growth. And CooperSurgical's revenue range is $106 million to $109 million or roughly 5% to 8% pro forma growth.
We expect non-GAAP gross margin for the fourth quarter to be slightly over 64%, driven by a strong quarter for CooperVision. This would result in a full year gross margin around 63%. OpEx is expected to be slightly under 39% for the fourth quarter as well as for the full year. Operating margin is expected to be around 26% in Q4, which would result in the full year margin being in the mid-24% range. Interest expense is expected to be a little over $7 million in Q4 or slightly over $28 million for the year. Our effective tax rate guidance is the same as last quarter. Thus, a full year rate of around 8% translates to 10.5% to 11% in Q4. Our expected share count is around 49.1 million shares. Our non-GAAP earnings per share is expected to be $2.15 to $2.30 in the fourth quarter, which equates to $8.32 to $8.47 for the full year.
From our last earnings call, currency was a positive in Q3, helping roughly $0.04. But we are expecting a negative impact in Q4 of roughly $0.02 from our previous guidance. Unfortunately, some of the positives we experienced in Q3 from currencies such as the yen and the euro are now being more than offset by the move in the pound since Brexit occurred in late June. As Bob mentioned, as currency holds, we should see a lot of benefit next year led by cost of goods as roughly 40% of CooperVision's product is manufactured in pound with roughly a 6-month lag to the P&L. To be clear, this is roughly 40% of CooperVision's manufacturing, so on a consolidated basis, this is roughly 30% of our total cost of goods. Also note, the pound move associated with Brexit occurred in late June, so this positive impact starts in January, so a more muted positive impact in fiscal Q1 versus the remainder of the year.
The other point to note, as I mentioned earlier, is our effective tax rate guidance remains unchanged, which means a Q4 tax rate range of about 10.5% to 11%. Regarding cash flow, our CapEx was low this quarter but we do expect around $50 million in Q4, so around $170 million of CapEx for the year now. This should result in free cash flow over $300 million and adjusted free cash flow when excluding integration-related activity of well north of $300 million.
With that, let me turn it back to Kim for the Q&A session."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thank you, Greg. Operator, we're ready to take some questions.",10,"Thank you, Greg. Operator, we're ready to take some questions."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Jeff Johnson from Robert W. Baird.",16,"[Operator Instructions] Our first question comes from the line of Jeff Johnson from Robert W. Baird."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Greg, I just want to say it's been great working for you -- or working with you, not for you, but working with you for the last few years. And best of luck in the future. And Al, plus or minus, we'll see how it goes here over the next few years. That was",162,"Greg, I just want to say it's been great working for you -- or working with you, not for you, but working with you for the last few years. And best of luck in the future. And Al, plus or minus, we'll see how it goes here over the next few years. That was a joke. And so, Bob, I just want to start with you just on kind of the monthly trend here. It's always tough to read CLI data and try to translate that given the off 1 month, how your fiscal quarter closes. But if I look, it looks as if maybe the forward month slowed a little bit. Looking at CLI data versus your reported number for the quarter, there has been some question of utilization issues out there. So just any color you can give us on kind of the monthly gating of what you have been seeing in the industry here over the last few months."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes. Good question, Jeff. And yes, that's kind of jumped off the page a little, that July must have been soft relatively speaking. There's really primarily but one answer to that, and it's an industry-wide answer but not for the reasons most people would",200,"Yes. Good question, Jeff. And yes, that's kind of jumped off the page a little, that July must have been soft relatively speaking. There's really primarily but one answer to that, and it's an industry-wide answer but not for the reasons most people would think. Rarely in the past have we talked about workdays in a month, but in this case, I'll highlight the fact that in July this year, there were 19 workdays compared to 22 last year because of the way we can sell. And that translates to about a 17% -- 16%, 17% reduction in revenue if we had the same revenue per day or the orders per day. So pretty profound impact that weighted heavily because of the anomaly of the way we can sell. Conversely, you get some of that back in August. Relative to a full quarter however, probably the best way to look at it is workdays were down 3% this year in the third quarter, and they'll be up 1.5% in the fourth quarter. So there's one more workday in the fourth quarter. So it smooths out within the quarter, but there is an anomaly between July and August caused by workdays."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Brian Weinstein from William Blair.",14,"And our next question comes from the line of Brian Weinstein from William Blair."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Can you guys just talk a little bit about what you're seeing, obviously, from the competitive launch from J&J. And then also, you have a couple lunches in the FRP space. How are you seeing that kind of 2-week and monthly space playing out at this point? A",65,"Can you guys just talk a little bit about what you're seeing, obviously, from the competitive launch from J&J. And then also, you have a couple lunches in the FRP space. How are you seeing that kind of 2-week and monthly space playing out at this point? And any color you can talk about with respect to the just the competitive launch in general."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, the competitive launch, J&J has been active in taking OASYS 2-week, which was their sweet spot, and expanding it into a 1 Day -- a 1-week and then a 1 Day. And now they're moving with a different package into the monthly modality with VITA. The amoun",507,"Yes, the competitive launch, J&J has been active in taking OASYS 2-week, which was their sweet spot, and expanding it into a 1 Day -- a 1-week and then a 1 Day. And now they're moving with a different package into the monthly modality with VITA. The amount of push they put behind VITA out of the gate [ph] was nothing compared to a year ago when they launched the OASYS 1 Day modality. So a lot more muted. Having said that, they're one of the more active ones in the space, albeit leveraging their OASYS franchise, if you will. Interestingly, they still do not call OASYS 1 Day a silicone hydrogel lens. But as we all know, it is a silicone hydrogel lens. As I think I indicated in the past, it was my belief that there would be some swapping of the 2-week noncompliance into the monthly compliance, which in essence is a clever way of saying it's a trade-up strategy, and I think we're seeing more and more of that as they're trying to continue the deceleration or the negative growth of the 2-week space, which they own 90% of, and migrate it into more profitable profit bucket. And there is no doubt profitable bucket means the 1 Day modality, but quite frankly, their strategy is not shortsighted, so to speak, when it comes to monthly price point yields more revenue than a 2-week noncompliance. And most -- the vast majority of the 2-week wearers are noncompliant. As far as our product in the non-1 Day space, we rolled out initially Biofinity Energys. It's just getting -- it's very early in the game but so far so good. There's a lot of excitement about a novel win that really addresses people with iPhones and being in front of screens -- TV screens and computer screens professionally. So there's a lot of interest by the eye care professionals that we have engaged in discussions thus far. We also are -- got approval to launch Vitality in the 2-week space. And Vitality is targeted to replace our low gross margin Avaira product in the 2-week space. That low gross margin came about a number of years ago when we had to recall and had to change the manufacturing technique, which became very cumbersome. So it is a significant step-up in gross margin, and it's very early in that launch. I think it was late July. And the intent there is it will probably take us 2 to 3 years to roll out the entire family of the toric and the sphere worldwide in this migration. This year we'll go faster, and the majority of the Avaira product line is 70% of it or more is the sphere side. So that one will show up quicker. But it's an inventory turn. And when you have toric, it takes longer to transition, if you will, that. So we're excited about that. And then, of course, we have all the action that's going on in the 1 Day space."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Jon Buck from Stifel.",12,"Our next question comes from the line of Jon Buck from Stifel."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Maybe 2. I'll ask them both upfront. The CSI margins, Greg, were down, a decent sequential pullback from fiscal Q2 results. Not asking for guidance for next year, but is sort of a 61% gross margin the right place to be looking for when we think about the",109,"Maybe 2. I'll ask them both upfront. The CSI margins, Greg, were down, a decent sequential pullback from fiscal Q2 results. Not asking for guidance for next year, but is sort of a 61% gross margin the right place to be looking for when we think about the recent acquisitions weighing on the margin a bit? And then separately, for CVI, Bob, can you just talk to the EMEA market? I mean, you're gaining a lot of share in APAC and you seem to be well positioned in the U.S. The gains seem to be accelerating. Can you talk about what you're seeing in the EMEA market regarding share?"
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Jon, on the gross margin, I think what you should expect to see is 61 is the low point. You should see it be a little bit higher than that. And again, the base business will kick in a little bit. The new acquisitions come with a lower gross margin, and so",62,"Jon, on the gross margin, I think what you should expect to see is 61 is the low point. You should see it be a little bit higher than that. And again, the base business will kick in a little bit. The new acquisitions come with a lower gross margin, and so that so you did see that pressure, especially in Q3."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","As far as the EMEA market, we continue to gain share there, and happy to say we're right on the heels of the #1 player there, which is Alcon, in the market. And that happens to be the part of the world where we have the highest market share in EMEA. Our o",164,"As far as the EMEA market, we continue to gain share there, and happy to say we're right on the heels of the #1 player there, which is Alcon, in the market. And that happens to be the part of the world where we have the highest market share in EMEA. Our overall market share is 23%. But in Europe, it's 33%, contrast to where we're weakest, yes, but growing fast in Asia Pac. So the market there remains focused in on the 1 Day modality. Eastern Europe continues to be a robust area. And then the Biofinity continues to charge very nicely there. And then, of course, the other thing is the U.S. market was the first one to arrive with specialty lenses, torics and multifocals. And now the rest of the world, including EMEA, is catching up. So you have a more robust market there, which plays to Cooper's strengths, recognizing we're #1 in the world in the specialty lens area overall."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Matt Mishan from KeyBanc.",13,"And our next question comes from the line of Matt Mishan from KeyBanc."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Bob, could you give us a sense of what is driving the double-digit growth in Asia Pac? And with MyDay being a bigger piece over there going into next year, is double-digit growth sustainable for a little bit? And then can you talk a little bit about what",64,"Bob, could you give us a sense of what is driving the double-digit growth in Asia Pac? And with MyDay being a bigger piece over there going into next year, is double-digit growth sustainable for a little bit? And then can you talk a little bit about what you see as the opportunity for MyDay toric in Japan and why you launched there first?"
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Sure. First of all, double-digit in Asia Pac is somewhat a reflection of our immaturity in that market with a fabulous product portfolio. So we have a great product portfolio. A lot of it emanated out of EMEA. So it started in Europe and it came to the U.",294,"Sure. First of all, double-digit in Asia Pac is somewhat a reflection of our immaturity in that market with a fabulous product portfolio. So we have a great product portfolio. A lot of it emanated out of EMEA. So it started in Europe and it came to the U.S. And really, Asia PAC is the last to get it all. In addition, we were clearly under-indexed overall in that market. We have invested over the last 3 or 4 years heavily in some areas like China and the surrounding geographic area. So we're starting to get momentum there. As far as MyDay in Japan, MyDay is a 1 Day product. There are silicone hydrogel players in the Japanese market. TruEye started there, so in essence, the silicone hydrogel market really started for all practical purposes in Japan. The beauty of having a MyDay toric in Japan, first of all, we have clariti available in the rest of the world. clariti has a sphere, a toric and a multifocal. In Japan, we only have MyDay at this juncture, and having a toric to go along with it has a halo effect. We will be the only one in the Japanese market with a silicone hydrogel sphere and a toric. While the toric market is not as mature as even the European market, it's early in the cycle there. It is a nice halo effect. A lot of practitioners want it, and particularly more so some of your independents in Japan. So it's a good story with not only the large retailers that exist there but also the independents. So yes, I do expect that we will put up robust numbers going forward, double-digit numbers, certainly in many quarters going forward in the Asia Pac marketplace."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Matt O'Brien from Piper Jaffray.",15,"And our next question comes from the line of Matt O'Brien from Piper Jaffray."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","This is actually, JP in for Matt. I just wanted to dig deeper on gross margins. And I know you're not giving guidance for 2017, but you've got a lot going on. You've got a weaker British pound, which as you said, after 6 months, once you worked around inv",170,"This is actually, JP in for Matt. I just wanted to dig deeper on gross margins. And I know you're not giving guidance for 2017, but you've got a lot going on. You've got a weaker British pound, which as you said, after 6 months, once you worked around inventory, you'll see a benefit there. And then clariti, as it continues to ramp, should be accretive to deferred [ph] gross margin. You just launched a 2-week product. That has the gross margin as well. So I'm just trying to think of the reason why we can't get above 65% next year. And then just a longer-term question on gross margin, when you did the Sauflon acquisition, you've kind of gotten visibility of doing silicone hydrogel without having the need for alcohol in the manufacturing process. And just trying to think of when you can take that manufacturing ability and start launching your own organic products with that kind of unique process and when we should expect some products like that."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","On the gross margin, you've covered a lot of the points that I would say are some tailwinds and where clariti is coming in at far better than we first thought when we bought the company. The pound, as we mentioned, will -- especially the pound at these ra",155,"On the gross margin, you've covered a lot of the points that I would say are some tailwinds and where clariti is coming in at far better than we first thought when we bought the company. The pound, as we mentioned, will -- especially the pound at these rates, as I mentioned in the earlier comments, will have a nice impact going forward. At the same time, again, we are -- you saw the acquisitions that CooperSurgical is doing, and that will have some impact on the overall gross margins because as you get into more lab-based businesses, they're going to come with lower gross margins. And so as you said, we're not giving guidance for next year. You've seen the gross margins start to edge up throughout the entire year, so you can see that where we're looking at in the fourth quarter is, again, higher than where we were in the third quarter."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","And I think just on the comment on the Sauflon platform, yes, we're ecstatic about the alcohol-free nature of it and the fact that it's so flexible that we have the sphere, the toric and the multifocal to leverage. We're ecstatic by the fact that we were",134,"And I think just on the comment on the Sauflon platform, yes, we're ecstatic about the alcohol-free nature of it and the fact that it's so flexible that we have the sphere, the toric and the multifocal to leverage. We're ecstatic by the fact that we were able to ramp up very quickly, and therefore, we're not capacity constrained. So that is clearly a tailwind in a high gross margin area. However, I would agree with Greg's point that with the surgical acquisitions that we have made and with surgical now in around 61, going up a little from there, there is a mix headwind that comes into play. So directionally, you're right, there's a tremendous amount of tailwinds to help us out. And we'll see where that all ends down on the road."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Joanne Wuensch from BMO Capital Markets.",14,"Our next question comes from the line of Joanne Wuensch from BMO Capital Markets."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Congratulations to Greg and Al. Multipart question. First -- 2 multipart questions. FX. We all saw the surge in the stock price after the Brexit moment, and so I'm sort of curious what you're thinking of the FX impact maybe for 2017, without giving guidan",151,"Congratulations to Greg and Al. Multipart question. First -- 2 multipart questions. FX. We all saw the surge in the stock price after the Brexit moment, and so I'm sort of curious what you're thinking of the FX impact maybe for 2017, without giving guidance but maybe as a contributor, so that we sort of get our heads around it with no surprises when you do give guidance. The second part of that question has to do with what was the FX impact on EPS in the third quarter and the current thinking for the full year. And then my second question has to do -- more big picture. We've all been very worried and very focused about J&J's product launches, and while Shiva and Bausch have struggled, is there anything that you see coming down sort of the pike that we need to be aware of as we look forward?"
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Okay. Joanne, I'll jump in on the FX questions real quick. So from a third quarter perspective, if you look at the actuals, we had a $0.06 benefit year-over-year. And that was about $0.04 above what we have guided to, what was in our guidance in Q3 -- or",258,"Okay. Joanne, I'll jump in on the FX questions real quick. So from a third quarter perspective, if you look at the actuals, we had a $0.06 benefit year-over-year. And that was about $0.04 above what we have guided to, what was in our guidance in Q3 -- or I'm sorry, Q2. If you look to the full year, we're looking at -- FX is about flat. It's about up $0.02 for the full year, year-over-year. You talked about Brexit. One of the things to keep in mind, and I mentioned that in the script, is when it hit. It hit in late June. So we would start to see the benefit of that really coming in, in January. So Q1 will get a little bit of the benefit, and then provided the rates stay where they're at, you'll get that benefit throughout the rest of the year. So it's a  nice benefit. From a CooperVision perspective, about 40% of our COGS are in pound-based manufacturing. And that's 30% roughly for the total company. So you'll see that flow through again in a good part of next year provided the pound stays at about these rates. It's definitely down quite a bit from prior years, and that's -- we win more on -- when that happens from a pound perspective, we win more on the manufacturing than we lose on the revenue. But in the short term like Q4, we actually get impacted by the revenue first and the benefit will come out outside of this fiscal year."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","As far as some of the product launches of J&J, when we look at J&J, B&L and Alcon, J&J is that one that probably has their act together, the best of the 3. And Alcon obviously is still in a remaking mode. B&L is in a remaking mode, changing their structur",555,"As far as some of the product launches of J&J, when we look at J&J, B&L and Alcon, J&J is that one that probably has their act together, the best of the 3. And Alcon obviously is still in a remaking mode. B&L is in a remaking mode, changing their structure yet again, I think. And J&J, with a fairly weak product portfolio, is a good marketing company. And so I would compliment them on making the best of the product portfolio they have. Some of their programs, the whole disruption they've caused in the marketplace over the last few years with directions going all the way with UPP and then directions going the other way, they've taken some bumps in terms of the messaging. So 1 Day, they're saying to you we're the friend with the independents with these products. And then the next day, they are saying, well, we have a different story to tell you but it's not going to be UPP. So there is no doubt there's some reaction to that. As far as VITA, for example, their new product launch in the monthly space, very much it's moving into a space where it's going against some franchise products, and Biofinity is a franchise product. And Biofinity is the product that has a toric, a sphere and a multifocal. Plus now it has things like Energys, which is an enhanced product for people that, like 99% of the people on the planet, are using more and more technology. So I don't expect them to get too robust about that. I do think that's a lot different than what they did a year ago with OASYS 1 Day where they basically said, ""We want to participate in the shift of silicone hydrogel wearers, leaving the 2-week space and catch some in the 1 Day market with a huge trade-up."" So they're playing out that strategy. To a large degree, they cannibalize TruEye in the U.S., not worldwide but in the U.S. And OASYS 1 Day and TruEye and MyDay are giving the competition, in this case Alcon's TOTAL1, a run for their money. Now Alcon got out there first when there was only one competitor in that space, which was TruEye. J&J knew that was a deficient product in the U.S., and I'm not sure why in the U.S. when it actually has done pretty well historically in Japan. But for whatever reason, the U.S. is a weaker product. So product rollouts, we hear a lot of noise about B&L on ULTRA, which is their answer to trying to refresh the product line for monthly products, monthly silicone hydrogel products. They've gone and expended now, I think, from beyond a sphere. But a lot of what B&L is doing is capturing some of their legacy products, so PureVision and SofLens 66. So when you put it all together, B&L has some new products, ULTRA, but it's about holding breakeven with the entire product portfolio, including the fall-off of their legacy product. So worldwide, I think the last quarter, they're probably 1% to 2% growth. So they would have lost some margins here last quarter. Alcon, likewise, came up with 2% number in a market growing 5%. So last year, so the gainers were Cooper and with a robust 10% in J&J."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Larry Biegelsen from Wells Fargo.",14,"And our next question comes from the line of Larry Biegelsen from Wells Fargo."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Congratulations, Greg and Al. Just my multipart question here. Bob, is it safe to assume that August bounced back from what sounds like a weak July because of the day count? Second, on 2017, you guys have historically given some color. Even last year you",125,"Congratulations, Greg and Al. Just my multipart question here. Bob, is it safe to assume that August bounced back from what sounds like a weak July because of the day count? Second, on 2017, you guys have historically given some color. Even last year you did on EPS. Is it safe to assume that you're pretty comfortable with consensus top and bottom line at this point, roughly speaking? Otherwise, you would -- if there was something out of whack, you would call it out? And lastly, the inventory write-offs and the idle equipment charges we saw in fiscal Q2, which resulted in that $0.30 hit, should we -- are those over? Or do you expect more of those either in the fourth quarter or 2017?"
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","All right. First question on August and July, yes, it's safe to assume that the anomalies between the weak July and August have to do with workdays not anything ingrained in the marketplace. Relative to 2017 where we educated we're not prepared at this ju",350,"All right. First question on August and July, yes, it's safe to assume that the anomalies between the weak July and August have to do with workdays not anything ingrained in the marketplace. Relative to 2017 where we educated we're not prepared at this juncture to put specifics on the line, no, we wouldn't comment one way or the other on what consensus is out there. I would highlight, however, that some of the analysts have more aggressive foreign exchange rates. And some analysts maybe -- I think Greg kind of hit the nail on the head. Some of the models on the impact of the pound, et cetera, emphasizing that is 30% of our worldwide instead of 40% of our worldwide cost of goods is an important attribute. So hopefully, we gave some color for people to sharpen the pencil with their models, in some case. But beyond saying there's a lot of tailwinds that we're standing by and happy with. And the foreign exchange rates will be whatever they are, and they change literally by the hour. We're not going to add any more color at this juncture. As far as the 10-10-10 hit, $0.10 in the second quarter, $0.10 in the third quarter, $0.10 in the fourth quarter, due to idle equipment and inventory write-offs that were over and above normal, they are in the numbers. There are other write-offs that are routine, and they continue throughout 2016 and will continue throughout 2017. Directionally, we indicated that a lot of those call-out charges are associated with some of our improving efficiencies a lot more than we thought. So that led us to idling some equipment. So directionally, you can see the growth numbers in our 1 Day silicone hydrogel franchise of 40%. That certainly will go towards improving absorption. And importantly, when something goes from idle to used in production, it goes from a direct period charge, which is what the 10-10-10 is about, to -- suddenly it moves on to the balance sheet when it's making inventory. So that will continue throughout 2017, if you will."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Larry Keusch from Raymond James.",14,"And our next question comes from the line of Larry Keusch from Raymond James."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Also congrats to Greg and to Al. I guess, again, a 2-part financial question here. On the CapEx, I mean, if you go back and look, it tends to be cyclical. And you do get into periods where there is investment as you guys bring out new lines and expand cap",186,"Also congrats to Greg and to Al. I guess, again, a 2-part financial question here. On the CapEx, I mean, if you go back and look, it tends to be cyclical. And you do get into periods where there is investment as you guys bring out new lines and expand capacity. There are also periods of time where you grow into that capacity, and in this case, you've got some of these idle equipment sitting around now that will add to that. So I just wanted to get your take on where you think CapEx can go here over the next several years. I think you said $170-ish million for this year. But where does it go? And how does that translate to free cash flow generation? And I guess along with that, should we expect no additional Sauflon integration charges next year? And then the other part of the question is I think certainly the odds of an interest rate increase have gone up, and we can see something coming in this month. And how are you thinking about that? And what's built into guidance?"
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, a few things on that. The cyclicality of the CapEx spend, you're absolutely right, we ramped up for Biofinity and Avaira in the last decade. We're very capital intensive. We got real efficient. We ramped down. And then all of a sudden, particularly",418,"Well, a few things on that. The cyclicality of the CapEx spend, you're absolutely right, we ramped up for Biofinity and Avaira in the last decade. We're very capital intensive. We got real efficient. We ramped down. And then all of a sudden, particularly with the Sauflon acquisition and with MyDay rollout of silicone hydrogel 1 Day, we became very capital intensive again over the last several years. And lo and behold, we got real efficient, and here we are again, a little ahead of ourselves in the perfect world. The translation there is we think we have a pretty long runway on improving efficiencies that will continue over the next several -- multiple years, and that will be somewhat of a cap on CapEx requirements. We've taken the CapEx needs this year from $200 million down $30 million to $170 million. The outlook for post 2016 will be for less than that. We're thinking in that $150 million range. So year-over-year, a reduction of -- in that $50 million range. When you look at cash flow, we've now taken our -- should get to $300 million to a lot stronger statement above $300 million. So we're $300 million headed towards $400 million. No real change in that signal on that going forward. There is, in my opinion, multiple tiers of runway on some of those efficiencies that were talking about. As far as Sauflon or interest charges, the -- what's built into our thinking is given that we have forward cash flow generation, we see that as part of a minimizer. So when you have $1.4 million in debt worldwide, you're generating $300 million to $400 million in cash flow, that will serve to offset. We do expect that probably between now and year-end, there will be some movement in rates, and of course, we've only guided through year-end. So at this juncture, we haven't really guided -- if the Treasury goes crazy, then that will obviously influence the guidance we come out with in December. But I think between foreign exchange volatility and interest rates, depending on who's got their mouth open on a given moment out there, it seems like the government is very -- more proactive in trying to direct economic thinking, which is a detriment, I think, overall because it does create uncertainty in volatility. But we're still in the low inflationary modality. We can all speculate and pretend we're autonomous. So stay tuned and we'll refresh what our thinking is in December."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Steve Willoughby from Cleveland Research.",14,"And our next question comes from the line of Steve Willoughby from Cleveland Research."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Just first on this year's guidance. Greg, if I heard you correctly, it sounds like FX was an incremental $0.04 positive forward here in the third quarter but an incremental $0.02 headwind versus what you're expecting for the fourth quarter. So I'm just tr",87,"Just first on this year's guidance. Greg, if I heard you correctly, it sounds like FX was an incremental $0.04 positive forward here in the third quarter but an incremental $0.02 headwind versus what you're expecting for the fourth quarter. So I'm just trying to correlate that to your -- the guidance, the updated full year guidance you've given where you brought down the high end just a little bit, if it looks like net-net FX is about an incremental $0.02 positive to your previous guidance."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, the last time we gave guidance, we talked it being about a wash. And net-net, you're right, it's a $0.02 positive for '16 at this point year-over-year.",28,"Yes, the last time we gave guidance, we talked it being about a wash. And net-net, you're right, it's a $0.02 positive for '16 at this point year-over-year."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","So what's the driver to the reduction, I guess, of the full year guidance then?",16,"So what's the driver to the reduction, I guess, of the full year guidance then?"
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","The reduction to the full year guidance?",7,"The reduction to the full year guidance?"
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Correct, yes. I mean -- sorry, go ahead, Bob.",9,"Correct, yes. I mean -- sorry, go ahead, Bob."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Overall, against our guidance, we raised the midpoint of our guidance.",11,"Overall, against our guidance, we raised the midpoint of our guidance."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, we actually raised the midpoint by $0.04. It was the FX that we experienced and it, too, was related to probably an operational increase.",25,"Yes, we actually raised the midpoint by $0.04. It was the FX that we experienced and it, too, was related to probably an operational increase."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","So we took it up, not down.",7,"So we took it up, not down."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes on the line of Andrew Hanover from JPMorgan.",13,"And our next question comes on the line of Andrew Hanover from JPMorgan."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Congrats, Greg and Al. I wanted to go back to the fewer and extra selling days in the third quarter and expected in the fourth quarter. And what was the impact on growth in the third quarter? And what are you [indiscernible] for the fourth quarter?",46,"Congrats, Greg and Al. I wanted to go back to the fewer and extra selling days in the third quarter and expected in the fourth quarter. And what was the impact on growth in the third quarter? And what are you [indiscernible] for the fourth quarter?"
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, if you took work days in the quarter, it would be a 3% headwind in Q3 and a 1.5% tailwind in Q4, all other things being equal.",28,"Yes, if you took work days in the quarter, it would be a 3% headwind in Q3 and a 1.5% tailwind in Q4, all other things being equal."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Steven Lichtman from Oppenheimer.",13,"And our next question comes from the line of Steven Lichtman from Oppenheimer."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Two questions. Bob, within your 1 Day silicone hydrogel franchise, in the recent period here, last few months, is the incremental contribution from MyDay and clariti pretty balanced? Or has one been contributing more incrementally over the past few months",88,"Two questions. Bob, within your 1 Day silicone hydrogel franchise, in the recent period here, last few months, is the incremental contribution from MyDay and clariti pretty balanced? Or has one been contributing more incrementally over the past few months? And where do you see now the mix going between those 2 products over time? And then, Greg, the tax rate popping up here in the fourth quarter, why are we going to see that move higher? And any change in your thoughts on tax rate beyond '16?"
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","So in the midst of MyDay and clariti, obviously MyDay is off of a smaller base. So its percentages are higher. And clariti, which has a big European franchise, has a bigger hurdle. clariti is still the one that is targeting the mass market, and therefore,",122,"So in the midst of MyDay and clariti, obviously MyDay is off of a smaller base. So its percentages are higher. And clariti, which has a big European franchise, has a bigger hurdle. clariti is still the one that is targeting the mass market, and therefore, will always be most likely the bigger product. It's the one with the toric and the multifocal, which also will make it the bigger product. So it's still about, I don't know, 70-30-ish. However, with MyDay off of a lower base going into Japan, you may see it, as that rollout occurs, take over somewhat bigger portion of the pie given Japan is such a huge 1 Day market. I guess, Greg, on the tax rate?"
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, on the tax rate, since the March guidance, we've been guiding to the 8% for the year, around 8%. And so we're still holding to that. And when you look at it, things have been choppy, and it also depends, in a lot of times, when discretes are released",114,"Yes, on the tax rate, since the March guidance, we've been guiding to the 8% for the year, around 8%. And so we're still holding to that. And when you look at it, things have been choppy, and it also depends, in a lot of times, when discretes are released this year. We had discretes released in Q1 where normally it's Q3. Typically, Q4 is a higher quarter. Last year was an exception to that, and that was based on a lot of work around the integration and restructuring cost, which allowed deductions. So the Q4 rate being in that 10.5% to 11% is probably more typical outside just the last year or so."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","Thank you, and that concludes our question-and-answer session for today. I would like to turn the conference back over to Bob Weiss for any closing comments.",26,"Thank you, and that concludes our question-and-answer session for today. I would like to turn the conference back over to Bob Weiss for any closing comments."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, I want to once again thank Greg for 6 great years and wish him the best going forward. He will be around, as we indicated, throughout the transition period throughout the rest of this calendar year. And importantly, we look forward to updating you o",107,"Well, I want to once again thank Greg for 6 great years and wish him the best going forward. He will be around, as we indicated, throughout the transition period throughout the rest of this calendar year. And importantly, we look forward to updating you on our year-end results in December. And I think the date there is December 8, if I'm not mistaken. And a lot of good stuff going on, so we look forward to giving you an update on that. Everyone, have a great Labor Day weekend. And summer has come and summer has gone already and life goes on. With that, we'll conclude."
263609,378695672,1040827,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","Thank you. Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program, and you may now disconnect. Everyone, have a great day.",28,"Thank you. Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program, and you may now disconnect. Everyone, have a great day."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","Good day, ladies and gentlemen, and thank you for standing by. Welcome to The Cooper Companies Third Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to hand the meeting over",52,"Good day, ladies and gentlemen, and thank you for standing by. Welcome to The Cooper Companies Third Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to hand the meeting over to Kim Duncan, Vice President of Investor Relations. Please go ahead."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Good afternoon, and welcome to The Cooper Companies Third Quarter 2016 Earnings Conference Call. I'm Kim Duncan, Vice President of Investor Relations. And giving prepared remarks on today's call are Bob Weiss, Chief Executive Officer; and Greg Matz, Chief",321,"Good afternoon, and welcome to The Cooper Companies Third Quarter 2016 Earnings Conference Call. I'm Kim Duncan, Vice President of Investor Relations. And giving prepared remarks on today's call are Bob Weiss, Chief Executive Officer; and Greg Matz, Chief Financial Officer.
Before we get started, I'd like to remind you that this conference call contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including all revenue and earnings per share guidance and other statements regarding anticipated results of operations, market or regulatory conditions and integration of any acquisitions or their failure to achieve anticipated benefits. Forward-looking statements depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Events that could cause our actual results and future actions of the company to differ materially from those described in forward-looking statements are set forth under the caption Forward-Looking Statements in today's earnings release and are described in our SEC filings, including the Business section of Cooper's annual report on Form 10-K. These are publicly available and on request from the company's Investor Relations department.
Before I turn the call over to Bob, let me comment on the agenda for the call. Bob will begin by providing highlights on the quarter, followed by Greg, who will then discuss the third quarter financial results. We will keep the formal presentation to roughly 30 minutes and then open up the call for questions. We expect the call to last approximately 1 hour. We request that anyone asking questions, please limit yourself to one question. Should you have any additional questions, please call our Investor line at (925) 460-3663 or email ir@cooperco.com. As a reminder, this call is being webcast, and a copy of the earnings release is available through the Investor Relations section of The Cooper Companies website.
And with that, I'll turn the call over to Bob for his opening remarks."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thank you, Kim, and good afternoon, everyone. Welcome to our third quarter 2006 (sic) [ 2016 ] conference call.Let me start by highlighting 3 key points. First, I'm pleased to report another strong quarter, including the first-ever quarter with revenues",1313,"Thank you, Kim, and good afternoon, everyone. Welcome to our third quarter 2006 (sic) [ 2016 ] conference call.
Let me start by highlighting 3 key points. First, I'm pleased to report another strong quarter, including the first-ever quarter with revenues over $500 million. This includes CooperVision reporting revenues over $400 million for the first time and CooperSurgical reporting revenues over $100 million for the first time. This resulted in non-GAAP earnings per share of $2.30 and free cash flow of $98 million.
Second, CooperVision posted strong results in all key areas of its business, resulting in 6% as reported in constant currency growth. Single-use silicone hydrogel lenses grew 40%, while 2-week and monthly silicone hydrogel lenses grew a combined 11%, both in constant currency.
Third, CooperSurgical had another strong quarter, posting revenue growth of 38% or 6% pro forma. Fertility was the highlight, posting the strongest quarter in many years with growth of 108% or 10% pro forma.
Moving into details. CooperVision reported second quarter revenues of $410 million, up 6%. This was another strong quarter and continues to show the strength of our product portfolio. The Americas grew 6% in constant currency with strength in multiple categories led by Biofinity and our 1 Day silicone hydrogel franchise. Our enhanced clariti lens continues to perform well, and MyDay had another strong quarter.
During the quarter, we received FDA approval for Avaira Vitality and began to launch in the U.S. in late July. You'll recall, Avaira Vitality is the replacement product for Avaira in the 2-week silicone hydrogel market. The market reaction has been positive. We remain optimistic about this upgraded product.
We also introduced Biofinity Energys at the American Optometric Association conference in July and began the launch in August. This premium Biofinity product has received excellent reviews, and we're confident we will have great success in this offering.
EMEA posted a solid quarter growing 3% year-over-year in constant currency against the tough comp. Growth was driven by Biofinity and the 1 Day silicone hydrogel franchise. Asia Pacific had a very strong quarter with 16% constant currency growth. Growth was strong throughout the region, driven by Biofinity and the 1 Day silicone hydrogel franchise. Within Japan, our MyDay sphere launch is progressing well, and we introduced MyDay toric during the quarter. We believe both MyDay sphere and toric have the potential to be a very successful premium offering in this market.
Turning to our product categories. Torics grew a healthy 10% year-over-year and multifocals grew 5%, both in constant currency. We remain the global leader in specialty lenses, and our success with Biofinity and clariti in both of these categories should continue to drive growth for many years.
Looking at silicone hydrogel lenses. These products grew 16% in constant currency and now represent 61% of our total sales. Within the 2-week and monthly space, Biofinity and Avaira combined to grow 11% in constant currency. We remain under-indexed for the 2-week and monthly silicone hydrogel space at 75% of revenue versus the market at 79%, so we expect to continue growing faster than the market given our strong product portfolio.
Regarding our silicone hydrogel 1 Day lenses, clariti and MyDay, they combined to grow 40% in constant currency. The biggest driver in the contact lens market is 1 Day growth, and we strongly believe we have the best product portfolio offering in this space as the only company with premium and mass market lenses, including a full portfolio of 1 Day silicone hydrogel, sphere, toric and multifocal lenses.
Now let me comment on the overall contact lens market. And remember, this information is on the last page of the earnings release. For the calendar quarter Q2, we continued taking share, growing 10% with the market up 5%. Geographically, CooperVision grew 8% in the Americas while the market was up 4%. In Asian Pacific, we grew 20% with the market up 4%. And in EMEA, we grew 9% with the market up 7%. On a modality basis, single-use lenses continue driving growth with CooperVision up 18% and the market up 10%. For non-silicone hydrogel -- for non-single-use lenses, we grew 7% while the market grew 1%.
As you can see, our growth remains diverse and strong. On a trailing 12-month basis, CooperVision grew 8% and the market grew 5%. Going forward, I expect the market to continue growing 4% to 6% over the next 5 years and most likely closer to 6%. The drivers will continue to be the shift to daily geographic expansion and the expansion of the wearer base. We expect to continue taking market share led by our strong silicone hydrogel portfolio.
Moving to CooperSurgical. We reported Q2 revenues of $105 million, up 38% year-over-year, driven by strong organic growth and acquisitions. On a pro forma basis, growth was up 6%.
Our fertility products led the way, up 108% or 10% pro forma. Within fertility, we had growth throughout the business and continue to believe our market-leading product portfolio, which includes medical devices, genetic testing and capital equipment, is the broadest portfolio in the space and should continue to drive growth for many years to come.
Within our office and surgical category, our growth moderated slightly from the last few quarters, up 3%. We're continuing to execute on several product launches, including our disposable hysteroscope EndoSee, and we believe we will -- we're well positioned in this segment going forward.
Regarding acquisitions, we've been actively working on integrating the deals we've done over the past year, and the strategic rationale behind these deals remains intact. We are very focused on becoming a full-service provider within the global IVF space.
Finally, on CooperSurgical, we're continuing to execute on several initiatives, which should significantly strengthen the business and pay dividends for many years to come. These include transitioning to a geographic sales model, adding sales reps in under-penetrated areas, launching products in new markets and increasing our focus on high-growth areas such as IVF genetic testing. To some degree, these investments are masking all our strong underlying operating performance, but it's critical that we lay the groundwork to support the business on a long-term growth -- from a long-term growth perspective.
Now turning to guidance. I'll let Greg go through the details, but let me touch on a few items. For Q4, we're guiding CooperVision to roughly 5% to 7.5% constant currency growth and CooperSurgical roughly to 5% to 8% pro forma growth. So similar growth to Q3. Regarding non-GAAP earnings per share for Q4, we're guiding to $2.15 to $2.30. Regarding fiscal 2017, it's too early to provide financial guidance, but I will say it should be a strong year given the momentum in our 2 businesses as well as recent currency moves. From a longer-term perspective, we're still targeting operating margins of 27% or higher in 2020.
In conclusion, I want to express my appreciation to our employees for all their hard work and dedication. I also want to say a special thank you to Greg Matz, who has announced his planned retirement after more than 6 years of service of our company, including roughly the last 5 years as our CFO. Greg will be greatly missed and we wish him the best in his future endeavors. With Greg's departure, we have announced that Al White, who many of you know really well, will succeed Greg as CFO. Al will assume this role in addition to his current leadership responsibilities with CooperSurgical. I am very confident that his leadership and abilities will allow us to continue driving long-term shareholder value. From a timing perspective, Greg will remain CFO until the end of the fiscal year, and then Al will take over the position. Greg will remain with us through March of next year to ensure a smooth transition.
And now I'll turn it over to Greg to cover our financial results."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thanks, Bob, and good afternoon, everyone. Bob provided overall summary of our performance, including a review of the market and our revenue picture. I'm going to focus primarily on our non-GAAP results for the quarter. For the reconciliation to GAAP numb",1175,"Thanks, Bob, and good afternoon, everyone. Bob provided overall summary of our performance, including a review of the market and our revenue picture. I'm going to focus primarily on our non-GAAP results for the quarter. For the reconciliation to GAAP numbers, please refer to our earnings release.
Looking at gross margins. In Q3, the non-GAAP gross margin was 63.6% compared with 62.4% in the prior year. This increase is largely due to a favorable mix led by Biofinity and favorable FX offset by recent CSI acquisitions, which have lower gross margins. CooperVision on a non-GAAP basis reported gross margin of 64.2% versus 61.8% in Q3 of last year. The factors which impacted margin were the items I just mentioned. CooperSurgical had a non-GAAP gross margin of 61.2%, which compares to Q3 '15 of 65.4%. Acquisitions in the genetic testing space were the primary drivers for this reduction.
Now looking at operating expenses. On a non-GAAP basis, SG&A increased approximately 8% to $179.7 million or 35% of revenue, down from approximately 36% of revenue in the prior year. The primary driver behind this drop was strong spending controls as we had leverage in both CooperVision and CooperSurgical.
Now looking at R&D. In Q3, R&D on a non-GAAP basis decreased 2% to $16 million or 3.1% of revenue, down from 3.5% of revenue in the prior year. The primary driver is the leverage we're seeing from the Sauflon acquisition.
Moving to operating margins. For Q3, consolidated GAAP operating income and margin were $102.7 million and 19.9% of revenue versus $50.3 million and 10.9% of revenue in Q3 last year. Non-GAAP operating income and margin were $131.6 million and 25.6% of revenue versus $106.1 million and 23% of revenue for the prior year. The primary difference in the operating margin year-over-year is improved gross margins and operating expense leverage. In Q3, CooperVision's non-GAAP operating income and margin were $119.4 million and 29.1% of revenue versus $97.7 million and 25.3% of revenue in the prior year. CooperSurgical's non-GAAP operating income and margin were $23.5 million and 22.4% of revenue versus Q3 '15 of $19.5 million of operating income and 25.6% of revenue.
Looking at depreciation and amortization. In Q3, depreciation was $33.9 million, down $7.5 million year-over-year. Amortization was $15.6 million, up $3.1 million, reflecting our recent acquisition activity. Interest expense was $8 million for the quarter, up $3.3 million year-over-year, primarily due to higher debt interest rates associated with acquisitions.
Looking at the effective tax rate. In Q3, the non-GAAP effective tax rate was 7.7% versus a non-GAAP effective tax rate of 3.1% in Q3 '15. As a reminder, in the prior year, we had a higher dollar amount of Q3 discreet items related to prior years, which reversed in that quarter.
On earnings per share, our Q3 earnings per share on a GAAP and a non-GAAP basis was $1.79 and $2.30, respectively, versus $0.91 and $1.97 for GAAP and non-GAAP in the prior year.
Looking at some balance sheet and liquidity items. In Q3, we had cash provided by operations of $128.9 million with capital expenditures of $31.1 million, resulting in $97.8 million of free cash flow. Excluding integration cost of $6.5 million, adjusted free cash flow was $104.3 million. Total debt increased slightly within the quarter by $2.7 million to $1,444,100,000, primarily due to higher average cash balances and acquisitions, largely offset by operational cash flow generation.
Inventories decreased by approximately $3.3 million to $430.3 million from last quarter. In CooperVision, we saw overall inventory decline as growth in silicone daily inventory to support our product launches was offset by a reduction in our hydrogel inventory. In CooperSurgical, we saw a small increase largely due to new acquisitions. For the quarter, we're seeing month on hand at 6.5 months, down from 7 months last quarter. Days sales outstanding is at 54 days, same as last quarter and down 1 day from the prior year.
Now turning to guidance. For our main currencies, we're using 1.10 for the euro, 104 for the yen and 1.30 for the pound.
And looking at the full year. The consolidated revenue range is being raised on the low end to reflect our Q3 performance and is now $1.944 billion to $1.957 billion or approximately 6% to 7% pro forma growth, up from the previous 5.5% to 7% range.
For the fourth quarter, CooperVision's revenue range is $390 million to $400 million or roughly 5% to 7.5% constant currency growth. And CooperSurgical's revenue range is $106 million to $109 million or roughly 5% to 8% pro forma growth.
We expect non-GAAP gross margin for the fourth quarter to be slightly over 64%, driven by a strong quarter for CooperVision. This would result in a full year gross margin around 63%. OpEx is expected to be slightly under 39% for the fourth quarter as well as for the full year. Operating margin is expected to be around 26% in Q4, which would result in the full year margin being in the mid-24% range. Interest expense is expected to be a little over $7 million in Q4 or slightly over $28 million for the year. Our effective tax rate guidance is the same as last quarter. Thus, a full year rate of around 8% translates to 10.5% to 11% in Q4. Our expected share count is around 49.1 million shares. Our non-GAAP earnings per share is expected to be $2.15 to $2.30 in the fourth quarter, which equates to $8.32 to $8.47 for the full year.
From our last earnings call, currency was a positive in Q3, helping roughly $0.04. But we are expecting a negative impact in Q4 of roughly $0.02 from our previous guidance. Unfortunately, some of the positives we experienced in Q3 from currencies such as the yen and the euro are now being more than offset by the move in the pound since Brexit occurred in late June. As Bob mentioned, if currency holds, we should see a lot of benefit next year led by cost of goods as roughly 40% of CooperVision's product is manufactured in pounds with roughly a 6-month lag to the P&L. To be clear, this is roughly 40% of CooperVision's manufacturing, so on a consolidated basis, this is roughly 30% of our total cost of goods. Also note, the pound move associated with Brexit occurred in late June, so this positive impact starts in January, so a more muted positive impact in fiscal Q1 versus the remainder of the year.
The other point to note, as I mentioned earlier, is our effective tax rate guidance remains unchanged, which means a Q4 tax rate range of about 10.5% to 11%. Regarding cash flow, our CapEx was low this quarter but we do expect around $50 million in Q4, so around $170 million of CapEx for the year now. This should result in free cash flow over $300 million and adjusted free cash flow when excluding integration-related activity of well north of $300 million.
With that, let me turn it back to Kim for the Q&A session."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thank you, Greg. Operator, we're ready to take some questions.",10,"Thank you, Greg. Operator, we're ready to take some questions."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Jeff Johnson from Robert W. Baird.",16,"[Operator Instructions] Our first question comes from the line of Jeff Johnson from Robert W. Baird."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Greg, I just want to say it's been great working for you -- or working with you, not for you, but working with you for the last few years. And best of luck in the future. And Al, plus or minus, we'll see how it goes here over the next few years. That was",162,"Greg, I just want to say it's been great working for you -- or working with you, not for you, but working with you for the last few years. And best of luck in the future. And Al, plus or minus, we'll see how it goes here over the next few years. That was a joke. And so, Bob, I just want to start with you just on kind of the monthly trend here. It's always tough to read CLI data and try to translate that given the off 1 month, how your fiscal quarter closes. But if I look, it looks as if maybe the forward month slowed a little bit. Looking at CLI data versus your reported number for the quarter, there has been some question of utilization issues out there. So just any color you can give us on kind of the monthly gating of what you have been seeing in the industry here over the last few months."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes. Good question, Jeff. And yes, that's kind of jumped off the page a little, that July must have been soft relatively speaking. There's really primarily but one answer to that, and it's an industry-wide answer but not for the reasons most people would",198,"Yes. Good question, Jeff. And yes, that's kind of jumped off the page a little, that July must have been soft relatively speaking. There's really primarily but one answer to that, and it's an industry-wide answer but not for the reasons most people would think. Rarely in the past have we talked about workdays in a month, but in this case, I'll highlight the fact that in July this year, there were 19 workdays compared to 22 last year because of the way weekends fell. And that translates to about a 17% -- 16%, 17% reduction in revenue if you had the same revenue per day or the orders per day. So pretty profound impact that weighted heavily because of the anomaly of the way weekends fell. Conversely, you get some of that back in August. Relative to the full quarter however, probably the best way to look at it is, workdays were down 3% this year in the third quarter, and they'll be up 1.5% in the fourth quarter. So there's one more workday in the fourth quarter. So it smooths out within the quarter, but there is an anomaly between July and August caused by workdays."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Brian Weinstein from William Blair.",14,"And our next question comes from the line of Brian Weinstein from William Blair."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Can you guys just talk a little bit about what you're seeing, obviously, from the competitive launch from J&J. And then also, you have a couple of launches in the FRP space. How are you seeing that kind of 2-week and monthly space playing out at this poin",66,"Can you guys just talk a little bit about what you're seeing, obviously, from the competitive launch from J&J. And then also, you have a couple of launches in the FRP space. How are you seeing that kind of 2-week and monthly space playing out at this point? And any color you can talk about with respect to the just the competitive launch in general."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, the competitive launch, J&J has been active in taking OASYS 2-week, which was their sweet spot, and expanding it into a 1 Day -- a 1-week and then a 1 Day. And now they're moving with a different package into the monthly modality with VITA. The amoun",506,"Yes, the competitive launch, J&J has been active in taking OASYS 2-week, which was their sweet spot, and expanding it into a 1 Day -- a 1-week and then a 1 Day. And now they're moving with a different package into the monthly modality with VITA. The amount of push they put behind VITA out of the gate [ph] was nothing compared to a year ago when they launched the OASYS 1 Day modality. So a lot more muted. Having said that, they're one of the more active ones in the space, albeit leveraging their OASYS franchise, if you will. Interestingly, they still do not call OASYS 1 Day a silicone hydrogel lens. But as we all know, it is a silicone hydrogel lens. As I think I indicated in the past, it was my belief that there would be some swapping of the 2-week noncompliant into the monthly compliant, which in essence is a clever way of saying it's a trade-up strategy, and I think we're seeing more and more of that as they're trying to continue the deceleration or the negative growth of the 2-week space, which they own 90% of, and migrate it into more profitable buckets. And there is no doubt profitable bucket means the 1 Day modality, but quite frankly, their strategy is not shortsighted, so to speak, when it comes to monthly price point yields more revenue than a 2-week noncompliant. And most -- the vast majority of the 2-week wearers are noncompliant. As far as our product in the non-1 Day space, we rolled out initially Biofinity Energys. It's getting -- it's very early in the game, but so far so good. There's a lot of excitement about a novel win that really addresses people with iPhones and being in front of screens -- TV screens and computer screens professionally. So there's a lot of interest by the eye care professionals that we have engaged in discussion thus far. We also are -- got approval to launch Vitality in the 2-week space. And Vitality is targeted to replace our low gross margin Avaira product in the 2-week space. That low gross margin came about a number of years ago when we had a recall and had to change the manufacturing technique, which became very cumbersome. So it is a significant step-up in gross margin, and it's very early in that launch. I think it was late July. And the intent there is, it will probably take us 2 to 3 years to roll out the entire family of the toric and the sphere worldwide in this migration. The sphere will go faster, and the majority of the Avaira product line is -- 70% of it or more is the sphere side. So that one will show up quicker. But it's an inventory turn. And when you have toric, it takes longer to transition, if you will, that. So we're excited about that. And then, of course, we have all the action that's going on in the 1 Day space."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Jon Buck from Stifel.",12,"Our next question comes from the line of Jon Buck from Stifel."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Maybe 2. I'll ask them both upfront. The CSI margins, Greg, were down, a decent sequential pullback from fiscal Q2 results. Not asking for guidance for next year, but is sort of the 61% gross margin the right place to be, looking forward when we think abo",109,"Maybe 2. I'll ask them both upfront. The CSI margins, Greg, were down, a decent sequential pullback from fiscal Q2 results. Not asking for guidance for next year, but is sort of the 61% gross margin the right place to be, looking forward when we think about the recent acquisitions weighing on the margin a bit? And then separately, for CVI, Bob, can you just talk to the EMEA market? I mean, you're gaining a lot of share in APAC and you seem to be well positioned in the U.S. The gains seem to be accelerating. Can you talk about what you're seeing in the EMEA market regarding share?"
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Jon, on the gross margin, I think what you should expect to see is 61% is a low point. You should see it be a little bit higher than that. And again, the base business will kick in a little bit. The new acquisitions come with a lower gross margin, and so",62,"Jon, on the gross margin, I think what you should expect to see is 61% is a low point. You should see it be a little bit higher than that. And again, the base business will kick in a little bit. The new acquisitions come with a lower gross margin, and so that so you did see that pressure, especially in Q3."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","As far as the EMEA market, we continue to gain share there, and happy to say we're right on the heels of the #1 player there, which is Alcon, in the market. And that happens to be the part of the world where we have the highest market share in EMEA. Our o",165,"As far as the EMEA market, we continue to gain share there, and happy to say we're right on the heels of the #1 player there, which is Alcon, in the market. And that happens to be the part of the world where we have the highest market share in EMEA. Our overall market share is 23%. But in Europe, it's 33%, contrasted to where we're the weakest yet, but growing fast in Asia Pac. So the market there remains focused in on the 1 Day modality. Eastern Europe continues to be a robust area. And then the Biofinity continues to charge very nicely there. And then, of course, the other thing is the U.S. market was the first one to arrive with specialty lenses, torics and multifocals. And now the rest of the world, including EMEA, is catching up. So you have a more robust market there, which plays to Cooper's strengths, recognizing we're #1 in the world in the specialty lens area overall."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Matt Mishan from KeyBanc.",13,"And our next question comes from the line of Matt Mishan from KeyBanc."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Bob, could you give us a sense of what is driving the double-digit growth in Asia Pac? And with MyDay being a bigger piece over there going into next year, is double-digit growth sustainable for a little bit? And then can you talk a little bit about what",64,"Bob, could you give us a sense of what is driving the double-digit growth in Asia Pac? And with MyDay being a bigger piece over there going into next year, is double-digit growth sustainable for a little bit? And then can you talk a little bit about what you see as the opportunity for MyDay toric in Japan and why you launched there first?"
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Sure. First of all, double-digit in Asia Pac is somewhat a reflection of our immaturity in that market with a fabulous product portfolio. So we have a great product portfolio. A lot of it emanated out of EMEA. So it started in Europe and it came to the U.",294,"Sure. First of all, double-digit in Asia Pac is somewhat a reflection of our immaturity in that market with a fabulous product portfolio. So we have a great product portfolio. A lot of it emanated out of EMEA. So it started in Europe and it came to the U.S. And really, Asia PAC is the last to get it all. In addition, we were clearly under-indexed overall in that market. We have invested over the last 3 or 4 years heavily in some areas like China and the surrounding geographic area. So we're starting to get momentum there. As far as MyDay in Japan, MyDay is a 1 Day product. There are silicone hydrogel players in the Japanese market. TruEye started there, so in essence, the silicone hydrogel market really started for all practical purposes in Japan. The beauty of having a MyDay toric in Japan, first of all, we have clariti available in the rest of the world. clariti has a sphere, a toric and a multifocal. In Japan, we only have MyDay at this juncture, and having a toric to go along with it has a halo effect. We will be the only one in the Japanese market with a silicone hydrogel sphere and a toric. While the toric market is not as mature as even the European market, it's early in the cycle there. It is a nice halo effect. A lot of practitioners want it, and particularly more so some of your independents in Japan. So it's a good story with not only the large retailers that exist there but also the independents. So yes, I do expect that we will put up robust numbers going forward, double-digit numbers, certainly in many quarters going forward in the Asia Pac marketplace."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Matt O'Brien from Piper Jaffray.",15,"And our next question comes from the line of Matt O'Brien from Piper Jaffray."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","This is actually, JP in for Matt. I just wanted to dig deeper on gross margins. And I know you're not giving guidance for 2017, but you've got a lot going on. You've got a weaker British pound, which as you said, after 6 months, once you work through inve",175,"This is actually, JP in for Matt. I just wanted to dig deeper on gross margins. And I know you're not giving guidance for 2017, but you've got a lot going on. You've got a weaker British pound, which as you said, after 6 months, once you work through inventory, you'll see a benefit there. And then clariti, as it continues to ramp, should be accretive to [indiscernible] gross margin. You just launched a 2-week product. That has better gross margins as well. So I'm just trying to think of -- is there any reason why we can't get above 65% next year? And then just a longer-term question on gross margin, I mean, when you did the Sauflon acquisition, you've kind of gotten this ability of doing silicone hydrogel without having the need for alcohol in the manufacturing process. And just trying to think of when you can take that manufacturing ability and start launching your own organic products with that kind of unique process and when we should expect some products like that."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","On the gross margin, you've covered a lot of the points that they are obviously some tailwinds in -- where clariti is coming in at far better than we first thought when we bought the company. The pound, as we mentioned, will -- especially with the pound a",157,"On the gross margin, you've covered a lot of the points that they are obviously some tailwinds in -- where clariti is coming in at far better than we first thought when we bought the company. The pound, as we mentioned, will -- especially with the pound at these rates, as I mentioned in the earlier comments, will have a nice impact going forward. At the same time, again, we are -- you saw the acquisitions that CooperSurgical is doing, and that will have some impact on the overall gross margins because as you get into more lab-based businesses, they're going to come with lower gross margins. And so as you said, we're not giving guidance for next year. You've seen the gross margins start to edge up throughout the entire year, so you can see that where we're looking at being in the fourth quarter is, again, higher than where we were in the third quarter."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","And I think just on the comment on the Sauflon platform, yes, we're ecstatic about the alcohol-free nature of it and the fact that it's so flexible that we have the sphere, the toric and the multifocal to leverage. We're ecstatic by the fact that we were",134,"And I think just on the comment on the Sauflon platform, yes, we're ecstatic about the alcohol-free nature of it and the fact that it's so flexible that we have the sphere, the toric and the multifocal to leverage. We're ecstatic by the fact that we were able to ramp up very quickly, and therefore, we're not capacity constrained. So that is clearly a tailwind in a high gross margin area. However, I would agree with Greg's point that with the surgical acquisitions that we have made and with surgical now in around 61%, going up a little from there, there is a mix headwind that comes into play. So directionally, you're right, there's a tremendous amount of tailwinds to help us out. And we'll see where that all ends down on the road."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Joanne Wuensch from BMO Capital Markets.",14,"Our next question comes from the line of Joanne Wuensch from BMO Capital Markets."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Congratulations to Greg and Al. Multipart questions. First -- 2 multipart questions. FX. We all saw the surge in the stock price after the Brexit moment, and so I'm sort of curious what you're thinking of the FX impact maybe for 2017, without giving guida",151,"Congratulations to Greg and Al. Multipart questions. First -- 2 multipart questions. FX. We all saw the surge in the stock price after the Brexit moment, and so I'm sort of curious what you're thinking of the FX impact maybe for 2017, without giving guidance, but maybe as a contributor, so that we sort of get our heads around it with no surprises when you do give guidance. The second part of that question has to do with what was the FX impact on EPS in the third quarter and the current thinking for the full year? And then my second question has to do -- more big picture. We've all been very worried and very focused about J&J's product launches, and while Seva and Bausch have struggled, is there anything that you see coming down sort of the pike that we need to be aware of as we look forward?"
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Okay. Joanne, I'll jump in on the FX questions real quick. So from a third quarter perspective, if you look at the actuals, we had a $0.06 benefit year-over-year. And that was about $0.04 above what we had guided to, or what was in our guidance in Q3 -- o",258,"Okay. Joanne, I'll jump in on the FX questions real quick. So from a third quarter perspective, if you look at the actuals, we had a $0.06 benefit year-over-year. And that was about $0.04 above what we had guided to, or what was in our guidance in Q3 -- or I'm sorry, Q2. If you look for the full year, we're looking at -- FX is about flat. It's about up $0.02 for the full year, year-over-year. You talked about Brexit. One of the things to keep in mind, and I mentioned that in the script, is when it hit. It hit in late June. So we would start to see the benefit of that really coming in, in January. So Q1 will get a little bit of the benefit, and then provided the rates stay where they're at, you'll get that benefit throughout the rest of the year. So it's a nice benefit. From a CooperVision perspective, about 40% of our COGS are in pound-based manufacturing. And that's 30% roughly for the total company. So you'll see that flow through again a good part of next year provided the pound stays at about these rates. It's definitely down quite a bit from prior years, and that's -- we win more on -- when that happens from a pound perspective, we win more on the manufacturing than we lose on the revenue. But in the short term like Q4, we actually get impacted by the revenue first and the benefit will come out outside of this fiscal year."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","As far as some of the product launches of J&J, when we look at J&J, B&L and Alcon, J&J is that one that probably has their act together, the best of the 3. And Alcon obviously is still in a remaking mode. B&L is in a remaking mode, changing their structur",557,"As far as some of the product launches of J&J, when we look at J&J, B&L and Alcon, J&J is that one that probably has their act together, the best of the 3. And Alcon obviously is still in a remaking mode. B&L is in a remaking mode, changing their structure yet again, I think. And J&J, with a fairly weak product portfolio, is a good marketing company. And so I would compliment them on making the best of the product portfolio they have. Some of their programs, the whole disruption they've caused in the marketplace over the last 2 years with directionally going all the way with UPP and then directionally going the other way, they've taken some bumps in terms of their messaging. So one day they're saying to you, ""We're the friend with the independents with these products."" And then the next day, they are saying, ""Well, we have a different story to tell you, but it's not going to be UPP."" So there is no doubt there's some reaction to that. As far as VITA, for example, their new product launch in the monthly space, very much it's moving into a space where it's going against some franchised products, and Biofinity is a franchised product. And Biofinity is the product that has a toric, a sphere and a multifocal. Plus now it has things like Energys, which is an enhanced product for people that -- like 99% of the people on the planet, are using more and more technology. So I don't expect them to get too robust about that. I do think that's a lot different than what they did a year ago with OASYS 1 Day where they basically said, ""We want to participate in the shift of silicone hydrogel wearers, leaving the 2-week space and catch some in the 1 Day market with a huge trade-up."" So they're playing out that strategy. To a large degree, they cannibalize TruEye in the U.S., not worldwide but in the U.S. And OASYS 1 Day and TruEye and MyDay are giving the competition, in this case Alcon's TOTAL1, a run for their money. Now Alcon got out there first when there was only one competitor in that space, which was TruEye. J&J knew that was a deficient product in the U.S., and I'm not sure why in the U.S. when it actually has done pretty well historically in Japan. But for whatever reason, the U.S., it's a weaker product. So product rollouts, we hear a lot of noise about B&L on ULTRA, which is their answer to trying to refresh the product line for monthly products, monthly silicone hydrogel products. They've gone and expanded now, I think, from beyond a sphere. But a lot of what B&L is doing is capturing some of their legacy products, so PureVision and SofLens 66. So when you put it all together, B&L has some new products, ULTRA, but it's about holding breakeven with the entire product portfolio, including the fall-off of their legacy products. So worldwide, I think the last quarter, they're probably 1% to 2% growth. So they would have lost some margins here last quarter. Alcon, likewise, came up with 2% numbers in a market growing 5%. So they lost share, so the gainers were Cooper and with a robust 10% in J&J."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Larry Biegelsen from Wells Fargo.",14,"And our next question comes from the line of Larry Biegelsen from Wells Fargo."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Congratulations, Greg and Al. Just my multipart question here. Bob, is it safe to assume that August bounced back from what sounds like a weak July because of the day count? Second, on 2017, you guys have historically given some color. Even last year you",125,"Congratulations, Greg and Al. Just my multipart question here. Bob, is it safe to assume that August bounced back from what sounds like a weak July because of the day count? Second, on 2017, you guys have historically given some color. Even last year you did on EPS. Is it safe to assume that you're pretty comfortable with consensus top and bottom line at this point, roughly speaking? Otherwise, you would -- if there was something out of whack, you would call it out? And lastly, the inventory write-offs and the idle equipment charges we saw in fiscal Q2, which resulted in that $0.30 hit, should we -- are those over? Or do you expect more of those either in the fourth quarter or 2017?"
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","All right. First question on August and July, yes, it's safe to assume that the anomalies between the weak July and August have to do with workdays, not anything ingrained in the marketplace. Relative to 2017 where we indicated we're not prepared at this",351,"All right. First question on August and July, yes, it's safe to assume that the anomalies between the weak July and August have to do with workdays, not anything ingrained in the marketplace. Relative to 2017 where we indicated we're not prepared at this juncture to put specifics on the line, no, we wouldn't comment one way or the other on what consensus is out there. I would highlight, however, that some of the analysts have more aggressive foreign exchange rates. And some analysts maybe -- I think Greg kind of hit the nail on the head. Some of the models on the impact of the pound, et cetera, emphasizing that it's on 30% of our worldwide instead of 40% of our worldwide cost of goods is an important attribute. So hopefully, we gave some color for people to sharpen the pencil with their models, in some case. But beyond saying there's a lot of tailwinds that we're standing by and happy with. And the foreign exchange rates will be whatever they are, and they change literally by the hour. We're not going to add any more color at this juncture. As far as the 10-10-10 hit, $0.10 in the second quarter, $0.10 in the third quarter, $0.10 in the fourth quarter, due to idle equipment and inventory write-offs that were over and above normal, they are in the numbers. There are other write-offs that are routine, and they continued throughout 2016 and will continue throughout 2017. Directionally, we indicated that a lot of those call-out charges are associated with some of our improving efficiency a lot more than we thought. So that led us to idling some equipment. So directionally, you can see the growth numbers in our 1 Day silicone hydrogel franchise of 40%. That certainly will go towards improving absorption. And importantly, when something goes from idle to use in production, it goes from a direct period charge, which is what the 10-10-10 is about, to -- suddenly it moves on to the balance sheet when it's making inventory. So that will continue throughout 2017, if you will."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Larry Keusch from Raymond James.",14,"And our next question comes from the line of Larry Keusch from Raymond James."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Also congrats to Greg and to Al. I guess, again, a 2-part financial question here. On the CapEx, I mean, if you go back and look, it tends to be cyclical. And you do get into periods where there is investment as you guys bring out new lines and expand cap",186,"Also congrats to Greg and to Al. I guess, again, a 2-part financial question here. On the CapEx, I mean, if you go back and look, it tends to be cyclical. And you do get into periods where there is investment as you guys bring out new lines and expand capacity. There are also periods of time where you grow into that capacity, and in this case, you've got some of these idle equipment sitting around now that will add to that. So I just wanted to get your take on where you think CapEx can go here over the next several years. I think you said $170-ish million for this year. But where does it go? And how does that translate to free cash flow generation? And I guess along with that, should we expect no additional Sauflon integration charges next year? And then the other part of the question is I think certainly the odds of an interest rate increase have gone up, and we can see something coming in this month. And how are you thinking about that? And what's built into guidance?"
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, a few things on that. The cyclicality of the CapEx spend, you're absolutely right, we ramped up for Biofinity and Avaira in the last decade. We were very capital intense. We got real efficient. We ramped down. And then all of a sudden, particularly",418,"Well, a few things on that. The cyclicality of the CapEx spend, you're absolutely right, we ramped up for Biofinity and Avaira in the last decade. We were very capital intense. We got real efficient. We ramped down. And then all of a sudden, particularly with the Sauflon acquisition and with MyDay rollout of silicone hydrogel 1 Day, we became very capital intense again over the last several years. And lo and behold, we got real efficient, and here we are again, a little ahead of ourselves in the perfect world. The translation there is we think we have a pretty long runway on improving efficiencies that will continue over the next several -- multiple years, and that will be somewhat of a cap on CapEx requirements. We've taken the CapEx needs this year from $200 million down $30 million to $170 million. The outlook for post-2016 will be for less than that. We're thinking in that $150 million range. So year-over-year, a reduction of -- in that $50 million range. When you look at cash flow, we've now taken our -- should get to $300 million to a lot stronger statement above $300 million. So we're $300 million headed towards $400 million. No real change in that signal on that going forward. There is, in my opinion, multiple years of runway on some of those efficiencies that we're talking about. As far as Sauflon or interest charges, the -- what's built into our thinking is given that we have solid cash flow generation, we see that as part of a minimizer. So when you have $1.4 million in debt worldwide, you're generating $300 million to $400 million in cash flow that will serve to offset. We do expect that probably between now and year-end, there will be some movement in rates, and of course, we've only guided through year-end. So at this juncture, we haven't really guided -- if the Treasury goes crazy, then that will obviously influence the guidance we come out with in December. But I think between foreign exchange volatility and interest rates, depending on who's got their mouth open on a given moment out there, it seems like the government is very -- more proactive in trying to direct economic thinking, which is a detriment, I think, overall because it does create uncertainty in volatility. But we're still on a low inflationary modality. We can all speculate and pretend we're autonomous. So stay tuned and we'll refresh what our thinking is in December."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Steve Willoughby from Cleveland Research.",14,"And our next question comes from the line of Steve Willoughby from Cleveland Research."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Congrats Greg and congrats Al. Just first on this year's guidance. Greg, if I heard you correctly, it sounds like FX was an incremental $0.04 positive forward [ph] here in the third quarter but an incremental $0.02 headwind versus what you're expecting fo",92,"Congrats Greg and congrats Al. Just first on this year's guidance. Greg, if I heard you correctly, it sounds like FX was an incremental $0.04 positive forward [ph] here in the third quarter but an incremental $0.02 headwind versus what you're expecting for the fourth quarter. So I'm just trying to correlate that to your -- the guidance, the updated full year guidance you've given where you brought down the high end just a little bit, if it looks like net-net FX is about an incremental $0.02 positive to your previous guidance."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, the last time we gave guidance, we talked it being about a wash. And net-net, you're right, it's a $0.02 positive for '16 at this point year-over-year.",28,"Yes, the last time we gave guidance, we talked it being about a wash. And net-net, you're right, it's a $0.02 positive for '16 at this point year-over-year."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","So what's the driver to the reduction, I guess, of the full year guidance then?",16,"So what's the driver to the reduction, I guess, of the full year guidance then?"
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","The reduction to the full year guidance?",7,"The reduction to the full year guidance?"
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Correct, yes. I mean -- sorry, go ahead, Bob.",9,"Correct, yes. I mean -- sorry, go ahead, Bob."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","That's only -- I was going to say, I'm not sure overall, against our guidance, we raised the midpoint of our guidance.",23,"That's only -- I was going to say, I'm not sure overall, against our guidance, we raised the midpoint of our guidance."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, we actually raised the midpoint by $0.04. $0.02 was the FX that we experienced and, then, $0.02 was related to probably an operational increase.",25,"Yes, we actually raised the midpoint by $0.04. $0.02 was the FX that we experienced and, then, $0.02 was related to probably an operational increase."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","So we took it up, not down.",7,"So we took it up, not down."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes on the line of Andrew Hanover from JPMorgan.",13,"And our next question comes on the line of Andrew Hanover from JPMorgan."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Congrats, Greg and Al. I wanted to go back to the fewer and extra selling days in the third quarter and expected in the fourth quarter. And what was the impact on growth in the third quarter? And what are your [indiscernible] for the fourth quarter?",46,"Congrats, Greg and Al. I wanted to go back to the fewer and extra selling days in the third quarter and expected in the fourth quarter. And what was the impact on growth in the third quarter? And what are your [indiscernible] for the fourth quarter?"
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, if you took work days in the quarter, it would be a 3% headwind in Q3 and a 1.5% tailwind in Q4, all other things being equal.",28,"Yes, if you took work days in the quarter, it would be a 3% headwind in Q3 and a 1.5% tailwind in Q4, all other things being equal."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Steven Lichtman from Oppenheimer.",13,"And our next question comes from the line of Steven Lichtman from Oppenheimer."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Two questions. Bob, within your 1 Day silicone hydrogel franchise, in the recent period here, last few months, is the incremental contribution from MyDay and clariti pretty balanced? Or has one been contributing more incrementally over the past few months",88,"Two questions. Bob, within your 1 Day silicone hydrogel franchise, in the recent period here, last few months, is the incremental contribution from MyDay and clariti pretty balanced? Or has one been contributing more incrementally over the past few months? And where do you see now the mix going between those 2 products over time? And then, Greg, the tax rate popping up here in the fourth quarter, why are we going to see that move higher? And any change in your thoughts on tax rate beyond '16?"
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","So on the mix of MyDay and clariti, obviously, MyDay is off of a smaller base. So its percentages are higher. And clariti, which has a big European franchise, has a bigger hurdle. clariti is still the one that is targeting the mass market, and therefore,",122,"So on the mix of MyDay and clariti, obviously, MyDay is off of a smaller base. So its percentages are higher. And clariti, which has a big European franchise, has a bigger hurdle. clariti is still the one that is targeting the mass market, and therefore, will always be most likely the bigger product. It's the one with the toric and the multifocal, which also will make it the bigger product. So it's still about, I don't know, 70-30-ish. However, with MyDay off of a lower base going into Japan, you may see it, as that rollout occurs, take over somewhat bigger portion of the pie given Japan is such a huge 1 Day market. I guess, Greg, on the tax rate?"
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, on the tax rate, since the March guidance, we've been guiding to the 8% for the year, around 8%. And so we're still holding to that. And when you look at it, things have been choppy, and it also depends, a lot of times, when discretes are released. T",114,"Yes, on the tax rate, since the March guidance, we've been guiding to the 8% for the year, around 8%. And so we're still holding to that. And when you look at it, things have been choppy, and it also depends, a lot of times, when discretes are released. This year, we had discretes released in Q1 where normally it's Q3. Typically, Q4 is a higher quarter. Last year was an exception to that, and that was based on a lot of work around the integration and restructuring cost, which allowed deductions. So the Q4 rate being in that 10.5% to 11% is probably the more typical outside just the last year or so."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","Thank you, and that concludes our question-and-answer session for today. I would like to turn the conference back over to Bob Weiss for any closing comments.",26,"Thank you, and that concludes our question-and-answer session for today. I would like to turn the conference back over to Bob Weiss for any closing comments."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, I want to once again thank Greg for 6 great years and wish him the best going forward. He will be around, as we indicated, throughout the transition period, throughout the rest of this calendar year. And importantly, we look forward to updating you",107,"Well, I want to once again thank Greg for 6 great years and wish him the best going forward. He will be around, as we indicated, throughout the transition period, throughout the rest of this calendar year. And importantly, we look forward to updating you on our year-end results in December. And I think the date there is December 8, if I'm not mistaken. And a lot of good stuff going on, so we look forward to giving you an update on that. Everyone, have a great Labor Day weekend. And summer has come and summer has gone already and life goes on. With that, we'll conclude."
263609,378695672,1040836,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","Thank you. Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program, and you may now disconnect. Everyone, have a great day.",28,"Thank you. Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program, and you may now disconnect. Everyone, have a great day."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","Good day, ladies and gentlemen, and thank you for standing by. Welcome to The Cooper Companies Third Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to hand the meeting over",52,"Good day, ladies and gentlemen, and thank you for standing by. Welcome to The Cooper Companies Third Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to hand the meeting over to Kim Duncan, Vice President of Investor Relations. Please go ahead."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Good afternoon, and welcome to The Cooper Companies Third Quarter 2016 Earnings Conference Call. I'm Kim Duncan, Vice President of Investor Relations. And giving prepared remarks on today's call are Bob Weiss, Chief Executive Officer; and Greg Matz, Chief",321,"Good afternoon, and welcome to The Cooper Companies Third Quarter 2016 Earnings Conference Call. I'm Kim Duncan, Vice President of Investor Relations. And giving prepared remarks on today's call are Bob Weiss, Chief Executive Officer; and Greg Matz, Chief Financial Officer.
Before we get started, I'd like to remind you that this conference call contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including all revenue and earnings per share guidance and other statements regarding anticipated results of operations, market or regulatory conditions and integration of any acquisitions or their failure to achieve anticipated benefits. Forward-looking statements depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Events that could cause our actual results and future actions of the company to differ materially from those described in forward-looking statements are set forth under the caption Forward-Looking Statements in today's earnings release and are described in our SEC filings, including the Business section of Cooper's annual report on Form 10-K. These are publicly available and on request from the company's Investor Relations department.
Before I turn the call over to Bob, let me comment on the agenda for the call. Bob will begin by providing highlights on the quarter, followed by Greg, who will then discuss the third quarter financial results. We will keep the formal presentation to roughly 30 minutes and then open up the call for questions. We expect the call to last approximately 1 hour. We request that anyone asking questions, please limit yourself to one question. Should you have any additional questions, please call our Investor line at (925) 460-3663 or email ir@cooperco.com. As a reminder, this call is being webcast, and a copy of the earnings release is available through the Investor Relations section of The Cooper Companies website.
And with that, I'll turn the call over to Bob for his opening remarks."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thank you, Kim, and good afternoon, everyone. Welcome to our third quarter 2006 (sic) [ 2016 ] conference call.Let me start by highlighting 3 key points. First, I'm pleased to report another strong quarter, including the first-ever quarter with revenues",1313,"Thank you, Kim, and good afternoon, everyone. Welcome to our third quarter 2006 (sic) [ 2016 ] conference call.
Let me start by highlighting 3 key points. First, I'm pleased to report another strong quarter, including the first-ever quarter with revenues over $500 million. This includes CooperVision reporting revenues over $400 million for the first time and CooperSurgical reporting revenues over $100 million for the first time. This resulted in non-GAAP earnings per share of $2.30 and free cash flow of $98 million.
Second, CooperVision posted strong results in all key areas of its business, resulting in 6% as reported in constant currency growth. Single-use silicone hydrogel lenses grew 40%, while 2-week and monthly silicone hydrogel lenses grew a combined 11%, both in constant currency.
Third, CooperSurgical had another strong quarter, posting revenue growth of 38% or 6% pro forma. Fertility was the highlight, posting the strongest quarter in many years with growth of 108% or 10% pro forma.
Moving into details. CooperVision reported second quarter revenues of $410 million, up 6%. This was another strong quarter and continues to show the strength of our product portfolio. The Americas grew 6% in constant currency with strength in multiple categories led by Biofinity and our 1 Day silicone hydrogel franchise. Our enhanced clariti lens continues to perform well, and MyDay had another strong quarter.
During the quarter, we received FDA approval for Avaira Vitality and began to launch in the U.S. in late July. You'll recall, Avaira Vitality is the replacement product for Avaira in the 2-week silicone hydrogel market. The market reaction has been positive. We remain optimistic about this upgraded product.
We also introduced Biofinity Energys at the American Optometric Association conference in July and began the launch in August. This premium Biofinity product has received excellent reviews, and we're confident we will have great success in this offering.
EMEA posted a solid quarter growing 3% year-over-year in constant currency against the tough comp. Growth was driven by Biofinity and the 1 Day silicone hydrogel franchise. Asia Pacific had a very strong quarter with 16% constant currency growth. Growth was strong throughout the region, driven by Biofinity and the 1 Day silicone hydrogel franchise. Within Japan, our MyDay sphere launch is progressing well, and we introduced MyDay toric during the quarter. We believe both MyDay sphere and toric have the potential to be a very successful premium offering in this market.
Turning to our product categories. Torics grew a healthy 10% year-over-year and multifocals grew 5%, both in constant currency. We remain the global leader in specialty lenses, and our success with Biofinity and clariti in both of these categories should continue to drive growth for many years.
Looking at silicone hydrogel lenses. These products grew 16% in constant currency and now represent 61% of our total sales. Within the 2-week and monthly space, Biofinity and Avaira combined to grow 11% in constant currency. We remain under-indexed for the 2-week and monthly silicone hydrogel space at 75% of revenue versus the market at 79%, so we expect to continue growing faster than the market given our strong product portfolio.
Regarding our silicone hydrogel 1 Day lenses, clariti and MyDay, they combined to grow 40% in constant currency. The biggest driver in the contact lens market is 1 Day growth, and we strongly believe we have the best product portfolio offering in this space as the only company with premium and mass market lenses, including a full portfolio of 1 Day silicone hydrogel, sphere, toric and multifocal lenses.
Now let me comment on the overall contact lens market. And remember, this information is on the last page of the earnings release. For the calendar quarter Q2, we continued taking share, growing 10% with the market up 5%. Geographically, CooperVision grew 8% in the Americas while the market was up 4%. In Asian Pacific, we grew 20% with the market up 4%. And in EMEA, we grew 9% with the market up 7%. On a modality basis, single-use lenses continue driving growth with CooperVision up 18% and the market up 10%. For non-silicone hydrogel -- for non-single-use lenses, we grew 7% while the market grew 1%.
As you can see, our growth remains diverse and strong. On a trailing 12-month basis, CooperVision grew 8% and the market grew 5%. Going forward, I expect the market to continue growing 4% to 6% over the next 5 years and most likely closer to 6%. The drivers will continue to be the shift to daily geographic expansion and the expansion of the wearer base. We expect to continue taking market share led by our strong silicone hydrogel portfolio.
Moving to CooperSurgical. We reported Q2 revenues of $105 million, up 38% year-over-year, driven by strong organic growth and acquisitions. On a pro forma basis, growth was up 6%.
Our fertility products led the way, up 108% or 10% pro forma. Within fertility, we had growth throughout the business and continue to believe our market-leading product portfolio, which includes medical devices, genetic testing and capital equipment, is the broadest portfolio in the space and should continue to drive growth for many years to come.
Within our office and surgical category, our growth moderated slightly from the last few quarters, up 3%. We're continuing to execute on several product launches, including our disposable hysteroscope EndoSee, and we believe we will -- we're well positioned in this segment going forward.
Regarding acquisitions, we've been actively working on integrating the deals we've done over the past year, and the strategic rationale behind these deals remains intact. We are very focused on becoming a full-service provider within the global IVF space.
Finally, on CooperSurgical, we're continuing to execute on several initiatives, which should significantly strengthen the business and pay dividends for many years to come. These include transitioning to a geographic sales model, adding sales reps in under-penetrated areas, launching products in new markets and increasing our focus on high-growth areas such as IVF genetic testing. To some degree, these investments are masking all our strong underlying operating performance, but it's critical that we lay the groundwork to support the business on a long-term growth -- from a long-term growth perspective.
Now turning to guidance. I'll let Greg go through the details, but let me touch on a few items. For Q4, we're guiding CooperVision to roughly 5% to 7.5% constant currency growth and CooperSurgical roughly to 5% to 8% pro forma growth. So similar growth to Q3. Regarding non-GAAP earnings per share for Q4, we're guiding to $2.15 to $2.30. Regarding fiscal 2017, it's too early to provide financial guidance, but I will say it should be a strong year given the momentum in our 2 businesses as well as recent currency moves. From a longer-term perspective, we're still targeting operating margins of 27% or higher in 2020.
In conclusion, I want to express my appreciation to our employees for all their hard work and dedication. I also want to say a special thank you to Greg Matz, who has announced his planned retirement after more than 6 years of service of our company, including roughly the last 5 years as our CFO. Greg will be greatly missed and we wish him the best in his future endeavors. With Greg's departure, we have announced that Al White, who many of you know really well, will succeed Greg as CFO. Al will assume this role in addition to his current leadership responsibilities with CooperSurgical. I am very confident that his leadership and abilities will allow us to continue driving long-term shareholder value. From a timing perspective, Greg will remain CFO until the end of the fiscal year, and then Al will take over the position. Greg will remain with us through March of next year to ensure a smooth transition.
And now I'll turn it over to Greg to cover our financial results."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thanks, Bob, and good afternoon, everyone. Bob provided overall summary of our performance, including a review of the market and our revenue picture. I'm going to focus primarily on our non-GAAP results for the quarter. For the reconciliation to GAAP numb",1175,"Thanks, Bob, and good afternoon, everyone. Bob provided overall summary of our performance, including a review of the market and our revenue picture. I'm going to focus primarily on our non-GAAP results for the quarter. For the reconciliation to GAAP numbers, please refer to our earnings release.
Looking at gross margins. In Q3, the non-GAAP gross margin was 63.6% compared with 62.4% in the prior year. This increase is largely due to a favorable mix led by Biofinity and favorable FX offset by recent CSI acquisitions, which have lower gross margins. CooperVision on a non-GAAP basis reported gross margin of 64.2% versus 61.8% in Q3 of last year. The factors which impacted margin were the items I just mentioned. CooperSurgical had a non-GAAP gross margin of 61.2%, which compares to Q3 '15 of 65.4%. Acquisitions in the genetic testing space were the primary drivers for this reduction.
Now looking at operating expenses. On a non-GAAP basis, SG&A increased approximately 8% to $179.7 million or 35% of revenue, down from approximately 36% of revenue in the prior year. The primary driver behind this drop was strong spending controls as we had leverage in both CooperVision and CooperSurgical.
Now looking at R&D. In Q3, R&D on a non-GAAP basis decreased 2% to $16 million or 3.1% of revenue, down from 3.5% of revenue in the prior year. The primary driver is the leverage we're seeing from the Sauflon acquisition.
Moving to operating margins. For Q3, consolidated GAAP operating income and margin were $102.7 million and 19.9% of revenue versus $50.3 million and 10.9% of revenue in Q3 last year. Non-GAAP operating income and margin were $131.6 million and 25.6% of revenue versus $106.1 million and 23% of revenue for the prior year. The primary difference in the operating margin year-over-year is improved gross margins and operating expense leverage. In Q3, CooperVision's non-GAAP operating income and margin were $119.4 million and 29.1% of revenue versus $97.7 million and 25.3% of revenue in the prior year. CooperSurgical's non-GAAP operating income and margin were $23.5 million and 22.4% of revenue versus Q3 '15 of $19.5 million of operating income and 25.6% of revenue.
Looking at depreciation and amortization. In Q3, depreciation was $33.9 million, down $7.5 million year-over-year. Amortization was $15.6 million, up $3.1 million, reflecting our recent acquisition activity. Interest expense was $8 million for the quarter, up $3.3 million year-over-year, primarily due to higher debt interest rates associated with acquisitions.
Looking at the effective tax rate. In Q3, the non-GAAP effective tax rate was 7.7% versus a non-GAAP effective tax rate of 3.1% in Q3 '15. As a reminder, in the prior year, we had a higher dollar amount of Q3 discreet items related to prior years, which reversed in that quarter.
On earnings per share, our Q3 earnings per share on a GAAP and a non-GAAP basis was $1.79 and $2.30, respectively, versus $0.91 and $1.97 for GAAP and non-GAAP in the prior year.
Looking at some balance sheet and liquidity items. In Q3, we had cash provided by operations of $128.9 million with capital expenditures of $31.1 million, resulting in $97.8 million of free cash flow. Excluding integration cost of $6.5 million, adjusted free cash flow was $104.3 million. Total debt increased slightly within the quarter by $2.7 million to $1,444,100,000, primarily due to higher average cash balances and acquisitions, largely offset by operational cash flow generation.
Inventories decreased by approximately $3.3 million to $430.3 million from last quarter. In CooperVision, we saw overall inventory decline as growth in silicone daily inventory to support our product launches was offset by a reduction in our hydrogel inventory. In CooperSurgical, we saw a small increase largely due to new acquisitions. For the quarter, we're seeing month on hand at 6.5 months, down from 7 months last quarter. Days sales outstanding is at 54 days, same as last quarter and down 1 day from the prior year.
Now turning to guidance. For our main currencies, we're using 1.10 for the euro, 104 for the yen and 1.30 for the pound.
And looking at the full year. The consolidated revenue range is being raised on the low end to reflect our Q3 performance and is now $1.944 billion to $1.957 billion or approximately 6% to 7% pro forma growth, up from the previous 5.5% to 7% range.
For the fourth quarter, CooperVision's revenue range is $390 million to $400 million or roughly 5% to 7.5% constant currency growth. And CooperSurgical's revenue range is $106 million to $109 million or roughly 5% to 8% pro forma growth.
We expect non-GAAP gross margin for the fourth quarter to be slightly over 64%, driven by a strong quarter for CooperVision. This would result in a full year gross margin around 63%. OpEx is expected to be slightly under 39% for the fourth quarter as well as for the full year. Operating margin is expected to be around 26% in Q4, which would result in the full year margin being in the mid-24% range. Interest expense is expected to be a little over $7 million in Q4 or slightly over $28 million for the year. Our effective tax rate guidance is the same as last quarter. Thus, a full year rate of around 8% translates to 10.5% to 11% in Q4. Our expected share count is around 49.1 million shares. Our non-GAAP earnings per share is expected to be $2.15 to $2.30 in the fourth quarter, which equates to $8.32 to $8.47 for the full year.
From our last earnings call, currency was a positive in Q3, helping roughly $0.04. But we are expecting a negative impact in Q4 of roughly $0.02 from our previous guidance. Unfortunately, some of the positives we experienced in Q3 from currencies such as the yen and the euro are now being more than offset by the move in the pound since Brexit occurred in late June. As Bob mentioned, if currency holds, we should see a lot of benefit next year led by cost of goods as roughly 40% of CooperVision's product is manufactured in pounds with roughly a 6-month lag to the P&L. To be clear, this is roughly 40% of CooperVision's manufacturing, so on a consolidated basis, this is roughly 30% of our total cost of goods. Also note, the pound move associated with Brexit occurred in late June, so this positive impact starts in January, so a more muted positive impact in fiscal Q1 versus the remainder of the year.
The other point to note, as I mentioned earlier, is our effective tax rate guidance remains unchanged, which means a Q4 tax rate range of about 10.5% to 11%. Regarding cash flow, our CapEx was low this quarter but we do expect around $50 million in Q4, so around $170 million of CapEx for the year now. This should result in free cash flow over $300 million and adjusted free cash flow when excluding integration-related activity of well north of $300 million.
With that, let me turn it back to Kim for the Q&A session."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thank you, Greg. Operator, we're ready to take some questions.",10,"Thank you, Greg. Operator, we're ready to take some questions."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","[Operator Instructions] Our first question comes from the line of Jeff Johnson from Robert W. Baird.",16,"[Operator Instructions] Our first question comes from the line of Jeff Johnson from Robert W. Baird."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Greg, I just want to say it's been great working for you -- or working with you, not for you, but working with you for the last few years. And best of luck in the future. And Al, plus or minus, we'll see how it goes here over the next few years. That was",162,"Greg, I just want to say it's been great working for you -- or working with you, not for you, but working with you for the last few years. And best of luck in the future. And Al, plus or minus, we'll see how it goes here over the next few years. That was a joke. And so, Bob, I just want to start with you just on kind of the monthly trend here. It's always tough to read CLI data and try to translate that given the off 1 month, how your fiscal quarter closes. But if I look, it looks as if maybe the forward month slowed a little bit. Looking at CLI data versus your reported number for the quarter, there has been some question of utilization issues out there. So just any color you can give us on kind of the monthly gating of what you have been seeing in the industry here over the last few months."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes. Good question, Jeff. And yes, that's kind of jumped off the page a little, that July must have been soft relatively speaking. There's really primarily but one answer to that, and it's an industry-wide answer but not for the reasons most people would",198,"Yes. Good question, Jeff. And yes, that's kind of jumped off the page a little, that July must have been soft relatively speaking. There's really primarily but one answer to that, and it's an industry-wide answer but not for the reasons most people would think. Rarely in the past have we talked about workdays in a month, but in this case, I'll highlight the fact that in July this year, there were 19 workdays compared to 22 last year because of the way weekends fell. And that translates to about a 17% -- 16%, 17% reduction in revenue if you had the same revenue per day or the orders per day. So pretty profound impact that weighted heavily because of the anomaly of the way weekends fell. Conversely, you get some of that back in August. Relative to the full quarter however, probably the best way to look at it is, workdays were down 3% this year in the third quarter, and they'll be up 1.5% in the fourth quarter. So there's one more workday in the fourth quarter. So it smooths out within the quarter, but there is an anomaly between July and August caused by workdays."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Brian Weinstein from William Blair.",14,"And our next question comes from the line of Brian Weinstein from William Blair."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Can you guys just talk a little bit about what you're seeing, obviously, from the competitive launch from J&J. And then also, you have a couple of launches in the FRP space. How are you seeing that kind of 2-week and monthly space playing out at this poin",66,"Can you guys just talk a little bit about what you're seeing, obviously, from the competitive launch from J&J. And then also, you have a couple of launches in the FRP space. How are you seeing that kind of 2-week and monthly space playing out at this point? And any color you can talk about with respect to the just the competitive launch in general."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, the competitive launch, J&J has been active in taking OASYS 2-week, which was their sweet spot, and expanding it into a 1 Day -- a 1-week and then a 1 Day. And now they're moving with a different package into the monthly modality with VITA. The amoun",506,"Yes, the competitive launch, J&J has been active in taking OASYS 2-week, which was their sweet spot, and expanding it into a 1 Day -- a 1-week and then a 1 Day. And now they're moving with a different package into the monthly modality with VITA. The amount of push they put behind VITA out of the gate [ph] was nothing compared to a year ago when they launched the OASYS 1 Day modality. So a lot more muted. Having said that, they're one of the more active ones in the space, albeit leveraging their OASYS franchise, if you will. Interestingly, they still do not call OASYS 1 Day a silicone hydrogel lens. But as we all know, it is a silicone hydrogel lens. As I think I indicated in the past, it was my belief that there would be some swapping of the 2-week noncompliant into the monthly compliant, which in essence is a clever way of saying it's a trade-up strategy, and I think we're seeing more and more of that as they're trying to continue the deceleration or the negative growth of the 2-week space, which they own 90% of, and migrate it into more profitable buckets. And there is no doubt profitable bucket means the 1 Day modality, but quite frankly, their strategy is not shortsighted, so to speak, when it comes to monthly price point yields more revenue than a 2-week noncompliant. And most -- the vast majority of the 2-week wearers are noncompliant. As far as our product in the non-1 Day space, we rolled out initially Biofinity Energys. It's getting -- it's very early in the game, but so far so good. There's a lot of excitement about a novel win that really addresses people with iPhones and being in front of screens -- TV screens and computer screens professionally. So there's a lot of interest by the eye care professionals that we have engaged in discussion thus far. We also are -- got approval to launch Vitality in the 2-week space. And Vitality is targeted to replace our low gross margin Avaira product in the 2-week space. That low gross margin came about a number of years ago when we had a recall and had to change the manufacturing technique, which became very cumbersome. So it is a significant step-up in gross margin, and it's very early in that launch. I think it was late July. And the intent there is, it will probably take us 2 to 3 years to roll out the entire family of the toric and the sphere worldwide in this migration. The sphere will go faster, and the majority of the Avaira product line is -- 70% of it or more is the sphere side. So that one will show up quicker. But it's an inventory turn. And when you have toric, it takes longer to transition, if you will, that. So we're excited about that. And then, of course, we have all the action that's going on in the 1 Day space."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Jon Buck from Stifel.",12,"Our next question comes from the line of Jon Buck from Stifel."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Maybe 2. I'll ask them both upfront. The CSI margins, Greg, were down, a decent sequential pullback from fiscal Q2 results. Not asking for guidance for next year, but is sort of the 61% gross margin the right place to be, looking forward when we think abo",109,"Maybe 2. I'll ask them both upfront. The CSI margins, Greg, were down, a decent sequential pullback from fiscal Q2 results. Not asking for guidance for next year, but is sort of the 61% gross margin the right place to be, looking forward when we think about the recent acquisitions weighing on the margin a bit? And then separately, for CVI, Bob, can you just talk to the EMEA market? I mean, you're gaining a lot of share in APAC and you seem to be well positioned in the U.S. The gains seem to be accelerating. Can you talk about what you're seeing in the EMEA market regarding share?"
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Jon, on the gross margin, I think what you should expect to see is 61% is a low point. You should see it be a little bit higher than that. And again, the base business will kick in a little bit. The new acquisitions come with a lower gross margin, and so",62,"Jon, on the gross margin, I think what you should expect to see is 61% is a low point. You should see it be a little bit higher than that. And again, the base business will kick in a little bit. The new acquisitions come with a lower gross margin, and so that so you did see that pressure, especially in Q3."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","As far as the EMEA market, we continue to gain share there, and happy to say we're right on the heels of the #1 player there, which is Alcon, in the market. And that happens to be the part of the world where we have the highest market share in EMEA. Our o",165,"As far as the EMEA market, we continue to gain share there, and happy to say we're right on the heels of the #1 player there, which is Alcon, in the market. And that happens to be the part of the world where we have the highest market share in EMEA. Our overall market share is 23%. But in Europe, it's 33%, contrasted to where we're the weakest yet, but growing fast in Asia Pac. So the market there remains focused in on the 1 Day modality. Eastern Europe continues to be a robust area. And then the Biofinity continues to charge very nicely there. And then, of course, the other thing is the U.S. market was the first one to arrive with specialty lenses, torics and multifocals. And now the rest of the world, including EMEA, is catching up. So you have a more robust market there, which plays to Cooper's strengths, recognizing we're #1 in the world in the specialty lens area overall."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Matt Mishan from KeyBanc.",13,"And our next question comes from the line of Matt Mishan from KeyBanc."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Bob, could you give us a sense of what is driving the double-digit growth in Asia Pac? And with MyDay being a bigger piece over there going into next year, is double-digit growth sustainable for a little bit? And then can you talk a little bit about what",64,"Bob, could you give us a sense of what is driving the double-digit growth in Asia Pac? And with MyDay being a bigger piece over there going into next year, is double-digit growth sustainable for a little bit? And then can you talk a little bit about what you see as the opportunity for MyDay toric in Japan and why you launched there first?"
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Sure. First of all, double-digit in Asia Pac is somewhat a reflection of our immaturity in that market with a fabulous product portfolio. So we have a great product portfolio. A lot of it emanated out of EMEA. So it started in Europe and it came to the U.",294,"Sure. First of all, double-digit in Asia Pac is somewhat a reflection of our immaturity in that market with a fabulous product portfolio. So we have a great product portfolio. A lot of it emanated out of EMEA. So it started in Europe and it came to the U.S. And really, Asia PAC is the last to get it all. In addition, we were clearly under-indexed overall in that market. We have invested over the last 3 or 4 years heavily in some areas like China and the surrounding geographic area. So we're starting to get momentum there. As far as MyDay in Japan, MyDay is a 1 Day product. There are silicone hydrogel players in the Japanese market. TruEye started there, so in essence, the silicone hydrogel market really started for all practical purposes in Japan. The beauty of having a MyDay toric in Japan, first of all, we have clariti available in the rest of the world. clariti has a sphere, a toric and a multifocal. In Japan, we only have MyDay at this juncture, and having a toric to go along with it has a halo effect. We will be the only one in the Japanese market with a silicone hydrogel sphere and a toric. While the toric market is not as mature as even the European market, it's early in the cycle there. It is a nice halo effect. A lot of practitioners want it, and particularly more so some of your independents in Japan. So it's a good story with not only the large retailers that exist there but also the independents. So yes, I do expect that we will put up robust numbers going forward, double-digit numbers, certainly in many quarters going forward in the Asia Pac marketplace."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Matt O'Brien from Piper Jaffray.",15,"And our next question comes from the line of Matt O'Brien from Piper Jaffray."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","This is actually, JP in for Matt. I just wanted to dig deeper on gross margins. And I know you're not giving guidance for 2017, but you've got a lot going on. You've got a weaker British pound, which as you said, after 6 months, once you work through inve",175,"This is actually, JP in for Matt. I just wanted to dig deeper on gross margins. And I know you're not giving guidance for 2017, but you've got a lot going on. You've got a weaker British pound, which as you said, after 6 months, once you work through inventory, you'll see a benefit there. And then clariti, as it continues to ramp, should be accretive to [indiscernible] gross margin. You just launched a 2-week product. That has better gross margins as well. So I'm just trying to think of -- is there any reason why we can't get above 65% next year? And then just a longer-term question on gross margin, I mean, when you did the Sauflon acquisition, you've kind of gotten this ability of doing silicone hydrogel without having the need for alcohol in the manufacturing process. And just trying to think of when you can take that manufacturing ability and start launching your own organic products with that kind of unique process and when we should expect some products like that."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","On the gross margin, you've covered a lot of the points that they are obviously some tailwinds in -- where clariti is coming in at far better than we first thought when we bought the company. The pound, as we mentioned, will -- especially with the pound a",157,"On the gross margin, you've covered a lot of the points that they are obviously some tailwinds in -- where clariti is coming in at far better than we first thought when we bought the company. The pound, as we mentioned, will -- especially with the pound at these rates, as I mentioned in the earlier comments, will have a nice impact going forward. At the same time, again, we are -- you saw the acquisitions that CooperSurgical is doing, and that will have some impact on the overall gross margins because as you get into more lab-based businesses, they're going to come with lower gross margins. And so as you said, we're not giving guidance for next year. You've seen the gross margins start to edge up throughout the entire year, so you can see that where we're looking at being in the fourth quarter is, again, higher than where we were in the third quarter."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","And I think just on the comment on the Sauflon platform, yes, we're ecstatic about the alcohol-free nature of it and the fact that it's so flexible that we have the sphere, the toric and the multifocal to leverage. We're ecstatic by the fact that we were",134,"And I think just on the comment on the Sauflon platform, yes, we're ecstatic about the alcohol-free nature of it and the fact that it's so flexible that we have the sphere, the toric and the multifocal to leverage. We're ecstatic by the fact that we were able to ramp up very quickly, and therefore, we're not capacity constrained. So that is clearly a tailwind in a high gross margin area. However, I would agree with Greg's point that with the surgical acquisitions that we have made and with surgical now in around 61%, going up a little from there, there is a mix headwind that comes into play. So directionally, you're right, there's a tremendous amount of tailwinds to help us out. And we'll see where that all ends down on the road."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","Our next question comes from the line of Joanne Wuensch from BMO Capital Markets.",14,"Our next question comes from the line of Joanne Wuensch from BMO Capital Markets."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Congratulations to Greg and Al. Multipart questions. First -- 2 multipart questions. FX. We all saw the surge in the stock price after the Brexit moment, and so I'm sort of curious what you're thinking of the FX impact maybe for 2017, without giving guida",151,"Congratulations to Greg and Al. Multipart questions. First -- 2 multipart questions. FX. We all saw the surge in the stock price after the Brexit moment, and so I'm sort of curious what you're thinking of the FX impact maybe for 2017, without giving guidance, but maybe as a contributor, so that we sort of get our heads around it with no surprises when you do give guidance. The second part of that question has to do with what was the FX impact on EPS in the third quarter and the current thinking for the full year? And then my second question has to do -- more big picture. We've all been very worried and very focused about J&J's product launches, and while Seva and Bausch have struggled, is there anything that you see coming down sort of the pike that we need to be aware of as we look forward?"
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Okay. Joanne, I'll jump in on the FX questions real quick. So from a third quarter perspective, if you look at the actuals, we had a $0.06 benefit year-over-year. And that was about $0.04 above what we had guided to, or what was in our guidance in Q3 -- o",258,"Okay. Joanne, I'll jump in on the FX questions real quick. So from a third quarter perspective, if you look at the actuals, we had a $0.06 benefit year-over-year. And that was about $0.04 above what we had guided to, or what was in our guidance in Q3 -- or I'm sorry, Q2. If you look for the full year, we're looking at -- FX is about flat. It's about up $0.02 for the full year, year-over-year. You talked about Brexit. One of the things to keep in mind, and I mentioned that in the script, is when it hit. It hit in late June. So we would start to see the benefit of that really coming in, in January. So Q1 will get a little bit of the benefit, and then provided the rates stay where they're at, you'll get that benefit throughout the rest of the year. So it's a nice benefit. From a CooperVision perspective, about 40% of our COGS are in pound-based manufacturing. And that's 30% roughly for the total company. So you'll see that flow through again a good part of next year provided the pound stays at about these rates. It's definitely down quite a bit from prior years, and that's -- we win more on -- when that happens from a pound perspective, we win more on the manufacturing than we lose on the revenue. But in the short term like Q4, we actually get impacted by the revenue first and the benefit will come out outside of this fiscal year."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","As far as some of the product launches of J&J, when we look at J&J, B&L and Alcon, J&J is that one that probably has their act together, the best of the 3. And Alcon obviously is still in a remaking mode. B&L is in a remaking mode, changing their structur",557,"As far as some of the product launches of J&J, when we look at J&J, B&L and Alcon, J&J is that one that probably has their act together, the best of the 3. And Alcon obviously is still in a remaking mode. B&L is in a remaking mode, changing their structure yet again, I think. And J&J, with a fairly weak product portfolio, is a good marketing company. And so I would compliment them on making the best of the product portfolio they have. Some of their programs, the whole disruption they've caused in the marketplace over the last 2 years with directionally going all the way with UPP and then directionally going the other way, they've taken some bumps in terms of their messaging. So one day they're saying to you, ""We're the friend with the independents with these products."" And then the next day, they are saying, ""Well, we have a different story to tell you, but it's not going to be UPP."" So there is no doubt there's some reaction to that. As far as VITA, for example, their new product launch in the monthly space, very much it's moving into a space where it's going against some franchised products, and Biofinity is a franchised product. And Biofinity is the product that has a toric, a sphere and a multifocal. Plus now it has things like Energys, which is an enhanced product for people that -- like 99% of the people on the planet, are using more and more technology. So I don't expect them to get too robust about that. I do think that's a lot different than what they did a year ago with OASYS 1 Day where they basically said, ""We want to participate in the shift of silicone hydrogel wearers, leaving the 2-week space and catch some in the 1 Day market with a huge trade-up."" So they're playing out that strategy. To a large degree, they cannibalize TruEye in the U.S., not worldwide but in the U.S. And OASYS 1 Day and TruEye and MyDay are giving the competition, in this case Alcon's TOTAL1, a run for their money. Now Alcon got out there first when there was only one competitor in that space, which was TruEye. J&J knew that was a deficient product in the U.S., and I'm not sure why in the U.S. when it actually has done pretty well historically in Japan. But for whatever reason, the U.S., it's a weaker product. So product rollouts, we hear a lot of noise about B&L on ULTRA, which is their answer to trying to refresh the product line for monthly products, monthly silicone hydrogel products. They've gone and expanded now, I think, from beyond a sphere. But a lot of what B&L is doing is capturing some of their legacy products, so PureVision and SofLens 66. So when you put it all together, B&L has some new products, ULTRA, but it's about holding breakeven with the entire product portfolio, including the fall-off of their legacy products. So worldwide, I think the last quarter, they're probably 1% to 2% growth. So they would have lost some margins here last quarter. Alcon, likewise, came up with 2% numbers in a market growing 5%. So they lost share, so the gainers were Cooper and with a robust 10% in J&J."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Larry Biegelsen from Wells Fargo.",14,"And our next question comes from the line of Larry Biegelsen from Wells Fargo."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Congratulations, Greg and Al. Just my multipart question here. Bob, is it safe to assume that August bounced back from what sounds like a weak July because of the day count? Second, on 2017, you guys have historically given some color. Even last year you",125,"Congratulations, Greg and Al. Just my multipart question here. Bob, is it safe to assume that August bounced back from what sounds like a weak July because of the day count? Second, on 2017, you guys have historically given some color. Even last year you did on EPS. Is it safe to assume that you're pretty comfortable with consensus top and bottom line at this point, roughly speaking? Otherwise, you would -- if there was something out of whack, you would call it out? And lastly, the inventory write-offs and the idle equipment charges we saw in fiscal Q2, which resulted in that $0.30 hit, should we -- are those over? Or do you expect more of those either in the fourth quarter or 2017?"
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","All right. First question on August and July, yes, it's safe to assume that the anomalies between the weak July and August have to do with workdays, not anything ingrained in the marketplace. Relative to 2017 where we indicated we're not prepared at this",351,"All right. First question on August and July, yes, it's safe to assume that the anomalies between the weak July and August have to do with workdays, not anything ingrained in the marketplace. Relative to 2017 where we indicated we're not prepared at this juncture to put specifics on the line, no, we wouldn't comment one way or the other on what consensus is out there. I would highlight, however, that some of the analysts have more aggressive foreign exchange rates. And some analysts maybe -- I think Greg kind of hit the nail on the head. Some of the models on the impact of the pound, et cetera, emphasizing that it's on 30% of our worldwide instead of 40% of our worldwide cost of goods is an important attribute. So hopefully, we gave some color for people to sharpen the pencil with their models, in some case. But beyond saying there's a lot of tailwinds that we're standing by and happy with. And the foreign exchange rates will be whatever they are, and they change literally by the hour. We're not going to add any more color at this juncture. As far as the 10-10-10 hit, $0.10 in the second quarter, $0.10 in the third quarter, $0.10 in the fourth quarter, due to idle equipment and inventory write-offs that were over and above normal, they are in the numbers. There are other write-offs that are routine, and they continued throughout 2016 and will continue throughout 2017. Directionally, we indicated that a lot of those call-out charges are associated with some of our improving efficiency a lot more than we thought. So that led us to idling some equipment. So directionally, you can see the growth numbers in our 1 Day silicone hydrogel franchise of 40%. That certainly will go towards improving absorption. And importantly, when something goes from idle to use in production, it goes from a direct period charge, which is what the 10-10-10 is about, to -- suddenly it moves on to the balance sheet when it's making inventory. So that will continue throughout 2017, if you will."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Larry Keusch from Raymond James.",14,"And our next question comes from the line of Larry Keusch from Raymond James."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Also congrats to Greg and to Al. I guess, again, a 2-part financial question here. On the CapEx, I mean, if you go back and look, it tends to be cyclical. And you do get into periods where there is investment as you guys bring out new lines and expand cap",186,"Also congrats to Greg and to Al. I guess, again, a 2-part financial question here. On the CapEx, I mean, if you go back and look, it tends to be cyclical. And you do get into periods where there is investment as you guys bring out new lines and expand capacity. There are also periods of time where you grow into that capacity, and in this case, you've got some of these idle equipment sitting around now that will add to that. So I just wanted to get your take on where you think CapEx can go here over the next several years. I think you said $170-ish million for this year. But where does it go? And how does that translate to free cash flow generation? And I guess along with that, should we expect no additional Sauflon integration charges next year? And then the other part of the question is I think certainly the odds of an interest rate increase have gone up, and we can see something coming in this month. And how are you thinking about that? And what's built into guidance?"
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, a few things on that. The cyclicality of the CapEx spend, you're absolutely right, we ramped up for Biofinity and Avaira in the last decade. We were very capital intense. We got real efficient. We ramped down. And then all of a sudden, particularly",418,"Well, a few things on that. The cyclicality of the CapEx spend, you're absolutely right, we ramped up for Biofinity and Avaira in the last decade. We were very capital intense. We got real efficient. We ramped down. And then all of a sudden, particularly with the Sauflon acquisition and with MyDay rollout of silicone hydrogel 1 Day, we became very capital intense again over the last several years. And lo and behold, we got real efficient, and here we are again, a little ahead of ourselves in the perfect world. The translation there is we think we have a pretty long runway on improving efficiencies that will continue over the next several -- multiple years, and that will be somewhat of a cap on CapEx requirements. We've taken the CapEx needs this year from $200 million down $30 million to $170 million. The outlook for post-2016 will be for less than that. We're thinking in that $150 million range. So year-over-year, a reduction of -- in that $50 million range. When you look at cash flow, we've now taken our -- should get to $300 million to a lot stronger statement above $300 million. So we're $300 million headed towards $400 million. No real change in that signal on that going forward. There is, in my opinion, multiple years of runway on some of those efficiencies that we're talking about. As far as Sauflon or interest charges, the -- what's built into our thinking is given that we have solid cash flow generation, we see that as part of a minimizer. So when you have $1.4 million in debt worldwide, you're generating $300 million to $400 million in cash flow that will serve to offset. We do expect that probably between now and year-end, there will be some movement in rates, and of course, we've only guided through year-end. So at this juncture, we haven't really guided -- if the Treasury goes crazy, then that will obviously influence the guidance we come out with in December. But I think between foreign exchange volatility and interest rates, depending on who's got their mouth open on a given moment out there, it seems like the government is very -- more proactive in trying to direct economic thinking, which is a detriment, I think, overall because it does create uncertainty in volatility. But we're still on a low inflationary modality. We can all speculate and pretend we're autonomous. So stay tuned and we'll refresh what our thinking is in December."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Steve Willoughby from Cleveland Research.",14,"And our next question comes from the line of Steve Willoughby from Cleveland Research."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Congrats Greg and congrats Al. Just first on this year's guidance. Greg, if I heard you correctly, it sounds like FX was an incremental $0.04 positive forward [ph] here in the third quarter but an incremental $0.02 headwind versus what you're expecting fo",92,"Congrats Greg and congrats Al. Just first on this year's guidance. Greg, if I heard you correctly, it sounds like FX was an incremental $0.04 positive forward [ph] here in the third quarter but an incremental $0.02 headwind versus what you're expecting for the fourth quarter. So I'm just trying to correlate that to your -- the guidance, the updated full year guidance you've given where you brought down the high end just a little bit, if it looks like net-net FX is about an incremental $0.02 positive to your previous guidance."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, the last time we gave guidance, we talked it being about a wash. And net-net, you're right, it's a $0.02 positive for '16 at this point year-over-year.",28,"Yes, the last time we gave guidance, we talked it being about a wash. And net-net, you're right, it's a $0.02 positive for '16 at this point year-over-year."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","So what's the driver to the reduction, I guess, of the full year guidance then?",16,"So what's the driver to the reduction, I guess, of the full year guidance then?"
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","The reduction to the full year guidance?",7,"The reduction to the full year guidance?"
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Correct, yes. I mean -- sorry, go ahead, Bob.",9,"Correct, yes. I mean -- sorry, go ahead, Bob."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","That's only -- I was going to say, I'm not sure overall, against our guidance, we raised the midpoint of our guidance.",23,"That's only -- I was going to say, I'm not sure overall, against our guidance, we raised the midpoint of our guidance."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, we actually raised the midpoint by $0.04. $0.02 was the FX that we experienced and, then, $0.02 was related to probably an operational increase.",25,"Yes, we actually raised the midpoint by $0.04. $0.02 was the FX that we experienced and, then, $0.02 was related to probably an operational increase."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","So we took it up, not down.",7,"So we took it up, not down."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes on the line of Andrew Hanover from JPMorgan.",13,"And our next question comes on the line of Andrew Hanover from JPMorgan."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Congrats, Greg and Al. I wanted to go back to the fewer and extra selling days in the third quarter and expected in the fourth quarter. And what was the impact on growth in the third quarter? And what are your [indiscernible] for the fourth quarter?",46,"Congrats, Greg and Al. I wanted to go back to the fewer and extra selling days in the third quarter and expected in the fourth quarter. And what was the impact on growth in the third quarter? And what are your [indiscernible] for the fourth quarter?"
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, if you took work days in the quarter, it would be a 3% headwind in Q3 and a 1.5% tailwind in Q4, all other things being equal.",28,"Yes, if you took work days in the quarter, it would be a 3% headwind in Q3 and a 1.5% tailwind in Q4, all other things being equal."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Steven Lichtman from Oppenheimer.",13,"And our next question comes from the line of Steven Lichtman from Oppenheimer."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Two questions. Bob, within your 1 Day silicone hydrogel franchise, in the recent period here, last few months, is the incremental contribution from MyDay and clariti pretty balanced? Or has one been contributing more incrementally over the past few months",88,"Two questions. Bob, within your 1 Day silicone hydrogel franchise, in the recent period here, last few months, is the incremental contribution from MyDay and clariti pretty balanced? Or has one been contributing more incrementally over the past few months? And where do you see now the mix going between those 2 products over time? And then, Greg, the tax rate popping up here in the fourth quarter, why are we going to see that move higher? And any change in your thoughts on tax rate beyond '16?"
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","So on the mix of MyDay and clariti, obviously, MyDay is off of a smaller base. So its percentages are higher. And clariti, which has a big European franchise, has a bigger hurdle. clariti is still the one that is targeting the mass market, and therefore,",122,"So on the mix of MyDay and clariti, obviously, MyDay is off of a smaller base. So its percentages are higher. And clariti, which has a big European franchise, has a bigger hurdle. clariti is still the one that is targeting the mass market, and therefore, will always be most likely the bigger product. It's the one with the toric and the multifocal, which also will make it the bigger product. So it's still about, I don't know, 70-30-ish. However, with MyDay off of a lower base going into Japan, you may see it, as that rollout occurs, take over somewhat bigger portion of the pie given Japan is such a huge 1 Day market. I guess, Greg, on the tax rate?"
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, on the tax rate, since the March guidance, we've been guiding to the 8% for the year, around 8%. And so we're still holding to that. And when you look at it, things have been choppy, and it also depends, a lot of times, when discretes are released. T",114,"Yes, on the tax rate, since the March guidance, we've been guiding to the 8% for the year, around 8%. And so we're still holding to that. And when you look at it, things have been choppy, and it also depends, a lot of times, when discretes are released. This year, we had discretes released in Q1 where normally it's Q3. Typically, Q4 is a higher quarter. Last year was an exception to that, and that was based on a lot of work around the integration and restructuring cost, which allowed deductions. So the Q4 rate being in that 10.5% to 11% is probably the more typical outside just the last year or so."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","Thank you, and that concludes our question-and-answer session for today. I would like to turn the conference back over to Bob Weiss for any closing comments.",26,"Thank you, and that concludes our question-and-answer session for today. I would like to turn the conference back over to Bob Weiss for any closing comments."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, I want to once again thank Greg for 6 great years and wish him the best going forward. He will be around, as we indicated, throughout the transition period, throughout the rest of this calendar year. And importantly, we look forward to updating you",107,"Well, I want to once again thank Greg for 6 great years and wish him the best going forward. He will be around, as we indicated, throughout the transition period, throughout the rest of this calendar year. And importantly, we look forward to updating you on our year-end results in December. And I think the date there is December 8, if I'm not mistaken. And a lot of good stuff going on, so we look forward to giving you an update on that. Everyone, have a great Labor Day weekend. And summer has come and summer has gone already and life goes on. With that, we'll conclude."
263609,378695672,1040956,"The Cooper Companies Inc., Q3 2016 Earnings Call, Sep 01, 2016",2016-09-01,"Earnings Calls","The Cooper Companies, Inc.","Operator","Thank you. Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program, and you may now disconnect. Everyone, have a great day.",28,"Thank you. Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program, and you may now disconnect. Everyone, have a great day."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Cooper Companies Incorporated Fourth Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to introduce your host for today",49,"Good day, ladies and gentlemen, and welcome to the Cooper Companies Incorporated Fourth Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to introduce your host for today's conference, Miss Kim Duncan, Vice President. Ma'am, you may begin."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Good afternoon. And welcome to the Cooper Companies' Fourth Quarter and Full Year 2016 Earnings Conference Call. I'm Kim Duncan, Vice President of Investor Relations, and giving prepared remarks on today's call are Bob Weiss, Chief Executive Officer; and",317,"Good afternoon. And welcome to the Cooper Companies' Fourth Quarter and Full Year 2016 Earnings Conference Call. I'm Kim Duncan, Vice President of Investor Relations, and giving prepared remarks on today's call are Bob Weiss, Chief Executive Officer; and Al White, Chief Financial Officer and Chief Strategy Officer. 
Before we get started, I'd like to remind you that this conference call contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including all revenue and earnings per share guidance and other statements regarding anticipated results of operations, market or regulatory conditions and integration of any acquisitions or their failure to achieved anticipated benefits. Forward-looking statements depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Events that could cause our actual results and future actions of the company to differ materially from those described in forward-looking statements are set forth under the caption Forward-looking Statements in today's earnings release and are described in our SEC filings, including the business section of Cooper's annual report on Form 10-K. These are publicly available and on request from the company's Investor Relations Department. 
Before I turn the call over to Bob, let me comment on the agenda for the call. Bob will begin by providing highlights on the quarter, followed by Al who will then discuss the fourth quarter and full year financial results. We will keep the formal presentation to roughly 30 minutes then open the call for questions. We expect this call to last approximately 1 hour. [Operator Instructions]. Should you have any additional questions, please call our investor line at (925) 460-3663 or e-mail ir@cooperco.com. [ph] This call is being webcast and a copy of the earnings release is available through the Investor Relations section of the Cooper Companies website. And with that, I'll turn the call over to Bob for his opening remarks."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thank you, Kim, and good afternoon, everyone. Welcome to the fourth quarter and full year 2016 conference call. Let me start by saying I'm very proud of our accomplishments this quarter, including record revenue and free cash flow. We also delivered a ver",1188,"Thank you, Kim, and good afternoon, everyone. Welcome to the fourth quarter and full year 2016 conference call. Let me start by saying I'm very proud of our accomplishments this quarter, including record revenue and free cash flow. We also delivered a very strong fiscal year gaining share in the $7.2 billion contact lens industry, continuing our approach into the 1 Day silicone hydrogel space, expanding our Biofinity franchise and posting strong growth in our CooperSurgical business. We enter fiscal 2017 with strong momentum. We remain confident we will see market share gains in both of our businesses for the foreseeable future. 
Let me highlight 3 key points for the quarter. First, I'm pleased to report another strong quarter, with revenues over $5 million. This includes CooperVision reporting revenues over $400 million and CooperSurgical reporting revenues over $100 million. This resulted in non-GAAP earnings per share of $2.28 and free cash flow of $158 million. Second, CooperVision posted strong results in all key areas of its business, resulting in 10% as reported and 11% constant currency revenue growth. This includes 1 Day silicone hydrogel lenses growing 53% and 2-week and monthly silicone hydrogel lenses growing a combined 14%, both in constant currency. Third, CooperSurgical had another strong quarter, posting revenue growth of 20% or 6% pro forma. Fertility was a highlight, posting growth of 74% or 80% [ph] pro forma. Moving into the details. CooperVision reported fourth quarter revenue of $412 million, up 10% as reported and 11% in constant currency. This is the fastest CooperVision has grown in 11 quarters. The Americas grew 8% in constant currency with strengths in multiple categories including Biofinity and 1 Day silicone hydrogel lenses. Biofinity continues to be our workhorse and we began our launch in Biofinity Energys in mid-August to strong reviews. Our enhanced clariti lens is also performing well and MyDay had another very strong quarter. EMEA posted a very strong quarter, up 12% in constant currency. Growth was driven by Biofinity and our 1 Day silicone hydrogel franchise. Asia Pacific also had a very strong quarter, up 13% in constant currency. Growth is strong throughout the region, driven by Biofinity and our 1 Day silicone hydrogel franchise. Within Japan, our MyDay sphere and toric [ph] launch is progressing well. And while it's still early, we continue to believe MyDay can be a very successful premium offering in that market. 
Turning to product categories. Parts [ph] grew a healthy 14% and multifocals 10%, both in constant currency. We remain a global leader in specialty lenses, and our success in Biofinity and clariti in both of these categories should continue to drive growth for many years to come. 
Looking at silicone hydrogel lenses. These products grew 21% in constant currency and now represents 62% of our sales. We expect this strong growth to continue, given our product portfolio which includes Biofinity, Vitality, [ph] our newly launched 2-week product and our diverse 1 Day offering. And remember, the biggest driver in the contact lens market is the 1 Day growth, and we strongly believe we have the best product offering in this space as the only company selling premium and mass market silicone hydrogel lenses, including a portfolio of sphere, toric and multifocal lenses. We are also investing in sales and marketing to support our strong product portfolio. Forecasting new hires is always challenging, especially when you're evaluating opportunities around the world. But we believe CooperVision can add numerous sales reps and get a very nice return given our strong product platform, our capacity and our growth opportunities that we see. We believe this initiative -- we began this initiative in our fourth quarter and expect it to continue through fiscal 2017 and possibly into 2018. For competitive reasons, I won't get into many details but, suffice it to say, we carefully evaluate our hiring and expect to realize a solid return from this activity. 
Now let me comment on our overall contact lens market and remember, this information is on the last page of our earnings release. For calendar Q3 2016, we continue To taking share growing 6%, with the market up 1%. Geographically, CooperVision grew 3% in the Americas while the market was down 3%. In the EMEA, we were up 8%, and the market was up 7%. In Asia Pacific, we grew 9%, with the market up 3%. On a modality basis, single-use lenses continued driving growth, with CooperVision up 12% and the market up 8%. For non-single-use lenses, we grew 3% while the market declined 4%. As you can see, our growth remains diverse and strong. On a trailing 12-month basis, CooperVision grew 8% while the market grew 3%. Although the market remains choppy and hard to read at times, we continue to believe it will strengthen and grow towards [ph] 6% over the next 5 years driven by continuing shift to dailies, G rep expansion [ph] and an expansion of the wearer base. We expect to continue taking market share led by our strong portfolio of market-leading products. 
Moving to CooperSurgical, we reported fourth quarter revenues of $107 million, up 30% year-over-year, driven by organic growth and acquisitions. On a pro forma basis, we grew 6%. Fertility led the way, up 74% or 8% pro forma. Within Fertility, we had growth throughout the business and continue to believe our market-leading product portfolio which includes medical devices, genetic testing and capital equipment is the broadest portfolio in the space and should continue to drive growth for many years to come. 
Within our office and surgical category, growth was 5%. We're continuing to execute on several product launches, including our disposable hysteroscope EndoSee [ph], and we continue to see success in this area. Regarding other activity, we announced on November 6 that we acquired the Wallace [ph] portfolio from Smiths Medical [ph] for approximately $168 million. This is a great strategic fit with our existing global IVF portfolio as it brings the gold standard of embryo transport catheters [ph] along with several other premier products. Finally, CooperSurgical -- on CooperSurgical, we're busy integrating recent acquisitions but also executing on several initiatives which should significantly strengthen the business. These include transitioning to a global sales model, adding sales reps in underpenetrated areas, launching products into new markets and increasing our focus on high-growth areas such as IVF genetic testing. We have made a lot of progress in these areas over the past year and expect to continue -- even have more progress as we go forward.  
Now before I turn it over to Al, let me comment on a couple other items. We anticipate another strong year of revenue growth in 2017, including CooperVision growing 6% to 8% in constant currency and CooperSurgical growing 6% to 8% pro forma. We also remain bullish on our future and are updating our long-term objectives for operating margins of 28% and free cash flow generation of over $2 billion by 2021. 
In conclusion, I want to express my appreciation to our employees for all their hard work and dedication. And now I'll turn it over to Al to cover the financial results."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thank you, Bob, and good afternoon, everyone. Bob did an excellent job covering revenues, so I'll focus on the rest of our Q4 financial performance along with guidance. Most of my commentary will be on a non-GAAP basis, and a full reconciliation between o",745,"Thank you, Bob, and good afternoon, everyone. Bob did an excellent job covering revenues, so I'll focus on the rest of our Q4 financial performance along with guidance. Most of my commentary will be on a non-GAAP basis, and a full reconciliation between our GAAP and non-GAAP results is included in today's earnings release. 
For the quarter, gross margins were slightly over 64%, with both CooperVision and CooperSurgical up year-over-year. CooperVision improved roughly 50 basis points to 64.8% driven by factors such as currency and product mix while CooperSurgical grew roughly 30 basis points to 62.5% driven by cost-reduction efforts. Operating expenses grew 11.7% in the quarter driven heavily by CooperSurgical's acquisition-related activity. Within operating expenses, sales and marketing expenses grew 14% as both CooperVision and CooperSurgical executed on sales and marketing expansion plans to capitalize on strong product portfolios. Outside of sales and marketing, we drove leverage through general cost controls. Operating margins were 25.1%, up nicely from 24% last year driven by gross margin improvement and operating expense leverage. 
Moving to interest expense. We reported $5.3 million, which was lower than our guidance as we had a true-up of roughly $1.5 million. This true-up was associated with an overallocation of commitment fees in Q2 and Q3 related to the refinancing of our credit facilities completed in Q2 of this year. What should have happened is Q2 interest expense should have been lower by $600,000, and Q3 should have been lower by $900,000. Our effective tax rate was 10.3%, and the resulting non-GAAP EPS was $2.28 with roughly 49.3 million average shares outstanding. Total debt decreased this quarter by $110 million to roughly $1.33 billion driven by strong free cash flow of $158 million comprised of $193 million of operating cash flow and $35 million of CapEx. 
Regarding full year fiscal 2016 results, consolidated revenues were $1.967 billion, up 9.4% or 7.3% pro forma; CooperVision revenues were $1.577 billion, up 6% or 7.5% in constant currency; and CooperSurgical's revenues were $390 million, up 26% or 6.3% pro forma; non-GAAP EPS was $8.44, up 13%; lastly, free cash flow was $357 million. So all in, a very strong year. 
Moving to fiscal 2017 guidance. Let me start by commenting on currency which has moved significantly against us over the past month or so. For 2017, we're estimating a negative year-over-year currency impact to revenues of approximately $57 million and negative $0.10 to EPS. Incorporating this into our outlook, we expect fiscal 2017 consolidated revenues of $2.09 billion to $2.13 billion. This is comprised of $1.62 billion to $1.65 billion at CooperVision which equates to roughly 6% to 8% constant currency growth and $470 million to $480 million in CooperSurgical which equates to roughly 6% to 8% pro forma growth. We expect gross margins to improve to around 64.5% and operating margins to improve to 25%. Interest expense is expected to be around $28 million which includes the additional debt from the Wallace acquisition along with an assumption of 125 basis points rate increase. The effective tax rate is expected to be around 10%. This may be higher than many you were expecting, but it's based on our current forecast which includes fewer discrete items and is, thus, [ph] more of a true run rate of our current operations. 
Non-GAAP EPS for fiscal 2017 is expected to be in the range of $9 to $9.30 based on 49.4 million shares outstanding. To provide color on this, the higher year-over-year tax rate will negatively impact earnings by roughly $0.20, and FX will negatively impact earnings by $0.10. We also anticipate continuing to invest in sales and marketing above and beyond our normal level, and this will likely be in excess of $10 million or $0.20 in fiscal 2017. Having said that, we do have several positives such as accretion from our CSI acquisition, less idle equipment and inventory charges, savings from manufacturing improvements and the royalty roll-off, and these will help drive earnings growth. Regarding Q1, we anticipate revenues of $494 million to $508 million. This is comprised of $383 million to $393 million at CooperVision or roughly 7% to 10% constant currency growth, and $111 million to $115 million at CooperSurgical which equates to roughly 3% to 7% pro forma growth. For Q1 non-GAAP EPS, we expect $1.78 to $1.88 and note, this assumes a 10% tax rate as compared to last year's 3.9%. And with that, I'll hand it back to the operator for questions."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","[Operator Instructions] And our first question comes from the line of Jon Block of Stifel.",15,"[Operator Instructions] And our first question comes from the line of Jon Block of Stifel."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Maybe the first question, still working through some numbers, it didn't really surprise us all too much on the fiscal 2017 guide. You went through a lot of numbers. The lowest [ph] on 1Q, is that just a function of you do have the pound [ph] benefit for f",150,"Maybe the first question, still working through some numbers, it didn't really surprise us all too much on the fiscal 2017 guide. You went through a lot of numbers. The lowest [ph] on 1Q, is that just a function of you do have the pound [ph] benefit for fiscal 2017 but again, it really takes effect come January so you only have that for a slight stub of 1Q that can be causing approximately $0.20 discount -- sorry, $0.20 disconnects where you guided 1Q versus 3Q, that's a specific number? And maybe, Bob, maybe just to take a step back, just some market commentary. The down 3% U.S. is very surprising. We get your number, up 3% per your release. J&J, I think was up 5% and change, U.S. So how could 2/3 of the market be up a weighted 5% and we see negative 3% in the market data?"
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, I'll answer the first one, and then I'll let Bob get into the market data. Yes, I agree with you. I mean, when you look at the pound move, most of that starts for us in January, so we -- the 1 month in the first quarter. So when you look at the incre",103,"Yes, I'll answer the first one, and then I'll let Bob get into the market data. Yes, I agree with you. I mean, when you look at the pound move, most of that starts for us in January, so we -- the 1 month in the first quarter. So when you look at the incremental sales and marketing investments and you look at the higher tax rate which is somewhere around $0.13 for Q1 combined with only getting the pound benefit for really the month of January, I think that's probably where -- that probably comprises, certainly, the vast majority of the delta."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, as far as the market, I think we've all scratched our head a little about kind of the results being reported by us and the various market players compared to some of the data we see in industry data. And probably the best way to think about it is tha",293,"Yes, as far as the market, I think we've all scratched our head a little about kind of the results being reported by us and the various market players compared to some of the data we see in industry data. And probably the best way to think about it is that, a year ago, the Americas showed 11% growth and the entire market showed 8% growth worldwide driven very heavily by the Americas. This year, that kind of slips splits [ph] to a negative of 3% for the Americas and only 1% for worldwide. So you really have to look at 5 quarters or better yet, even 2 rolling years because of what happened a year ago was all the activity by J&J as they rolled out new products or things going on with UPP, so channel fill, [ph] so you end up with probably a delink [ph] between the way data comes into CLI and the public company. There's variances there, too, and including some of the activity associated with that. So when I think of the market, I kind of say, ""All right, let's put the 2 together."" Last year is 11, this year it's negative 3, that's 8. Divided by 2, it looks more like 4 to me. And in the interim, we had a fourth quarter 4, a second quarter 4 and then a flat first quarter last year. So last year -- my way of thinking, last year rippled into the first quarter, so that 11% third quarter showed up as a neutral first quarter. The long and the short of it is it's probably best to look at it as 5 -- the average of 5 quarters if you're going to make much sense out of it."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Larry Biegelsen of Wells Fargo.",14,"And our next question comes from the line of Larry Biegelsen of Wells Fargo."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Bob, I'm sure it's going to get asked on this call, so I may as well ask about it. Just any thoughts on corporate tax reform and how -- and Cooper's view on this and how you think it could impact you guys? And then one other question, just on the quarter",75,"Bob, I'm sure it's going to get asked on this call, so I may as well ask about it. Just any thoughts on corporate tax reform and how -- and Cooper's view on this and how you think it could impact you guys? And then one other question, just on the quarter itself, the 11%, obviously, quite strong. Was there anything onetime in the quarter, selling days, stocking, et cetera, that helped you this quarter?"
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, I'll do the second one first which is there's nothing unusual about the 11%. We're obviously rolling out some new products. We had a slightly easier comp from a year ago, particularly relative to the Europe theater which is going through consolidatio",201,"Yes, I'll do the second one first which is there's nothing unusual about the 11%. We're obviously rolling out some new products. We had a slightly easier comp from a year ago, particularly relative to the Europe theater which is going through consolidation last year with Sauflon but, by and large, a solid quarter. As far as tax reform, well, tax reform has been talked about forever, and I could give you 2 theories on -- if I just walked in on one thing that's being turned around out there, 35% going to 15%, suffice                                                                                              it to say that wouldn't be bad for most anyone and will serve as a neutralizer to a degree on however it shakes out the rest of the world. There are too many different debates going on out there. There's the fact that any meaningful change would require a vote of 60% of the Senate to go along with it, and that could be tough or only come with a lot of compromise. So I think it would be way premature to know if it's a net plus or a net minus, but most people wouldn't complain about a huge reduction in the corporate tax rate."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Matt Mishan of KeyBanc.",13,"And our next question comes from the line of Matt Mishan of KeyBanc."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Could you go a little bit further into the investment you guys are making in SG&A in really around the cadence? And maybe break out with the difference is between the growth in SG&A from the investment with growth in SG&A from the acquisitions that you're",61,"Could you go a little bit further into the investment you guys are making in SG&A in really around the cadence? And maybe break out with the difference is between the growth in SG&A from the investment with growth in SG&A from the acquisitions that you're making just so we can get a better sense for how to model this."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","So the investment we're making in SG&A is sales and marketing. We're leveraging the rest of the infrastructure. And in the area of sales and marketing, that is both on the Vision side, heavily -- feet on the Street, we're under-indexed compared to our com",297,"So the investment we're making in SG&A is sales and marketing. We're leveraging the rest of the infrastructure. And in the area of sales and marketing, that is both on the Vision side, heavily -- feet on the Street, we're under-indexed compared to our competitors. And as I indicated, I'm not going to start quoting numbers of adds in terms of number of sales force we're adding. But suffice it to say, we also are rolling out many new products. Some of them are conceptually new like Energist [ph]. So there'll be a certain amount of energy also supporting those new products. And putting the 2 together, we will -- we're giving you guidance at 6% to 8% top line growth for both Surgical and Vision. We will be, suffice it to say, growing our sales and marketing at a rate faster primarily in the area of both feet on the Street and, to a                                                                       lesser extent, the marketing support behind that. Beyond that, we're not -- like I said, we're not going to really get into how under-indexed we are compared to our competitors. And I would say it's -- in many cases, it will be not across the board. If you have a vacancy or you're under-indexed in a geographic area, and I've always used an example of a city like Las Vegas and said, ""You know, if you didn't have a salesperson in Las Vegas, it's a pretty big town, maybe you ought to have a salesperson there as you have a lot of products to talk about."" So in some cases, it's adding junior people to support senior people in other places that will be having feet on the Street where you're currently making telephone calls and kind of piggybacking on that."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","And one quick add comment, when you look at the breakdown between Vision and Surgical, it's probably easiest to think about it from a sales and marketing perspective, as if sales and marketing in each business is going to grow somewhat similar of what the",78,"And one quick add comment, when you look at the breakdown between Vision and Surgical, it's probably easiest to think about it from a sales and marketing perspective, as if sales and marketing in each business is going to grow somewhat similar of what their revenues are at their as-reported revenues. So if you look at that on a CooperSurgical basis, obviously, it's quite a bit higher on a percentage growth basis than Vision due to the acquisitions."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Matthew O'Brien of Piper Jaffray.",15,"And our next question comes from the line of Matthew O'Brien of Piper Jaffray."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Just on the dailies side, the performance in the quarter was a slight acceleration over what we saw last quarter. Can you talk a little bit about where that came from be it MyDay, be it clariti, maybe MyDay in Japan? And then, on top of that, just the 2-y",76,"Just on the dailies side, the performance in the quarter was a slight acceleration over what we saw last quarter. Can you talk a little bit about where that came from be it MyDay, be it clariti, maybe MyDay in Japan? And then, on top of that, just the 2-year stacks on the non-daily side appears to decelerate. Could you just talk a little bit about what's going on there? Are you seeing some [ph] impact?"
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes. On the dailies side, there was some acceleration. Having said that, we kind of targeted for basically some approaching 50% for the year, a slight acceleration from the prior years, the way we thought about it coming into this year. So it's kind of mo",366,"Yes. On the dailies side, there was some acceleration. Having said that, we kind of targeted for basically some approaching 50% for the year, a slight acceleration from the prior years, the way we thought about it coming into this year. So it's kind of moving along those lines. And the way it's moving is, obviously, the more mature market is EMEA where these products started out, both MyDay and clariti. The least mature is Japan and the Americas, so we're very early in the cycle in those 2 areas and rapidly expanding the offering even in Europe. So it's geographically across all theaters and very much -- we've now kind of did the redo of the first clariti that was out there, and that's performing real well. So we're now expanding our attention into more than our own accounts. Initially, we had to take care of our accounts that we had given the first generation, if you will, product to. So a long way to go, and we're very early in the cycle and obviously moving off of a larger base as we go forward. As far as the deceleration in the planned replacement area, the non-1 Day, really, that market, if we look at it from a 2.5-year, 3-year perspective, is around breakeven, with the growth all being driven by the 1 Day. That's -- and pretty consistent over the last 4 years, and we don't see that changing. Actually, it's been consistent a lot -- a driver longer than 4 years, but more so outside the U.S. and more recently inside the U.S., so don't see any changes there. There is activity in the planned replacement market, things like Biofinity, obviously, are still putting up terrific numbers so there's room to grow. And particularly as we think about the geographic expansion, some of what goes into China and into some of those theaters, maybe a little less weighted initially in the 1 Day modality, although that -- we can't make that statement about every country. So a lot of opportunities even in the planned replacement arena, and we're obviously continuing to grow that while the market may -- not growing, if you will."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Joanne Wuensch of BMO Capital Markets.",15,"And our next question comes from the line of Joanne Wuensch of BMO Capital Markets."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Can you hear me, okay?",5,"Can you hear me, okay?"
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","I can hear you fine.",5,"I can hear you fine."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Wonderful. Two questions. The first one, is the new SG&A rate for 2017, can we think of that as the go-forward rate? Or do we think of that as a period of investment and then it should ease off? And then the second question, to circle back to the tax issu",104,"Wonderful. Two questions. The first one, is the new SG&A rate for 2017, can we think of that as the go-forward rate? Or do we think of that as a period of investment and then it should ease off? And then the second question, to circle back to the tax issue, we're getting questions from investors regarding your buy-in plan and what it means -- may or may not mean for Cooper which manufactures a fair bit outside of the United States, generates a fair bit of its revenue outside the United States, and I was curious if you had look into that yet."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","So on the SG&A, if it's short-term or long-term, the sales and marketing, we plan on continuing to invest throughout 2017. And as I indicated in my commentary, to the extent that we'll look [ph] into 2018 where we're getting the top line growth we want, w",478,"So on the SG&A, if it's short-term or long-term, the sales and marketing, we plan on continuing to invest throughout 2017. And as I indicated in my commentary, to the extent that we'll look [ph] into 2018 where we're getting the top line growth we want, we will continue that modality. The driver there is if you have a lot of products to talk about and you have the capacity then you should try selling the product and leverage the capacity. We know we have excess capacity, and why not use it? So to the extent we're getting our payback, which will include diminishing the idle charges that we're incurring in cost of goods as a byproduct, we're going to do it. And we obviously have an agenda of gaining market share, and we've certainly done a good job of that the last 7 years. And if I look at it over the last 12 months, it's been greater than 2% that we've grown in the market. You can't make much out of this quarter's numbers because we grew 6 in the market, 1 -- grew 1. I'm not going to say we're growing 6x the market but, obviously, we are growing around that 2x. Relative to the rest of operating cost, this fusion, [ph] G&A and even, to a lesser extent, R&D, we expect to get leverage out of those around the world. So it isn't to say that operating cost in total will keep going up as a percentage of revenue. [indiscernible] plan, I'm not going to get too detailed into it because there are too many soft spots and too many assumptions you'd have to make but I guess I'd point one thing out which I think is very important, when we look at -- people think we're very oriented towards outside the U.S. the way we think. But the fact of the matter is our headcount around the world is pretty balanced U.S. and the rest of the world, both as to revenue and as to headcount. And that is after you count Puerto Rico where we make 1 billion lenses in Puerto Rico. That is a possession of the United States and is part of U.S. So when we kind of think about this, we convey [ph] that we're hearing about, we, the U.S. against the rest of the world. We, the U.S. 5% compared to 95% of those outside the U.S. It is not as imbalanced in Cooper's model as some may think it is. Long and the short of it is I'm not going to overreact to any theory that's thrown around out there, and I'll react to legislation. There hasn't been meaningful legislations since, I think, 1986. There's been a few things along the way that have come and gone, but it would be very premature to overanalyze it."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question come from Steve Willoughby of Cleveland Research.",11,"And our next question come from Steve Willoughby of Cleveland Research."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","I guess, first, Al, if we look back a month ago as it relates to FX, what would you be thinking in terms of the impact from FX to the total company for 2017 at that point versus the $0.10 headwind you're expecting now?",44,"I guess, first, Al, if we look back a month ago as it relates to FX, what would you be thinking in terms of the impact from FX to the total company for 2017 at that point versus the $0.10 headwind you're expecting now?"
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, Steve, tough to say, right, because it depends what day you chose. When Trump [ph] was elected, so to speak, I mean that's when currency rates really started moving. So if you go back to that day or prior to that day, we, at one point in time, would",104,"Well, Steve, tough to say, right, because it depends what day you chose. When Trump [ph] was elected, so to speak, I mean that's when currency rates really started moving. So if you go back to that day or prior to that day, we, at one point in time, would have been $0.30, $0.40 positive. We would have the wind in our back. We probably ended up with -- I don't know what the exact numbers are, but it wouldn't surprise me if it's a $0.50 swing from what it was to what it is today, maybe even a little bit more than that."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Okay. And then just a follow-up, with the roughly 50% 1 Day silicone hydrogel growth this year, do you have any expectations on what that looks like next year?",29,"Okay. And then just a follow-up, with the roughly 50% 1 Day silicone hydrogel growth this year, do you have any expectations on what that looks like next year?"
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, as I indicated, it's [indiscernible]. I wouldn't expect the 50% to be sustainable, but I think in terms of whole dollars, that certainly should be something we would expect. We have so much opportunity and we have the capacity that I'll say we'll pu",67,"Well, as I indicated, it's [indiscernible]. I wouldn't expect the 50% to be sustainable, but I think in terms of whole dollars, that certainly should be something we would expect. We have so much opportunity and we have the capacity that I'll say we'll put up solid numbers throughout 2017, but I'm not going to say it's any 1 particular [ph] percentage, let's put it that way."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Larry Keusch of Raymond James.",14,"And our next question comes from the line of Larry Keusch of Raymond James."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","A couple of questions here. Just, Al, I'm wondering if you could talk a little bit about the FX assumptions that you are using for 2017 on the major currencies?",30,"A couple of questions here. Just, Al, I'm wondering if you could talk a little bit about the FX assumptions that you are using for 2017 on the major currencies?"
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Sure. Pretty much today's rates. I mean, they obviously bounce around a lot, but the euro at about 1.06, the yen at 1.14, pound at 1.26. I mean that's kind of similar to where they are today, right? And then other currencies around the world would be pret",51,"Sure. Pretty much today's rates. I mean, they obviously bounce around a lot, but the euro at about 1.06, the yen at 1.14, pound at 1.26. I mean that's kind of similar to where they are today, right? And then other currencies around the world would be pretty similar to that."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Okay, perfect. And then 2 other ones quickly here. I know you mentioned the outlook for free cash flow generation in totality through 2021, but how are you thinking about free cash flow generation this year and maybe wrap into that CapEx? And then I guess",113,"Okay, perfect. And then 2 other ones quickly here. I know you mentioned the outlook for free cash flow generation in totality through 2021, but how are you thinking about free cash flow generation this year and maybe wrap into that CapEx? And then I guess that last thing is just struggling a little bit with the first quarter and why it's so low. I understand the tax rate, obviously, due to tough comparison. But can you talk a little bit about perhaps the gating for the spending of this incremental for sales and marketing, and is it weighted towards the first quarter or is it sort of more ratable through the year?"
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, I'll hit cash flow, and I'll let Bob go through on the marketing side. For this year, we're probably going to be 400 -- it should to be north of $400 million of free cash. Currency is hurting us a little bit right now, but it should be somewhere in t",105,"Yes, I'll hit cash flow, and I'll let Bob go through on the marketing side. For this year, we're probably going to be 400 -- it should to be north of $400 million of free cash. Currency is hurting us a little bit right now, but it should be somewhere in that $400 million range. CapEx, we'll see how that plays out. It looks like it's going to be somewhere around the $150 million for the year. So if you work off those numbers, $400 million and $150 million, that's probably not a bad way to look at this year at this point in time."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes. And I think as far as the gating of the investment spend and is it a drag on the first quarter? Yes, it is drag partly because of the fact that our first quarter is always the lightest on a revenue base -- from a revenue point of view which has alway",139,"Yes. And I think as far as the gating of the investment spend and is it a drag on the first quarter? Yes, it is drag partly because of the fact that our first quarter is always the lightest on a revenue base -- from a revenue point of view which has always been the case, and we started -- a lot of our investment started ramping in the fourth quarter so it's rolling into the first quarter, obviously, as part of the infrastructure already and will be somewhat of a drag. Some of our investments, if you will, that started in the fourth quarter and worked their way through the first quarter will start yielding, if you will, as the year progresses. We started expecting a return from some of that towards the back half of the year."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Andrew Hanover of JPMorgan.",13,"And our next question comes from the line of Andrew Hanover of JPMorgan."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Al, just wanted to go back just through '17 guidance. It looks like it's extremely conservative at least from what I can tell right this second. I think this is the first time you've embedded an interest rate increase in the numbers, 125 bps. So just wond",85,"Al, just wanted to go back just through '17 guidance. It looks like it's extremely conservative at least from what I can tell right this second. I think this is the first time you've embedded an interest rate increase in the numbers, 125 bps. So just wondering is that around -- is that an impact of around $0.18? And then I'm just trying to get a better feel for FX, SG&A, the higher tax rate and what's driving the higher tax rate for the year?"
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, a couple of comments. I mean, if you look at our debt levels, $1.3 billion. We acquired Wallace, obviously, so another $150 million-plus on that. It's pretty straightforward to do the math on the increase. We assumed a 25 basis point rate increase ha",238,"Yes, a couple of comments. I mean, if you look at our debt levels, $1.3 billion. We acquired Wallace, obviously, so another $150 million-plus on that. It's pretty straightforward to do the math on the increase. We assumed a 25 basis point rate increase happening, with the Fed moving here in the month of December so kind of fully baked in that end for the year, if you will. We -- probably a little conservative on interest expense, where we're at, based on the amount of cash flow we're generating and so forth and where we'll come out on the pricing grid, but we'll see how that plays out. When you look at the tax rate itself, we've been running kind of on a look-through basis, if you will, somewhere around that 10%. We've had a number of discrete items that have come through. We've had acquisition-related activity and so forth that have allowed some write-offs and so forth that have pushed the tax rate down. Could it come in lower than 10%? It could, but I would tell you right now, based on what we have today, we're looking at somewhere around that 10%, with Q1, Q2, Q4 probably being somewhat similar and, as usual, Q3 being a little lighter but not as dramatic as what you've seen in prior years where you would see a quarter that was a 3% or 4% quarter as an example."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","And I think one way of looking at that is our fourth quarter effective tax rate is 10.3. That is excluding any discrete items. So that's kind of what the business run ex the discrete items we've had year after year but do not anticipate going forward.",48,"And I think one way of looking at that is our fourth quarter effective tax rate is 10.3. That is excluding any discrete items. So that's kind of what the business run ex the discrete items we've had year after year but do not anticipate going forward."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Jeff Johnson of Robert Baird.",14,"And our next question comes from the line of Jeff Johnson of Robert Baird."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Bob, I wanted to start with you just on the sales force. So if I think about your sales force, I think it's about half to maybe 55% the size of your 2 larger competitors. And your market share is kind of in that same range. And so on the face of it, it se",189,"Bob, I wanted to start with you just on the sales force. So if I think about your sales force, I think it's about half to maybe 55% the size of your 2 larger competitors. And your market share is kind of in that same range. And so on the face of it, it seems like your sales force isn't overly undersized, I guess. And then I think about your private label business, it's somewhere around 25% or 30% of revenue, and I'd assume that's a lower touch business. Just wanting to understand why is the big focus on sales force additions at this point and what's really driving that? And then maybe, Al, for you, a follow-up question. I think I agree your EPS guidance looks like maybe there's some levers of conservatism in there, but 6% to 8% CVI growth in a fairly choppy market and maybe in a med tech market that's a little uncertain right now doesn't feel overly conservative to me, so maybe if you can address your thoughts on the 6% to 8% CVI growth for '17, that would be helpful as well."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, Jeff, on the size of our sales force compared to our competitors, I think if we compare our 23% market share to Alcon's, which is just a tad above ours, suffice it to say, the size of their sales force compared to ours is nowhere comparable. And J&J,",200,"Yes, Jeff, on the size of our sales force compared to our competitors, I think if we compare our 23% market share to Alcon's, which is just a tad above ours, suffice it to say, the size of their sales force compared to ours is nowhere comparable. And J&J, if we're going to do allocations against market share, with their 40% market share or there are and about to our 23%, that would barely line up. I think more importantly is, it really is about, if you have the product, and we have the broadest product portfolio and you have the capacity, something we have not had in the past, at least relative to clariti, MyDay and to a lesser extent, even Biofinity. So if you have your capacity you want, why wouldn't you test the water and see how good your products are? Why wouldn't you go after your competitors accounts more aggressively? And we can't do it if we're under index on feet on the street. So it's one thing if you're kind of growing methodically and you're confined with how much you can grow. It's another thing if you don't have those limitations, which I'll call capacity."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes and I'll comment a little bit on the growth rate assumption. If you at CooperVision last year, they grew 7.5% in constant currency, 11% in Q4. So obviously a lot of momentum there. You look at the Q1 guidance, the 7% to 10% and expecting that momentum",168,"Yes and I'll comment a little bit on the growth rate assumption. If you at CooperVision last year, they grew 7.5% in constant currency, 11% in Q4. So obviously a lot of momentum there. You look at the Q1 guidance, the 7% to 10% and expecting that momentum to continue, and Jeff, I think where you're going with this to your point, is when you look at 6% to 8% for the year and you roll that Q1 in, you'd be talking about implied guidance, if you will, Q2 to Q4 for CooperVision in the upper 6x which would be decelerating in the face of decent investment. So I think that's a very fair question. I would tell you I think that giving a 6% to 8% range in today's world is prudent and a good way to look at the business but I don't think anybody would be very happy, I'm putting it to you that way if we're growing in the 6% to 7% range."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Anthony Petrone with Jefferies.",13,"And our next question comes from the line of Anthony Petrone with Jefferies."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Maybe just 1 question on the sales investments and then just one of the competitive landscape to follow up there. Just in terms of feet on the street, I'm just wondering how much of the investment is focused on optometrists, that channel as opposed to oth",133,"Maybe just 1 question on the sales investments and then just one of the competitive landscape to follow up there. Just in terms of feet on the street, I'm just wondering how much of the investment is focused on optometrists, that channel as opposed to other retail channels. And I guess, the core of that is we're under the impression that it's still the majority of sales for Cooper comes from optometrist. So just wondering if you're doubling down on that channel or expanding in other retail channels? And then, in terms of the competitive landscape, it would just be great to get an update, sort of where [indiscernible] sits at this point. It looks like they're still in a position of giving up some share and similarly, Bausch & Lomb and J&J."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Sure. Our focus in terms of feet on the street and whether it's independent ODs or ODs that are at the retail level is OD, wherever they are and a lot of -- Cooper is very open as part of its strategy, being, it could be branded, affinity or it could be p",330,"Sure. Our focus in terms of feet on the street and whether it's independent ODs or ODs that are at the retail level is OD, wherever they are and a lot of -- Cooper is very open as part of its strategy, being, it could be branded, affinity or it could be private label. So we're indifferent to what is called but what we have learned in the past is just because you send a bunch of your product, whether it's private label or branded, to a large retailer, if you don't work it, it's not going to work itself. You have to go to OD, whether they're under the umbrella of a retailer or not. That as contrasted to maybe an online or some other mechanism, we don't waste our time with that. If you don't like subscription, you don't have our attention and that will continue. Relative to the competitive landscape, yes, our competitors continue to be in various stages of disarray. We know what the CEO and Chairman of Novartis basically said. They are restructuring that organization. The risk disruption there. They have a tired product line, B&L, likewise is in a very disruptive environment, to say the least. And J&J has done a pretty good job of marketing 1 product, OASYS, by any other name is OASYS. So it's all over. 1 Day, 1 week, 2 week, 1 month, called Vita. So of the 3 competitors, I would say J&J kind of have, in fact, together, better than the other 2. But having said that, they're obviously presenting some opportunities in their approach. Are they in UPP, 1 Day and then they're out of UPP the next day? UPP wholesale across all of their products and then they had the entire team come up with a different plan. So we've been pretty steady state in the way we're approaching the market. We have the product portfolio and well, we kind of feel good about our competitors."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Brian Weinstein with William Blair.",14,"And our next question comes from the line of Brian Weinstein with William Blair."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","First one on margins, you guys have targeted an improvement in MyDay over the year and talked about clariti getting north of corporate margins. Can you just comment kind of where the margins are in those products? And then Bob, for you. You had talked pre",131,"First one on margins, you guys have targeted an improvement in MyDay over the year and talked about clariti getting north of corporate margins. Can you just comment kind of where the margins are in those products? And then Bob, for you. You had talked previously about 50% of the $10 billion market to be in the 1 Day modality and of that, about somewhere between 20% and 77% to be in silicone hydrogel and thought maybe the middle of that made sense. With more experience now of how these products are rolling out, do you have confidence that over the next few years that you're going to be turning more above that 50% of the market towards that 77%? Where do you think that, that could be now by 2020?"
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, I think we're rapidly approaching the 50% market for 1 Day and within 1 Day, silicone hydrogel is continuing to make solid progress growing 20%-ish in that market. And therefore, it's now I think over 20% of the -- or close to 25% of the 1 Day market",270,"Yes, I think we're rapidly approaching the 50% market for 1 Day and within 1 Day, silicone hydrogel is continuing to make solid progress growing 20%-ish in that market. And therefore, it's now I think over 20% of the -- or close to 25% of the 1 Day market. So I do believe, the 1 Day will be more than 50% of the, let's say, that target $10 billion down the road 2020, 2021. And who knows? Foreign exchange keeps coming along kind of putting a dent into some of that, so assuming the dollar stabilizes, we're directionally headed towards that $10 billion. 1 Day will be greater than 50% and there's no doubt that silicone hydrogel 1 Day will be much greater than 20% of that 1 Day market. And will it be similar to the planned replacement where it's close to 80%? 79% to 80% or a lot less? I think there are some reasons that it won't -- well beyond 50% barrier short-term because there's so much activity in the non-silicone hydrogel mass market space, that somewhat barrier. To answer your question about our cost coming down, MyDay is making good progress. We believe it's in the 30s now and we would expect that in 2018 sometime will be honing in on that 50% target for 1 Day gross margin. And clariti, because of its novel approach to manufacturing and cost, will not be a drag and it's not a drag today on our gross margin. So the mix you see is holding its own within that mix and is not a headwind on gross margin percentage."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Steven Lichtman with Oppenheimer.",13,"And our next question comes from the line of Steven Lichtman with Oppenheimer."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Just a couple of B&L follow-ups. First, in terms of the investment marketing, should we be thinking about that as -- solely sales force hire investments or is there any discrete marketing investments that are embedded in there? And then, secondly, Al, the",67,"Just a couple of B&L follow-ups. First, in terms of the investment marketing, should we be thinking about that as -- solely sales force hire investments or is there any discrete marketing investments that are embedded in there? And then, secondly, Al, the idle equipment charges, the enhanced charges we've seen owing to the efficiencies, how should we be thinking about those rolling off in 2017?"
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","So on the sales and marketing, it's more than just feet on the street, albeit the concentration and the focus is more so feet on the street. But with the new products, the Energys, with conversion of -- from Avaira to Vitality with a new toric -- a new My",265,"So on the sales and marketing, it's more than just feet on the street, albeit the concentration and the focus is more so feet on the street. But with the new products, the Energys, with conversion of -- from Avaira to Vitality with a new toric -- a new MyDay toric, all that activity, there certainly is  and particularly upfront as you come out with new products, some energy on the marketing side, some of that will tail off and some of that will continue as you roll it out around the world. So nothing -- I would say, nothing imminent where it's certainly in a non-investment mode over the next 1 to 2 years. So the roll-off of idle equipment is somewhat a function of success of the growth of our various areas whether it's Vitality, whether it's 1 Day, whether its clariti, the growth in those products will form the basis of consuming some of that idle equipment over the next 1 to 2 years. We indicated partly because of the continuing successes in cutting cost and getting better yields and getting better throughput, we're now talking about lines with north of $80 million unit production that 2 years ago, we didn't even have on the drawing board by way of a thought. So those kind of profound changes means we'll be able to continue to ramp up and continue to be ahead of the curve in terms of the demand side for quite a while in some of those areas, clariti and MyDay. I don't know what other color you want to..."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Just to quickly. Bob's exactly right, quantify that just a little bit. We had thought last year about kind of $0.10 quarter, above and beyond for idle equipment and some inventory charges. And we had that in Q2, Q3, Q4. I would say that we're continuing t",195,"Just to quickly. Bob's exactly right, quantify that just a little bit. We had thought last year about kind of $0.10 quarter, above and beyond for idle equipment and some inventory charges. And we had that in Q2, Q3, Q4. I would say that we're continuing to have that right now. Those idle charges are mostly linked to the daily side. So the growth that you're seeing is absolutely fantastic for us. Continuing growth like that put those lines to use and the idle equipment goes down. So the expansion focus on sales and marketing to drive topline growth and driving single-use, one of the nice benefits of that is it's going to put equipment to work. We obviously don't need to buy new equipment which helps free cash flow and we would move equipment charges and put that into production. So I would say that we're still kind of looking at that $0.10 a quarter here to start the year and depending upon our success that will moved down and hopefully move to 0 by the end of this year but more likely, we'll see those charges even moved into 2018 a little bit."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And I'm showing no further questions at this time. I would now like to hand the call over to Mr. Bob Weiss for closing remarks.",26,"And I'm showing no further questions at this time. I would now like to hand the call over to Mr. Bob Weiss for closing remarks."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, I want to thank you for joining our call today and I wish everyone the happiest of holidays coming up. And we look forward to updating you on the progress we're making and on our new product rollout on our call in March which I believe is going to b",70,"Well, I want to thank you for joining our call today and I wish everyone the happiest of holidays coming up. And we look forward to updating you on the progress we're making and on our new product rollout on our call in March which I believe is going to be March 2, 2017. We look forward to talking to you then. Thank you, all. Thank you. That's it operator."
263609,408515230,1100119,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This concludes today's program. You may all disconnect. Everyone, have a great day.",23,"Ladies and gentlemen, thank you for participating in today's conference. This concludes today's program. You may all disconnect. Everyone, have a great day."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Cooper Companies Incorporated Fourth Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to introduce your host for today",49,"Good day, ladies and gentlemen, and welcome to the Cooper Companies Incorporated Fourth Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to introduce your host for today's conference, Miss Kim Duncan, Vice President. Ma'am, you may begin."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Good afternoon. And welcome to the Cooper Companies' Fourth Quarter and Full Year 2016 Earnings Conference Call. I'm Kim Duncan, Vice President of Investor Relations, and giving prepared remarks on today's call are Bob Weiss, Chief Executive Officer; and",316,"Good afternoon. And welcome to the Cooper Companies' Fourth Quarter and Full Year 2016 Earnings Conference Call. I'm Kim Duncan, Vice President of Investor Relations, and giving prepared remarks on today's call are Bob Weiss, Chief Executive Officer; and Al White, Chief Financial Officer and Chief Strategy Officer. 
Before we get started, I'd like to remind you that this conference call contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including all revenue and earnings per share guidance and other statements regarding anticipated results of operations, market or regulatory conditions and integration of any acquisitions or their failure to achieved anticipated benefits. Forward-looking statements depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Events that could cause our actual results and future actions of the company to differ materially from those described in forward-looking statements are set forth under the caption Forward-looking Statements in today's earnings release and are described in our SEC filings, including the business section of Cooper's annual report on Form 10-K. These are publicly available and on request from the company's Investor Relations Department. 
Before I turn the call over to Bob, let me comment on the agenda for the call. Bob will begin by providing highlights on the quarter, followed by Al who will then discuss the fourth quarter and full year financial results. We will keep the formal presentation to roughly 30 minutes then open the call for questions. We expect this call to last approximately 1 hour. [Operator Instructions]. Should you have any additional questions, please call our investor line at (925) 460-3663 or e-mail ir@cooperco.com. This call is being webcast and a copy of the earnings release is available through the Investor Relations section of the Cooper Companies website. And with that, I'll turn the call over to Bob for his opening remarks."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thank you, Kim, and good afternoon, everyone. Welcome to the fourth quarter and full year 2016 conference call. Let me start by saying I'm very proud of our accomplishments this quarter, including record revenue and free cash flow. We also delivered a ver",1176,"Thank you, Kim, and good afternoon, everyone. Welcome to the fourth quarter and full year 2016 conference call. Let me start by saying I'm very proud of our accomplishments this quarter, including record revenue and free cash flow. We also delivered a very strong fiscal year gaining share in the $7.2 billion contact lens industry, continuing our approach into the 1 Day silicone hydrogel space, expanding our Biofinity franchise and posting strong growth in our CooperSurgical business. We enter fiscal 2017 with strong momentum. We remain confident we will see market share gains in both of our businesses for the foreseeable future. 
Let me highlight 3 key points for the quarter. First, I'm pleased to report another strong quarter, with revenues over $5 million. This includes CooperVision reporting revenues over $400 million and CooperSurgical reporting revenues over $100 million. This resulted in non-GAAP earnings per share of $2.28 and free cash flow of $158 million. Second, CooperVision posted strong results in all key areas of its business, resulting in 10% as reported and 11% constant currency revenue growth. This includes 1 Day silicone hydrogel lenses growing 53% and 2-week and monthly silicone hydrogel lenses growing a combined 14%, both in constant currency. Third, CooperSurgical had another strong quarter, posting revenue growth of 20% or 6% pro forma. Fertility was a highlight, posting growth of 74% or 8% pro forma. Moving into the details. CooperVision reported fourth quarter revenue of $412 million, up 10% as reported and 11% in constant currency. This is the fastest CooperVision has grown in 11 quarters. The Americas grew 8% in constant currency with strengths in multiple categories including Biofinity and 1 Day silicone hydrogel lenses. Biofinity continues to be our workhorse and we began our launch in Biofinity Energys in mid-August to strong reviews. Our enhanced clariti lens is also performing well and MyDay had another very strong quarter. EMEA posted a very strong quarter, up 12% in constant currency. Growth was driven by Biofinity and our 1 Day silicone hydrogel franchise. Asia Pacific also had a very strong quarter, up 13% in constant currency. Growth is strong throughout the region, driven by Biofinity and our 1 Day silicone hydrogel franchise. Within Japan, our MyDay sphere and toric launch is progressing well. And while it's still early, we continue to believe MyDay can be a very successful premium offering in that market. 
Turning to product categories. Torics grew a healthy 14% and multifocals 10%, both in constant currency. We remain a global leader in specialty lenses, and our success in Biofinity and clariti in both of these categories should continue to drive growth for many years to come. 
Looking at silicone hydrogel lenses. These products grew 21% in constant currency and now represents 62% of our sales. We expect this strong growth to continue, given our product portfolio which includes Biofinity, Vitality, our newly launched 2-week product and our diverse 1 Day offering. And remember, the biggest driver in the contact lens market is the 1 Day growth, and we strongly believe we have the best product offering in this space as the only company selling premium and mass market silicone hydrogel lenses, including a portfolio of sphere, toric and multifocal lenses. We are also investing in sales and marketing to support our strong product portfolio. Forecasting new hires is always challenging, especially when you're evaluating opportunities around the world. But we believe CooperVision can add numerous sales reps and get a very nice return given our strong product platform, our capacity and our growth opportunities that we see. We believe this initiative -- we began this initiative in our fourth quarter and expect it to continue through fiscal 2017 and possibly into 2018. For competitive reasons, I won't get into many details but, suffice it to say, we carefully evaluate our hiring and expect to realize a solid return from this activity. 
Now let me comment on our overall contact lens market and remember, this information is on the last page of our earnings release. For calendar Q3 2016, we continue taking share, growing 6%, with the market up 1%. Geographically, CooperVision grew 3% in the Americas while the market was down 3%. In the EMEA, we were up 8%, and the market was up 7%. In Asia Pacific, we grew 9%, with the market up 3%. On a modality basis, single-use lenses continued driving growth, with CooperVision up 12% and the market up 8%. For non-single-use lenses, we grew 3% while the market declined 4%. As you can see, our growth remains diverse and strong. On a trailing 12-month basis, CooperVision grew 8% while the market grew 3%. Although the market remains choppy and hard to read at times, we continue to believe it will strengthen and grow towards 6% over the next 5 years driven by continuing shift to dailies, geographic expansion and an expansion of the wearer base. We expect to continue taking market share led by our strong portfolio of market-leading products. 
Moving to CooperSurgical, we reported fourth quarter revenues of $107 million, up 30% year-over-year, driven by organic growth and acquisitions. On a pro forma basis, we grew 6%. Fertility led the way, up 74% or 8% pro forma. Within Fertility, we had growth throughout the business and continue to believe our market-leading product portfolio which includes medical devices, genetic testing and capital equipment is the broadest portfolio in the space and should continue to drive growth for many years to come. 
Within our office and surgical category, growth was 5%. We're continuing to execute on several product launches, including our disposable hysteroscope, EndoSee, and we continue to see success in this area. Regarding other activity, we announced on November 6 that we acquired the Wallace portfolio from Smiths Medical for approximately $168 million. This is a great strategic fit with our existing global IVF portfolio as it brings the gold standard of embryo transfer catheters along with several other premier products. Finally, CooperSurgical -- on CooperSurgical, we're busy integrating recent acquisitions but also executing on several initiatives which should significantly strengthen the business. These include transitioning to a global sales model, adding sales reps in underpenetrated areas, launching products into new markets and increasing our focus on high-growth areas such as IVF genetic testing. We have made a lot of progress in these areas over the past year and expect to continue -- even have more progress as we go forward.  
Now before I turn it over to Al, let me comment on a couple other items. We anticipate another strong year of revenue growth in 2017, including CooperVision growing 6% to 8% in constant currency and CooperSurgical growing 6% to 8% pro forma. We also remain bullish on our future and are updating our long-term objectives for operating margins of 28% and free cash flow generation of over $2 billion by 2021. 
In conclusion, I want to express my appreciation to our employees for all their hard work and dedication. And now I'll turn it over to Al to cover the financial results."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thank you, Bob, and good afternoon, everyone. Bob did an excellent job covering revenues, so I'll focus on the rest of our Q4 financial performance along with guidance. Most of my commentary will be on a non-GAAP basis, and a full reconciliation between o",744,"Thank you, Bob, and good afternoon, everyone. Bob did an excellent job covering revenues, so I'll focus on the rest of our Q4 financial performance along with guidance. Most of my commentary will be on a non-GAAP basis, and a full reconciliation between our GAAP and non-GAAP results is included in today's earnings release. 
For the quarter, gross margins were slightly over 64%, with both CooperVision and CooperSurgical up year-over-year. CooperVision improved roughly 50 basis points to 64.8% driven by factors such as currency and product mix while CooperSurgical grew roughly 30 basis points to 62.5% driven by cost-reduction efforts. Operating expenses grew 11.7% in the quarter driven heavily by CooperSurgical's acquisition-related activity. Within operating expenses, sales and marketing expenses grew 14% as both CooperVision and CooperSurgical executed on sales and marketing expansion plans to capitalize on strong product portfolios. Outside of sales and marketing, we drove leverage through general cost controls. Operating margins were 25.1%, up nicely from 24% last year driven by gross margin improvement and operating expense leverage. 
Moving to interest expense. We reported $5.3 million, which was lower than our guidance as we had a true-up of roughly $1.5 million. This true-up was associated with an overallocation of commitment fees in Q2 and Q3 related to the refinancing of our credit facilities completed in Q2 of this year. What should have happened is Q2 interest expense should have been lower by $600,000, and Q3 should have been lower by $900,000. Our effective tax rate was 10.3%, and the resulting non-GAAP EPS was $2.28 with roughly 49.3 million average shares outstanding. Total debt decreased this quarter by $110 million to roughly $1.33 billion driven by strong free cash flow of $158 million comprised of $193 million of operating cash flow and $35 million of CapEx. 
Regarding full year fiscal 2016 results, consolidated revenues were $1.967 billion, up 9.4% or 7.3% pro forma; CooperVision revenues were $1.577 billion, up 6% or 7.5% in constant currency; and CooperSurgical's revenues were $390 million, up 26% or 6.3% pro forma; non-GAAP EPS was $8.44, up 13%; lastly, free cash flow was $357 million. So all in, a very strong year. 
Moving to fiscal 2017 guidance. Let me start by commenting on currency which has moved significantly against us over the past month or so. For 2017, we're estimating a negative year-over-year currency impact to revenues of approximately $57 million and negative $0.10 to EPS. Incorporating this into our outlook, we expect fiscal 2017 consolidated revenues of $2.09 billion to $2.13 billion. This is comprised of $1.62 billion to $1.65 billion at CooperVision which equates to roughly 6% to 8% constant currency growth and $470 million to $480 million in CooperSurgical which equates to roughly 6% to 8% pro forma growth. We expect gross margins to improve to around 64.5% and operating margins to improve to 25%. Interest expense is expected to be around $28 million which includes the additional debt from the Wallace acquisition along with an assumption of 125 basis points rate increase. The effective tax rate is expected to be around 10%. This may be higher than many you were expecting, but it's based on our current forecast which includes fewer discrete items and is, thus, more of a true run rate of our current operations. 
Non-GAAP EPS for fiscal 2017 is expected to be in the range of $9 to $9.30 based on 49.4 million shares outstanding. To provide color on this, the higher year-over-year tax rate will negatively impact earnings by roughly $0.20, and FX will negatively impact earnings by $0.10. We also anticipate continuing to invest in sales and marketing above and beyond our normal level, and this will likely be in excess of $10 million or $0.20 in fiscal 2017. Having said that, we do have several positives such as accretion from our CSI acquisition, less idle equipment and inventory charges, savings from manufacturing improvements and the royalty roll-off, and these will help drive earnings growth. Regarding Q1, we anticipate revenues of $494 million to $508 million. This is comprised of $383 million to $393 million at CooperVision or roughly 7% to 10% constant currency growth, and $111 million to $115 million at CooperSurgical which equates to roughly 3% to 7% pro forma growth. For Q1 non-GAAP EPS, we expect $1.78 to $1.88 and note, this assumes a 10% tax rate as compared to last year's 3.9%. And with that, I'll hand it back to the operator for questions."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","[Operator Instructions] And our first question comes from the line of Jon Block of Stifel.",15,"[Operator Instructions] And our first question comes from the line of Jon Block of Stifel."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Maybe the first question, still working through some numbers, it didn't really surprise us all too much on the fiscal 2017 guide. Al, you went through a lot of numbers. The lowest on 1Q, is that just a function of you do have the pound benefit for fiscal",149,"Maybe the first question, still working through some numbers, it didn't really surprise us all too much on the fiscal 2017 guide. Al, you went through a lot of numbers. The lowest on 1Q, is that just a function of you do have the pound benefit for fiscal 2017 but again, it really takes effect come January so you only have that for a slight stub of 1Q that can be causing approximately $0.20 discount -- sorry, $0.20 disconnects where you guided 1Q versus 3Q, that's a specific number? And maybe, Bob, maybe just to take a step back, just some market commentary. The down 3% U.S. is very surprising. We get your number, up 3% per your release. J&J, I think was up 5% and change, U.S. So how could 2/3 of the market be up a weighted 5% and we see negative 3% in the market data?"
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, I'll answer the first one, and then I'll let Bob get into the market data. Yes, I agree with you. I mean, when you look at the pound move, most of that starts for us in January, so we -- the 1 month in the first quarter. So when you look at the incre",103,"Yes, I'll answer the first one, and then I'll let Bob get into the market data. Yes, I agree with you. I mean, when you look at the pound move, most of that starts for us in January, so we -- the 1 month in the first quarter. So when you look at the incremental sales and marketing investments and you look at the higher tax rate which is somewhere around $0.13 for Q1 combined with only getting the pound benefit for really the month of January, I think that's probably where -- that probably comprises, certainly, the vast majority of the delta."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, as far as the market, I think we've all scratched our head a little about kind of the results being reported by us and the various market players compared to some of the data we see in industry data. And probably the best way to think about it is tha",289,"Yes, as far as the market, I think we've all scratched our head a little about kind of the results being reported by us and the various market players compared to some of the data we see in industry data. And probably the best way to think about it is that, a year ago, the Americas showed 11% growth and the entire market showed 8% growth worldwide driven very heavily by the Americas. This year, that kind of splits to a negative of 3% for the Americas and only 1% for worldwide. So you really have to look at 5 quarters or better yet, even 2 rolling years because of what happened a year ago was all the activity by J&J as they rolled out new products or things going on with UPP, so channel fill, so you end up with probably a delink between the way data comes into CLI and the public company. There's variances there, too, and including some of the activity associated with that. So when I think of the market, I kind of say, ""All right, let's put the 2 together."" Last year is 11%, this year it's negative 3%, that's 8%. Divided by 2, it looks more like 4% to me. And in the interim, we had a fourth quarter, 4%; a second quarter, 4%; and then a flat first quarter last year. So last year -- my way of thinking, last year rippled into the first quarter, so that 11% third quarter showed up as a neutral first quarter. The long and the short of it is it's probably best to look at it as 5 -- the average of 5 quarters if you're going to make much sense out of it."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Larry Biegelsen of Wells Fargo.",14,"And our next question comes from the line of Larry Biegelsen of Wells Fargo."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Bob, I'm sure it's going to get asked on this call, so I may as well ask about it. Just any thoughts on corporate tax reform and how -- and Cooper's view on this and how you think it could impact you guys? And then one other question, just on the quarter",75,"Bob, I'm sure it's going to get asked on this call, so I may as well ask about it. Just any thoughts on corporate tax reform and how -- and Cooper's view on this and how you think it could impact you guys? And then one other question, just on the quarter itself, the 11%, obviously, quite strong. Was there anything onetime in the quarter, selling days, stocking, et cetera, that helped you this quarter?"
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, I'll do the second one first which is there's nothing unusual about the 11%. We're obviously rolling out some new products. We had a slightly easier comp from a year ago, particularly relative to the Europe theater which is going through consolidatio",201,"Yes, I'll do the second one first which is there's nothing unusual about the 11%. We're obviously rolling out some new products. We had a slightly easier comp from a year ago, particularly relative to the Europe theater which is going through consolidation last year with Sauflon but, by and large, a solid quarter. As far as tax reform, well, tax reform has been talked about forever, and I could give you 2 theories on -- if I just walked in on one thing that's being turned around out there, 35% going to 15%, suffice                                                                                              it to say that wouldn't be bad for most anyone and will serve as a neutralizer to a degree on however it shakes out the rest of the world. There are too many different debates going on out there. There's the fact that any meaningful change would require a vote of 60% of the Senate to go along with it, and that could be tough or only come with a lot of compromise. So I think it would be way premature to know if it's a net plus or a net minus, but most people wouldn't complain about a huge reduction in the corporate tax rate."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Matt Mishan of KeyBanc.",13,"And our next question comes from the line of Matt Mishan of KeyBanc."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Could you go a little bit further into the investment you guys are making in SG&A in really around the cadence? And maybe break out with the difference is between the growth in SG&A from the investment with growth in SG&A from the acquisitions that you're",61,"Could you go a little bit further into the investment you guys are making in SG&A in really around the cadence? And maybe break out with the difference is between the growth in SG&A from the investment with growth in SG&A from the acquisitions that you're making just so we can get a better sense for how to model this."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","So the investment we're making in SG&A is sales and marketing. We're leveraging the rest of the infrastructure. And in the area of sales and marketing, that is both on the Vision side, heavily -- feet on the street, we're under-indexed compared to our com",296,"So the investment we're making in SG&A is sales and marketing. We're leveraging the rest of the infrastructure. And in the area of sales and marketing, that is both on the Vision side, heavily -- feet on the street, we're under-indexed compared to our competitors. And as I indicated, I'm not going to start quoting numbers of adds in terms of number of sales force we're adding. But suffice it to say, we also are rolling out many new products. Some of them are conceptually new like Energys. So there'll be a certain amount of energy also supporting those new products. And putting the 2 together, we will -- we're giving you guidance at 6% to 8% top line growth for both Surgical and Vision. We will be, suffice it to say, growing our sales and marketing at a rate faster primarily in the area of both feet on the street and, to a                                                                       lesser extent, the marketing support behind that. Beyond that, we're not -- like I said, we're not going to really get into how under-indexed we are compared to our competitors. And I would say it's -- in many cases, it will be not across the board. If you have a vacancy or you're under-indexed in a geographic area, and I've always used an example of a city like Las Vegas and said, ""You know, if you didn't have a salesperson in Las Vegas, it's a pretty big town, maybe you ought to have a salesperson there as you have a lot of products to talk about."" So in some cases, it's adding junior people to support senior people in other places that will be having feet on the street where you're currently making telephone calls and kind of piggybacking on that."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","And one quick add comment, when you look at the breakdown between Vision and Surgical, it's probably easiest to think about it from a sales and marketing perspective, as if sales and marketing in each business is going to grow somewhat similar of what the",78,"And one quick add comment, when you look at the breakdown between Vision and Surgical, it's probably easiest to think about it from a sales and marketing perspective, as if sales and marketing in each business is going to grow somewhat similar of what their revenues are at their as-reported revenues. So if you look at that on a CooperSurgical basis, obviously, it's quite a bit higher on a percentage growth basis than Vision due to the acquisitions."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Matthew O'Brien of Piper Jaffray.",15,"And our next question comes from the line of Matthew O'Brien of Piper Jaffray."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Just on the dailies side, the performance in the quarter was a slight acceleration over what we saw last quarter. Can you talk a little bit about where that came from be it MyDay, be it clariti, maybe MyDay in Japan? And then, on top of that, just the 2-y",76,"Just on the dailies side, the performance in the quarter was a slight acceleration over what we saw last quarter. Can you talk a little bit about where that came from be it MyDay, be it clariti, maybe MyDay in Japan? And then, on top of that, just the 2-year stacks on the non-daily side appears to decelerate. Could you just talk a little bit about what's going on there? Are you seeing some VITA impact?"
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes. On the dailies side, there was some acceleration. Having said that, we kind of targeted for basically some approaching 50% for the year, a slight acceleration from the prior years, the way we thought about it coming into this year. So it's kind of mo",366,"Yes. On the dailies side, there was some acceleration. Having said that, we kind of targeted for basically some approaching 50% for the year, a slight acceleration from the prior years, the way we thought about it coming into this year. So it's kind of moving along those lines. And the way it's moving is, obviously, the more mature market is EMEA where these products started out, both MyDay and clariti. The least mature is Japan and the Americas, so we're very early in the cycle in those 2 areas and rapidly expanding the offering even in Europe. So it's geographically across all theaters and very much -- we've now kind of did the redo of the first clariti that was out there, and that's performing real well. So we're now expanding our attention into more than our own accounts. Initially, we had to take care of our accounts that we had given the first generation, if you will, product to. So a long way to go, and we're very early in the cycle and obviously moving off of a larger base as we go forward. As far as the deceleration in the planned replacement area, the non-1 Day, really, that market, if we look at it from a 2.5-year, 3-year perspective, is around breakeven, with the growth all being driven by the 1 Day. That's -- and pretty consistent over the last 4 years, and we don't see that changing. Actually, it's been consistent a lot -- a driver longer than 4 years, but more so outside the U.S. and more recently inside the U.S., so don't see any changes there. There is activity in the planned replacement market, things like Biofinity, obviously, are still putting up terrific numbers so there's room to grow. And particularly as we think about the geographic expansion, some of what goes into China and into some of those theaters, maybe a little less weighted initially in the 1 Day modality, although that -- we can't make that statement about every country. So a lot of opportunities even in the planned replacement arena, and we're obviously continuing to grow that while the market may -- not growing, if you will."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Joanne Wuensch of BMO Capital Markets.",15,"And our next question comes from the line of Joanne Wuensch of BMO Capital Markets."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Can you hear me, okay?",5,"Can you hear me, okay?"
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","I can hear you fine.",5,"I can hear you fine."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Wonderful. Two questions. The first one, is the new SG&A rate for 2017, can we think of that as the go-forward rate? Or do we think of that as a period of investment and then it should ease off? And then the second question, to circle back to the tax issu",104,"Wonderful. Two questions. The first one, is the new SG&A rate for 2017, can we think of that as the go-forward rate? Or do we think of that as a period of investment and then it should ease off? And then the second question, to circle back to the tax issue, we're getting questions from investors regarding your buy-in plan and what it means -- may or may not mean for Cooper which manufactures a fair bit outside of the United States, generates a fair bit of its revenue outside the United States, and I was curious if you had look into that yet."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","So on the SG&A, if it's short-term or long-term, the sales and marketing, we plan on continuing to invest throughout 2017. And as I indicated in my commentary, to the extent that we look into 2018 where we're getting the top line growth we want, we will c",479,"So on the SG&A, if it's short-term or long-term, the sales and marketing, we plan on continuing to invest throughout 2017. And as I indicated in my commentary, to the extent that we look into 2018 where we're getting the top line growth we want, we will continue that modality. The driver there is if you have a lot of products to talk about and you have the capacity then you should try selling the product and leverage the capacity. We know we have excess capacity, and why not use it? So to the extent we're getting our payback, which will include diminishing the idle charges that we're incurring in cost of goods as a byproduct, we're going to do it. And we obviously have an agenda of gaining market share, and we've certainly done a good job of that the last 7 years. And if I look at it over the last 12 months, it's been greater than 2% that we've grown in the market. You can't make much out of this quarter's numbers because we grew 6 in the market, 1 -- grew 1. I'm not going to say we're growing 6x the market but, obviously, we are growing around that 2x. Relative to the rest of operating cost, distribution, G&A and even, to a lesser extent, R&D, we expect to get leverage out of those around the world. So it isn't to say that operating cost in total will keep going up as a percentage of revenue. As far as the buy-in plan, I'm not going to get too detailed into it because there are too many soft spots and too many assumptions you'd have to make but I guess I'd point one thing out which I think is very important, when we look at -- people think we're very oriented towards outside the U.S. the way we think. But the fact of the matter is our headcount around the world is pretty balanced U.S. and the rest of the world, both as to revenue and as to headcount. And that is after you count Puerto Rico where we make 1 billion lenses in Puerto Rico. That is a possession of the United States and is part of U.S. So when we kind of think about this, we, they that we're hearing about -- we, the U.S. against the rest of the world. We, the U.S., 5% compared to 95% of those outside the U.S. It is not as imbalanced in Cooper's model as some may think it is. Long and the short of it is I'm not going to overreact to any theory that's thrown around out there, and I'll react to legislation. There hasn't been meaningful legislations since, I think, 1986. There's been a few things along the way that have come and gone, but it would be very premature to overanalyze it."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question come from Steve Willoughby of Cleveland Research.",11,"And our next question come from Steve Willoughby of Cleveland Research."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","I guess, first, Al, if we look back a month ago as it relates to FX, what would you be thinking in terms of the impact from FX to the total company for 2017 at that point versus the $0.10 headwind you're expecting now?",44,"I guess, first, Al, if we look back a month ago as it relates to FX, what would you be thinking in terms of the impact from FX to the total company for 2017 at that point versus the $0.10 headwind you're expecting now?"
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, Steve, tough to say, right, because it depends what day you chose. When Trump was elected, so to speak, I mean that's when currency rates really started moving. So if you go back to that day or prior to that day, we, at one point in time, would have",103,"Well, Steve, tough to say, right, because it depends what day you chose. When Trump was elected, so to speak, I mean that's when currency rates really started moving. So if you go back to that day or prior to that day, we, at one point in time, would have been $0.30, $0.40 positive. We would have the wind in our back. We probably ended up with -- I don't know what the exact numbers are, but it wouldn't surprise me if it's a $0.50 swing from what it was to what it is today, maybe even a little bit more than that."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Okay. And then just a follow-up, with the roughly 50% 1 Day silicone hydrogel growth this year, do you have any expectations on what that looks like next year?",29,"Okay. And then just a follow-up, with the roughly 50% 1 Day silicone hydrogel growth this year, do you have any expectations on what that looks like next year?"
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, as I indicated, it's off of a larger base. Now I wouldn't expect the 50% to be sustainable, but I think in terms of whole dollars, that certainly should be something we would expect. We have so much opportunity and we have the capacity that I'll say",71,"Well, as I indicated, it's off of a larger base. Now I wouldn't expect the 50% to be sustainable, but I think in terms of whole dollars, that certainly should be something we would expect. We have so much opportunity and we have the capacity that I'll say we'll put up solid numbers throughout 2017, but I'm not going to say it's any 1 particular percentage, let's put it that way."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Larry Keusch of Raymond James.",14,"And our next question comes from the line of Larry Keusch of Raymond James."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","A couple of questions here. Just, Al, I'm wondering if you could talk a little bit about the FX assumptions that you are using for 2017 on the major currencies.",30,"A couple of questions here. Just, Al, I'm wondering if you could talk a little bit about the FX assumptions that you are using for 2017 on the major currencies."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Sure. Pretty much today's rates. I mean, they obviously bounce around a lot, but the euro at about 1.06, the yen at 1.14, pound at 1.26. I mean that's kind of similar to where they are today, right? And then other currencies around the world would be pret",51,"Sure. Pretty much today's rates. I mean, they obviously bounce around a lot, but the euro at about 1.06, the yen at 1.14, pound at 1.26. I mean that's kind of similar to where they are today, right? And then other currencies around the world would be pretty similar to that."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Okay, perfect. And then 2 other ones quickly here. I know you mentioned the outlook for free cash flow generation in totality through 2021, but how are you thinking about free cash flow generation this year and maybe wrap into that CapEx? And then I guess",113,"Okay, perfect. And then 2 other ones quickly here. I know you mentioned the outlook for free cash flow generation in totality through 2021, but how are you thinking about free cash flow generation this year and maybe wrap into that CapEx? And then I guess that last thing is just struggling a little bit with the first quarter and why it's so low. I understand the tax rate, obviously, due to tough comparison. But can you talk a little bit about perhaps the gating for the spending of this incremental for sales and marketing, and is it weighted towards the first quarter or is it sort of more ratable through the year?"
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, I'll hit cash flow, and I'll let Bob go through on the marketing side. For this year, we're probably going to be 400 -- it should to be north of $400 million of free cash. Currency is hurting us a little bit right now, but it should be somewhere in t",105,"Yes, I'll hit cash flow, and I'll let Bob go through on the marketing side. For this year, we're probably going to be 400 -- it should to be north of $400 million of free cash. Currency is hurting us a little bit right now, but it should be somewhere in that $400 million range. CapEx, we'll see how that plays out. It looks like it's going to be somewhere around the $150 million for the year. So if you work off those numbers, $400 million and $150 million, that's probably not a bad way to look at this year at this point in time."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes. And I think as far as the gating of the investment spend and is it a drag on the first quarter? Yes, it is drag partly because of the fact that our first quarter is always the lightest on a revenue base -- from a revenue point of view which has alway",139,"Yes. And I think as far as the gating of the investment spend and is it a drag on the first quarter? Yes, it is drag partly because of the fact that our first quarter is always the lightest on a revenue base -- from a revenue point of view which has always been the case, and we started -- a lot of our investment started ramping in the fourth quarter so it's rolling into the first quarter, obviously, as part of the infrastructure already and will be somewhat of a drag. Some of our investments, if you will, that started in the fourth quarter and worked their way through the first quarter will start yielding, if you will, as the year progresses. We started expecting a return from some of that towards the back half of the year."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Andrew Hanover of JPMorgan.",13,"And our next question comes from the line of Andrew Hanover of JPMorgan."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Al, just wanted to go back just through '17 guidance. It looks like it's extremely conservative at least from what I can tell right this second. I think this is the first time you've embedded an interest rate increase in the numbers, 125 bps. So just wond",85,"Al, just wanted to go back just through '17 guidance. It looks like it's extremely conservative at least from what I can tell right this second. I think this is the first time you've embedded an interest rate increase in the numbers, 125 bps. So just wondering is that around -- is that an impact of around $0.18? And then I'm just trying to get a better feel for FX, SG&A, the higher tax rate and what's driving the higher tax rate for the year?"
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, a couple of comments. I mean, if you look at our debt levels, $1.3 billion. We acquired Wallace, obviously, so another $150 million-plus on that. It's pretty straightforward to do the math on the increase. We assumed a 25 basis point rate increase ha",238,"Yes, a couple of comments. I mean, if you look at our debt levels, $1.3 billion. We acquired Wallace, obviously, so another $150 million-plus on that. It's pretty straightforward to do the math on the increase. We assumed a 25 basis point rate increase happening, with the Fed moving here in the month of December so kind of fully baked in that end for the year, if you will. We -- probably a little conservative on interest expense, where we're at, based on the amount of cash flow we're generating and so forth and where we'll come out on the pricing grid, but we'll see how that plays out. When you look at the tax rate itself, we've been running kind of on a look-through basis, if you will, somewhere around that 10%. We've had a number of discrete items that have come through. We've had acquisition-related activity and so forth that have allowed some write-offs and so forth that have pushed the tax rate down. Could it come in lower than 10%? It could, but I would tell you right now, based on what we have today, we're looking at somewhere around that 10%, with Q1, Q2, Q4 probably being somewhat similar and, as usual, Q3 being a little lighter but not as dramatic as what you've seen in prior years where you would see a quarter that was a 3% or 4% quarter as an example."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","And I think one way of looking at that is our fourth quarter effective tax rate is 10.3. That is excluding any discrete items. So that's kind of what the business run ex the discrete items we've had year after year but do not anticipate going forward.",48,"And I think one way of looking at that is our fourth quarter effective tax rate is 10.3. That is excluding any discrete items. So that's kind of what the business run ex the discrete items we've had year after year but do not anticipate going forward."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Jeff Johnson of Robert Baird.",14,"And our next question comes from the line of Jeff Johnson of Robert Baird."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Bob, I wanted to start with you just on the sales force. So if I think about your sales force, I think it's about half to maybe 55% the size of your 2 larger competitors. And your market share is kind of in that same range. And so on the face of it, it se",189,"Bob, I wanted to start with you just on the sales force. So if I think about your sales force, I think it's about half to maybe 55% the size of your 2 larger competitors. And your market share is kind of in that same range. And so on the face of it, it seems like your sales force isn't overly undersized, I guess. And then I think about your private label business, it's somewhere around 25% or 30% of revenue, and I'd assume that's a lower touch business. Just wanting to understand why is the big focus on sales force additions at this point and what's really driving that? And then maybe, Al, for you, a follow-up question. I think I agree your EPS guidance looks like maybe there's some levers of conservatism in there, but 6% to 8% CVI growth in a fairly choppy market and maybe in a med tech market that's a little uncertain right now doesn't feel overly conservative to me, so maybe if you can address your thoughts on the 6% to 8% CVI growth for '17, that would be helpful as well."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, Jeff, on the size of our sales force compared to our competitors, I think if we compare our 23% market share to Alcon's, which is just a tad above ours, suffice it to say, the size of their sales force compared to ours is nowhere comparable. And J&J,",200,"Yes, Jeff, on the size of our sales force compared to our competitors, I think if we compare our 23% market share to Alcon's, which is just a tad above ours, suffice it to say, the size of their sales force compared to ours is nowhere comparable. And J&J, if we're going to do allocations against market share, with their 40% market share or there and thereabout to our 23%, that would barely line up. I think more importantly is it really is about if you have the product and we have the broadest product portfolio and you have the capacity, something we have not had in the past at least relative to clariti, MyDay and, to a lesser extent, even Biofinity. So if you have your -- the capacity you want, why wouldn't you test the water and see how good your products are? Why wouldn't you go after your competitors' accounts more aggressively? And we can't do it if we're under-indexed on feet on the street. So it's one thing if you're kind of growing methodically and you're confined with how much you can grow, it's another thing if you don't have those limitations which I'll call capacity."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, and I'll comment a little bit on the growth rate assumption. If you look at CooperVision last year, they grew 7.5% in constant currency, 11% in Q4 so, obviously, a lot of momentum there. You look at the Q1 guidance, the 7% to 10% and expecting that m",171,"Yes, and I'll comment a little bit on the growth rate assumption. If you look at CooperVision last year, they grew 7.5% in constant currency, 11% in Q4 so, obviously, a lot of momentum there. You look at the Q1 guidance, the 7% to 10% and expecting that momentum to continue -- and Jeff, I think, where you're going with this, to your point, is if you look at 6% to 8% for the year and you roll that Q1 in, you'd be talking about implied guidance, if you will, of Q2 to Q4 for CooperVision in the upper 6x which would be decelerating in the face of some decent investments. So I think that's a very fair question. I would tell you I think that giving a 6% to 8% range in today's world is prudent and a good way to look at the business, but I don't think anybody would be very happy, I'll put to you that way, if we were growing in the 6% to 7% range."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Anthony Petrone of Jefferies.",13,"And our next question comes from the line of Anthony Petrone of Jefferies."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Maybe just one question on the sales investments and then one just on the competitive landscape to follow up there. Just in terms of feet on the street, I'm just wondering how much of the investment is focused on optometrists, that channel, as opposed to",132,"Maybe just one question on the sales investments and then one just on the competitive landscape to follow up there. Just in terms of feet on the street, I'm just wondering how much of the investment is focused on optometrists, that channel, as opposed to other retail channels. And I guess the core of that is that we're under the impression that still the majority of sales for Cooper comes from optometrists. So just wondering if you're doubling down in that channel or expanding in other retail channels? And in terms of the competitive landscape, it would just be great to get an update, sort of where Alcon sits at this point. It looks like they're still in a position of giving up some share and, similarly, Bausch & Lomb and J&J."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Sure. Our focus in terms of feet on the street and whether it's independent ODs or ODs that are at the retail level is the OD, wherever they are. And a lot of our -- Cooper is very open as part of its strategy being -- it could be a branded entity or it c",331,"Sure. Our focus in terms of feet on the street and whether it's independent ODs or ODs that are at the retail level is the OD, wherever they are. And a lot of our -- Cooper is very open as part of its strategy being -- it could be a branded entity or it could be private label. So we're indifferent to what it's called. But what we have learned in the past is just because you send a bunch of your product, whether it's private label or branded, to a large retailer, if you don't work it, it's not going to work itself. You have to go to the OD, whether they're under an umbrella of a retailer or not. That has contrasted to maybe an online or some other mechanism, we don't waste our time with that. If you don't like the prescription, you don't have our attention, and that will continue. Relative to the competitive landscape, yes, our competitors continue to be in various stages of disarray, Alcon, we know what the CEO and Chairman of Novartis basically said, they are restructuring that organization. There is disruption there. They have a tired product line. B&L likewise is in a very disruptive environment to say the least. And J&J has done a pretty good job of marketing 1 product, OASYS. By any other name, it's OASYS, so it's all over, 1-day, 1-week, 2-week, 1-month called VITA. So of the 3 competitors, I would say J&J kind of has its act together better than the other 2. But having said that, they're obviously presenting some opportunities in their approach, they're in UPP one day and then they're out of UPP the next day. UPP wholesale across all of their products and then they vacate the entire thing, come up with a different plan. So we've been pretty steady state in the way we're approaching the market. We have the product portfolio and we kind of feel good about our competitors."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Brian Weinstein of William Blair.",14,"And our next question comes from the line of Brian Weinstein of William Blair."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","First one on margins, you guys had targeted some improvement in MyDay by the end of the year and talked about clariti getting north of corporate margins. Can you just comment kind of where the margins are in those products? And then Bob, for you, you had",133,"First one on margins, you guys had targeted some improvement in MyDay by the end of the year and talked about clariti getting north of corporate margins. Can you just comment kind of where the margins are in those products? And then Bob, for you, you had talked previously about 50% of the $10 billion market to be in the 1 day modality; of that, about somewhere between 20% and 77% to be in silicone hydrogel, and thought maybe the middle of that made sense. With more experience now of how these products are rolling out, do you have more confidence that over the next few years that you're going to be turning more above that 50% of the market towards that 77%? Where do you think that, that could be by 2020?"
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes. I think we're rapidly approaching the 50% mark for 1 Day. And within 1 Day, silicone hydrogel is continuing to make solid progress, growing 20%-ish in that market. And therefore, it's now I think over 20% of the -- or close to 25% of the 1 day market",276,"Yes. I think we're rapidly approaching the 50% mark for 1 Day. And within 1 Day, silicone hydrogel is continuing to make solid progress, growing 20%-ish in that market. And therefore, it's now I think over 20% of the -- or close to 25% of the 1 day market. So I do believe the 1-days will be more than 50% of the -- let's say, that target, $10 billion down the road 2020, 2021. And who knows? Foreign exchange keeps coming along, kind of putting a dent into some of that. So assuming the dollar stabilizes, we're directionally headed towards that $10 billion. 1 Day will be greater than 50%, and there's no doubt that silicone hydrogel 1 Day will be much greater than 20% of that 1 day market. And will it be similar to the planned replacement where it's close to 80%, 79% to 80%, or a lot less? I think there are some reasons that it won't go well beyond the 50% barrier short-term because there is so much activity in the non-silicone hydrogel mass market space that will be somewhat a barrier. To answer your question about our cost coming down, MyDay is making good progress. We believe it's in the 30s now and we would expect that in 2018, some time, will be honing in on that 50% target for 1 Day gross margin. And clariti, because of its novel approach to manufacturing and cost, will not be a drag. And it's not a drag today on our gross margin. So the mix you see is holding its own within that mix and is not a headwind on gross margin percentages."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Steven Lichtman of Oppenheimer.",13,"And our next question comes from the line of Steven Lichtman of Oppenheimer."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Just a couple of P&L follow-ups. First, in terms of the investment in sales and marketing, should we be thinking about that as solely sales force hire investments? Or is there any discrete marketing investments that are embedded in there? And then, second",70,"Just a couple of P&L follow-ups. First, in terms of the investment in sales and marketing, should we be thinking about that as solely sales force hire investments? Or is there any discrete marketing investments that are embedded in there? And then, secondly, Al, on the idle equipment charges, the enhanced charges we've seen owing to the efficiencies, how should we be thinking about those rolling off in 2017?"
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","So on the sales and marketing, it's more than just feet on the street, albeit the concentration and the focus is more so feet on the street. But with the new products, with Energys, with conversion of -- from Avaira to Vitality with a new toric -- a new M",266,"So on the sales and marketing, it's more than just feet on the street, albeit the concentration and the focus is more so feet on the street. But with the new products, with Energys, with conversion of -- from Avaira to Vitality with a new toric -- a new MyDay toric, all that activity, there certainly is -- and particularly upfront, as you come out with new products, some energy on the marketing side, some of that will tail off and some of it will continue as you roll it out around the world. So nothing -- I would say, nothing imminent where it's suddenly in a non-investment mode over the next 1 to 2 years. The roll-off of idle equipment is somewhat a function of the success of the growth of our various areas. Whether it's Vitality, whether it's MyDay, whether it's clariti, the growth in those products will form the basis of consuming some of that idle equipment over the next 1 to 2 years. We indicated partly because of the continuing successes in cutting cost and getting better yields and getting better throughput, we're now talking about lines with north of $80 million unit production that 2 years ago we didn't even have on the drawing board by way of a thought. So those kind of profound changes means we'll be able to continue to ramp up and continue to be ahead of the curve in terms of the demand side for quite a while in some of those areas, clariti and MyDay. Al, I don't know what other color you want to..."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Maybe just quickly -- Bob's exactly right, quantify that just a little bit. We had thought last year about kind of $0.10 a quarter above and beyond for idle equipment and some inventory charges. And we had that in Q2, Q3, Q4. I would say that we're contin",200,"Maybe just quickly -- Bob's exactly right, quantify that just a little bit. We had thought last year about kind of $0.10 a quarter above and beyond for idle equipment and some inventory charges. And we had that in Q2, Q3, Q4. I would say that we're continuing to have that right now. Those idle charges are mostly linked to the dailies side. So the growth that you're seeing is absolutely fantastic for us. Continuing growth like that put those lines to use and the idle equipment goes down. So the expansion, the focus on sales and marketing to drive topline growth and driving single-use, one of the nice benefits of that is it's going to put equipment to work. We obviously don't need to buy new equipment, which helps free cash flow and we would move idle equipment charges and put that into production. So I would say that we're still kind of looking at that $0.10 a quarter here to start the year. But then depending upon our success that will move down and hopefully move to 0 by the end of this year. But more likely, we'll see those charges even move into 2018 a little bit."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And I'm showing no further questions at this time. I would now like to turn the call over to Mr. Bob Weiss for closing remarks.",26,"And I'm showing no further questions at this time. I would now like to turn the call over to Mr. Bob Weiss for closing remarks."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, I want to thank you for joining our call today, and I wish everyone the happiest of holidays coming up. And we look forward to updating you on the progress we're making and on our new product rollout on our call in March which I believe is going to",70,"Well, I want to thank you for joining our call today, and I wish everyone the happiest of holidays coming up. And we look forward to updating you on the progress we're making and on our new product rollout on our call in March which I believe is going to be March 2, 2017. We look forward to talking to you then. Thank you, all. Thank you. That's it, operator."
263609,408515230,1100152,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This concludes today's program. You may all disconnect. Everyone, have a great day.",23,"Ladies and gentlemen, thank you for participating in today's conference. This concludes today's program. You may all disconnect. Everyone, have a great day."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Cooper Companies Incorporated Fourth Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to introduce your host for today",49,"Good day, ladies and gentlemen, and welcome to the Cooper Companies Incorporated Fourth Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to introduce your host for today's conference, Miss Kim Duncan, Vice President. Ma'am, you may begin."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Good afternoon and welcome to the Cooper Companies Fourth Quarter and Full Year 2016 Earnings Conference Call. I'm Kim Duncan, Vice President of Investor Relations, and giving prepared remarks on today's call are Bob Weiss, Chief Executive Officer; and Al",316,"Good afternoon and welcome to the Cooper Companies Fourth Quarter and Full Year 2016 Earnings Conference Call. I'm Kim Duncan, Vice President of Investor Relations, and giving prepared remarks on today's call are Bob Weiss, Chief Executive Officer; and Al White, Chief Financial Officer and Chief Strategy Officer. 
Before we get started, I'd like to remind you that this conference call contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including all revenue and earnings per share guidance and other statements regarding anticipated results of operations, market or regulatory conditions and integration of any acquisitions or their failure to achieved anticipated benefits. Forward-looking statements depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Events that could cause our actual results and future actions of the company to differ materially from those described in forward-looking statements are set forth under the caption Forward-Looking Statements in today's earnings release and are described in our SEC filings, including the business section of Cooper's annual report on Form 10-K. These are publicly available and on request from the company's Investor Relations Department. 
Before I turn the call over to Bob, let me comment on the agenda for the call. Bob will begin by providing highlights on the quarter, followed by Al who will then discuss the fourth quarter and full year financial results. We will keep the formal presentation to roughly 30 minutes, then open the call for questions. We expect this call to last approximately 1 hour. [Operator Instructions]. Should you have any additional questions, please call our investor line at (925) 460-3663 or e-mail ir@cooperco.com. This call is being webcast and a copy of the earnings release is available through the Investor Relations section of the Cooper Companies website. 
And with that, I'll turn the call over to Bob for his opening remarks."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thank you, Kim, and good afternoon, everyone. Welcome to the fourth quarter and full year 2016 conference call. Let me start by saying I'm very proud of our accomplishments this quarter, including record revenue and free cash flow. We also delivered a ver",1177,"Thank you, Kim, and good afternoon, everyone. Welcome to the fourth quarter and full year 2016 conference call. Let me start by saying I'm very proud of our accomplishments this quarter, including record revenue and free cash flow. We also delivered a very strong fiscal year gaining share in the $7.2 billion contact lens industry, continuing our approach into the 1 Day silicone hydrogel space, expanding our Biofinity franchise and posting strong growth in our CooperSurgical business. We enter fiscal 2017 with strong momentum. We remain confident we will see market share gains in both of our businesses for the foreseeable future. 
Let me highlight 3 key points for the quarter. First, I'm pleased to report another strong quarter, with revenues over $500 million. This includes CooperVision reporting revenues over $400 million and CooperSurgical reporting revenues over $100 million. This resulted in non-GAAP earnings per share of $2.28 and free cash flow of $158 million. Second, CooperVision posted strong results in all key areas of its business, resulting in 10% as reported and 11% constant currency revenue growth. This includes 1 Day silicone hydrogel lenses growing 53% and 2-week and monthly silicone hydrogel lenses growing a combined 14%, both in constant currency. Third, CooperSurgical had another strong quarter, posting revenue growth of 20% or 6% pro forma. Fertility was a highlight, posting growth of 74% or 8% pro forma. 
Moving into the details. CooperVision reported fourth quarter revenue of $412 million, up 10% as reported and 11% in constant currency. This is the fastest CooperVision has grown in 11 quarters. The Americas grew 8% in constant currency with strength in multiple categories including Biofinity and 1 Day silicone hydrogel lenses. Biofinity continues to be our workhorse and we began our launch in Biofinity Energys in mid-August to strong reviews. Our enhanced clariti lens is also performing well and MyDay had another very strong quarter. EMEA posted a very strong quarter, up 12% in constant currency. Growth was driven by Biofinity and our 1 Day silicone hydrogel franchise. Asia Pacific also had a very strong quarter, up 13% in constant currency. Growth is strong throughout the region, driven by Biofinity and our 1 Day silicone hydrogel franchise. Within Japan, our MyDay sphere and toric launch is progressing well. And while it's still early, we continue to believe MyDay can be a very successful premium offering in that market. 
Turning to product categories. Torics grew a healthy 14% and multifocals 10%, both in constant currency. We remain a global leader in specialty lenses, and our success in Biofinity and clariti in both of these categories should continue to drive growth for many years to come.  Looking at silicone hydrogel lenses. These products grew 21% in constant currency and now represents 62% of our sales. We expect this strong growth to continue, given our product portfolio which includes Biofinity, Vitality, our new launched 2-week product and our diverse 1 Day offering. And remember, the biggest driver in the contact lens market is the 1 Day growth, and we strongly believe we have the best product offering in the space as the only company selling premium and mass market silicone hydrogel lenses, including a portfolio of sphere, toric and multifocal lenses. We are also investing in sales and marketing to support our strong product portfolio. 
Forecasting new hires is always challenging, especially when you're evaluating opportunities around the world. But we believe CooperVision can add numerous sales reps and get a very nice return given our strong product platform, our capacity and our growth opportunities that we see. We believe this initiative -- we began this initiative in our fourth quarter and expect it to continue through fiscal 2017 and possibly into 2018. For competitive reasons, I won't get into many details but, suffice it to say, we carefully evaluate our hiring and expect to realize a solid return from this activity. 
Now let me comment on our overall contact lens market and remember, this information is on the last page of our earnings release. For calendar Q3 2016, we continued taking share, growing 6%, with the market up 1%. Geographically, CooperVision grew 3% in the Americas while the market was down 3%. In the EMEA, we were up 8%, and the market was up 7%. In Asia Pacific, we grew 9%, with the market up 3%. On a modality basis, single-use lenses continued driving growth, with CooperVision up 12% and the market up 8%. For non-single-use lenses, we grew 3% while the market declined 4%. As you can see, our growth remains diverse and strong. On a trailing 12-month basis, CooperVision grew 8% while the market grew 3%. Although the market remains choppy and hard to read at times, we continue to believe it will strengthen and grow 4% to 6% over the next 5 years driven by continuing shift to dailies, geographic expansion and an expansion of the wearer base. We expect to continue taking market share led by our strong portfolio of market-leading products. 
Moving to CooperSurgical, we reported fourth quarter revenues of $107 million, up 30% year-over-year, driven by organic growth and acquisitions. On a pro forma basis, we grew 6%. Fertility led the way, up 74% or 8% pro forma. Within Fertility, we had growth throughout the business and continue to believe our market-leading product portfolio which includes medical devices, genetic testing and capital equipment is the broadest portfolio in the space and should continue to drive growth for many years to come.  Within our office and surgical category, growth was 5%. 
We're continuing to execute on several product launches, including our disposable hysteroscope, EndoSee, and we continue to see success in this area. Regarding other activity, we announced on November 6 that we acquired the Wallace portfolio from Smiths Medical for approximately $168 million. This is a great strategic fit with our existing global IVF portfolio as it brings the gold standard of embryo transfer catheters along with several other premier products. Finally, CooperSurgical -- on CooperSurgical, we're busy integrating recent acquisitions but also executing on several initiatives which should significantly strengthen the business. These include transitioning to a global sales model, adding sales reps in underpenetrated areas, launching products into new markets and increasing our focus on high-growth areas such as IVF genetic testing. We have made a lot of progress in these areas over the past year and expect to continue -- even have more progress as we go forward.  
Now before I turn it over to Al, let me comment on a couple other items. We anticipate another strong year of revenue growth in 2017, including CooperVision growing 6% to 8% in constant currency and CooperSurgical growing 6% to 8% pro forma. We also remain bullish on our future and are updating our long-term objectives for operating margins of 28% and free cash flow generation of over $2 billion by 2021. 
In conclusion, I want to express my appreciation to our employees for all their hard work and dedication. And now I'll turn it over to Al to cover the financial results."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thank you, Bob, and good afternoon, everyone. Bob did an excellent job covering revenues, so I'll focus on the rest of our Q4 financial performance along with guidance. Most of my commentary will be on a non-GAAP basis, and a full reconciliation between o",746,"Thank you, Bob, and good afternoon, everyone. Bob did an excellent job covering revenues, so I'll focus on the rest of our Q4 financial performance along with guidance. Most of my commentary will be on a non-GAAP basis, and a full reconciliation between our GAAP and non-GAAP results is included in today's earnings release. 
For the quarter, gross margins were slightly over 64%, with both CooperVision and CooperSurgical up year-over-year. CooperVision improved roughly 50 basis points to 64.8% driven by factors such as currency and product mix while CooperSurgical grew roughly 30 basis points to 62.5% driven by cost-reduction efforts. Operating expenses grew 11.7% in the quarter driven heavily by CooperSurgical's acquisition-related activity. Within operating expenses, sales and marketing expenses grew 14% as both CooperVision and CooperSurgical executed on sales and marketing expansion plans to capitalize on strong product portfolios. Outside of sales and marketing, we drove leverage through general cost controls. Operating margins were 25.1%, up nicely from 24% last year driven by gross margin improvement and operating expense leverage. 
Moving to interest expense. We reported $5.3 million, which was lower than our guidance as we had a true-up of roughly $1.5 million. This true-up was associated with an over allocation of commitment fees in Q2 and Q3 related to the refinancing of our credit facilities completed in Q2 of this year. What should have happened is Q2 interest expense should have been lower by $600,000, and Q3 should have been lower by $900,000. Our effective tax rate was 10.3%, and the resulting non-GAAP EPS was $2.28 with roughly 49.3 million average shares outstanding. Total debt decreased this quarter by $110 million to roughly $1.33 billion driven by strong free cash flow of $158 million comprised of $193 million of operating cash flow and $35 million of CapEx. 
Regarding full year fiscal 2016 results, consolidated revenues were $1.967 billion, up 9.4% or 7.3% pro forma; CooperVision revenues were $1.577 billion, up 6% or 7.5% in constant currency; and CooperSurgical's revenues were $390 million, up 26% or 6.3% pro forma; non-GAAP EPS was $8.44, up 13%; lastly, free cash flow was $357 million. So all in, a very strong year. 
Moving to fiscal 2017 guidance. Let me start by commenting on currency, which has moved significantly against us over the past month or so. For 2017, we're estimating a negative year-over-year currency impact to revenues of approximately $57 million and negative $0.10 to EPS. Incorporating this into our outlook, we expect fiscal 2017 consolidated revenues of $2.09 billion to $2.13 billion. This is comprised of $1.62 billion to $1.65 billion at CooperVision which equates to roughly 6% to 8% constant currency growth and $470 million to $480 million in CooperSurgical which equates to roughly 6% to 8% pro forma growth. We expect gross margins to improve to around 64.5% and operating margins to improve to 25%. Interest expense is expected to be around $28 million which includes the additional debt from the Wallace acquisition along with an assumption of 125 basis points rate increase. The effective tax rate is expected to be around 10%. This may be higher than many of you were expecting, but it's based on our current forecast which includes fewer discrete items, and is thus more of a true run rate of our current operations. 
Non-GAAP EPS for fiscal 2017 is expected to be in the range of $9 to $9.30 based on 49.4 million shares outstanding. To provide color on this, the higher year-over-year tax rate will negatively impact earnings by roughly $0.20, and FX will negatively impact earnings by $0.10. We also anticipate continuing to invest in sales and marketing above and beyond our normal level, and this will likely be in excess of $10 million or $0.20 in fiscal 2017. Having said that, we do have several positives such as accretion from our CSI acquisition, less idle equipment and inventory charges, savings from manufacturing improvements and the royalty roll-off, and these will help drive earnings growth. Regarding Q1, we anticipate revenues of $494 million to $508 million. This is comprised of $383 million to $393 million at CooperVision or roughly 7% to 10% constant currency growth, and $111 million to $115 million at CooperSurgical which equates to roughly 3% to 7% pro forma growth. For Q1 non-GAAP EPS, we expect $1.78 to $1.88 and note, this assumes a 10% tax rate as compared to last year's 3.9%. 
And with that, I'll hand it back to the operator for questions."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","[Operator Instructions] And our first question comes from the line of Jon Block of Stifel.",15,"[Operator Instructions] And our first question comes from the line of Jon Block of Stifel."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Maybe the first question, still working through some numbers, it didn't really surprise us all too much on the fiscal 2017 guide. Al, you went through a lot of numbers. The lowest on 1Q, is that just a function of you do have the pound benefit for fiscal",149,"Maybe the first question, still working through some numbers, it didn't really surprise us all too much on the fiscal 2017 guide. Al, you went through a lot of numbers. The lowest on 1Q, is that just a function of you do have the pound benefit for fiscal 2017 but again, it really takes effect come January so you only had that for a slight stub of 1Q that can be causing approximately $0.20 discount -- sorry, $0.20 disconnects where you guided 1Q versus Street, that's a specific number? And maybe, Bob, maybe just to take a step back, just some market commentary. The down 3% U.S. is very surprising. We get your number, up 3% per your release. J&J, I think was up 5% and change, U.S. So how could 2/3 of the market be up a weighted 5% and we see negative 3% in the market data?"
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, I'll answer the first one, and then let Bob get into the market data. Yes, I agree with you. I mean, when you look at the pound move, most of that starts for us in January, so we get it for  1 month in the first quarter. So when you look at the incre",103,"Yes, I'll answer the first one, and then let Bob get into the market data. Yes, I agree with you. I mean, when you look at the pound move, most of that starts for us in January, so we get it for  1 month in the first quarter. So when you look at the incremental sales and marketing investments and you look at the higher tax rate which is somewhere around $0.13 for Q1 combined with only getting the pound benefit for really the month of January, I think that's probably where -- that probably comprises, certainly, the vast majority of the delta."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, as far as the market, I think we've all scratched our head a little about kind of the results being reported by us and the various market players compared to some of the data we see in industry data. And probably the best way to think about it is tha",289,"Yes, as far as the market, I think we've all scratched our head a little about kind of the results being reported by us and the various market players compared to some of the data we see in industry data. And probably the best way to think about it is that, a year ago, the Americas showed 11% growth and the entire market showed 8% growth worldwide driven very heavily by the Americas. This year, that kind of flips to a negative of 3% for the Americas and only 1% for worldwide. So you really have to look at 5 quarters or better yet, even 2 rolling years because of what happened a year ago was all the activity by J&J as they rolled out new products or things going on with UPP, so channel fill, so you end up with probably a delink between the way data comes into CLI and the public company. There's variances there, too, and including some of the activity associated with that. So when I think of the market, I kind of say, ""All right, let's put the 2 together."" Last year is 11%, this year it's negative 3%, that's 8%. Divided by 2, it looks more like 4% to me. And in the interim, we had a fourth quarter, 4%; a second quarter, 4%; and then a flat first quarter last year. So last year -- my way of thinking, last year rippled into the first quarter, so that 11% third quarter showed up as a neutral first quarter. The long and the short of it is it's probably best to look at it as 5 -- the average of 5 quarters if you're going to make much sense out of it."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Larry Biegelsen of Wells Fargo.",14,"And our next question comes from the line of Larry Biegelsen of Wells Fargo."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Bob, I'm sure it's going to get asked on this call, so I may as well ask about it. Just any thoughts on corporate tax reform and how -- and Cooper's view on this and how you think it could impact you guys? And then one other question, just on the quarter",75,"Bob, I'm sure it's going to get asked on this call, so I may as well ask about it. Just any thoughts on corporate tax reform and how -- and Cooper's view on this and how you think it could impact you guys? And then one other question, just on the quarter itself, the 11%, obviously, quite strong. Was there anything onetime in the quarter, selling days, stocking, et cetera, that helped you this quarter?"
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, I'll do the second one first which is there's nothing unusual about the 11%. We're obviously rolling out some new products. We had a slightly easier comp from a year ago, particularly relative to the Europe theater which is going through consolidatio",201,"Yes, I'll do the second one first which is there's nothing unusual about the 11%. We're obviously rolling out some new products. We had a slightly easier comp from a year ago, particularly relative to the Europe theater which is going through consolidation last year with Sauflon but, by and large, a solid quarter. As far as tax reform, well, tax reform has been talked about forever, and I could give you 2 theories on, if I just lock in on one thing that's being thrown around out there, the 35% going to 15%, suffice it to say that wouldn't be bad for most anyone and will serve as a neutralizer to a degree on however it shakes out the rest of the world. There are too many different debates going on out there. There's the fact that any meaningful change would require a vote of 60% of the Senate to go along with it, and that could be tough or only come with a lot of compromise. So I think it would be way premature to know if it's a net plus or a net minus, but most people wouldn't complain about a huge reduction in the corporate tax rate."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Matt Mishan of KeyBanc.",13,"And our next question comes from the line of Matt Mishan of KeyBanc."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Could you go a little bit further into the investment you guys are making in SG&A in really around the cadence? And maybe break out with the difference is between the growth in SG&A from the investment and the growth in SG&A from the acquisitions that you",62,"Could you go a little bit further into the investment you guys are making in SG&A in really around the cadence? And maybe break out with the difference is between the growth in SG&A from the investment and the growth in SG&A from the acquisitions that you're making just so we can get a better sense for how to model this."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","So the investment we're making in SG&A is sales and marketing. We're leveraging the rest of the infrastructure. And in the area of sales and marketing, that is both on the Vision side, heavily feet on the street, we're under-indexed compared to our compet",296,"So the investment we're making in SG&A is sales and marketing. We're leveraging the rest of the infrastructure. And in the area of sales and marketing, that is both on the Vision side, heavily feet on the street, we're under-indexed compared to our competitors. And as I indicated, I'm not going to start quoting numbers of adds in terms of number of sales force we're adding. But suffice it to say, we also are rolling out many new products. Some of them are conceptually new like Energys. So there'll be a fair amount of energy also supporting those new products. And putting the 2 together, we will  while we're giving you guidance at 6% to 8% top line growth for both Surgical and Vision. We will be, suffice it to say, growing our sales and marketing at a rate faster primarily in the area of both feet on the street and, to a lesser extent, the marketing support behind that. Beyond that, we're not -- like I said, we're not going to really get into how under-indexed we are compared to our competitors. And I would say it's -- in many cases, it will be not across the board. If you have a vacancy or you're under-indexed in a geographic area, and I've always used an example of a city like Las Vegas and said, ""You know, if you didn't have a salesperson in Las Vegas, it's a pretty big town, maybe you ought to have a salesperson there if you have a lot of products to talk about."" So in some cases, it's adding junior people to support senior people, in other places there will be having feet on the street where you're currently making telephone calls and kind of piggybacking on that."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","And one quick add comment, when you look at the breakdown between Vision and Surgical, it's probably easiest to think about it from a sales and marketing perspective, as if sales and marketing in each business is going to grow somewhat similar of what the",77,"And one quick add comment, when you look at the breakdown between Vision and Surgical, it's probably easiest to think about it from a sales and marketing perspective, as if sales and marketing in each business is going to grow somewhat similar of what their revenues are, their as-reported revenues. So if you look at that on a CooperSurgical basis, obviously, it's quite a bit higher on a percentage growth basis than Vision due to the acquisitions."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Matthew O'Brien of Piper Jaffray.",15,"And our next question comes from the line of Matthew O'Brien of Piper Jaffray."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Just on the dailies side, the performance in the quarter was a slight acceleration over what we saw last quarter. Can you talk a little bit about where that came from, be it MyDay, be it clariti, maybe MyDay in Japan? And then, on top of that, just the 2-",76,"Just on the dailies side, the performance in the quarter was a slight acceleration over what we saw last quarter. Can you talk a little bit about where that came from, be it MyDay, be it clariti, maybe MyDay in Japan? And then, on top of that, just the 2-year stacks on the non-daily side appears to decelerate. Could you just talk a little bit about what's going on there? Are you seeing some VITA impact?"
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes. On the dailies side, there was some acceleration. Having said that, we kind of targeted for basically some approaching 50% for the year, a slight acceleration from the prior year is the way we thought about it coming into this year. So it's kind of m",367,"Yes. On the dailies side, there was some acceleration. Having said that, we kind of targeted for basically some approaching 50% for the year, a slight acceleration from the prior year is the way we thought about it coming into this year. So it's kind of moving along those lines. And the way it's moving is, obviously, the more mature market is EMEA where these products started out, both MyDay and clariti. The least mature is Japan and the Americas, so we're very early in the cycle in those 2 areas and rapidly expanding the offering even in Europe. So it's geographically across all theaters and very much -- we've now kind of did the redo of the first clariti that was out there, and that's performing real well. So we're now expanding our attention into more than our own accounts. Initially, we had to take care of our accounts that we had given the first generation, if you will, product to. So a long way to go, and we're very early in the cycle and obviously moving off of a larger base as we go forward. As far as the deceleration in the planned replacement area, the non-1 Day, really, that market, if we look at it from a 2.5-year, 3-year perspective, is in around breakeven, with the growth all being driven by the 1 Day. That's been pretty consistent over the last 4 years, and we don't see that changing. Actually, it's been consistent a lot -- a driver longer than 4 years, but more so outside the U.S. and more recently inside the U.S., so don't see any changes there. There is activity in the planned replacement market, things like Biofinity, obviously, are still putting up terrific numbers so there's room to grow. And particularly as we think about the geographic expansion, some of what goes into China and into some of those theaters, maybe a little less weighted initially in the 1 Day modality, although that -- we can't make that statement about every country. So a lot of opportunity even in the planned replacement arena, and we're obviously continuing to grow that while the market may be not growing, if you will."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Joanne Wuensch of BMO Capital Markets.",15,"And our next question comes from the line of Joanne Wuensch of BMO Capital Markets."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Two questions. The first one, is the new SG&A rate for 2017, do we think of that as the go-forward rate? Or do we think of that as a period of investment and then it should ease off? And then the second question, to circle back to the tax issue, we're get",103,"Two questions. The first one, is the new SG&A rate for 2017, do we think of that as the go-forward rate? Or do we think of that as a period of investment and then it should ease off? And then the second question, to circle back to the tax issue, we're getting questions from investors regarding your buy-in plan and what it means -- may or may not mean for Cooper which manufactures a fair bit outside of the United States, generates a fair bit of its revenue outside the United States, and I was curious if you had looked into that yet."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","So on the SG&A, if it's short-term or long-term, the sales and marketing, we plan on continuing to invest throughout 2017. And as I indicated in my commentary, to the extent it rolls into 2018 where we're getting the top line growth we want, we will conti",479,"So on the SG&A, if it's short-term or long-term, the sales and marketing, we plan on continuing to invest throughout 2017. And as I indicated in my commentary, to the extent it rolls into 2018 where we're getting the top line growth we want, we will continue that modality. The driver there is if you have a lot of products to talk about and you have the capacity then you should try selling the product and leverage the capacity. We know we have excess capacity, and why not use it? So to the extent we're getting our payback, which will include diminishing the idle charges that we're incurring on cost of goods as a byproduct, we're going to do it. And we obviously have an agenda of gaining market share, and we've certainly done a good job of that the last 7 years. And if I look at it over the last 12 months, it's been greater than 2% that we've grown in the market. You can't make much out of this quarter's numbers because we grew 6 and the market 1 -- grew 1. I'm not going to say we're growing 6x the market but, obviously, we are growing around that 2x. Relative to the rest of operating cost, distribution, G&A and even, to a lesser extent, R&D, we expect to get leverage out of those around the world. So it isn't to say that operating cost in total will keep going up as a percentage of revenue. As far as the Ryan plan, I'm not going to get too detailed into it because there are too many soft spots and too many assumptions you'd have to make. But I guess I'd point one thing out which I think is very important. When we look at -- people think we're very oriented towards outside the U.S. the way we think. But the fact of the matter is our headcount around the world is pretty balanced U.S. and the rest of the world, both as to revenue and as to headcount. And that is after you count Puerto Rico where we make 1 billion lenses in Puerto Rico, that is a possession of the United States and is part of U.S. So when we kind of think about this, we, they that we're hearing about -- we, the U.S. against the rest of the world; we, the U.S., 5% compared to 95% of those outside the U.S., it is not as imbalanced in Cooper's model as some may think it is. Long and the short of it is I'm not going to overreact to any theory that gets thrown around out there, and I'll react to legislation. There hasn't been meaningful legislation since, I think, 1986. There's been a few things along the way that have come and gone, but it would be very premature to overanalyze it."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Steve Willoughby of Cleveland Research.",14,"And our next question comes from the line of Steve Willoughby of Cleveland Research."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","I guess, first, Al, if we look back a month ago as it relates to FX, what would you be thinking in terms of the impact from FX to the total company for 2017 at that point versus the $0.10 headwind you're expecting now?",44,"I guess, first, Al, if we look back a month ago as it relates to FX, what would you be thinking in terms of the impact from FX to the total company for 2017 at that point versus the $0.10 headwind you're expecting now?"
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, Steve, tough to say, right, because it depends what day you chose. When Trump was elected, so to speak, I mean that's when currency rates really started moving. So if you go back to that day or prior to that day, we, at one point in time, would have",102,"Well, Steve, tough to say, right, because it depends what day you chose. When Trump was elected, so to speak, I mean that's when currency rates really started moving. So if you go back to that day or prior to that day, we, at one point in time, would have been $0.30, $0.40 positive. We would have had the wind at our back. We probably ended up with -- I don't know what the exact numbers are, but wouldn't surprise me if it's $0.50 swing from what it was to what it is today, maybe even a little bit more than that."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Okay. And then just a follow-up, with the roughly 50% 1 Day silicone hydrogel growth this year, do you have any expectations for kind of what that looks like next year?",31,"Okay. And then just a follow-up, with the roughly 50% 1 Day silicone hydrogel growth this year, do you have any expectations for kind of what that looks like next year?"
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, as I indicated, it's off of a larger base. So I wouldn't expect the 50% to be sustainable, but I think in terms of whole dollars, that certainly should be something we would expect. We have so much opportunity and we have the capacity that all I'll",74,"Well, as I indicated, it's off of a larger base. So I wouldn't expect the 50% to be sustainable, but I think in terms of whole dollars, that certainly should be something we would expect. We have so much opportunity and we have the capacity that all I'll say is we'll put up solid numbers throughout 2017, but I'm not going to say it's any one, particularly in percentage, let's put it that way."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Larry Keusch of Raymond James.",14,"And our next question comes from the line of Larry Keusch of Raymond James."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Couple questions here. Just, Al, I'm wondering if you could talk a little bit about the FX assumptions that you are using for 2017 on the major currencies.",28,"Couple questions here. Just, Al, I'm wondering if you could talk a little bit about the FX assumptions that you are using for 2017 on the major currencies."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Sure. Pretty much today's rates. I mean, they're obviously bouncing around a lot, but the euro at about 1.06, the yen at 1.14, pound at 1.26. And I mean that's kind of similar to where they are today, right? And then other currencies around the world woul",52,"Sure. Pretty much today's rates. I mean, they're obviously bouncing around a lot, but the euro at about 1.06, the yen at 1.14, pound at 1.26. And I mean that's kind of similar to where they are today, right? And then other currencies around the world would be pretty similar to that."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Okay, perfect. And then 2 other ones quickly here. I know you mentioned the outlook for free cash flow generation in totality through 2021, but how are you thinking about free cash flow generation this year and maybe wrap into that CapEx? And then I guess",113,"Okay, perfect. And then 2 other ones quickly here. I know you mentioned the outlook for free cash flow generation in totality through 2021, but how are you thinking about free cash flow generation this year and maybe wrap into that CapEx? And then I guess that last thing is just struggling a little bit with the first quarter and why it's so low. I understand the tax rate, obviously, there's a tough comparison. But can you talk a little bit about perhaps the gating for the spending of this incremental for sales and marketing, and is it weighted towards the first quarter or is it sort of more ratable through the year?"
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, I'll hit cash flow, and I'll let Bob go through on the marketing side. For this year, we're probably going to be 400 -- should to be north of $400 million of free cash. Currency is hurting us a little bit right now, but it should be somewhere in that",104,"Yes, I'll hit cash flow, and I'll let Bob go through on the marketing side. For this year, we're probably going to be 400 -- should to be north of $400 million of free cash. Currency is hurting us a little bit right now, but it should be somewhere in that $400 million range. CapEx, we'll see how that plays out. It looks like it's going to be somewhere around the $150 million for the year. So if you work off those numbers, $400 million and $150 million, that's probably not a bad way to look at this year at this point in time."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes. And I think as far as the gating of the investment spend and is it a drag on the first quarter, yes, it is drag partly because of the fact that our first quarter is always the lightest on a revenue base -- from a revenue point of view which has alway",140,"Yes. And I think as far as the gating of the investment spend and is it a drag on the first quarter, yes, it is drag partly because of the fact that our first quarter is always the lightest on a revenue base -- from a revenue point of view which has always been the case, and we started -- a lot of our investment started ramping in the fourth quarter so it's rolling into the first quarter, obviously, as part of the infrastructure already and will be somewhat of a drag. Some of our investments, if you will, that started in the fourth quarter and worked their way through the first quarter will start yielding, if you will, as the year progresses and we start expecting a return from some of that towards the back half of the year."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Andrew Hanover of JPMorgan.",13,"And our next question comes from the line of Andrew Hanover of JPMorgan."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Al, I just wanted to go back just through '17 guidance. And just it looks like it's extremely conservative at least from what I can tell right this second. I think this is the first time you've embedded an interest rate increase in the numbers. And kind o",92,"Al, I just wanted to go back just through '17 guidance. And just it looks like it's extremely conservative at least from what I can tell right this second. I think this is the first time you've embedded an interest rate increase in the numbers. And kind of 125 bps, I was just wondering is that around -- is that an impact of around $0.18? And then I'm just trying to get a better feel for FX, SG&A, the higher tax rate and what's driving the higher tax rate for the year?"
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, a couple comments. I mean, if you look at our debt levels, $1.3 billion. We acquired Wallace, obviously, so another $150 million-plus on that. It's pretty straightforward to do the math on the increase. We assumed a 25 basis point rate increase happe",236,"Yes, a couple comments. I mean, if you look at our debt levels, $1.3 billion. We acquired Wallace, obviously, so another $150 million-plus on that. It's pretty straightforward to do the math on the increase. We assumed a 25 basis point rate increase happening, with the Fed moving here in the month of December, so kind of fully baking that in for the year, if you will. We -- probably a little conservative on interest expense where we're at, based on the amount of cash flow we're generating and so forth and where we'll come out on the pricing grid, but we'll see how that plays out. When you look at the tax rate itself, we've been running kind of on a look-through basis, if you will, somewhere around that 10%. We've had a number of discrete items that have come through. We've had acquisition-related activity and so forth that have allowed some write-offs and so forth that have pushed the tax rate down. Could it come in lower than 10%? It could. But I would tell you right now, based on what we have today, we're looking at somewhere around that 10%, with Q1, Q2, Q4 probably being somewhat similar and, as usual, Q3 being a little lighter but not as dramatic as what you've seen in prior years where you would see a quarter that was a 3% or 4% quarter as an example."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","And I think one way of looking at that is our fourth quarter effective tax rate is 10.3%. That is excluding any discrete items. So that's kind of what the business run ex the discrete items we've had year after year but do not anticipate going forward.",48,"And I think one way of looking at that is our fourth quarter effective tax rate is 10.3%. That is excluding any discrete items. So that's kind of what the business run ex the discrete items we've had year after year but do not anticipate going forward."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Jeff Johnson of Robert Baird.",14,"And our next question comes from the line of Jeff Johnson of Robert Baird."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Bob, I wanted to start with you just on the sales force. So if I think about your sales force, I think it's about half to maybe 55% the size of your 2 larger competitors. And your market share is kind of in that same range. And so on the face of it, it se",189,"Bob, I wanted to start with you just on the sales force. So if I think about your sales force, I think it's about half to maybe 55% the size of your 2 larger competitors. And your market share is kind of in that same range. And so on the face of it, it seems like your sales force isn't overly undersized, I guess. And then I think about your private label business, it's somewhere around 25% or 30% of revenue, and I'd assume that's a lower touch business. Just wanting to understand why is the big focus on sales force additions at this point and what's really driving that? And then maybe, Al, for you, a follow-up question. I think I agree, your EPS guidance looks like maybe there's some levers of conservatism in there, but 6% to 8% CVI growth in a fairly choppy market and maybe in a med tech market that's a little uncertain right now doesn't feel overly conservative to me, so maybe if you can address your thoughts on the 6% to 8% CVI growth for '17, that would be helpful as well."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, Jeff, on the size of our sales force compared to our competitors, I think if we compare our 23% market share to Alcon's, which is just a tad above ours, suffice it to say, the size of their sales force compared to ours is nowhere comparable. And J&J,",200,"Yes, Jeff, on the size of our sales force compared to our competitors, I think if we compare our 23% market share to Alcon's, which is just a tad above ours, suffice it to say, the size of their sales force compared to ours is nowhere comparable. And J&J, if we're going to do allocations against market share, with their 40% market share or there and thereabout to our 23%, that would barely line up. I think more importantly is it really is about if you have the product and we have the broadest product portfolio and you have the capacity, something we have not had in the past at least relative to clariti, MyDay and, to a lesser extent, even Biofinity. So if you have your -- the capacity you want, why wouldn't you test the water and see how good your products are? Why wouldn't you go after your competitors' accounts more aggressively? And we can't do it if we're under-indexed on feet on the street. So it's one thing if you're kind of growing methodically and you're confined with how much you can grow, it's another thing if you don't have those limitations which I'll call capacity."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, and I'll comment a little bit on the growth rate assumption. I mean if you look at CooperVision last year, they grew 7.5% in constant currency, 11% in Q4 so, obviously, a lot of momentum there. You look at the Q1 guidance of 7% to 10% and expecting t",174,"Yes, and I'll comment a little bit on the growth rate assumption. I mean if you look at CooperVision last year, they grew 7.5% in constant currency, 11% in Q4 so, obviously, a lot of momentum there. You look at the Q1 guidance of 7% to 10% and expecting that momentum to continue, and Jeff, I think, where you're going with this, to your point, is if you look at 6% to 8% for the year and you roll that Q1 in, you'd be talking about implied guidance, if you will, of Q2 to Q4 for CooperVision in the upper 6s which would be decelerating in the face of some decent investment. So I think that's a very fair question. I would tell you I think that giving a 6% to 8% range in today's world is prudent and a good way to look at the business, but I don't think anybody would be very happy, let me put it to you that way, if we were growing in the 6% to 7% range."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Anthony Petrone of Jefferies.",13,"And our next question comes from the line of Anthony Petrone of Jefferies."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Maybe just one question on the sales investments and then one just on the competitive landscape to follow up there. Just in terms of feet on the street, I'm just wondering how much of the investment is focused on optometrists, that channel, as opposed to",132,"Maybe just one question on the sales investments and then one just on the competitive landscape to follow up there. Just in terms of feet on the street, I'm just wondering how much of the investment is focused on optometrists, that channel, as opposed to other retail channels. And I guess the core of that is that we're under the impression that still the majority of sales for Cooper comes from optometrists. So just wondering if you're doubling down in that channel or expanding in other retail channels? And in terms of the competitive landscape, it would just be great to get an update, sort of where Alcon sits at this point. It looks like they're still in a position of giving up some share and, similarly, Bausch & Lomb and J&J."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Sure. Our focus in terms of feet on the street and whether it's independent ODs or ODs that are at the retail level is the OD, wherever they are. And a lot of our -- Cooper is very open as part of its strategy being -- it could be a branded entity or it c",333,"Sure. Our focus in terms of feet on the street and whether it's independent ODs or ODs that are at the retail level is the OD, wherever they are. And a lot of our -- Cooper is very open as part of its strategy being -- it could be a branded entity or it could be private label. So we're indifferent to what it's called. But what we have learned in the past is just because you send a bunch of your product, whether it's private label or branded, to a large retailer, if you don't work it, it's not going to work itself. You have to go to the OD, whether they're under an umbrella of a retailer or not. That has contrasted to maybe an online or some other mechanism, we don't waste our time with that. If you don't like the prescription, you don't have our attention, and that will continue. Relative to the competitive landscape, yes, our competitors continue to be in various stages of disarray, Alcon, we know what the CEO and Chairman of Novartis basically said, they are restructuring that organization. There is disruption there. They have a tired product line. B&L likewise is in a very disruptive environment to say the least. And J&J has done a pretty good job of marketing 1 product, OASYS. By any other name, it is OASYS, so it's all over, 1-day, 1-week, 2-week, 1-month called VITA. So of the 3 competitors, I would say J&J kind of has its act together better than the other 2. But having said that, they're obviously presenting some opportunity in their approach, are they in UPP one day and then they're out of UPP the next day. UPP wholesale across all of their products and then they vacate the entire thing, come up with a different plan. So we've been pretty steady state in the way we're approaching the market. We have the product portfolio and we kind of feel good about our competitors."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Brian Weinstein of William Blair.",14,"And our next question comes from the line of Brian Weinstein of William Blair."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","First one on margins, you guys had targeted some improvement in MyDay by the end of the year and talked about clariti getting north of corporate margins. Can you just comment kind of where the margins are in those products? And then, Bob, for you, you had",133,"First one on margins, you guys had targeted some improvement in MyDay by the end of the year and talked about clariti getting north of corporate margins. Can you just comment kind of where the margins are in those products? And then, Bob, for you, you had talked previously about 50% of the $10 billion market to be in the 1 day modality; of that, about somewhere between 20% and 77% to be in silicone hydrogel, and thought maybe the middle of that made sense. With more experience now of how these products are rolling out, do you have more confidence that over the next few years that you're going to be turning more above that 50% of the market towards that 77%? Where do you think that, that could be by 2020?"
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes. I think we're rapidly approaching the 50% mark for 1 Day. And within 1 Day, silicone hydrogel is continuing to make solid progress, growing 20%-ish in that market. And therefore, it's now I think over 20% of the -- or close to 25% of the 1 day market",276,"Yes. I think we're rapidly approaching the 50% mark for 1 Day. And within 1 Day, silicone hydrogel is continuing to make solid progress, growing 20%-ish in that market. And therefore, it's now I think over 20% of the -- or close to 25% of the 1 day market. So I do believe the 1-days will be more than 50% of the -- let's say, that target, $10 billion down the road 2020, 2021. And who knows? Foreign exchange keeps coming along, kind of putting a dent into some of that. So assuming the dollar stabilizes, we're directionally headed towards that $10 billion. 1 Day will be greater than 50%, and there's no doubt that silicone hydrogel 1 Day will be much greater than 20% of that 1 day market. And will it be similar to the planned replacement where it's close to 80%, 79% to 80%, or a lot less? I think there are some reasons that it won't get well beyond the 50% barrier short-term because there is so much activity in the non-silicone hydrogel mass market space that, that will be somewhat a barrier. To answer your question about our cost coming down, MyDay is making good progress. We believe it's in the 30s now and we would expect that by 2018 sometime, will be honing in on that 50% target for 1 Day gross margin. And clariti, because of its novel approach to manufacturing and cost, will not be a drag. And it's not a drag today on our gross margin. So the mix you see, it's holding its own within that mix and is not a headwind on gross margin percentages."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Steven Lichtman of Oppenheimer.",13,"And our next question comes from the line of Steven Lichtman of Oppenheimer."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Just a couple of P&L follow-ups. First, in terms of the investment in sales and marketing, should we be thinking about that as sort of solely sales force hire investments? Or is there any discrete marketing investments that are embedded in there? And then",72,"Just a couple of P&L follow-ups. First, in terms of the investment in sales and marketing, should we be thinking about that as sort of solely sales force hire investments? Or is there any discrete marketing investments that are embedded in there? And then, secondly, Al, on the idle equipment charges, the enhanced charges we've seen owing to the efficiencies, how should we be thinking about those rolling off in 2017?"
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","So on the sales and marketing, it's more than just feet on the street, albeit the concentration and the focus is more so feet on the street. But with the new products, with Energys, with conversion of -- from Avaira to Vitality, with a new toric -- a new",266,"So on the sales and marketing, it's more than just feet on the street, albeit the concentration and the focus is more so feet on the street. But with the new products, with Energys, with conversion of -- from Avaira to Vitality, with a new toric -- a new MyDay toric, all that activity, there certainly is -- and particularly upfront, as you come out with new products, some energy on the marketing side. Some of that will tail off and some of it will continue as you roll it out around the world. So nothing -- I would say, nothing imminent where it's suddenly in a non-investment mode over the next 1 to 2 years. The roll-off of idle equipment is somewhat a function of the success of the growth of our various areas. Whether it's Vitality, whether it's MyDay, whether it's clariti, the growth in those products will form the basis of consuming some of that idle equipment over the next 1 to 2 years. We indicated partly because of the continuing successes in cutting costs and getting better yields and getting better throughput, we're now talking about lines with north of $80 million unit production that 2 years ago we didn't even have on the drawing board by way of a thought. So those kind of profound changes means we'll be able to continue to ramp up and continue to be ahead of the curve in terms of the demand side for quite a while in some of those areas, clariti and MyDay. Al, I don't know what other color you want to..."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes. Maybe just to quickly -- Bob's exactly right, quantify that just a little bit. We had talked last year about kind of $0.10 a quarter above and beyond for idle equipment and some inventory charges. And we had that in Q2, Q3, Q4. I would say that we're",202,"Yes. Maybe just to quickly -- Bob's exactly right, quantify that just a little bit. We had talked last year about kind of $0.10 a quarter above and beyond for idle equipment and some inventory charges. And we had that in Q2, Q3, Q4. I would say that we're continuing to have that right now. Those idle charges are mostly linked to the dailies side. So the growth that you're seeing is absolutely fantastic for us. Continuing growth like that puts those lines to use and the idle equipment goes down. So the expansion, the focus on sales and marketing to drive topline growth, driving single-use, one of the nice benefits of that is it's going to put equipment to work. We obviously don't need to buy new equipment, which helps free cash flow and we would move idle equipment charges and put that into production. So I would say that we're still kind of looking at that $0.10 a quarter here to start the year. But then depending upon our success that will move down and hopefully move to 0 by the end of this year. But more than likely, we'll see those charges even move into 2018 a little bit."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And I'm showing no further questions at this time. I would now like to turn the call over to Mr. Bob Weiss for closing remarks.",26,"And I'm showing no further questions at this time. I would now like to turn the call over to Mr. Bob Weiss for closing remarks."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, I want to thank you for joining our call today, and I wish everyone the happiest of holidays coming up. And we look forward to updating you on the progress we're making and on our new product rollout on our call in March which I believe is going to",70,"Well, I want to thank you for joining our call today, and I wish everyone the happiest of holidays coming up. And we look forward to updating you on the progress we're making and on our new product rollout on our call in March which I believe is going to be March 2, 2017. We look forward to talking to you then. Thank you, all. Thank you. That's it, operator."
263609,408515230,1100183,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This concludes today's program. You may all disconnect. Everyone, have a great day.",23,"Ladies and gentlemen, thank you for participating in today's conference. This concludes today's program. You may all disconnect. Everyone, have a great day."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","Good day, ladies and gentlemen, and welcome to the Cooper Companies Incorporated Fourth Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to introduce your host for today",49,"Good day, ladies and gentlemen, and welcome to the Cooper Companies Incorporated Fourth Quarter 2016 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to introduce your host for today's conference, Miss Kim Duncan, Vice President. Ma'am, you may begin."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Good afternoon and welcome to the Cooper Companies Fourth Quarter and Full Year 2016 Earnings Conference Call. I'm Kim Duncan, Vice President of Investor Relations, and giving prepared remarks on today's call are Bob Weiss, Chief Executive Officer; and Al",316,"Good afternoon and welcome to the Cooper Companies Fourth Quarter and Full Year 2016 Earnings Conference Call. I'm Kim Duncan, Vice President of Investor Relations, and giving prepared remarks on today's call are Bob Weiss, Chief Executive Officer; and Al White, Chief Financial Officer and Chief Strategy Officer. 
Before we get started, I'd like to remind you that this conference call contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including all revenue and earnings per share guidance and other statements regarding anticipated results of operations, market or regulatory conditions and integration of any acquisitions or their failure to achieved anticipated benefits. Forward-looking statements depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Events that could cause our actual results and future actions of the company to differ materially from those described in forward-looking statements are set forth under the caption Forward-Looking Statements in today's earnings release and are described in our SEC filings, including the business section of Cooper's annual report on Form 10-K. These are publicly available and on request from the company's Investor Relations Department. 
Before I turn the call over to Bob, let me comment on the agenda for the call. Bob will begin by providing highlights on the quarter, followed by Al who will then discuss the fourth quarter and full year financial results. We will keep the formal presentation to roughly 30 minutes, then open the call for questions. We expect this call to last approximately 1 hour. [Operator Instructions] Should you have any additional questions, please call our investor line at (925) 460-3663 or e-mail ir@cooperco.com. This call is being webcast and a copy of the earnings release is available through the Investor Relations section of the Cooper Companies website. 
And with that, I'll turn the call over to Bob for his opening remarks."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thank you, Kim, and good afternoon, everyone. Welcome to the fourth quarter and full year 2016 conference call. Let me start by saying I'm very proud of our accomplishments this quarter, including record revenue and free cash flow. We also delivered a ver",1177,"Thank you, Kim, and good afternoon, everyone. Welcome to the fourth quarter and full year 2016 conference call. Let me start by saying I'm very proud of our accomplishments this quarter, including record revenue and free cash flow. We also delivered a very strong fiscal year gaining share in the $7.2 billion contact lens industry, continuing our approach into the 1 Day silicone hydrogel space, expanding our Biofinity franchise and posting strong growth in our CooperSurgical business. We enter fiscal 2017 with strong momentum. We remain confident we will see market share gains in both of our businesses for the foreseeable future. 
Let me highlight 3 key points for the quarter. First, I'm pleased to report another strong quarter, with revenues over $500 million. This includes CooperVision reporting revenues over $400 million and CooperSurgical reporting revenues over $100 million. This resulted in non-GAAP earnings per share of $2.28 and free cash flow of $158 million. Second, CooperVision posted strong results in all key areas of its business, resulting in 10% as reported and 11% constant currency revenue growth. This includes 1 Day silicone hydrogel lenses growing 53% and 2-week and monthly silicone hydrogel lenses growing a combined 14%, both in constant currency. Third, CooperSurgical had another strong quarter, posting revenue growth of 20% or 6% pro forma. Fertility was a highlight, posting growth of 74% or 8% pro forma. 
Moving into the details. CooperVision reported fourth quarter revenue of $412 million, up 10% as reported and 11% in constant currency. This is the fastest CooperVision has grown in 11 quarters. The Americas grew 8% in constant currency with strength in multiple categories including Biofinity and 1 Day silicone hydrogel lenses. Biofinity continues to be our workhorse and we began our launch in Biofinity Energys in mid-August to strong reviews. Our enhanced clariti lens is also performing well and MyDay had another very strong quarter. EMEA posted a very strong quarter, up 12% in constant currency. Growth was driven by Biofinity and our 1 Day silicone hydrogel franchise. Asia Pacific also had a very strong quarter, up 13% in constant currency. Growth is strong throughout the region, driven by Biofinity and our 1 Day silicone hydrogel franchise. Within Japan, our MyDay sphere and toric launch is progressing well. And while it's still early, we continue to believe MyDay can be a very successful premium offering in that market. 
Turning to product categories. Torics grew a healthy 14% and multifocals 10%, both in constant currency. We remain a global leader in specialty lenses, and our success in Biofinity and clariti in both of these categories should continue to drive growth for many years to come.  Looking at silicone hydrogel lenses. These products grew 21% in constant currency and now represents 62% of our sales. We expect this strong growth to continue, given our product portfolio which includes Biofinity, Vitality, our new launched 2-week product and our diverse 1 Day offering. And remember, the biggest driver in the contact lens market is the 1 Day growth, and we strongly believe we have the best product offering in the space as the only company selling premium and mass market silicone hydrogel lenses, including a portfolio of sphere, toric and multifocal lenses. We are also investing in sales and marketing to support our strong product portfolio. 
Forecasting new hires is always challenging, especially when you're evaluating opportunities around the world. But we believe CooperVision can add numerous sales reps and get a very nice return given our strong product platform, our capacity and our growth opportunities that we see. We believe this initiative -- we began this initiative in our fourth quarter and expect it to continue through fiscal 2017 and possibly into 2018. For competitive reasons, I won't get into many details but, suffice it to say, we carefully evaluate our hiring and expect to realize a solid return from this activity. 
Now let me comment on our overall contact lens market and remember, this information is on the last page of our earnings release. For calendar Q3 2016, we continued taking share, growing 6%, with the market up 1%. Geographically, CooperVision grew 3% in the Americas while the market was down 3%. In the EMEA, we were up 8%, and the market was up 7%. In Asia Pacific, we grew 9%, with the market up 3%. On a modality basis, single-use lenses continued driving growth, with CooperVision up 12% and the market up 8%. For non-single-use lenses, we grew 3% while the market declined 4%. As you can see, our growth remains diverse and strong. On a trailing 12-month basis, CooperVision grew 8% while the market grew 3%. Although the market remains choppy and hard to read at times, we continue to believe it will strengthen and grow 4% to 6% over the next 5 years driven by continuing shift to dailies, geographic expansion and an expansion of the wearer base. We expect to continue taking market share led by our strong portfolio of market-leading products. 
Moving to CooperSurgical, we reported fourth quarter revenues of $107 million, up 30% year-over-year, driven by organic growth and acquisitions. On a pro forma basis, we grew 6%. Fertility led the way, up 74% or 8% pro forma. Within Fertility, we had growth throughout the business and continue to believe our market-leading product portfolio which includes medical devices, genetic testing and capital equipment is the broadest portfolio in the space and should continue to drive growth for many years to come.  Within our office and surgical category, growth was 5%. 
We're continuing to execute on several product launches, including our disposable hysteroscope, EndoSee, and we continue to see success in this area. Regarding other activity, we announced on November 6 that we acquired the Wallace portfolio from Smiths Medical for approximately $168 million. This is a great strategic fit with our existing global IVF portfolio as it brings the gold standard of embryo transfer catheters along with several other premier products. Finally, CooperSurgical -- on CooperSurgical, we're busy integrating recent acquisitions but also executing on several initiatives which should significantly strengthen the business. These include transitioning to a global sales model, adding sales reps in underpenetrated areas, launching products into new markets and increasing our focus on high-growth areas such as IVF genetic testing. We have made a lot of progress in these areas over the past year and expect to continue -- even have more progress as we go forward.  
Now before I turn it over to Al, let me comment on a couple other items. We anticipate another strong year of revenue growth in 2017, including CooperVision growing 6% to 8% in constant currency and CooperSurgical growing 6% to 8% pro forma. We also remain bullish on our future and are updating our long-term objectives for operating margins of 28% and free cash flow generation of over $2 billion by 2021. 
In conclusion, I want to express my appreciation to our employees for all their hard work and dedication. And now I'll turn it over to Al to cover the financial results."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Thank you, Bob, and good afternoon, everyone. Bob did an excellent job covering revenues, so I'll focus on the rest of our Q4 financial performance along with guidance. Most of my commentary will be on a non-GAAP basis, and a full reconciliation between o",746,"Thank you, Bob, and good afternoon, everyone. Bob did an excellent job covering revenues, so I'll focus on the rest of our Q4 financial performance along with guidance. Most of my commentary will be on a non-GAAP basis, and a full reconciliation between our GAAP and non-GAAP results is included in today's earnings release. 
For the quarter, gross margins were slightly over 64%, with both CooperVision and CooperSurgical up year-over-year. CooperVision improved roughly 50 basis points to 64.8% driven by factors such as currency and product mix while CooperSurgical grew roughly 30 basis points to 62.5% driven by cost-reduction efforts. Operating expenses grew 11.7% in the quarter driven heavily by CooperSurgical's acquisition-related activity. Within operating expenses, sales and marketing expenses grew 14% as both CooperVision and CooperSurgical executed on sales and marketing expansion plans to capitalize on strong product portfolios. Outside of sales and marketing, we drove leverage through general cost controls. Operating margins were 25.1%, up nicely from 24% last year driven by gross margin improvement and operating expense leverage. 
Moving to interest expense. We reported $5.3 million, which was lower than our guidance as we had a true-up of roughly $1.5 million. This true-up was associated with an over allocation of commitment fees in Q2 and Q3 related to the refinancing of our credit facilities completed in Q2 of this year. What should have happened is Q2 interest expense should have been lower by $600,000, and Q3 should have been lower by $900,000. Our effective tax rate was 10.3%, and the resulting non-GAAP EPS was $2.28 with roughly 49.3 million average shares outstanding. Total debt decreased this quarter by $110 million to roughly $1.33 billion driven by strong free cash flow of $158 million comprised of $193 million of operating cash flow and $35 million of CapEx. 
Regarding full year fiscal 2016 results, consolidated revenues were $1.967 billion, up 9.4% or 7.3% pro forma; CooperVision revenues were $1.577 billion, up 6% or 7.5% in constant currency; and CooperSurgical's revenues were $390 million, up 26% or 6.3% pro forma; non-GAAP EPS was $8.44, up 13%; lastly, free cash flow was $357 million. So all in, a very strong year. 
Moving to fiscal 2017 guidance. Let me start by commenting on currency, which has moved significantly against us over the past month or so. For 2017, we're estimating a negative year-over-year currency impact to revenues of approximately $57 million and negative $0.10 to EPS. Incorporating this into our outlook, we expect fiscal 2017 consolidated revenues of $2.09 billion to $2.13 billion. This is comprised of $1.62 billion to $1.65 billion at CooperVision which equates to roughly 6% to 8% constant currency growth and $470 million to $480 million in CooperSurgical which equates to roughly 6% to 8% pro forma growth. We expect gross margins to improve to around 64.5% and operating margins to improve to 25%. Interest expense is expected to be around $28 million which includes the additional debt from the Wallace acquisition along with an assumption of 125 basis points rate increase. The effective tax rate is expected to be around 10%. This may be higher than many of you were expecting, but it's based on our current forecast which includes fewer discrete items, and is thus more of a true run rate of our current operations. 
Non-GAAP EPS for fiscal 2017 is expected to be in the range of $9 to $9.30 based on 49.4 million shares outstanding. To provide color on this, the higher year-over-year tax rate will negatively impact earnings by roughly $0.20, and FX will negatively impact earnings by $0.10. We also anticipate continuing to invest in sales and marketing above and beyond our normal level, and this will likely be in excess of $10 million or $0.20 in fiscal 2017. Having said that, we do have several positives such as accretion from our CSI acquisition, less idle equipment and inventory charges, savings from manufacturing improvements and the royalty roll-off, and these will help drive earnings growth. Regarding Q1, we anticipate revenues of $494 million to $508 million. This is comprised of $383 million to $393 million at CooperVision or roughly 7% to 10% constant currency growth, and $111 million to $115 million at CooperSurgical which equates to roughly 3% to 7% pro forma growth. For Q1 non-GAAP EPS, we expect $1.78 to $1.88 and note, this assumes a 10% tax rate as compared to last year's 3.9%. 
And with that, I'll hand it back to the operator for questions."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","[Operator Instructions] And our first question comes from the line of Jon Block of Stifel.",15,"[Operator Instructions] And our first question comes from the line of Jon Block of Stifel."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Maybe the first question, still working through some numbers, it didn't really surprise us all too much on the fiscal 2017 guide. Al, you went through a lot of numbers. The lowest on 1Q, is that just a function of you do have the pound benefit for fiscal",149,"Maybe the first question, still working through some numbers, it didn't really surprise us all too much on the fiscal 2017 guide. Al, you went through a lot of numbers. The lowest on 1Q, is that just a function of you do have the pound benefit for fiscal 2017 but again, it really takes effect come January so you only had that for a slight stub of 1Q that can be causing approximately $0.20 discount -- sorry, $0.20 disconnects where you guided 1Q versus Street, that's a specific number? And maybe, Bob, maybe just to take a step back, just some market commentary. The down 3% U.S. is very surprising. We get your number, up 3% per your release. J&J, I think was up 5% and change, U.S. So how could 2/3 of the market be up a weighted 5% and we see negative 3% in the market data?"
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, I'll answer the first one, and then let Bob get into the market data. Yes, I agree with you. I mean, when you look at the pound move, most of that starts for us in January, so we get it for  1 month in the first quarter. So when you look at the incre",103,"Yes, I'll answer the first one, and then let Bob get into the market data. Yes, I agree with you. I mean, when you look at the pound move, most of that starts for us in January, so we get it for  1 month in the first quarter. So when you look at the incremental sales and marketing investments and you look at the higher tax rate which is somewhere around $0.13 for Q1 combined with only getting the pound benefit for really the month of January, I think that's probably where -- that probably comprises, certainly, the vast majority of the delta."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, as far as the market, I think we've all scratched our head a little about kind of the results being reported by us and the various market players compared to some of the data we see in industry data. And probably the best way to think about it is tha",289,"Yes, as far as the market, I think we've all scratched our head a little about kind of the results being reported by us and the various market players compared to some of the data we see in industry data. And probably the best way to think about it is that, a year ago, the Americas showed 11% growth and the entire market showed 8% growth worldwide driven very heavily by the Americas. This year, that kind of flips to a negative of 3% for the Americas and only 1% for worldwide. So you really have to look at 5 quarters or better yet, even 2 rolling years because of what happened a year ago was all the activity by J&J as they rolled out new products or things going on with UPP, so channel fill, so you end up with probably a delink between the way data comes into CLI and the public company. There's variances there, too, and including some of the activity associated with that. So when I think of the market, I kind of say, ""All right, let's put the 2 together."" Last year is 11%, this year it's negative 3%, that's 8%. Divided by 2, it looks more like 4% to me. And in the interim, we had a fourth quarter, 4%; a second quarter, 4%; and then a flat first quarter last year. So last year -- my way of thinking, last year rippled into the first quarter, so that 11% third quarter showed up as a neutral first quarter. The long and the short of it is it's probably best to look at it as 5 -- the average of 5 quarters if you're going to make much sense out of it."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Larry Biegelsen of Wells Fargo.",14,"And our next question comes from the line of Larry Biegelsen of Wells Fargo."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Bob, I'm sure it's going to get asked on this call, so I may as well ask about it. Just any thoughts on corporate tax reform and how -- and Cooper's view on this and how you think it could impact you guys? And then one other question, just on the quarter",75,"Bob, I'm sure it's going to get asked on this call, so I may as well ask about it. Just any thoughts on corporate tax reform and how -- and Cooper's view on this and how you think it could impact you guys? And then one other question, just on the quarter itself, the 11%, obviously, quite strong. Was there anything onetime in the quarter, selling days, stocking, et cetera, that helped you this quarter?"
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, I'll do the second one first which is there's nothing unusual about the 11%. We're obviously rolling out some new products. We had a slightly easier comp from a year ago, particularly relative to the Europe theater which is going through consolidatio",201,"Yes, I'll do the second one first which is there's nothing unusual about the 11%. We're obviously rolling out some new products. We had a slightly easier comp from a year ago, particularly relative to the Europe theater which is going through consolidation last year with Sauflon but, by and large, a solid quarter. As far as tax reform, well, tax reform has been talked about forever, and I could give you 2 theories on, if I just lock in on one thing that's being thrown around out there, the 35% going to 15%, suffice it to say that wouldn't be bad for most anyone and will serve as a neutralizer to a degree on however it shakes out the rest of the world. There are too many different debates going on out there. There's the fact that any meaningful change would require a vote of 60% of the Senate to go along with it, and that could be tough or only come with a lot of compromise. So I think it would be way premature to know if it's a net plus or a net minus, but most people wouldn't complain about a huge reduction in the corporate tax rate."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Matt Mishan of KeyBanc.",13,"And our next question comes from the line of Matt Mishan of KeyBanc."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Could you go a little bit further into the investment you guys are making in SG&A in really around the cadence? And maybe break out with the difference is between the growth in SG&A from the investment and the growth in SG&A from the acquisitions that you",62,"Could you go a little bit further into the investment you guys are making in SG&A in really around the cadence? And maybe break out with the difference is between the growth in SG&A from the investment and the growth in SG&A from the acquisitions that you're making just so we can get a better sense for how to model this."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","So the investment we're making in SG&A is sales and marketing. We're leveraging the rest of the infrastructure. And in the area of sales and marketing, that is both on the Vision side, heavily feet on the street, we're under-indexed compared to our compet",296,"So the investment we're making in SG&A is sales and marketing. We're leveraging the rest of the infrastructure. And in the area of sales and marketing, that is both on the Vision side, heavily feet on the street, we're under-indexed compared to our competitors. And as I indicated, I'm not going to start quoting numbers of adds in terms of number of sales force we're adding. But suffice it to say, we also are rolling out many new products. Some of them are conceptually new like Energys. So there'll be a fair amount of energy also supporting those new products. And putting the 2 together, we will  while we're giving you guidance at 6% to 8% top line growth for both Surgical and Vision. We will be, suffice it to say, growing our sales and marketing at a rate faster primarily in the area of both feet on the street and, to a lesser extent, the marketing support behind that. Beyond that, we're not -- like I said, we're not going to really get into how under-indexed we are compared to our competitors. And I would say it's -- in many cases, it will be not across the board. If you have a vacancy or you're under-indexed in a geographic area, and I've always used an example of a city like Las Vegas and said, ""You know, if you didn't have a salesperson in Las Vegas, it's a pretty big town, maybe you ought to have a salesperson there if you have a lot of products to talk about."" So in some cases, it's adding junior people to support senior people, in other places there will be having feet on the street where you're currently making telephone calls and kind of piggybacking on that."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","And one quick add comment, when you look at the breakdown between Vision and Surgical, it's probably easiest to think about it from a sales and marketing perspective, as if sales and marketing in each business is going to grow somewhat similar of what the",77,"And one quick add comment, when you look at the breakdown between Vision and Surgical, it's probably easiest to think about it from a sales and marketing perspective, as if sales and marketing in each business is going to grow somewhat similar of what their revenues are, their as-reported revenues. So if you look at that on a CooperSurgical basis, obviously, it's quite a bit higher on a percentage growth basis than Vision due to the acquisitions."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Matthew O'Brien of Piper Jaffray.",15,"And our next question comes from the line of Matthew O'Brien of Piper Jaffray."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Just on the dailies side, the performance in the quarter was a slight acceleration over what we saw last quarter. Can you talk a little bit about where that came from, be it MyDay, be it clariti, maybe MyDay in Japan? And then, on top of that, just the 2-",76,"Just on the dailies side, the performance in the quarter was a slight acceleration over what we saw last quarter. Can you talk a little bit about where that came from, be it MyDay, be it clariti, maybe MyDay in Japan? And then, on top of that, just the 2-year stacks on the non-daily side appears to decelerate. Could you just talk a little bit about what's going on there? Are you seeing some VITA impact?"
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes. On the dailies side, there was some acceleration. Having said that, we kind of targeted for basically some approaching 50% for the year, a slight acceleration from the prior year is the way we thought about it coming into this year. So it's kind of m",367,"Yes. On the dailies side, there was some acceleration. Having said that, we kind of targeted for basically some approaching 50% for the year, a slight acceleration from the prior year is the way we thought about it coming into this year. So it's kind of moving along those lines. And the way it's moving is, obviously, the more mature market is EMEA where these products started out, both MyDay and clariti. The least mature is Japan and the Americas, so we're very early in the cycle in those 2 areas and rapidly expanding the offering even in Europe. So it's geographically across all theaters and very much -- we've now kind of did the redo of the first clariti that was out there, and that's performing real well. So we're now expanding our attention into more than our own accounts. Initially, we had to take care of our accounts that we had given the first generation, if you will, product to. So a long way to go, and we're very early in the cycle and obviously moving off of a larger base as we go forward. As far as the deceleration in the planned replacement area, the non-1 Day, really, that market, if we look at it from a 2.5-year, 3-year perspective, is in around breakeven, with the growth all being driven by the 1 Day. That's been pretty consistent over the last 4 years, and we don't see that changing. Actually, it's been consistent a lot -- a driver longer than 4 years, but more so outside the U.S. and more recently inside the U.S., so don't see any changes there. There is activity in the planned replacement market, things like Biofinity, obviously, are still putting up terrific numbers so there's room to grow. And particularly as we think about the geographic expansion, some of what goes into China and into some of those theaters, maybe a little less weighted initially in the 1 Day modality, although that -- we can't make that statement about every country. So a lot of opportunity even in the planned replacement arena, and we're obviously continuing to grow that while the market may be not growing, if you will."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Joanne Wuensch of BMO Capital Markets.",15,"And our next question comes from the line of Joanne Wuensch of BMO Capital Markets."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Two questions. The first one, is the new SG&A rate for 2017, do we think of that as the go-forward rate? Or do we think of that as a period of investment and then it should ease off? And then the second question, to circle back to the tax issue, we're get",103,"Two questions. The first one, is the new SG&A rate for 2017, do we think of that as the go-forward rate? Or do we think of that as a period of investment and then it should ease off? And then the second question, to circle back to the tax issue, we're getting questions from investors regarding your buy-in plan and what it means -- may or may not mean for Cooper which manufactures a fair bit outside of the United States, generates a fair bit of its revenue outside the United States, and I was curious if you had looked into that yet."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","So on the SG&A, if it's short-term or long-term, the sales and marketing, we plan on continuing to invest throughout 2017. And as I indicated in my commentary, to the extent it rolls into 2018 where we're getting the top line growth we want, we will conti",479,"So on the SG&A, if it's short-term or long-term, the sales and marketing, we plan on continuing to invest throughout 2017. And as I indicated in my commentary, to the extent it rolls into 2018 where we're getting the top line growth we want, we will continue that modality. The driver there is if you have a lot of products to talk about and you have the capacity then you should try selling the product and leverage the capacity. We know we have excess capacity, and why not use it? So to the extent we're getting our payback, which will include diminishing the idle charges that we're incurring on cost of goods as a byproduct, we're going to do it. And we obviously have an agenda of gaining market share, and we've certainly done a good job of that the last 7 years. And if I look at it over the last 12 months, it's been greater than 2% that we've grown in the market. You can't make much out of this quarter's numbers because we grew 6 and the market 1 -- grew 1. I'm not going to say we're growing 6x the market but, obviously, we are growing around that 2x. Relative to the rest of operating cost, distribution, G&A and even, to a lesser extent, R&D, we expect to get leverage out of those around the world. So it isn't to say that operating cost in total will keep going up as a percentage of revenue. As far as the Ryan plan, I'm not going to get too detailed into it because there are too many soft spots and too many assumptions you'd have to make. But I guess I'd point one thing out which I think is very important. When we look at -- people think we're very oriented towards outside the U.S. the way we think. But the fact of the matter is our headcount around the world is pretty balanced U.S. and the rest of the world, both as to revenue and as to headcount. And that is after you count Puerto Rico where we make 1 billion lenses in Puerto Rico, that is a possession of the United States and is part of U.S. So when we kind of think about this, we, they that we're hearing about -- we, the U.S. against the rest of the world; we, the U.S., 5% compared to 95% of those outside the U.S., it is not as imbalanced in Cooper's model as some may think it is. Long and the short of it is I'm not going to overreact to any theory that gets thrown around out there, and I'll react to legislation. There hasn't been meaningful legislation since, I think, 1986. There's been a few things along the way that have come and gone, but it would be very premature to overanalyze it."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Steve Willoughby of Cleveland Research.",14,"And our next question comes from the line of Steve Willoughby of Cleveland Research."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","I guess, first, Al, if we look back a month ago as it relates to FX, what would you be thinking in terms of the impact from FX to the total company for 2017 at that point versus the $0.10 headwind you're expecting now?",44,"I guess, first, Al, if we look back a month ago as it relates to FX, what would you be thinking in terms of the impact from FX to the total company for 2017 at that point versus the $0.10 headwind you're expecting now?"
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, Steve, tough to say, right, because it depends what day you chose. When Trump was elected, so to speak, I mean that's when currency rates really started moving. So if you go back to that day or prior to that day, we, at one point in time, would have",102,"Well, Steve, tough to say, right, because it depends what day you chose. When Trump was elected, so to speak, I mean that's when currency rates really started moving. So if you go back to that day or prior to that day, we, at one point in time, would have been $0.30, $0.40 positive. We would have had the wind at our back. We probably ended up with -- I don't know what the exact numbers are, but wouldn't surprise me if it's $0.50 swing from what it was to what it is today, maybe even a little bit more than that."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Okay. And then just a follow-up, with the roughly 50% 1 Day silicone hydrogel growth this year, do you have any expectations for kind of what that looks like next year?",31,"Okay. And then just a follow-up, with the roughly 50% 1 Day silicone hydrogel growth this year, do you have any expectations for kind of what that looks like next year?"
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, as I indicated, it's off of a larger base. So I wouldn't expect the 50% to be sustainable, but I think in terms of whole dollars, that certainly should be something we would expect. We have so much opportunity and we have the capacity that all I'll",74,"Well, as I indicated, it's off of a larger base. So I wouldn't expect the 50% to be sustainable, but I think in terms of whole dollars, that certainly should be something we would expect. We have so much opportunity and we have the capacity that all I'll say is we'll put up solid numbers throughout 2017, but I'm not going to say it's any one, particularly in percentage, let's put it that way."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Larry Keusch of Raymond James.",14,"And our next question comes from the line of Larry Keusch of Raymond James."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Couple questions here. Just, Al, I'm wondering if you could talk a little bit about the FX assumptions that you are using for 2017 on the major currencies.",28,"Couple questions here. Just, Al, I'm wondering if you could talk a little bit about the FX assumptions that you are using for 2017 on the major currencies."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Sure. Pretty much today's rates. I mean, they're obviously bouncing around a lot, but the euro at about 1.06, the yen at 1.14, pound at 1.26. And I mean that's kind of similar to where they are today, right? And then other currencies around the world woul",52,"Sure. Pretty much today's rates. I mean, they're obviously bouncing around a lot, but the euro at about 1.06, the yen at 1.14, pound at 1.26. And I mean that's kind of similar to where they are today, right? And then other currencies around the world would be pretty similar to that."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Okay, perfect. And then 2 other ones quickly here. I know you mentioned the outlook for free cash flow generation in totality through 2021, but how are you thinking about free cash flow generation this year and maybe wrap into that CapEx? And then I guess",113,"Okay, perfect. And then 2 other ones quickly here. I know you mentioned the outlook for free cash flow generation in totality through 2021, but how are you thinking about free cash flow generation this year and maybe wrap into that CapEx? And then I guess that last thing is just struggling a little bit with the first quarter and why it's so low. I understand the tax rate, obviously, there's a tough comparison. But can you talk a little bit about perhaps the gating for the spending of this incremental for sales and marketing, and is it weighted towards the first quarter or is it sort of more ratable through the year?"
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, I'll hit cash flow, and I'll let Bob go through on the marketing side. For this year, we're probably going to be 400 -- should to be north of $400 million of free cash. Currency is hurting us a little bit right now, but it should be somewhere in that",104,"Yes, I'll hit cash flow, and I'll let Bob go through on the marketing side. For this year, we're probably going to be 400 -- should to be north of $400 million of free cash. Currency is hurting us a little bit right now, but it should be somewhere in that $400 million range. CapEx, we'll see how that plays out. It looks like it's going to be somewhere around the $150 million for the year. So if you work off those numbers, $400 million and $150 million, that's probably not a bad way to look at this year at this point in time."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes. And I think as far as the gating of the investment spend and is it a drag on the first quarter, yes, it is drag partly because of the fact that our first quarter is always the lightest on a revenue base -- from a revenue point of view which has alway",140,"Yes. And I think as far as the gating of the investment spend and is it a drag on the first quarter, yes, it is drag partly because of the fact that our first quarter is always the lightest on a revenue base -- from a revenue point of view which has always been the case, and we started -- a lot of our investment started ramping in the fourth quarter so it's rolling into the first quarter, obviously, as part of the infrastructure already and will be somewhat of a drag. Some of our investments, if you will, that started in the fourth quarter and worked their way through the first quarter will start yielding, if you will, as the year progresses and we start expecting a return from some of that towards the back half of the year."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Andrew Hanover of JPMorgan.",13,"And our next question comes from the line of Andrew Hanover of JPMorgan."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Al, I just wanted to go back just through '17 guidance. And just it looks like it's extremely conservative at least from what I can tell right this second. I think this is the first time you've embedded an interest rate increase in the numbers. And kind o",92,"Al, I just wanted to go back just through '17 guidance. And just it looks like it's extremely conservative at least from what I can tell right this second. I think this is the first time you've embedded an interest rate increase in the numbers. And kind of 125 bps, I was just wondering is that around -- is that an impact of around $0.18? And then I'm just trying to get a better feel for FX, SG&A, the higher tax rate and what's driving the higher tax rate for the year?"
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, a couple comments. I mean, if you look at our debt levels, $1.3 billion. We acquired Wallace, obviously, so another $150 million-plus on that. It's pretty straightforward to do the math on the increase. We assumed a 25 basis point rate increase happe",236,"Yes, a couple comments. I mean, if you look at our debt levels, $1.3 billion. We acquired Wallace, obviously, so another $150 million-plus on that. It's pretty straightforward to do the math on the increase. We assumed a 25 basis point rate increase happening, with the Fed moving here in the month of December, so kind of fully baking that in for the year, if you will. We -- probably a little conservative on interest expense where we're at, based on the amount of cash flow we're generating and so forth and where we'll come out on the pricing grid, but we'll see how that plays out. When you look at the tax rate itself, we've been running kind of on a look-through basis, if you will, somewhere around that 10%. We've had a number of discrete items that have come through. We've had acquisition-related activity and so forth that have allowed some write-offs and so forth that have pushed the tax rate down. Could it come in lower than 10%? It could. But I would tell you right now, based on what we have today, we're looking at somewhere around that 10%, with Q1, Q2, Q4 probably being somewhat similar and, as usual, Q3 being a little lighter but not as dramatic as what you've seen in prior years where you would see a quarter that was a 3% or 4% quarter as an example."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","And I think one way of looking at that is our fourth quarter effective tax rate is 10.3%. That is excluding any discrete items. So that's kind of what the business run ex the discrete items we've had year after year but do not anticipate going forward.",48,"And I think one way of looking at that is our fourth quarter effective tax rate is 10.3%. That is excluding any discrete items. So that's kind of what the business run ex the discrete items we've had year after year but do not anticipate going forward."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Jeff Johnson of Robert Baird.",14,"And our next question comes from the line of Jeff Johnson of Robert Baird."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Bob, I wanted to start with you just on the sales force. So if I think about your sales force, I think it's about half to maybe 55% the size of your 2 larger competitors. And your market share is kind of in that same range. And so on the face of it, it se",189,"Bob, I wanted to start with you just on the sales force. So if I think about your sales force, I think it's about half to maybe 55% the size of your 2 larger competitors. And your market share is kind of in that same range. And so on the face of it, it seems like your sales force isn't overly undersized, I guess. And then I think about your private label business, it's somewhere around 25% or 30% of revenue, and I'd assume that's a lower touch business. Just wanting to understand why is the big focus on sales force additions at this point and what's really driving that? And then maybe, Al, for you, a follow-up question. I think I agree, your EPS guidance looks like maybe there's some levers of conservatism in there, but 6% to 8% CVI growth in a fairly choppy market and maybe in a med tech market that's a little uncertain right now doesn't feel overly conservative to me, so maybe if you can address your thoughts on the 6% to 8% CVI growth for '17, that would be helpful as well."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, Jeff, on the size of our sales force compared to our competitors, I think if we compare our 23% market share to Alcon's, which is just a tad above ours, suffice it to say, the size of their sales force compared to ours is nowhere comparable. And J&J,",200,"Yes, Jeff, on the size of our sales force compared to our competitors, I think if we compare our 23% market share to Alcon's, which is just a tad above ours, suffice it to say, the size of their sales force compared to ours is nowhere comparable. And J&J, if we're going to do allocations against market share, with their 40% market share or there and thereabout to our 23%, that would barely line up. I think more importantly is it really is about if you have the product and we have the broadest product portfolio and you have the capacity, something we have not had in the past at least relative to clariti, MyDay and, to a lesser extent, even Biofinity. So if you have your -- the capacity you want, why wouldn't you test the water and see how good your products are? Why wouldn't you go after your competitors' accounts more aggressively? And we can't do it if we're under-indexed on feet on the street. So it's one thing if you're kind of growing methodically and you're confined with how much you can grow, it's another thing if you don't have those limitations which I'll call capacity."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes, and I'll comment a little bit on the growth rate assumption. I mean if you look at CooperVision last year, they grew 7.5% in constant currency, 11% in Q4 so, obviously, a lot of momentum there. You look at the Q1 guidance of 7% to 10% and expecting t",174,"Yes, and I'll comment a little bit on the growth rate assumption. I mean if you look at CooperVision last year, they grew 7.5% in constant currency, 11% in Q4 so, obviously, a lot of momentum there. You look at the Q1 guidance of 7% to 10% and expecting that momentum to continue, and Jeff, I think, where you're going with this, to your point, is if you look at 6% to 8% for the year and you roll that Q1 in, you'd be talking about implied guidance, if you will, of Q2 to Q4 for CooperVision in the upper 6s which would be decelerating in the face of some decent investment. So I think that's a very fair question. I would tell you I think that giving a 6% to 8% range in today's world is prudent and a good way to look at the business, but I don't think anybody would be very happy, let me put it to you that way, if we were growing in the 6% to 7% range."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Anthony Petrone of Jefferies.",13,"And our next question comes from the line of Anthony Petrone of Jefferies."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Maybe just one question on the sales investments and then one just on the competitive landscape to follow up there. Just in terms of feet on the street, I'm just wondering how much of the investment is focused on optometrists, that channel, as opposed to",132,"Maybe just one question on the sales investments and then one just on the competitive landscape to follow up there. Just in terms of feet on the street, I'm just wondering how much of the investment is focused on optometrists, that channel, as opposed to other retail channels. And I guess the core of that is that we're under the impression that still the majority of sales for Cooper comes from optometrists. So just wondering if you're doubling down in that channel or expanding in other retail channels? And in terms of the competitive landscape, it would just be great to get an update, sort of where Alcon sits at this point. It looks like they're still in a position of giving up some share and, similarly, Bausch & Lomb and J&J."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Sure. Our focus in terms of feet on the street and whether it's independent ODs or ODs that are at the retail level is the OD, wherever they are. And a lot of our -- Cooper is very open as part of its strategy being -- it could be a branded entity or it c",333,"Sure. Our focus in terms of feet on the street and whether it's independent ODs or ODs that are at the retail level is the OD, wherever they are. And a lot of our -- Cooper is very open as part of its strategy being -- it could be a branded entity or it could be private label. So we're indifferent to what it's called. But what we have learned in the past is just because you send a bunch of your product, whether it's private label or branded, to a large retailer, if you don't work it, it's not going to work itself. You have to go to the OD, whether they're under an umbrella of a retailer or not. That has contrasted to maybe an online or some other mechanism, we don't waste our time with that. If you don't like the prescription, you don't have our attention, and that will continue. Relative to the competitive landscape, yes, our competitors continue to be in various stages of disarray, Alcon, we know what the CEO and Chairman of Novartis basically said, they are restructuring that organization. There is disruption there. They have a tired product line. B&L likewise is in a very disruptive environment to say the least. And J&J has done a pretty good job of marketing 1 product, OASYS. By any other name, it is OASYS, so it's all over, 1-day, 1-week, 2-week, 1-month called VITA. So of the 3 competitors, I would say J&J kind of has its act together better than the other 2. But having said that, they're obviously presenting some opportunity in their approach, are they in UPP one day and then they're out of UPP the next day. UPP wholesale across all of their products and then they vacate the entire thing, come up with a different plan. So we've been pretty steady state in the way we're approaching the market. We have the product portfolio and we kind of feel good about our competitors."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Brian Weinstein of William Blair.",14,"And our next question comes from the line of Brian Weinstein of William Blair."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","First one on margins, you guys had targeted some improvement in MyDay by the end of the year and talked about clariti getting north of corporate margins. Can you just comment kind of where the margins are in those products? And then, Bob, for you, you had",133,"First one on margins, you guys had targeted some improvement in MyDay by the end of the year and talked about clariti getting north of corporate margins. Can you just comment kind of where the margins are in those products? And then, Bob, for you, you had talked previously about 50% of the $10 billion market to be in the 1 day modality; of that, about somewhere between 20% and 77% to be in silicone hydrogel, and thought maybe the middle of that made sense. With more experience now of how these products are rolling out, do you have more confidence that over the next few years that you're going to be turning more above that 50% of the market towards that 77%? Where do you think that, that could be by 2020?"
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes. I think we're rapidly approaching the 50% mark for 1 Day. And within 1 Day, silicone hydrogel is continuing to make solid progress, growing 20%-ish in that market. And therefore, it's now I think over 20% of the -- or close to 25% of the 1 day market",276,"Yes. I think we're rapidly approaching the 50% mark for 1 Day. And within 1 Day, silicone hydrogel is continuing to make solid progress, growing 20%-ish in that market. And therefore, it's now I think over 20% of the -- or close to 25% of the 1 day market. So I do believe the 1-days will be more than 50% of the -- let's say, that target, $10 billion down the road 2020, 2021. And who knows? Foreign exchange keeps coming along, kind of putting a dent into some of that. So assuming the dollar stabilizes, we're directionally headed towards that $10 billion. 1 Day will be greater than 50%, and there's no doubt that silicone hydrogel 1 Day will be much greater than 20% of that 1 day market. And will it be similar to the planned replacement where it's close to 80%, 79% to 80%, or a lot less? I think there are some reasons that it won't get well beyond the 50% barrier short-term because there is so much activity in the non-silicone hydrogel mass market space that, that will be somewhat a barrier. To answer your question about our cost coming down, MyDay is making good progress. We believe it's in the 30s now and we would expect that by 2018 sometime, will be honing in on that 50% target for 1 Day gross margin. And clariti, because of its novel approach to manufacturing and cost, will not be a drag. And it's not a drag today on our gross margin. So the mix you see, it's holding its own within that mix and is not a headwind on gross margin percentages."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And our next question comes from the line of Steven Lichtman of Oppenheimer.",13,"And our next question comes from the line of Steven Lichtman of Oppenheimer."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Analysts","Just a couple of P&L follow-ups. First, in terms of the investment in sales and marketing, should we be thinking about that as sort of solely sales force hire investments? Or is there any discrete marketing investments that are embedded in there? And then",72,"Just a couple of P&L follow-ups. First, in terms of the investment in sales and marketing, should we be thinking about that as sort of solely sales force hire investments? Or is there any discrete marketing investments that are embedded in there? And then, secondly, Al, on the idle equipment charges, the enhanced charges we've seen owing to the efficiencies, how should we be thinking about those rolling off in 2017?"
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","So on the sales and marketing, it's more than just feet on the street, albeit the concentration and the focus is more so feet on the street. But with the new products, with Energys, with conversion of -- from Avaira to Vitality, with a new toric -- a new",266,"So on the sales and marketing, it's more than just feet on the street, albeit the concentration and the focus is more so feet on the street. But with the new products, with Energys, with conversion of -- from Avaira to Vitality, with a new toric -- a new MyDay toric, all that activity, there certainly is -- and particularly upfront, as you come out with new products, some energy on the marketing side. Some of that will tail off and some of it will continue as you roll it out around the world. So nothing -- I would say, nothing imminent where it's suddenly in a non-investment mode over the next 1 to 2 years. The roll-off of idle equipment is somewhat a function of the success of the growth of our various areas. Whether it's Vitality, whether it's MyDay, whether it's clariti, the growth in those products will form the basis of consuming some of that idle equipment over the next 1 to 2 years. We indicated partly because of the continuing successes in cutting costs and getting better yields and getting better throughput, we're now talking about lines with north of $80 million unit production that 2 years ago we didn't even have on the drawing board by way of a thought. So those kind of profound changes means we'll be able to continue to ramp up and continue to be ahead of the curve in terms of the demand side for quite a while in some of those areas, clariti and MyDay. Al, I don't know what other color you want to..."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Yes. Maybe just to quickly -- Bob's exactly right, quantify that just a little bit. We had talked last year about kind of $0.10 a quarter above and beyond for idle equipment and some inventory charges. And we had that in Q2, Q3, Q4. I would say that we're",202,"Yes. Maybe just to quickly -- Bob's exactly right, quantify that just a little bit. We had talked last year about kind of $0.10 a quarter above and beyond for idle equipment and some inventory charges. And we had that in Q2, Q3, Q4. I would say that we're continuing to have that right now. Those idle charges are mostly linked to the dailies side. So the growth that you're seeing is absolutely fantastic for us. Continuing growth like that puts those lines to use and the idle equipment goes down. So the expansion, the focus on sales and marketing to drive topline growth, driving single-use, one of the nice benefits of that is it's going to put equipment to work. We obviously don't need to buy new equipment, which helps free cash flow and we would move idle equipment charges and put that into production. So I would say that we're still kind of looking at that $0.10 a quarter here to start the year. But then depending upon our success that will move down and hopefully move to 0 by the end of this year. But more than likely, we'll see those charges even move into 2018 a little bit."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","And I'm showing no further questions at this time. I would now like to turn the call over to Mr. Bob Weiss for closing remarks.",26,"And I'm showing no further questions at this time. I would now like to turn the call over to Mr. Bob Weiss for closing remarks."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Executives","Well, I want to thank you for joining our call today, and I wish everyone the happiest of holidays coming up. And we look forward to updating you on the progress we're making and on our new product rollout on our call in March which I believe is going to",70,"Well, I want to thank you for joining our call today, and I wish everyone the happiest of holidays coming up. And we look forward to updating you on the progress we're making and on our new product rollout on our call in March which I believe is going to be March 2, 2017. We look forward to talking to you then. Thank you, all. Thank you. That's it, operator."
263609,408515230,1100926,"The Cooper Companies Inc., Q4 2016 Earnings Call, Dec 08, 2016",2016-12-08,"Earnings Calls","The Cooper Companies, Inc.","Operator","Ladies and gentlemen, thank you for participating in today's conference. This concludes today's program. You may all disconnect. Everyone, have a great day.",23,"Ladies and gentlemen, thank you for participating in today's conference. This concludes today's program. You may all disconnect. Everyone, have a great day."
